



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification:</b> <b>C07K 16/24, A61K 39/395,</b> <b>A61P 43/00, C07K 16/00,</b> <b>C12N 5/10, C12N 15/13,</b> <b>C12N 15/63, C12P 21/08,</b> <b>G01N 33/577</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/56772</b> <b>(43) International Publication Date:</b> 28 September 2000 (28.09.2000)
<b>(21) International Application Number:</b> PCT/US00/07946 <b>(22) International Filing Date:</b> 24 March 2000 (24.03.2000) <b>(30) Priority Data:</b> 60/126,603 25 March 1999 (25.03.1999) US <b>(60) Parent Application or Grant</b> BASF AKTIENGESELLSCHAFT [/]; O. GENETICS INSTITUTE INC. [/]; O. SALFELD, Jochen, G. [/]; O. ROGUSKA, Michael [/]; O. PASKIND, Michael [/]; O. BANERJEE, Subhashis [/]; O. TRACEY, Daniel, E. [/]; O. WHITE, Michael [/]; O. KAYMAKCALAN, Zehra [/]; O. LABKOVSKY, Boris [/]; O. SAKORAFAS, Paul [/]; O. FRIEDRICH, Stuart [/]; O. MYLES, Angela [/]; O. VELDMAN, Geertruida, M. [/]; O. VENTURINI, Amy [/]; O. WARNE, Nicholas, W. [/]; O. WIDOM, Angela [/]; O. ELVIN, John, G. [/]; O. DUNCAN, Alexander, R. [/]; O. DERBYSHIRE, Elaine, J. [/]; O. CARMEN, Sara [/]; O. SMITH, Stephen [/]; O. HOLTET, Thor, Las [/]; O. DU FOU, Sarah, L. [/]; O. SALFELD, Jochen, G. [/]; O. ROGUSKA, Michael [/]; O. PASKIND, Michael [/]; O. BANERJEE, Subhashis [/]; O. TRACEY, Daniel, E. [/]; O. WHITE, Michael [/]; O. KAYMAKCALAN, Zehra [/]; O. LABKOVSKY, Boris [/]; O. SAKORAFAS, Paul [/]; O. FRIEDRICH, Stuart [/]; O. MYLES, Angela [/]; O. VELDMAN, Geertruida, M. [/]; O. VENTURINI, Amy [/]; O. WARNE, Nicholas, W. [/]; O. WIDOM, Angela [/]; O. ELVIN, John, G. [/]; O. DUNCAN, Alexander, R. [/]; O. DERBYSHIRE, Elaine, J. [/]; O. CARMEN, Sara [/]; O. SMITH, Stephen [/]; O. HOLTET, Thor, Las [/]; O. DU FOU, Sarah, L. [/]; O. KARA, Catherine, J. ; O.		<b>Published</b>
<b>(54) Title: HUMAN ANTIBODIES THAT BIND HUMAN IL-12 AND METHODS FOR PRODUCING</b> <b>(54) Titre: ANTICORPS HUMAINS SE LIANT A L'INTERLEUKINE-12 HUMAINE ET PROCEDES DE PRODUCTION DE CES</b> <b>DERNIERS</b>  <b>(57) Abstract</b> <p>Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.</p> <b>(57) Abrégé</b> <p>On décrit des anticorps humains, de préférence des anticorps humains de recombinaison qui se lient de manière spécifique à l'interleukine-12 humaine (hIL-12). Les anticorps préférés présentent une forte affinité pour hIL-12 et neutralisent l'activité hIL-12 in vitro et in vivo. Un anticorps selon la présente invention peut être un anticorps entier ou une partie de liaison d'antigène de ce dernier. Les anticorps ou les parties d'anticorps de cette invention sont utiles pour détecter hIL-12 et pour inhiber l'activité hIL-12, par exemple chez un patient humain souffrant d'une maladie dans laquelle l'activité hIL-12 est préjudiciable. On décrit également des acides nucléiques, des vecteurs et des cellules hôtes qui permettent d'exprimer les anticorps humains selon la présente invention ainsi que des procédés de synthèse desdits anticorps humains de recombinaison.</p>		

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>7</sup> : C07K 16/24, C12N 15/13, 15/63, 5/10, C07K 16/00, A61K 39/395, G01N 33/577, C12P 21/08, A61P 43/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 00/56772 (43) International Publication Date: 28 September 2000 (28.09.00)</p>
<p>(21) International Application Number: PCT/US00/07946 (22) International Filing Date: 24 March 2000 (24.03.00) (30) Priority Data: 60/126,603 25 March 1999 (25.03.99) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/126,603 (CIP) Filed on 25 March 1999 (25.03.99) (71) Applicants (for all designated States except US): BASF AKTIENGESELLSCHAFT [DE/DE]; Carl-Bosch Strasse 38, D-67056 Ludwigshafen (DE). GENETICS INSTITUTE INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): SALFELD, Jochen, G. [DE/US]; 177 Old Westborough Road, North Grafton, MA 01536 (US). ROGUSKA, Michael [US/US]; 16 Hilldale Road, Ashland, MA 01721 (US). PASKIND, Michael [US/US]; 253 Redemption Rock Trail, Sterling,</p>		<p>MA 01564 (US). BANERJEE, Subhashis [IN/US]; 25 Hapgood Way, Shrewsbury, MA 01545 (US). TRACEY, Daniel, E. [US/US]; 149 Shaker Road, Harvard, MA 01451 (US). WHITE, Michael [US/US]; 30 Angelica Drive, Framingham, MA 01701 (US). KAYMAKALAN, Zehra [TR/US]; 4 Picadilly Way, Westborough, MA 01581 (US). LABKOVSKY, Boris [US/US]; 107A-5 Broadmeadow Road, Marlborough, MA 01752 (US). SAKORAFAS, Paul [US/US]; 47 Court Street, Newton, MA 02160 (US). FRIEDRICH, Stuart [CA/US]; 20 Albion Street, Melrose, MA 02176 (US). MYLES, Angela [US/US]; Apartment #7, 11 Crescent Drive, Andover, MA 01810 (US). VELDMAN, Geertruida, M. [NL/NL]; 60 Woodmere Drive, Sudbury, MA 01776 (US). VENTURINI, Amy [US/US]; 207 Woburn Street, Lexington, MA 02420 (US). WARNE, Nicholas, W. [US/US]; 27 Farrwood Drive, Andover, MA 01810 (US). WIDOM, Angela [US/US]; 19 Cherokee Road, Acton, MA 01720 (US). ELVIN, John, G. [GB/GB]; 36 Perowne Street, Cambridge CB1 2AY (GB). DUNCAN, Alexander, R. [GB/GB]; 3 Hauwton Road, Little Shelford, Cambridge CB2 5HJ (GB). DERBYSHIRE, Elaine, J. [GB/GB]; 15 The Brambles, Studlands Rise, Royston, Hertfordshire SG8 9NQ (GB). CARMEN, Sara [GB/GB]; 136 Sturton Street, Cambridge CB1 2QF (GB). SMITH, Stephen [GB/GB]; 33 Church Road, Wicken, Ely, Cambridgeshire CB7 5XT (GB). HOLTET, Thor, Las [DK/GB]; 13 Mortimer Road, Royston, Hertfordshire (GB). DU FOU, Sarah, L. [GB/GB]; 76 Ickleford Road, Hitchin, Hertfordshire SG5 1TL (GB). (74) Agents: KARA, Catherine, J. et al.; Lahive &amp; Cockfield, LLP, 28 State Street, Boston, MA 02109 (US). (81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, XIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>
<p>(54) Title: HUMAN ANTIBODIES THAT BIND HUMAN IL-12 AND METHODS FOR PRODUCING (57) Abstract Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity <i>in vitro</i> and <i>in vivo</i>. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## Description

5

10

15

20

25

30

35

40

45

50

55



## HUMAN ANTIBODIES THAT BIND HUMAN IL-12 AND METHODS FOR PRODUCING

### Related Applications

This application is a non-provisional application claiming priority to U.S. provisional application Serial No. 60/126,603, filed March 25, 1999, the contents of which are hereby incorporated by reference.

### Background of the Invention

Human interleukin 12 (IL-12) has recently been characterized as a cytokine with a unique structure and pleiotropic effects (Kobayashi, *et al.* (1989) *J. Exp. Med.* 170:827-845; Sedcr, *et al.* (1993) *Proc. Natl. Acad. Sci.* 90:10188-10192; Ling, *et al.* (1995) *J. Exp. Med.* 154:116-127; Podlaski, *et al.* (1992) *Arch. Biochem. Biophys.* 294:230-237). IL-12 plays a critical role in the pathology associated with several diseases involving immune and inflammatory responses. A review of IL-12, its biological activities, and its role in disease can be found in Gately *et al.* (1998) *Ann. Rev. Immunol.* 16: 495-521.

Structurally, IL-12 is a heterodimeric protein comprising a 35 kDa subunit (p35) and a 40 kDa subunit (p40) which are both linked together by a disulfide bridge (referred to as the "p70 subunit"). The heterodimeric protein is produced primarily by antigen-presenting cells such as monocytes, macrophages and dendritic cells. These cell types also secrete an excess of the p40 subunit relative to p70 subunit. The p40 and p35 subunits are genetically unrelated and neither has been reported to possess biological activity, although the p40 homodimer may function as an IL-12 antagonist.

Functionally, IL-12 plays a central role in regulating the balance between antigen specific T helper-type (Th1) and type 2 (Th2) lymphocytes. The Th1 and Th2 cells govern the initiation and progression of autoimmune disorders, and IL-12 is critical in the regulation of Th1-lymphocyte differentiation and maturation. Cytokines released by the Th1 cells are inflammatory and include interferon  $\gamma$  (IFN $\gamma$ ), IL-2 and lymphotoxin (LT). Th2 cells secrete IL-4, IL-5, IL-6, IL-10 and IL-13 to facilitate humoral immunity, allergic reactions, and immunosuppression.

Consistent with the preponderance of Th1 responses in autoimmune diseases and the proinflammatory activities of IFN $\gamma$ , IL-12 may play a major role in the pathology associated with many autoimmune and inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis (MS), and Crohn's disease.

Human patients with MS have demonstrated an increase in IL-12 expression as documented by p40 mRNA levels in acute MS plaques. (Windhagen *et al.*, (1995) *J. Exp. Med.* 182: 1985-1996). In addition, *ex vivo* stimulation of antigen-presenting cells with CD40L-expressing T cells from MS patients resulted in increased IL-12 production compared with control T cells, consistent with the observation that CD40/CD40L interactions are potent inducers of IL-12.

Elevated levels of IL-12 p70 have been detected in the synovia of RA patients compared with healthy controls (Morita *et al* (1998) *Arthritis and Rheumatism*. 41: 306-314). Cytokine messenger ribonucleic acid (mRNA) expression profile in the RA synovia identified predominantly Th1 cytokines. (Bucht *et al.*, (1996) *Clin. Exp. Immunol.* 103: 347-367). IL-12 also appears to play a critical role in the pathology associated with Crohn's disease (CD). Increased expression of IFN $\gamma$  and IL-12 has been observed in the intestinal mucosa of patients with this disease (Fais *et al.* (1994) *J. Interferon Res.* 14:235-238; Parronchi *et al.*, (1997) *Am. J. Path.* 150:823-832; Monteleone *et al.*, (1997) *Gastroenterology*. 112:1169-1178, and Berrebi *et al.*, (1998) *Am. J. Path* 152:667-672). The cytokine secretion profile of T cells from the lamina propria of CD patients is characteristic of a predominantly Th1 response, including greatly elevated IFN $\gamma$  levels (Fuss, *et al.*, (1996) *J. Immunol.* 157:1261-1270). Moreover, colon tissue sections from CD patients show an abundance of IL-12 expressing macrophages and IFN $\gamma$  expressing T cells (Parronchi *et al* (1997) *Am. J. Path.* 150:823-832).

Due to the role of human IL-12 in a variety of human disorders, therapeutic strategies have been designed to inhibit or counteract IL-12 activity. In particular, antibodies that bind to, and neutralize, IL-12 have been sought as a means to inhibit IL-12 activity. Some of the earliest antibodies were murine monoclonal antibodies (mAbs), secreted by hybridomas prepared from lymphocytes of mice immunized with IL-12 (see *e.g.*, World Patent Application Publication No. WO 97/15327 by Strober *et al.*; Neurath *et al.* (1995) *J. Exp. Med.* 182:1281-1290; Duchmann *et al.* (1996) *J. Immunol.* 26:934-

5 938). These murine IL-12 antibodies are limited for their use *in vivo* due to problems  
associated with administration of mouse antibodies to humans, such as short serum half  
10 life, an inability to trigger certain human effector functions and elicitation of an  
unwanted immune response against the mouse antibody in a human (the "human anti-  
5 mouse antibody" (HAMA) reaction).

In general, attempts to overcome the problems associated with use of fully-  
15 murine antibodies in humans, have involved genetically engineering the antibodies to be  
more "human-like." For example, chimeric antibodies, in which the variable regions of  
the antibody chains are murine-derived and the constant regions of the antibody chains  
20 are human-derived, have been prepared (Junghans, *et al.* (1990) *Cancer Res.* 50:1495-  
1502; Brown *et al.* (1991) *Proc. Natl. Acad. Sci.* 88:2663-2667; Kettleborough *et al.*  
(1991) *Protein Engineering* 4:773-783). However, because these chimeric and  
humanized antibodies still retain some murine sequences, they still may elicit an  
25 unwanted immune reaction, the human anti-chimeric antibody (HACA) reaction,  
15 especially when administered for prolonged periods.

A preferred IL-12 inhibitory agent to murine antibodies or derivatives thereof  
(*e.g.*, chimeric or humanized antibodies) would be an entirely human anti-IL-12  
30 antibody, since such an agent should not elicit the HAMA reaction, even if used for  
prolonged periods. However, such antibodies have not been described in the art and,  
20 therefore are still needed.

### 35 Summary of the Invention

The present invention provides human antibodies that bind human IL-12. The  
invention also relates to the treatment or prevention of acute or chronic diseases or  
40 25 conditions whose pathology involves IL-12, using the human anti-IL-12 antibodies of  
the invention.

In one aspect, the invention provides an isolated human antibody, or an antigen-  
binding portion thereof, that binds to human IL-12.

45 In one embodiment, the invention provides a selectively mutated human IL-12  
30 antibody, comprising:

5 a human antibody or antigen-binding portion thereof, selectively mutated at a preferred selective mutagenesis position, contact or hypermutation position with an activity enhancing amino acid residue such that it binds to human IL-12.

10 In a preferred embodiment, the invention provides a selectively mutated human IL-12 antibody, comprising:

5 a human antibody or antigen-binding portion thereof, selectively mutated at a preferred selective mutagenesis position with an activity enhancing amino acid residue such that it binds to human IL-12.

15 In another preferred embodiment, the selectively mutated human IL-12 antibody or antigen-binding portion thereof is selectively mutated at more than one preferred selective mutagenesis position, contact or hypermutation positions with an activity enhancing amino acid residue. In another preferred embodiment, the selectively mutated human IL-12 antibody or antigen-binding portion thereof is selectively mutated at no more than three preferred selective mutagenesis positions, contact or hypermutation positions. In another preferred embodiment, the selectively mutated human IL-12 antibody or antigen-binding portion thereof is selectively mutated at no more than two preferred selective mutagenesis position, contact or hypermutation positions. In yet another preferred embodiment, the selectively mutated human IL-12 antibody or antigen-binding portion thereof, is selectively mutated such that a target specificity affinity level is attained, the target level being improved over that attainable when selecting for an antibody against the same antigen using phage display technology. In another preferred embodiment, the selectively mutated human IL-12 antibody further retains at least one desirable property or characteristic, *e.g.*, preservation of non-cross reactivity with other proteins or human tissues, preservation of epitope recognition, production of an antibody with a close to a germline immunoglobulin sequence.

25 In another embodiment, the invention provides an isolated human antibody, or antigen-binding portion thereof, that binds to human IL-12 and dissociates from human IL-12 with a  $K_{off}$  rate constant of  $0.1 \text{ s}^{-1}$  or less, as determined by surface plasmon resonance, or which inhibits phytohemagglutinin blast proliferation in an *in vitro* phytohemagglutinin blast proliferation assay (PHA assay) with an  $IC_{50}$  of  $1 \times 10^{-6} \text{ M}$  or less. More preferably, the isolated human antibody or an antigen-binding portion thereof, dissociates from human IL-12 with a  $K_{off}$  rate constant of  $1 \times 10^{-2} \text{ s}^{-1}$  or less, or

inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-7}$  M or less. More preferably, the isolated human antibody, or an antigen-binding portion thereof, dissociates from human IL-12 with a  $K_{off}$  rate constant of  $1 \times 10^{-3} s^{-1}$  or less, or inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-8}$  M or less. More preferably, the isolated human antibody, or an antigen-binding portion thereof, dissociates from human IL-12 with a  $K_{off}$  rate constant of  $1 \times 10^{-4} s^{-1}$  or less, or inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-9}$  M or less. More preferably, the isolated human antibody, or an antigen-binding portion thereof, dissociates from human IL-12 with a  $K_{off}$  rate constant of  $1 \times 10^{-5} s^{-1}$  or less, or inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-10}$  M or less. Even more preferably, the isolated human antibody, or an antigen-binding portion thereof, dissociates from human IL-12 with a  $K_{off}$  rate constant of  $1 \times 10^{-5} s^{-1}$  or less, or inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-11}$  M or less.

In another embodiment, the invention provides an isolated human antibody, or an antigen-binding portion thereof, which has the following characteristics:

a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-6}$  M or less;

b) has a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 1; and

c) has a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 2.

In a preferred embodiment, the isolated human antibody, or an antigen-binding portion thereof, has a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 3; and has a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 4. In a preferred embodiment, the isolated human antibody, or an antigen-binding portion thereof, has a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 5; and has a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 6. In a preferred embodiment, the isolated human antibody, or antigen binding portion thereof, has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7; and has a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8.

5 In another embodiment, the invention provides an isolated human antibody, or an antigen-binding portion thereof, which has the following characteristics:

- 10 a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-9}$  M or less;
- 5 b) has a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 9; and
- 15 c) has a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 10.

In a preferred embodiment, the isolated human antibody, or an antigen-binding  
20 portion thereof, has a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 11; and has a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 12. In a preferred embodiment, the isolated human antibody, or an antigen-binding  
25 portion thereof, has a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 13; and has a light chain CDR1 comprising the amino acid sequence of SEQ ID  
15 NO: 14. In a preferred embodiment, the isolated human antibody has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 15; and has a light chain variable region comprising the amino acid sequence of SEQ ID NO: 16.

30 In another embodiment, the invention provides an isolated human antibody, or an antigen-binding portion thereof, which

- 20 a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-9}$  M or less;
- 35 b) has a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 17; and
- 40 c) has a light chain CDR3 comprising the amino acid sequence of SEQ ID  
25 NO: 18.

In a preferred embodiment, the isolated human antibody, or an antigen-binding  
45 portion thereof, has a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 19; and a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 20. In a preferred embodiment, the isolated human antibody, or an antigen-binding  
30 portion thereof, has a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 21; and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 22. In a preferred embodiment, the isolated human antibody, or an antigen-binding  
50

5 portion thereof, has the heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 23, and a light chain variable region comprising the amino acid  
10 sequence of SEQ ID NO: 24. In a preferred embodiment, the isolated human antibody comprises a heavy chain constant region selected from the group consisting of IgG1,  
5 IgG2, IgG3, IgG4, IgM, IgA and IgE constant regions or any allelic variation thereof as discussed in Kabat *et al.* (Kabat, E.A., *et al.* (1991) *Sequences of Proteins of Immunological Interest, Fifth Edition*, U.S. Department of Health and Human Services, NIH Publication No. 91-3242), included herein by reference. In a more preferred  
15 embodiment, the antibody heavy chain constant region is IgG1. In another preferred  
20 embodiment, the isolated human antibody is a Fab fragment, or a F(ab')<sub>2</sub> fragment or a single chain Fv fragment.

In another embodiment, the invention provides an isolated human antibody, or an antigen-binding portion thereof, which

- 25 a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC<sub>50</sub> of  $1 \times 10^{-9}$  M or less;
- b) has a heavy chain CDR3 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 404-SEQ ID NO: 469; and
- 30 c) has a light chain CDR3 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 534-SEQ ID NO: 579.

20 In a preferred embodiment, the isolated human antibody, or an antigen-binding portion thereof, has a heavy chain CDR2 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 335-SEQ ID NO: 403; and a light chain CDR2 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 506-SEQ ID NO: 533. In a preferred embodiment, the isolated human antibody, or an  
35 antigen-binding portion thereof, has a heavy chain CDR1 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 288-SEQ ID NO: 334; and a light chain CDR1 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 470-SEQ ID NO: 505. In a preferred embodiment, the  
40 isolated human antibody, or an antigen-binding portion thereof, comprising a the heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 23, and a  
45 light chain variable region comprising the amino acid sequence of SEQ ID NO: 24. In a preferred embodiment, the isolated human antibody comprises a heavy chain constant  
50

5 region, or an Fab fragment or a F(ab')<sub>2</sub> fragment or a single chain Fv fragment as described above.

10 In another embodiment, the invention provides an isolated human antibody, or an antigen-binding portion thereof, which

5 a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC<sub>50</sub> of 1 x 10<sup>-9</sup> M or less;

15 b) has a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 25; and

10 c) has a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 26.

20 In a preferred embodiment, the isolated human antibody, or an antigen-binding portion thereof, has a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 27; and a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:

25 28. In a preferred embodiment, the isolated human antibody, or an antigen-binding

15 portion thereof, has a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 29; and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:

30 30. In a preferred embodiment, the isolated human antibody, or an antigen-binding portion thereof, which has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 31, and a light chain variable region comprising the amino

20 acid sequence of SEQ ID NO: 32. In a preferred embodiment, the isolated human antibody comprises a heavy chain constant region, or an Fab fragment, or a F(ab')<sub>2</sub> fragment or a single chain Fv fragment as described above.

35 In another embodiment, the invention provides an isolated human antibody, or an antigen-binding portion thereof, which

40 25 a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC<sub>50</sub> of 1 x 10<sup>-6</sup> M or less;

45 b) comprises a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 3 and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 5, 30 or a mutant thereof having one or more amino acid substitutions at a contact position or a hypermutation position, wherein said mutant has a k<sub>off</sub> rate no more than 10-fold higher than the antibody comprising a heavy chain CDR3 comprising the amino acid



sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 5; and

c) comprises a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 2, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 6, or a mutant thereof having one or more amino acid substitutions at a contact position or a hypermutation position, wherein said mutant has a  $k_{off}$  rate no more than 10-fold higher than the antibody comprising a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 2, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 6.

In another embodiment, the invention provides an isolated human antibody, or an antigen-binding portion thereof, which

a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-9}$  M or less;

b) comprises a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 9, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 11 and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 13, or a mutant thereof having one or more amino acid substitutions at a contact position or a hypermutation position, wherein said mutant has a  $k_{off}$  rate no more than 10-fold higher than the antibody comprising a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 9, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 11, and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 13; and

c) comprises a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 10, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 12, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 14, or a mutant thereof having one or more amino acid substitutions at a preferred selective mutagenesis position, contact position or a hypermutation position, wherein said mutant has a  $k_{off}$  rate no more than 10-fold higher than the antibody comprising a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 10, a light chain

CDR2 comprising the amino acid sequence of SEQ ID NO: 12, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 14.

In another embodiment, the invention provides an isolated human antibody, or an antigen-binding portion thereof, which

- a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-9}$  M or less;
- b) comprises a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 19 and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 21, or a mutant thereof having one or more amino acid substitutions at a preferred selective mutagenesis position, contact position or a hypermutation position, wherein said mutant has a  $k_{off}$  rate no more than 10-fold higher than the antibody comprising a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 21; and
- c) comprises a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 18, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 20, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 22, or a mutant thereof having one or more amino acid substitutions at preferred selective mutagenesis position, contact position or a hypermutation position, wherein said mutant has a  $k_{off}$  rate no more than 10-fold higher than the antibody comprising a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 18, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 20, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 22.

The invention also provides nucleic acid molecules encoding antibodies, or antigen binding portions thereof, of the invention. A preferred isolated nucleic acid encodes the heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 17. The isolated nucleic acid encoding an antibody heavy chain variable region. In another embodiment, the isolated nucleic acid encodes the CDR2 of the antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 19. In another embodiment, the isolated nucleic acid encodes the CDR1 of the antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 21. In another

embodiment, the isolated nucleic acid encodes an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 23. In another embodiment, the isolated nucleic acid encodes the light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 18. The isolated nucleic acid encoding an antibody light chain variable region. In another embodiment, the isolated nucleic acid encodes the CDR2 of the antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 20. In another embodiment, the isolated nucleic acid encodes the CDR1 of the antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 22. In another embodiment, the isolated nucleic acid encodes an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 24.

In another embodiment, the invention provides an isolated human antibody, or an antigen-binding portion thereof, which

- a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-9}$  M or less;
- b) comprises a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 25, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 27 and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 29, or a mutant thereof having one or more amino acid substitutions at a preferred selective mutagenesis position, contact position or a hypermutation position, wherein said mutant has a  $k_{off}$  rate no more than 10-fold higher than the antibody comprising a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 25, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 29; and
- c) comprises a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 26, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30, or a mutant thereof having one or more amino acid substitutions at a preferred selective mutagenesis position, contact position or a hypermutation position, wherein said mutant has a  $k_{off}$  rate no more than 10-fold higher than the antibody comprising a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 26, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30.

5 A preferred isolated nucleic acid encodes the heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 25. The isolated nucleic acid encoding an antibody heavy chain variable region. In another embodiment, the isolated nucleic acid  
10 encodes the CDR2 of the antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 27. In another embodiment, the isolated nucleic acid encodes the CDR1 of the antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 29. In another embodiment, the isolated nucleic acid encodes an antibody heavy chain variable region comprising the amino acid sequence of  
15 SEQ ID NO: 31. In another embodiment, the isolated nucleic acid encodes the light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 26. The isolated nucleic acid encoding an antibody light chain variable region. In another embodiment, the isolated nucleic acid encodes the CDR2 of the antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 28. In another embodiment, the isolated nucleic acid encodes the CDR1 of the antibody light chain variable region  
20 comprising the amino acid sequence of SEQ ID NO: 30. In another embodiment, the isolated nucleic acid encodes an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 32.

30 In another aspect, the invention provides an isolated human antibody, or an antigen-binding portion thereof, which has the following characteristics:

20 a) that binds to human IL-12 and dissociates from human IL-12 with a  $k_{off}$  rate constant of  $0.1 \text{ s}^{-1}$  or less, as determined by surface plasmon resonance, or which inhibits phytohemagglutinin blast proliferation in an *in vitro* phytohemagglutinin blast proliferation assay (PHA assay) with an  $IC_{50}$  of  $1 \times 10^{-6} \text{ M}$  or less.

40 25 b) has a heavy chain variable region comprising an amino acid sequence selected from a member of the  $V_H3$  germline family, wherein the heavy chain variable region has a mutation at a preferred selective mutagenesis position, contact or hypermutation position with an activity enhancing amino acid residue.

45 30 c) has a light chain variable region comprising an amino acid sequence selected from a member of the  $V_L1$  germline family, wherein the light chain variable region has a mutation at a preferred selective mutagenesis position, contact position or hypermutation position with an activity enhancing amino acid residue.

5 In another embodiment, the invention provides an isolated human antibody, or an antigen-binding portion thereof, which has the following characteristics:

10 a) that binds to human IL-12 and dissociates from human IL-12 with a  $k_{off}$  rate constant of  $0.1 s^{-1}$  or less, as determined by surface plasmon resonance, or which  
5 inhibits phytohemagglutinin blast proliferation in an *in vitro* phytohemagglutinin blast proliferation assay (PHA assay) with an  $IC_{50}$  of  $1 \times 10^{-6} M$  or less.

15 b) has a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 595-667, wherein the heavy chain variable region has a mutation at a preferred selective mutagenesis position, contact  
20 position or hypermutation position with an activity enhancing amino acid residue.

25 c) has a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 669-675, wherein the light chain variable region has a mutation at a preferred selective mutagenesis position, contact or  
hypermutation position with an activity enhancing amino acid residue.

30 In another embodiment, the invention provides an isolated human antibody, or an antigen-binding portion thereof, which has the following characteristics:

35 a) that binds to human IL-12 and dissociates from human IL-12 with a  $k_{off}$  rate constant of  $0.1 s^{-1}$  or less, as determined by surface plasmon resonance, or which  
inhibits phytohemagglutinin blast proliferation in an *in vitro* phytohemagglutinin blast  
20 proliferation assay (PHA assay) with an  $IC_{50}$  of  $1 \times 10^{-6} M$  or less.

35 b) has a heavy chain variable region comprising the COS-3 germline amino acid sequence, wherein the heavy chain variable region has a mutation at a preferred selective mutagenesis position, contact or hypermutation position with an activity enhancing amino acid residue.

40 25 c) has a light chain variable region comprising the DPL8 germline amino acid sequence, wherein the light chain variable region has a mutation at a preferred selective mutagenesis position, contact or hypermutation position with an activity  
enhancing amino acid residue.

45 In another embodiment, the invention provides an isolated human antibody, or an  
30 antigen-binding portion thereof, which has the following characteristics:

a) that binds to human IL-12 and dissociates from human IL-12 with a  $k_{\text{off}}$  rate constant of  $0.1 \text{ s}^{-1}$  or less, as determined by surface plasmon resonance, or which inhibits phytohemagglutinin blast proliferation in an *in vitro* phytohemagglutinin blast proliferation assay (PHA assay) with an  $\text{IC}_{50}$  of  $1 \times 10^{-6} \text{ M}$  or less.

b) has a heavy chain variable region comprising an amino acid sequence selected from a member of the  $V_{\text{H}}3$  germline family, wherein the heavy chain variable region comprises a CDR2 that is structurally similar to CDR2s from other  $V_{\text{H}}3$  germline family members, and a CDR1 that is structurally similar to CDR1s from other  $V_{\text{H}}3$  germline family members, and wherein the heavy chain variable region has a mutation at a preferred selective mutagenesis position, contact or hypermutation position with an activity enhancing amino acid residue;

c) has a light chain variable region comprising an amino acid sequence selected from a member of the  $V_{\text{L}}1$  germline family, wherein the light chain variable region comprises a CDR2 that is structurally similar to CDR2s from other  $V_{\text{L}}1$  germline family members, and a CDR1 that is structurally similar to CDR1s from other  $V_{\text{L}}1$  germline family members, and wherein the light chain variable region has a mutation at a preferred selective mutagenesis position, contact or hypermutation position with an activity enhancing amino acid residue.

In a preferred embodiment, the isolated human antibody, or antigen binding portion thereof, has a mutation in the heavy chain CDR3. In another preferred embodiment, the isolated human antibody, or antigen binding portion thereof, has a mutation in the light chain CDR3. In another embodiment, the isolated human antibody, or antigen binding portion thereof, has a mutation in the heavy chain CDR2. In another preferred embodiment, the isolated human antibody, or antigen binding portion thereof, has a mutation in the light chain CDR2. In another preferred embodiment, the isolated human antibody, or antigen binding portion thereof, has a mutation in the heavy chain CDR1. In another preferred embodiment, the isolated human antibody, or antigen binding portion thereof, has a mutation in the light chain CDR1.

In another aspect, the invention provides recombinant expression vectors carrying the antibody-encoding nucleic acids of the invention, and host cells into which such vectors have been introduced, are also encompassed by the invention, as are

5 methods of making the antibodies of the invention by culturing the host cells of the invention.

10 In another aspect, the invention provides an isolated human antibody, or antigen-binding portion thereof, that neutralizes the activity of human IL-12, and at least one  
5 additional primate IL-12 selected from the group consisting of baboon IL-12, marmoset IL-12, chimpanzee IL-12, cynomolgus IL-12 and rhesus IL-12, but which does not  
15 neutralize the activity of the mouse IL-12.

10 In another aspect, the invention provides a pharmaceutical composition comprising the antibody or an antigen binding portion thereof, of the invention and a  
pharmaceutically acceptable carrier.

20 In another aspect, the invention provides a composition comprising the antibody or an antigen binding portion thereof, and an additional agent, for example, a therapeutic agent.

25 In another aspect, the invention provides a method for inhibiting human IL-12 activity comprising contacting human IL-12 with the antibody of the invention, *e.g.*, J695, such that human IL-12 activity is inhibited.

30 In another aspect, the invention provides a method for inhibiting human IL-12 activity in a human subject suffering from a disorder in which IL-12 activity is detrimental, comprising administering to the human subject the antibody of the  
20 invention, *e.g.*, J695, such that human IL-12 activity in the human subject is inhibited. The disorder can be, for example, Crohn's disease, multiple sclerosis or rheumatoid  
35 arthritis.

40 In another aspect, the invention features a method for improving the activity of an antibody, or an antigen binding portion thereof, to attain a predetermined target  
25 activity, comprising:

- a) providing a parent antibody a antigen-binding portion thereof;
- b) selecting a preferred selective mutagenesis position selected from group consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32, L50, L91,  
45 L92, L93, L94.
- 30 c) individually mutating the selected preferred selective mutagenesis position to at least two other amino acid residues to hereby create a first panel of mutated  
50 antibodies, or antigen binding portions thereof;

5 d) evaluating the activity of the first panel of mutated antibodies, or  
antigen binding portions thereof to determine if mutation of a single selective  
mutagenesis position produces an antibody or antigen binding portion thereof with the  
10 predetermined target activity or a partial target activity;

5 e) combining in a stepwise fashion, in the parent antibody, or antigen binding  
portion thereof, individual mutations shown to have an improved activity, to form  
combination antibodies, or antigen binding portions thereof.

15 f) evaluating the activity of the combination antibodies, or antigen binding  
portions thereof to determine if the combination antibodies, or antigen binding portions  
10 thereof have the predetermined target activity or a partial target activity.

20 g) if steps d) or f) do not result in an antibody or antigen-binding portion thereof  
having the predetermined target activity, or result in an antibody with only a partial  
activity, additional amino acid residues selected from the group consisting of H35, H50,  
H53, H54, H95, H96, H97, H98, L30A and L96 are mutated to at least two other amino  
25 acid residues to thereby create a second panel of mutated antibodies or antigen-binding  
15 portions thereof;

h) evaluating the activity of the second panel of mutated antibodies or antigen  
30 binding portions thereof, to determine if mutation of a single amino acid residue  
selected from the group consisting of H35, H50, H53, H54, H95, H96, H97, H98, L30A  
20 and L96 results in an antibody or antigen binding portion thereof, having the predetermined  
target activity or a partial activity;

35 i) combining in stepwise fashion in the parent antibody, or antigen-binding  
portion thereof, individual mutations of step g) shown to have an improved activity, to  
form combination antibodies, or antigen binding portions thereof;

40 j) evaluating the activity of the combination antibodies or antigen binding  
portions thereof, to determine if the combination antibodies, or antigen binding  
portions thereof have the predetermined target activity or a partial target activity;

45 k) if steps h) or j) do not result in an antibody or antigen binding portion thereof  
having the predetermined target activity, or result in an antibody with only a partial  
30 activity, additional amino acid residues selected from the group consisting of H33B,  
H52B and L31A are mutated to at least two other amino acid residues to thereby create a  
50 third panel of mutated antibodies or antigen binding portions thereof;



5 l) evaluating the activity of the third panel of mutated antibodies or antigen  
binding portions thereof, to determine if a mutation of a single amino acid residue  
selected from the group consisting of H33B, H52B and L31A resulted in an antibody or  
10 antigen binding portion thereof, having the predetermined target activity or a partial  
5 activity;

m) combining in a stepwise fashion in the parent antibody, or antigen binding  
15 portion thereof, individual mutation of step k) shown to have an improved activity, to  
form combination antibodies, or antigen binding portions, thereof;

n) evaluating the activity of the combination antibodies or antigen-binding  
10 portions thereof, to determine if the combination antibodies, or antigen binding portions  
thereof have the predetermined target activity to thereby produce an antibody or antigen  
20 binding portion thereof with a predetermined target activity.

In another aspect, the invention provides a method for improving the activity of  
25 an antibody, or antigen-binding portion thereof, comprising:

15 a) providing a parent antibody or antigen-binding portion thereof;

b) selecting a preferred selective mutagenesis position, contact or hypermutation  
30 position within a complementarity determining region (CDR) for mutation, thereby  
identifying a selected preferred selective mutagenesis position, contact or hypermutation  
position;

20 c) individually mutating said selected preferred selective mutagenesis position,  
contact or hypermutation position to at least two other amino acid residues to thereby  
35 create a panel of mutated antibodies, or antigen-binding portions thereof;

d) evaluating the activity of the panel of mutated antibodies, or antigen-binding  
portions thereof, relative to the parent antibody or antigen-binding portion thereof;

40 25 e) repeating steps b) through d) for at least one other contact or hypermutation  
position;

f) combining, in the parent antibody, or antigen-binding portion thereof,  
45 individual mutations shown to have improved activity, to form combination antibodies,  
or antigen-binding portions thereof; and

g) evaluating the activity of the combination antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof; until an antibody, or antigen-binding portion thereof, with an improved activity, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

In one embodiment, the invention provides a method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

a) providing a recombinant parent antibody or antigen-binding portion thereof; that was obtained by selection in a phage-display system but whose activity is not further improved by mutagenesis in said phage-display system;

b) selecting a preferred selective mutagenesis position, contact or hypermutation position within a complementarity determining region (CDR) for mutation, thereby identifying a selected contact or hypermutation position;

c) individually mutating said selected preferred selective mutagenesis position, contact or hypermutation position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof, and expressing said panel in a non-phage display system;

d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof;

e) repeating steps b) through d) for at least one other contact or hypermutation position;

f) combining, in the parent antibody, or antigen-binding portion thereof, individual mutations shown to have improved activity, to form combination antibodies, or antigen-binding portions thereof; and

g) evaluating the activity of the combination antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof; until an antibody, or antigen-binding portion thereof, with an improved activity, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

In a preferred embodiment, the contact positions are selected from the group consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96. In another preferred embodiment, the hypermutation positions are selected from the group consisting of H30, H31, H31B, H32, H52, H56, H58, L30, L31, L32,

5 L53 and L93. In a more preferred embodiment the residues for selective mutagenesis are selected from the preferred selective mutagenesis positions from the group consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93, L94.

10 In a more preferred embodiment, the contact positions are selected from the group consisting of L50 and L94.

In another embodiment, the invention provides a method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

- 15 a) providing a recombinant parent antibody or antigen-binding portion thereof;
- b) selecting a preferred selective mutagenesis position, contact or hypermutation position within a complementarity determining region (CDR) for mutation, thereby identifying a selected contact or hypermutation position;
- 20 c) individually mutating said selected preferred selective mutagenesis position, contact or hypermutation position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof and expressing said panel in an appropriate expression system;
- d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;
- 30 e) evaluating the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof for at least one other property or characteristics, wherein the property or characteristic is one that needs to be retained in the antibody;
- 35 until an antibody, or antigen-binding portion thereof, with an improved activity and at least one retained property or characteristic, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

40 In a preferred embodiment, the contact positions are selected from the group consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce

45

50

55

an antibody with a close to germline immunoglobulin sequence. In another preferred embodiment, the hypermutation positions are selected from the group consisting of H30, H31, H31B, H32, H52, H56, H58, L30, L31, L32, L53 and L93 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence. In a more preferred embodiment the residues for selective mutagenesis are selected from the preferred selective mutagenesis positions from the group consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93, L94 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence. In a more preferred embodiment, the contact positions are selected from the group consisting of L50 and L94 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence.

In another embodiment of the invention provides a method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

- a) providing a recombinant parent antibody or antigen-binding portion thereof; that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in said phage-display system;
- b) selecting a preferred selective mutagenesis position, contact or hypermutation position within a complementarity determining region (CDR) for mutation, thereby identifying a selected preferred selective mutagenesis position, contact or hypermutation position;

c) individually mutating said selected preferred selective mutagenesis position, contact or hypermutation position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof, and expressing said panel in a non-phage display system;

d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;

e) evaluating the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof for at least one other property or characteristic, wherein the property or characteristic is one that needs to be retained, until an antibody, or antigen-binding portion thereof, with an improved activity and at least one retained property or characteristic, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

f) repeating steps a) through e) for at least one other preferred selective mutagenesis position, contact or hypermutation position;

g) combining, in the parent antibody, or antigen-binding portion thereof, at least two individual activity enhancing amino acid residues shown to have improved activity and at least one retained property or characteristic, to form combination antibodies, or antigen-binding portions thereof; and

h) evaluating the activity of the combination antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof; until an antibody, or antigen-binding portion thereof, with an improved activity and at least one retained property or characteristic, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

In a preferred embodiment, the contact positions are selected from the group consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence. In another preferred

embodiment, the hypermutation positions are selected from the group consisting of H30, H31, H31B, H32, H52, H56, H58, L30, L31, L32, L53 and L93 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence. In a more preferred embodiment the residues for selective mutagenesis are selected from the preferred selective mutagenesis positions from the group consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93, L94 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence. In a more preferred embodiment, the contact positions are selected from the group consisting of L50 and L94 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence.

In another embodiment, the invention provides a method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

- a) providing a recombinant parent antibody or antigen-binding portion thereof; that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in said phage-display system;
- b) selecting a contact or hypermutation position within a complementarity determining region (CDR) for mutation, thereby identifying a selected contact or hypermutation position;
- c) individually mutating said selected contact or hypermutation position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof, and expressing said panel in a non-phage display system;

5 d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;

10 e) evaluating the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof for at least one other property or characteristics, wherein the property or characteristic is one that needs to be retained;

15 until an antibody, or antigen-binding portion thereof, with an improved activity and at least one retained property or characteristic, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

20 In a preferred embodiment, the contact positions are selected from the group consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96 and the other characteristic is selected from 1) preservation of non-

25 crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence. In another preferred

30 embodiment, the hypermutation positions are selected from the group consisting of H30, H31, H31B, H32, H52, H56, H58, L30, L31, L32, L53 and L93 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline

35 immunoglobulin sequence. In a more preferred embodiment the residues for selective mutagenesis are selected from the preferred selective mutagenesis positions from the group consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93, L94 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope

40 recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence. In a more preferred

45

50

55

embodiment, the contact positions are selected from the group consisting of L50 and L94 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence.

In another embodiment, the invention provides a method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

- a) providing a recombinant parent antibody or antigen-binding portion thereof; that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in said phage-display system;
- b) selecting a preferred selective mutagenesis position, contact or hypermutation position within a complementarity determining region (CDR) for mutation, thereby identifying a selected preferred selective mutagenesis position contact or hypermutation position;
- c) individually mutating said selected preferred selective mutagenesis position, contact or hypermutation position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof, and expressing said panel in a non-phage display system;
- d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;
- e) evaluating the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof for at least one other property or characteristic, wherein the property or characteristic is one that needs to be retained, until an antibody, or antigen-binding portion thereof, with an improved activity and at least one retained property or characteristic, relative to the parent antibody, or antigen-binding portion thereof, is obtained.
- f) repeating steps a) through e) for at least one other preferred selective mutagenesis position, contact or hypermutation position;



5 g) combining, in the parent antibody, or antigen-binding portion thereof, at least two individual activity enhancing amino acid residues shown to have improved activity and at least one retained other characteristic, to form combination antibodies, or antigen-binding portions thereof; and

10 h) evaluating the activity of the combination antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, until an antibody, or antigen-binding portion thereof, with an improved activity and at least one retained property or characteristic, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

15 In a preferred embodiment, the contact positions are selected from the group consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence. In another preferred embodiment, the hypermutation positions are selected from the group consisting of H30, H31, H31B, H32, H52, H56, H58, L30, L31, L32, L53 and L93 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence. In a more preferred embodiment the residues for selective mutagenesis are selected from the preferred selective mutagenesis positions from the group consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93, L94 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence. In a more preferred embodiment, the contact positions are selected from the group consisting of L50 and

5 L94 and the other characteristic is selected from 1) preservation of non-crossreactivity  
with other proteins or human tissues, 2) preservation of epitope recognition, i.e.  
recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer  
10 preventing binding interference from free, soluble p40 and/or 3) to produce an antibody  
5 with a close to germline immunoglobulin sequence.

In another embodiment, the invention provides a method for improving the  
activity of an antibody, or antigen-binding portion thereof, comprising:

15 a) providing a parent antibody or antigen-binding portion thereof;  
b) selecting an amino acid residue within a complementarity determining region  
10 (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A,  
20 H53, H54, H56, H58, H59, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53,  
L55, L91, L92, L93, L94 and L96;

25 c) individually mutating said selected position to at least two other amino acid  
residues to thereby create a panel of mutated antibodies, or antigen-binding portions  
15 thereof;

d) evaluating the activity of the panel of mutated antibodies, or antigen-binding  
portions thereof, relative to the parent antibody or antigen-binding portion thereof  
thereby identifying an activity enhancing amino acid residue;

30 e) evaluating the panel of mutated antibodies, or antigen-binding portions  
20 thereof, relative to the parent antibody or antigen-binding portion thereof, for changes in  
at least one other property or characteristic;  
35 until an antibody, or antigen-binding portion thereof, with an improved activity, relative  
to the parent antibody, or antigen-binding portion thereof, is obtained.

40 Preferably, the other characteristic or property is selected from 1) preservation of  
25 non-crossreactivity with other proteins or human tissues, 2) preservation of epitope  
recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35  
heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce  
an antibody with a close to germline immunoglobulin sequence

45 In another embodiment, the invention provides a method for improving the  
30 activity of an antibody, or antigen-binding portion thereof, comprising:

a) providing a parent antibody or antigen-binding portion thereof;

5

10

15

20

25

30

35

40

45

50

55

- 27 -

b) selecting an amino acid residue within a complementarity determining region (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

c) individually mutating said selected position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof;

d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, thereby identifying an activity enhancing amino acid residue;

e) repeating steps b) through d) for at least one other CDR position which is neither the position selected under b) nor a position at H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

f) combining, in the parent antibody, or antigen-binding portion thereof, at least two individual activity enhancing amino acid residues shown to have improved activity, to form combination antibodies, or antigen-binding portions thereof; and

g) evaluating the activity of the combination antibodies, or antigen-binding portions thereof with two activity enhancing amino acid residues, relative to the parent antibody or antigen-binding portion thereof until an antibody, or antigen-binding portion thereof, with an improved activity, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

In another embodiment, the invention provides a method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

a) providing a recombinant parent antibody or antigen-binding portion thereof; that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in said phage-display system;

b) selecting an amino acid residue within a complementarity determining region (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and;

5 c) individually mutating said selected contact or hypermutation position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof, and expressing said panel in a non-phage display system;

10 d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;

15 e) evaluating the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, for changes in at least one other property or characteristic until an antibody, or antigen-binding portion thereof, with an improved activity, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

20 Preferably, the other characteristic or property is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence.

25 In another embodiment, the invention provides a method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

30 a) providing a parent antibody or antigen-binding portion thereof that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in said phage-display system;

35 b) selecting an amino acid residue within a complementarity determining region (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

40 c) individually mutating said selected position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof and expression in a non-phage display system;

45 d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;

5 c) repeating steps b) through d) for at least one other position within the CDR which is neither the position selected under b) nor a position at H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30,  
10 L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 ;

5 f) combining, in the parent antibody, or antigen-binding portion thereof, at least two individual activity enhancing amino acid residues shown to have improved activity, to form combination antibodies, or antigen-binding portions thereof; and

15 g) evaluating the activity and other property or characteristic of the combination antibodies, or antigen-binding portions thereof with two activity enhancing amino acid residues, relative to the parent antibody or antigen-binding portion thereof;  
20 until an antibody, or antigen-binding portion thereof, with an improved activity, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

25 Preferably, the other characteristic or property is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35  
30 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence.

35 In another embodiment, the invention provides a method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

40 20 a) providing a parent antibody or antigen-binding portion thereof;

35 b) selecting an amino acid residue within a complementarity determining region (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

40 25 c) individually mutating said selected position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof;

45 d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof,  
30 thereby identifying an activity enhancing amino acid residue;

5

10

15

20

25

30

35

40

45

50

55

5 e) evaluating the panel of mutated antibodies or antigen-binding portions thereof, relative to the parent antibody or antigen-portion thereof, for changes in at least one other property or characteristic;

10 f) repeating steps b) through e) for at least one other CDR position which is neither the position selected under b) nor a position at H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

15 g) combining, in the parent antibody, or antigen-binding portion thereof, at least two individual activity enhancing amino acid residues shown to have improved activity and not affecting at least one other property or characteristic, to form combination antibodies, or antigen-binding portions thereof; and

20 h) evaluating the activity and the retention of at least one other characteristic or property of the combination antibodies, or antigen-binding portions thereof with two activity enhancing amino acid residues, relative to the parent antibody or antigen-binding portion thereof until an antibody, or antigen-binding portion thereof, with an improved activity and at least one retained property or characteristic, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

25 In another embodiment the invention provides a method to improve the affinity of an antibody or antigen-binding portion thereof, comprising:

30 a) providing a parent antibody or antigen-binding portion thereof that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in said phage-display system;

35 b) selecting an amino acid residue within a complementarity determining region (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

40 c) individually mutating said selected position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof and expression in a non-phage display system;

45 d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;

5 e) evaluating the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, for changes in  
10 at least one other characteristic or property until an antibody, or antigen-binding portion thereof, with an improved activity, relative to the parent antibody, or antigen-binding  
5 portion thereof, is obtained.

In another embodiment, the invention provides a method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

15 a) providing a parent antibody or antigen-binding portion thereof;

b) selecting an amino acid residue within a complementarity determining region  
10 (CDR) for mutation at a position other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34,  
20 L50, L52, L53, L55, L91, L92, L93, L94 and L96;

c) individually mutating said selected position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions  
25 thereof;

d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, thereby identifying an activity enhancing amino acid residue;

e) evaluating the panel of mutated antibodies or antigen-binding portions thereof,  
20 relative to the parent antibody or antigen-portion thereof, for changes in at least one other property or characteristic;

f) repeating steps b) through e) for at least one other CDR position which is neither the position selected under b) nor a position at H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32,  
25 L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

g) combining, in the parent antibody, or antigen-binding portion thereof, at least two individual activity enhancing amino acid residues shown to have improved activity but not affecting at least one other property or characteristic, to form combination  
45 antibodies, or antigen-binding portions thereof with at least one retained property or  
30 characteristic; and

h) evaluating the activity and the retention of at least one property of characteristic of the combination antibodies, or antigen-binding portions thereof with two activity enhancing amino acid residues, relative to the parent antibody or antigen-binding portion thereof until an antibody, or antigen-binding portion thereof, with an improved activity and at least one retained property or characteristic, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

Preferably, the other characteristic or property is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence

In another embodiment, the invention provides a method for improving the activity of an antibody, or antigen-binding portion thereof, without affecting other characteristics, comprising:

a) providing a parent antibody or antigen-binding portion thereof;

b) selecting an amino acid residue within a complementarity determining region (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

c) individually mutating said selected position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof;

d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;

e) evaluating the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, for changes in at least one other property or characteristic until an antibody, or antigen-binding portion thereof, with an improved activity and retained other characteristic or property, relative to the parent antibody, or antigen-binding portion thereof, is obtained.



5 In another embodiment, the invention provides a method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

10 a) providing a parent antibody or antigen-binding portion thereof that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in said phage-display system;

15 b) selecting an amino acid residue within a complementarity determining region (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

20 c) individually mutating said selected position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof and expression in a non-phage display system;

25 d) evaluating the activity and retention of at least one other characteristic or property of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, thereby identifying an activity enhancing amino acid residue;

30 e) repeating steps b) through d) for at least one other CDR position which is neither the position selected under b nor other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

35 f) combining, in the parent antibody, or antigen-binding portion thereof, at least two individual activity enhancing amino acid residues shown to have improved activity and not to affect at least one other characteristic or property, to form combination antibodies, or antigen-binding portions thereof; and

40 g) evaluating the activity and retention of at least one other characteristic or property of the combination antibodies, or antigen-binding portions thereof with two activity enhancing amino acid residues, relative to the parent antibody or antigen-binding portion thereof until an antibody, or antigen-binding portion thereof, with an improved activity and at least one other retained characteristic or property, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

5

10

15

20

25

30

35

40

45

50

55

5 Preferably, the other characteristic or property is selected from 1) preservation of  
non-crossreactivity with other proteins or human tissues, 2) preservation of epitope  
recognition. i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35  
10 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce  
5 an antibody with a close to germline immunoglobulin sequence

### 15 Brief Description of the Drawings

Figures 1A-1B show the heavy chain variable region amino acid sequence  
alignments of a series of human antibodies that bind human IL-12 compared to germline  
10 sequences Cos-3/JH3 and Dp118 Lv1042. Kabat numbering is used to identify amino  
acid positions. For the Joe 9 wild type, the full sequence is shown. For the other  
20 antibodies, only those amino acids positions that differ from Joe 9 wild type are shown.

Figures 1C-1D show the light chain variable region amino acid sequence  
alignments of a series of human antibodies that bind human IL-12. Kabat numbering is  
25 used to identify amino acid positions. For the Joe 9 wild type, the full sequence is  
shown. For the other antibodies, only those amino acids positions that differ from Joe 9  
15 wild type are shown.

Figures 2A-2E show the CDR positions in the heavy chain of the Y61 antibody  
that were mutated by site-directed mutagenesis and the respective amino acid  
20 substitutions at each position. The graphs at the right of the figures show the off-rates  
for the substituted antibodies (black bars) as compared to unmutated Y61 (open bar).

Figures 2F-2H show the CDR positions in the light chain of the Y61 antibody  
that were mutated by site-directed mutagenesis and the respective amino acid  
substitutions at each position. The graphs at the right of the figures show the off-rates  
25 for the substituted antibodies (black bars) as compared to unmutated Y61 (open bar).

Figure 3 demonstrates the *in vivo* efficacy of the human anti-IL-12 antibody  
J695, on plasma neopterin levels in cynomolgus monkeys.

Figure 4 shows a graph of mean arthritic score versus days after immunization of  
45 mice with collagen, demonstrating that treatment with C17.15 significantly decreases  
arthrititis-related symptoms as compared to treatment with rat IgG.  
30

### Detailed Description of the Invention

In order that the present invention may be more readily understood, certain terms are first defined.

The term "activity enhancing amino acid residue" includes an amino acid residue which improves the activity of the antibody. It should be understood that the activity enhancing amino acid residue may replace an amino acid residue at a contact, hypermutation or preferred selective mutagenesis position and, further, more than one activity enhancing amino acid residue can be present within one or more CDRs. An activity enhancing amino acid residue include an amino acid residue that improves the binding specificity/affinity of an antibody, for example anti-human IL-12 antibody binding to human IL-12. The activity enhancing amino acid residue is also intended to include an amino acid residue that improves the neutralization potency of an antibody, for example, the human IL-12 antibody which inhibits human IL-12.

The term "antibody" includes an immunoglobulin molecule comprised of four polypeptide chains, two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CH1, CH2 and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

The term "antigen-binding portion" of an antibody (or "antibody portion") includes fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., hIL-12). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed within the term "antigen-binding portion" of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab')<sub>2</sub> fragment, a bivalent fragment comprising two Fab fragments linked by a

5 disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; (v) a dAb fragment (Ward *et al.*, (1989) *Nature* 341:544-546), which consists  
10 of a VH domain; and (vi) an isolated complementarity determining region (CDR).

5 Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions  
15 pair to form monovalent molecules (known as single chain Fv (scFv); see *e.g.*, Bird *et al.* (1988) *Science* 242:423-426; and Huston *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:5879-5883). Such single chain antibodies are also intended to be encompassed  
20 within the term "antigen-binding portion" of an antibody. Other forms of single chain antibodies, such as diabodies are also encompassed. Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the  
25 same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites (see *e.g.*, Holliger, P., *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90:6444-6448; Poljak, R.J., *et al.* (1994) *Structure* 2:1121-1123).  
30 Still further, an antibody or antigen-binding portion thereof may be part of a larger immunoadhesion molecules, formed by covalent or non-covalent association of the antibody or antibody portion with one or more other proteins or peptides. Examples of  
20 such immunoadhesion molecules include use of the streptavidin core region to make a tetrameric scFv molecule (Kipriyanov, S.M., *et al.* (1995) *Human Antibodies and Hybridomas* 6:93-101) and use of a cysteine residue, a marker peptide and a C-terminal polyhistidine tag to make bivalent and biotinylated scFv molecules (Kipriyanov, S.M., *et al.* (1994) *Mol. Immunol.* 31:1047-1058). Antibody portions, such as Fab and F(ab')<sub>2</sub>  
40 fragments, can be prepared from whole antibodies using conventional techniques, such as papain or pepsin digestion, respectively, of whole antibodies. Moreover, antibodies, antibody portions and immunoadhesion molecules can be obtained using standard  
45 recombinant DNA techniques, as described herein. Preferred antigen binding portions  
30 are complete domains or pairs of complete domains.

5 The term "backmutation" refers to a process in which some or all of the  
somatic mutated amino acids of a human antibody are replaced with the  
10 corresponding germline residues from a homologous germline antibody sequence. The  
heavy and light chain sequences of the human antibody of the invention are aligned  
5 separately with the germline sequences in the VBASE database to identify the sequences  
with the highest homology. Differences in the human antibody of the invention are  
15 returned to the germline sequence by mutating defined nucleotide positions encoding  
such different amino acid. The role of each amino acid thus identified as candidate for  
backmutation should be investigated for a direct or indirect role in antigen binding and  
20 any amino acid found after mutation to affect any desirable characteristic of the human  
antibody should not be included in the final human antibody; as an example, activity  
enhancing amino acids identified by the selective mutagenesis approach will not be  
subject to backmutation. To minimize the number of amino acids subject to  
25 backmutation those amino acid positions found to be different from the closest germline  
sequence but identical to the corresponding amino acid in a second germline sequence  
can remain, provided that the second germline sequence is identical and colinear to the  
sequence of the human antibody of the invention for at least 10, preferably 12 amino  
30 acids, on both sides of the amino acid in question. Backmutation may occur at any stage  
of antibody optimization; preferably, backmutation occurs directly before or after the  
selective mutagenesis approach. More preferably, backmutation occurs directly before  
the selective mutagenesis approach.

35 The phrase "human interleukin 12" (abbreviated herein as hIL-12, or IL-12), as  
used herein, includes a human cytokine that is secreted primarily by macrophages and  
dendritic cells. The term includes a heterodimeric protein comprising a 35 kD subunit  
40 (p35) and a 40 kD subunit (p40) which are both linked together with a disulfide bridge.  
The heterodimeric protein is referred to as a "p70 subunit". The structure of human IL-  
12 is described further in, for example, Kobayashi, *et al.* (1989) *J. Exp. Med.* 170:827-  
845; Seder, *et al.* (1993) *Proc. Natl. Acad. Sci.* 90:10188-10192; Ling, *et al.* (1995) *J.*  
45 *Exp. Med.* 154:116-127; Podlaski, *et al.* (1992) *Arch. Biochem. Biophys.* 294:230-237.  
The term human IL-12 is intended to include recombinant human IL-12 (rh IL-12),  
30 which can be prepared by standard recombinant expression methods.

5 The terms "Kabat numbering", "Kabat definitions and "Kabat labeling" are used interchangeably herein. These terms, which are recognized in the art, refer to a system of numbering amino acid residues which are more variable (*i.e.* hypervariable) than  
10 other amino acid residues in the heavy and light chain variable regions of an antibody, or an antigen binding portion thereof (Kabat *et al.* (1971) *Ann. NY Acad. Sci.* 190:382-391 and , Kabat, E.A., *et al.* (1991) *Sequences of Proteins of Immunological Interest, Fifth Edition*, U.S. Department of Health and Human Services, NIH Publication No. 91-  
15 3242). For the heavy chain variable region, the hypervariable region ranges from amino acid positions 31 to 35 for CDR1, amino acid positions 50 to 65 for CDR2, and amino acid positions 95 to 102 for CDR3. For the light chain variable region, the hypervariable  
20 region ranges from amino acid positions 24 to 34 for CDR1, amino acid positions 50 to 56 for CDR2, and amino acid positions 89 to 97 for CDR3.

The Kabat numbering is used herein to indicate the positions of amino acid  
25 modifications made in antibodies of the invention. For example, the Y61 anti-IL-12 antibody can be mutated from serine (S) to glutamic acid (E) at position 31 of the heavy  
15 chain CDR1 (H31S → E), or glycine (G) can be mutated to tyrosine (Y) at position 94 of the light chain CDR3 (L94G → Y).

The term "human antibody" includes antibodies having variable and constant regions corresponding to human germline immunoglobulin sequences as described by  
30 Kabat *et al.* (See Kabat, *et al.* (1991) *Sequences of Proteins of Immunological Interest, Fifth Edition*, U.S. Department of Health and Human Services, NIH Publication No. 91-  
35 3242). The human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (*e.g.*, mutations introduced by random or site-specific mutagenesis *in vitro* or by somatic mutation *in vivo*), for  
40 25 example in the CDRs and in particular CDR3. The mutations preferably are introduced using the "selective mutagenesis approach" described herein. The human antibody can have at least one position replaced with an amino acid residue, *e.g.*, an activity enhancing amino acid residue which is not encoded by the human germline  
45 immunoglobulin sequence. The human antibody can have up to twenty positions replaced with amino acid residues which are not part of the human germline  
30 immunoglobulin sequence. In other embodiments, up to ten, up to five, up to three or up to two positions are replaced. In a preferred embodiment, these replacements are within  
50

the CDR regions as described in detail below. However, the term "human antibody", as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

The phrase "recombinant human antibody" includes human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described further in Section II, below), antibodies isolated from a recombinant, combinatorial human antibody library (described further in Section III, below), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see e.g., Taylor, L.D., *et al.* (1992) *Nucl. Acids Res.* 20:6287-6295) or antibodies prepared, expressed, created or isolated by any other means that involves splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences (See Kabat, E.A., *et al.* (1991) *Sequences of Proteins of Immunological Interest, Fifth Edition*, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). In certain embodiments, however, such recombinant human antibodies are subjected to *in vitro* mutagenesis (or, when an animal transgenic for human Ig sequences is used, *in vivo* somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire *in vivo*. In certain embodiments, however, such recombinant antibodies are the result of selective mutagenesis approach or backmutation or both.

An "isolated antibody" includes an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds hIL-12 is substantially free of antibodies that specifically bind antigens other than hIL-12). An isolated antibody that specifically binds hIL-12 may bind IL-12 molecules from other species (discussed in further detail below). Moreover, an isolated antibody may be substantially free of other cellular material and/or chemicals.

5 A "neutralizing antibody" (or an "antibody that neutralized hIL-12 activity") includes an antibody whose binding to hIL-12 results in inhibition of the biological activity of hIL-12. This inhibition of the biological activity of hIL-12 can be assessed  
10 by measuring one or more indicators of hIL-12 biological activity, such as inhibition of human phytohemagglutinin blast proliferation in a phytohemagglutinin blast  
5 proliferation assay (PHA); or inhibition of receptor binding in a human IL-12 receptor binding assay (see Example 3-Interferon-gamma Induction Assay). These indicators of  
15 hIL-12 biological activity can be assessed by one or more of several standard *in vitro* or *in vivo* assays known in the art (see Example 3).

10 The term "activity" includes activities such as the binding specificity/affinity of an antibody for an antigen, for example, an anti-hIL-12 antibody that binds to an IL-12  
20 antigen and/or the neutralizing potency of an antibody, for example, an anti-hIL-12 antibody whose binding to hIL-12 inhibits the biological activity of hIL-12, e.g., inhibition of PHA blast proliferation or inhibition of receptor binding in a human IL-12  
25 receptor binding assay (see Example 3).

The phrase "surface plasmon resonance" includes an optical phenomenon that allows for the analysis of real-time biospecific interactions by detection of alterations in  
30 protein concentrations within a biosensor matrix, for example using the BIAcore system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, NJ). For further  
20 descriptions, see Example 5 and Jönsson, U., *et al.* (1993) *Ann. Biol. Clin.* 51:19-26; Jönsson, U., *et al.* (1991) *Biotechniques* 11:620-627; Johnsson, B., *et al.* (1995) *J. Mol. Recognit.* 8:125-131; and Johnsson, B., *et al.* (1991) *Anal. Biochem.* 198:268-277.

35 The term " $K_{off}$ ", as used herein, is intended to refer to the off rate constant for dissociation of an antibody from the antibody/antigen complex.

40 The term " $K_d$ ", as used herein, is intended to refer to the dissociation constant of a particular antibody-antigen interaction.

45 The phrase "nucleic acid molecule" includes DNA molecules and RNA molecules. A nucleic acid molecule may be single-stranded or double-stranded, but preferably is double-stranded DNA.

50 The phrase "isolated nucleic acid molecule", as used herein in reference to nucleic acids encoding antibodies or antibody portions (e.g., VH, VL, CDR3) that bind hIL-12 including "isolated antibodies", includes a nucleic acid molecule in which the



5 nucleotide sequences encoding the antibody or antibody portion are free of other  
nucleotide sequences encoding antibodies or antibody portions that bind antigens other  
than hIL-12, which other sequences may naturally flank the nucleic acid in human  
10 genomic DNA. Thus, for example, an isolated nucleic acid of the invention encoding a  
5 VH region of an anti-IL-12 antibody contains no other sequences encoding other VH  
regions that bind antigens other than IL-12. The phrase "isolated nucleic acid molecule"  
is also intended to include sequences encoding bivalent, bispecific antibodies, such as  
15 diabodies in which VH and VL regions contain no other sequences other than the  
sequences of the diabody.

10 The term "vector" includes a nucleic acid molecule capable of transporting  
another nucleic acid to which it has been linked. One type of vector is a "plasmid",  
which refers to a circular double stranded DNA loop into which additional DNA  
segments may be ligated. Another type of vector is a viral vector, wherein additional  
25 DNA segments may be ligated into the viral genome. Certain vectors are capable of  
15 autonomous replication in a host cell into which they are introduced (e.g., bacterial  
vectors having a bacterial origin of replication and episomal mammalian vectors). Other  
vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a  
host cell upon introduction into the host cell, and thereby are replicated along with the  
30 host genome. Moreover, certain vectors are capable of directing the expression of genes  
20 to which they are operatively linked. Such vectors are referred to herein as  
"recombinant expression vectors" (or simply, "expression vectors"). In general,  
expression vectors of utility in recombinant DNA techniques are often in the form of  
plasmids. In the present specification, "plasmid" and "vector" may be used  
interchangeably as the plasmid is the most commonly used form of vector. However,  
40 the invention is intended to include such other forms of expression vectors, such as viral  
25 vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated  
viruses), which serve equivalent functions.

45 The phrase "recombinant host cell" (or simply "host cell") includes a cell into  
which a recombinant expression vector has been introduced. It should be understood  
30 that such terms are intended to refer not only to the particular subject cell but to the  
progeny of such a cell. Because certain modifications may occur in succeeding  
generations due to either mutation or environmental influences, such progeny may not,  
50

in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein.

The term "modifying", as used herein, is intended to refer to changing one or more amino acids in the antibodies or antigen-binding portions thereof. The change can be produced by adding, substituting or deleting an amino acid at one or more positions. The change can be produced using known techniques, such as PCR mutagenesis.

The phrase "contact position" includes an amino acid position of in the CDR1, CDR2 or CDR3 of the heavy chain variable region or the light chain variable region of an antibody which is occupied by an amino acid that contacts antigen in one of the twenty-six known antibody-antigen structures. If a CDR amino acid in any of the 26 known solved structures of antibody-antigen complexes contacts the antigen, then that amino acid can be considered to occupy a contact position. Contact positions have a higher probability of being occupied by an amino acid which contact antigen than non-contact positions. Preferably a contact position is a CDR position which contains an amino acid that contacts antigen in greater than 3 of the 26 structures (>11.5 %). Most preferably a contact position is a CDR position which contains an amino acid that contacts antigen in greater than 8 of the 25 structures (>32%).

The term "hypermutation position" includes an amino acid residue that occupies position in the CDR1, CDR2 or CDR3 region of the heavy chain variable region or the light chain variable region of an antibody that is considered to have a high frequency or probability for somatic hypermutation during *in vivo* affinity maturation of the antibody. "High frequency or probability for somatic hypermutation" includes frequencies or probabilities of a 5 to about 40% chance that the residue will undergo somatic hypermutation during *in vivo* affinity maturation of the antibody. It should be understood that all ranges within this stated range are also intended to be part of this invention, e.g., 5 to about 30%, e.g., 5 to about 15%, e.g., 15 to about 30%.

The term "preferred selective mutagenesis position" includes an amino acid residue that occupies a position in the CDR1, CDR2 or CDR3 region of the heavy chain variable region or the light chain variable region which can be considered to be both a contact and a hypermutation position.

5           The phrase "selective mutagenesis approach" includes a method of improving the  
activity of an antibody by selecting and individually mutating CDR amino acids at at  
10       least one preferred selective mutagenesis position, hypermutation, and/or contact  
position. A "selectively mutated" human antibody is an antibody which contains a  
5       mutation at a position selected using a selective mutagenesis approach. In another  
embodiment, the selective mutagenesis approach is intended to provide a method of  
15       preferentially mutating selected individual amino acid residues in the CDR1, CDR2 or  
CDR3 of the heavy chain variable region (hereinafter H1, H2, and H3, respectively), or  
the CDR1, CDR2 or CDR3 of the light chain variable region (hereinafter referred to as  
10       L1, L2, and L3, respectively) of an antibody. Amino acid residues may be selected from  
preferred selective mutagenesis positions, contact positions, or hypermutation positions.  
Individual amino acids are selected based on their position in the light or heavy chain  
variable region. It should be understood that a hypermutation position can also be a  
25       contact position. In an embodiment, the selective mutagenesis approach is a "targeted  
approach". The language "targeted approach" is intended to include a method of  
15       preferentially mutating selected individual amino acid residues in the CDR1, CDR2 or  
CDR3 of the heavy chain variable region or the CDR1, CDR2 or CDR3 of the light  
chain variable region of an antibody in a targeted manner, *e.g.*, a "Group-wise targeted  
30       approach" or "CDR-wise targeted approach". In the "Group-wise targeted approach",  
individual amino acid residues in particular groups are targeted for selective mutations  
20       including groups I (including L3 and H3), II (including H2 and L1) and III (including  
L2 and H1), the groups being listed in order of preference for targeting. In the "CDR-  
wise targeted approach", individual amino acid residues in particular CDRs are targeted  
for selective mutations with the order of preference for targeting as follows: H3, L3,  
40       H2, L1, H1 and L2. The selected amino acid residue is mutated, *e.g.*, to at least two  
other amino acid residues, and the effect of the mutation on the activity of the antibody  
is determined. Activity is measured as a change in the binding specificity/affinity of the  
antibody, and/or neutralization potency of the antibody. It should be understood that the  
45       selective mutagenesis approach can be used for the optimization of any antibody  
derived from any source including phage display, transgenic animals with human IgG  
30       germline genes, human antibodies isolated from human B-cells. Preferably, the selective  
mutagenesis approach is used on antibodies which can not be optimized further using  
50

phage display technology. It should be understood that antibodies from any source including phage display, transgenic animals with human IgG germline genes, human antibodies isolated from human B-cells can be subject to backmutation prior to or after the selective mutagenesis approach.

The term "activity enhancing amino acid residue" includes an amino acid residue which improves the activity of the antibody. It should be understood that the activity enhancing amino acid residue may replace an amino acid residue at a preferred selective mutagenesis position, contact position, or a hypermutation position and, further, more than one activity enhancing amino acid residue can be present within one or more CDRs.

An activity enhancing amino acid residue include, an amino acid residue that improves the binding specificity/affinity of an antibody, for example anti-human IL-12 antibody binding to human IL-12. The activity enhancing amino acid residue is also intended to include an amino acid residue that improves the neutralization potency of an antibody, for example, the human IL-12 antibody which inhibits human IL-12.

Various aspects of the invention are described in further detail in the following subsections.

#### I. Human Antibodies that Bind Human IL-12

This invention provides isolated human antibodies, or antigen-binding portions thereof, that bind to human IL-12. Preferably, the human antibodies of the invention are recombinant, neutralizing human anti-hIL-12 antibodies. Antibodies of the invention that bind to human IL-12 can be selected, for example, by screening one or more human  $V_L$  and  $V_H$  cDNA libraries with hIL-12, such as by phage display techniques as described in Example 1. Screening of human  $V_L$  and  $V_H$  cDNA libraries initially identified a series of anti-IL-12 antibodies of which one antibody, referred to herein as "Joe 9" (or "Joe 9 wild type"), was selected for further development. Joe 9 is a relatively low affinity human IL-12 antibody (e.g., a  $K_{off}$  of about  $0.1 \text{ sec}^{-1}$ ), yet is useful for specifically binding and detecting hIL-12. The affinity of the Joe 9 antibody was improved by conducting mutagenesis of the heavy and light chain CDRs, producing a panel of light and heavy chain variable regions that were "mixed and matched" and further mutated, leading to numerous additional anti-hIL-12 antibodies with increased affinity for hIL-12 (see Example 1, Table 2 (see Appendix A) and the sequence alignments of Figures 1A-D).

Of these antibodies, the human anti-hIL-12 antibody referred to herein as Y61 demonstrated a significant improvement in binding affinity (e.g., a  $K_{off}$  of about  $2 \times 10^{-4}$  sec<sup>-1</sup>). The Y61 anti-hIL-12 antibody was selected for further affinity maturation by individually mutating specific amino acids residues within the heavy and light chain CDRs. Amino acids residues of Y61 were selected for site-specific mutation (selective mutagenesis approach) based on the amino acid residue occupying a preferred selective mutagenesis position, contact and/or a hypermutation position. A summary of the substitutions at selected positions in the heavy and light chain CDRs is shown in Figures 2A-2H. A preferred recombinant neutralizing antibody of the invention, referred to herein as J695, resulted from a Gly to Tyr substitution at position 50 of the light chain CDR2 of Y61, and a Gly to Tyr substitution at position 94 of the light chain CDR3 of Y61.

Amino acid sequence alignments of the heavy and light chain variable regions of a panel of anti-IL-12 antibodies of the invention, on the lineage from Joe 9 wild type to J695, are shown in Figures 1A-1D. These sequence alignments allowed for the identification of consensus sequences for preferred heavy and light chain variable regions of antibodies of the invention that bind hIL-12, as well as consensus sequences for the CDR3, CDR2, and CDR1, on the lineage from Joe 9 to J695. Moreover, the Y61 mutagenesis analysis summarized in Figures 2A-2H allowed for the identification of consensus sequences for heavy and light chain variable regions that bind hIL-12, as well as consensus sequences for the CDR3, CDR2, and CDR1 that bind hIL-12 on the lineage from Y61 to J695 that encompasses sequences with modifications from Y61 yet that retain good hIL-12 binding characteristics. Preferred CDR, VH and VL sequences of the invention (including consensus sequences) as identified by sequence identifiers in the attached Sequence Listing, are summarized below.

SEQ ID NO:	ANTIBODY CHAIN	REGION	SEQUENCE
1	Consensus Joe 9 to J695	CDR H3	(H/S) - G - S - (H/Y) - D - (N/T/Y)
2	Consensus	CDR L3	Q - (S/T) - Y - (D/E) - (S/R/K) - (S/G/Y) -

	Joe 9 to J695		(L/F/T/S) - (R/S/T/W/H) - (G/P) - (S/T/A/L) - (R/S/M/T/L) - (V/I/T/M/L)
3	Consensus Joe 9 to J695	CDR H2	F-I-R-Y-D-G-S-N-K-Y-Y-A-D-S-V-K-G
4	Consensus Joe 9 to J695	CDR L2	(G/Y) - N - (D/S) - (Q/N) - R - P - S
5	Consensus Joe 9 to J695	CDR H1	F-T-F-S - (S/E) - Y-G-M-H
6	Consensus Joe 9 to J695	CDR L1	(S/T) - G - (G/S) - (R/S) - S - N - I - (G/V) - (S/A) - (N/G/Y) - (T/D) - V - (K/H)
7	Consensus Joe 9 to J695	VH	(full VH sequence; see sequence listing)
8	Consensus Joe 9 to J695	VL	(full VL sequence; see sequence listing)
9	Consensus Y61 to J695	CDR H3	H - (G/V/C/H) - (S/T) - (H/T/V/R/I) - (D/S) - (N/K/A/T/S/F/W/H)
10	Consensus Y61 to J695	CDR L3	Q-S-Y - (D/S) - (Xaa) - (G/D/Q/L/F/R/H/N/Y) - T-H-P-A-L-L
11	Consensus Y61 to J695	CDR H2	(F/T/Y) - I - (R/A) - Y - (D/S/E/A) - (G/R) - S - (Xaa) - K - (Y/E) - Y-A-D-S-V-K-G
12	Consensus Y61 to J695	CDR L2	(G/Y/S/T/N/Q) - N-D-Q-R-P-S
13	Consensus Y61 to J695	CDR H1	F-T-F - (Xaa) - (Xaa) - (Y/H) - (G/M/A/N/S) - M-H
14	Consensus Y61 to J695	CDR L1	S-G-G-R-S-N-I-G - (S/C/R/N/D/T) - (N/M/I) - (T/Y/D/H/K/P) - V-K
15	Consensus Y61 to J695	VH	(full VH sequence; see sequence listing)
16	Consensus Y61 to J695	VL	(full VL sequence; see sequence listing)
17	Y61	CDR H3	H-G-S-H-D-N
18	Y61	CDR L3	Q-S-Y-D-R-G-T-H-P-A-L-L
19	Y61	CDR H2	F-I-R-Y-D-G-S-N-K-Y-Y-A-D-S-V-K-G
20	Y61	CDR L2	G-N-D-Q-R-P-S
21	Y61	CDR H1	F-T-F-S-S-Y-G-M-H
22	Y61	CDR L1	S-G-G-R-S-N-I-G-S-N-T-V-K

23	Y61	VH	(full VH sequence; see sequence listing)
24	Y61	VL	(full VL sequence; see sequence listing)
25	J695	CDR H3	H-G-S-H-D-N
26	J695	CDR L3	Q-S-Y-D-R-Y-T-H-P-A-L-L
27	J695	CDR H2	F-I-R-Y-D-G-S-N-K-Y-Y-A-D-S-V-K-G
28	J695	CDR L2	Y-N-D-Q-R-P-S
29	J695	CDR H1	F-T-F-S-S-Y-G-M-H
30	J695	CDR L1	S-G-S-R-S-N-I-G-S-N-T-V-K
31	J695	VH	(full VH sequence; see sequence listing)
32	J695	VL	(full VL sequence; see sequence listing)

Antibodies produced from affinity maturation of Joe 9 wild type were

functionally characterized by surface plasmon resonance analysis to determine the  $K_d$  and  $K_{off}$  rate. A series of antibodies were produced having a  $K_{off}$  rate within the range of about  $0.1 \text{ s}^{-1}$  to about  $1 \times 10^{-5} \text{ s}^{-1}$ , and more preferably a  $K_{off}$  of about  $1 \times 10^{-4} \text{ s}^{-1}$  to  $1 \times 10^{-5} \text{ s}^{-1}$  or less. Antibodies were also characterized *in vitro* for their ability to inhibit phytohemagglutinin (PHA) blast proliferation, as described in Example 3. A series of antibodies were produced having an  $IC_{50}$  value in the range of about  $1 \times 10^{-6} \text{ M}$  to about  $1 \times 10^{-11} \text{ M}$ , more preferably about  $1 \times 10^{-10} \text{ M}$  to  $1 \times 10^{-11} \text{ M}$  or less.

Accordingly, in one aspect, the invention provides an isolated human antibody, or antigen-binding portion thereof, that binds to human IL-12 and dissociates from human IL-12 with a  $K_{off}$  rate constant of  $0.1 \text{ s}^{-1}$  or less, as determined by surface plasmon resonance, or which inhibits phytohemagglutinin blast proliferation in an *in vitro* phytohemagglutinin blast proliferation assay (PHA assay) with an  $IC_{50}$  of  $1 \times 10^{-6} \text{ M}$  or less. In preferred embodiments, the isolated human IL-12 antibody, or an antigen-binding portion thereof, dissociates from human IL-12 with a  $K_{off}$  rate constant of  $1 \times 10^{-2} \text{ s}^{-1}$  or less, or inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-7} \text{ M}$  or less. In more preferred embodiments, the isolated human IL-12 antibody, or an antigen-binding portion thereof, dissociates from human IL-12 with a  $K_{off}$  rate constant of  $1 \times 10^{-3} \text{ s}^{-1}$  or less, or inhibits phytohemagglutinin

blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-8}$  M or less. In more preferred embodiments, the isolated human IL-12 antibody, or an antigen-binding portion thereof, dissociates from human IL-12 with a  $K_{off}$  rate constant of  $1 \times 10^{-4} s^{-1}$  or less, or inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-9}$  M or less. In more preferred embodiments, the isolated human IL-12 antibody, or an antigen-binding portion thereof, dissociates from human IL-12 with a  $K_{off}$  rate constant of  $1 \times 10^{-5} s^{-1}$  or less, or inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-10}$  M or less. In even more preferred embodiments, the isolated human IL-12 antibody, or an antigen-binding portion thereof, dissociates from human IL-12 with a  $K_{off}$  rate constant of  $1 \times 10^{-5} s^{-1}$  or less, or inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-11}$  M or less.

The dissociation rate constant ( $K_{off}$ ) of an IL-12 antibody can be determined by surface plasmon resonance (see Example 5). Generally, surface plasmon resonance analysis measures real-time binding interactions between ligand (recombinant human IL-12 immobilized on a biosensor matrix) and analyte (antibodies in solution) by surface plasmon resonance (SPR) using the BIAcore system (Pharmacia Biosensor, Piscataway, NJ). Surface plasmon analysis can also be performed by immobilizing the analyte (antibodies on a biosensor matrix) and presenting the ligand (recombinant IL-12 in solution). Neutralization activity of IL-12 antibodies, or antigen binding portions thereof, can be assessed using one or more of several suitable *in vitro* assays (see Example 3).

It is well known in the art that antibody heavy and light chain CDRs play an important role in the binding specificity/affinity of an antibody for an antigen. Accordingly, the invention encompasses human antibodies having light and heavy chain CDRs of Joe 9, as well as other antibodies having CDRs that have been modified to improve the binding specificity/affinity of the antibody. As demonstrated in Example 1, a series of modifications to the light and heavy chain CDRs results in affinity maturation of human anti-hIL-12 antibodies. The heavy and light chain variable region amino acid sequence alignments of a series of human antibodies ranging from Joe 9 wild type to J695 that bind human IL-12 is shown in Figures 1A-1D. Consensus sequence motifs for the CDRs of antibodies can be determined from the sequence alignment (as



summarized in the table above). For example, a consensus motif for the VH CDR3 of the lineage from Joe 9 to J695 comprises the amino acid sequence: (H/S)-G-S-(H/Y)-D-(N/T/Y) (SEQ ID NO: 1), which encompasses amino acids from position 95 to 102 of the consensus HCVR shown in SEQ ID NO: 7. A consensus motif for the VL CDR3 comprises the amino acid sequence: Q-(S/T)-Y-(D/E)-(S/R/K)-(S/G/Y)-(L/T/T/S)-(R/S/T/W/H)-(G/P)-(S/T/A/L)-(R/S/M/T/L-V/I/T/M/L) (SEQ ID NO: 2), which encompasses amino acids from position 89 to 97 of the consensus LCVR shown in SEQ ID NO: 8.

- Accordingly, in another aspect, the invention provides an isolated human antibody, or an antigen-binding portion thereof, which has the following characteristics:
- a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-6}$  M or less;
  - b) has a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 1; and
  - c) has a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 2.

In a preferred embodiment, the antibody further comprises a VH CDR2 comprising the amino acid sequence: F-I-R-Y-D-G-S-N-K-Y-Y-A-D-S-V-K-G (SEQ ID NO: 3) (which encompasses amino acids from position 50 to 65 of the consensus HCVR comprising the amino acid sequence SEQ ID NO: 7) and further comprises a VL CDR2 comprising the amino acid sequence: (G/Y)-N-(D/S)-(Q/N)-R-P-S (SEQ ID NO: 4) (which encompasses amino acids from position 50 to 56 of the consensus LCVR comprising the amino acid sequence SEQ ID NO: 8).

In another preferred embodiment, the antibody further comprises a VH CDR1 comprising the amino acid sequence: F-T-F-S-(S/E)-Y-G-M-H (SEQ ID NO: 5) (which encompasses amino acids from position 27 to 35 of the consensus HCVR comprising the amino acid sequence SEQ ID NO: 7) and further comprises a VL CDR1 comprising the amino acid sequence: (S/T)-G-(G/S)-(R/S)-S-N-I-(G/V)-(S/A)-(N/G/Y)-(T/D)-V-(K/H) (SEQ ID NO: 6) (which encompasses amino acids from position 24 to 34 of the consensus LCVR comprising the amino acid sequence SEQ ID NO: 8).

5 In yet another preferred embodiment, the antibody of the invention comprises a HCVR comprising the amino acid sequence of SEQ ID NO: 7 and a LCVR comprising the amino acid sequence of SEQ ID NO: 8.

10 Additional consensus motifs can be determined based on the mutational analysis performed on Y61 that led to the J695 antibody (summarized in Figures 2A-2H). As demonstrated by the graphs shown in Figures 2A-2H, certain residues of the heavy and light chain CDRs of Y61 were amenable to substitution without significantly impairing the hIL-12 binding properties of the antibody. For example, individual substitutions at position 30 in CDR H1 with twelve different amino acid residues did not significantly reduce the  $K_{off}$  rate of the antibody, indicating that this position is amenable to substitution with a variety of different amino acid residues. Thus, based on the mutational analysis (i.e., positions within Y61 that were amenable to substitution by other amino acid residues) consensus motifs were determined. The consensus motifs for the heavy and light chain CDR3s are shown in SEQ ID NOs: 9 and 10, respectively, consensus motifs for the heavy and light chain CDR2s are shown in SEQ ID NOs: 11 and 12, respectively, and consensus motifs for the heavy and light chain CDR1s are shown in SEQ ID NOs: 13 and 14, respectively. Consensus motifs for the VH and VL regions are shown in SEQ ID NOs: 15 and 16, respectively.

20 Accordingly, in one aspect, the invention features an isolated human antibody, or an antigen-binding portion thereof, which has the following characteristics:

- 35 a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-9}$  M or less;
- b) has a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 9; and
- 40 25 c) has a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 10.

45 In a preferred embodiment, the antibody further comprises a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 11 and further comprises a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 12.

30 In another preferred embodiment, the antibody further comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 13 and further comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 14.

5 In yet another preferred embodiment, the antibody of the invention comprises a HCVR comprising the amino acid sequence of SEQ ID NO: 15 and a LCVR comprising the amino acid sequence of SEQ ID NO: 16.

10 A preferred antibody of the invention, the human anti-hIL-12 antibody Y61, was produced by affinity maturation of Joe 9 wild type by PCR mutagenesis of the CDR3 (as described in Example 1). Y61 had an improved specificity/binding affinity determined by surface plasmon resonance and by *in vitro* neutralization assays. The heavy and light chain CDR3s of Y61 are shown in SEQ ID NOs: 17 and 18, respectively, the heavy and light chain CDR2s of Y61 are shown in SEQ ID NOs: 19 and 20, respectively, and the heavy and light chain CDR1s of Y61 are shown in SEQ ID NOs: 21 and 22, respectively. The VH of Y61 has the amino acid sequence of SEQ ID NO: 23 and the VL of Y61 has the amino acid sequence of SEQ ID NO: 24 (these sequences are also shown in Figures 1A-1D, aligned with Joe9).

25 Accordingly, in another aspect, the invention features an isolated human antibody, or an antigen-binding portion thereof, which

a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-9}$  M or less;

30 b) has a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 17; and

20 c) has a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 18.

35 In a preferred embodiment, the isolated human antibody, or an antigen-binding portion thereof, has a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 19 and a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:

40 20

45 In another preferred embodiment, the isolated human antibody, or an antigen-binding portion thereof has a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 21 and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 22.

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

5 In yet another preferred embodiment, the isolated human antibody, or an antigen-binding portion thereof, comprising a the heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 23, and a light chain variable region comprising  
10 the amino acid sequence of SEQ ID NO: 24.

5 In certain embodiments, the full length antibody comprises a heavy chain constant region, such as IgG1, IgG2, IgG3, IgG4, IgM, IgA and IgE constant regions, and any allotypic variant therein as described in Kabat (, Kabat, E.A., *et al.* (1991) *Sequences of Proteins of Immunological Interest, Fifth Edition*, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). Preferably, the antibody  
15 heavy chain constant region is an IgG1 heavy chain constant region. Alternatively, the antibody portion can be an Fab fragment, an F(ab')<sub>2</sub> fragment or a single chain Fv fragment.

Modifications of individual residues of Y61 led to the production of a panel of antibodies shown in Figures 2A-2H. The specificity/binding affinity of each antibody  
25 was determined by surface plasmon resonance and/or by *in vitro* neutralization assays.

Accordingly, in another aspect, the invention features an isolated human antibody, or an antigen-binding portion thereof, which

- 30 a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PIIA assay with an IC<sub>50</sub> of  $1 \times 10^{-9}$  M or less;
- 20 b) has a heavy chain CDR3 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 404-SEQ ID NO: 469; and
- 35 c) has a light chain CDR3 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 534-SEQ ID NO: 579.

In preferred embodiment, the isolated human antibody, or an antigen-binding  
40 portion thereof, has a heavy chain CDR2 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 335-SEQ ID NO: 403; and a light chain CDR2 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 506-SEQ ID NO: 533.

45 In another preferred embodiment, the isolated human antibody, or an antigen-binding portion thereof, has a heavy chain CDR1 comprising the amino acid sequence  
30 selected from the group consisting of SEQ ID NO: 288-SEQ ID NO: 334; and a light

chain CDR1 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 470-SEQ ID NO: 505.

In yet another preferred embodiment, the isolated human antibody, or an antigen-binding portion thereof, comprising a the heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 23, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 24.

In certain embodiments, the full length antibody comprising a heavy chain constant region such as IgG1, IgG2, IgG3, IgG4, IgM, IgA and IgE constant regions and any allotypic variant therein as described in Kabat (, Kabat, E.A., *et al.* (1991) *Sequences of Proteins of Immunological Interest, Fifth Edition*, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). Preferably, the antibody heavy chain constant region is an IgG1 heavy chain constant region. Alternatively, the antibody portion can be a Fab fragment, an F(ab')<sub>2</sub> fragment or a single chain Fv fragment.

A particularly preferred recombinant, neutralizing antibody of the invention, J695, was produced by site-directed mutagenesis of contact and hypermutation amino acids residues of antibody Y61 (see Example 2 and section III below). J695 differs from Y61 by a Gly to Tyr substitution in Y61 at position 50 of the light chain CDR2 and by a Gly to Tyr substitution at position 94 of the light chain CDR3. The heavy and light chain CDR3s of J695 are shown in SEQ ID NOs: 25 and 26, respectively, the heavy and light chain CDR2s of J695 are shown in SEQ ID NOs: 27 and 28, respectively, and the heavy and light chain CDR1s of J695 are shown in SEQ ID NOs: 29 and 30, respectively. The VH of J695 has the amino acid sequence of SEQ ID NO: 31 and the VL of J695 has the amino acid sequence of SEQ ID NO: 32 (these sequences are also shown in Figures 1A-1D, aligned with Joe9).

Accordingly, in another aspect, the invention features an isolated human antibody, or an antigen-binding portion thereof, which

a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC<sub>50</sub> of  $1 \times 10^{-9}$  M or less;

b) has a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 25; and

5 c) has a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 26.

10 In preferred embodiment, the isolated human antibody, or an antigen-binding portion thereof, has a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28.

15 In another preferred embodiment, the isolated human antibody, or an antigen-binding portion thereof, has a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 29, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30.

20 In yet another preferred embodiment, the isolated human antibody, or an antigen-binding portion thereof, has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 31, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 32.

25 In certain embodiments, the full length antibody comprises a heavy chain constant region, such as IgG1, IgG2, IgG3, IgG4, IgM, IgA and IgE constant regions and any allotypic variant therein as described in Kabat (. Kabat, E.A., *et al.* (1991) *Sequences of Proteins of Immunological Interest, Fifth Edition*, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). Preferably, the antibody heavy chain constant region is an IgG1 heavy chain constant region. Alternatively, the antibody portion can be an Fab fragment, an F(ab')<sub>2</sub> fragment or a single chain Fv fragment.

30 Additional mutations in the preferred consensus sequences for CDR3, CDR2, and CDR1 of antibodies on the lineage from Joe 9 to J695, or from the lineage Y61 to J695, can be made to provide additional anti-IL-12 antibodies of the invention. Such methods of modification can be performed using standard molecular biology techniques, such as by PCR mutagenesis, targeting individual contact or hypermutation amino acid residues in the light chain and/or heavy chain CDRs, followed by kinetic and functional analysis of the modified antibodies as described herein (e.g., neutralization assays described in Example 3. and by BIAcore analysis, as described in Example 5).

Accordingly, in another aspect the invention features an isolated human antibody, or an antigen-binding portion thereof, which

a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-6}$  M or less;

b) comprises a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 3 and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 5, or a mutant thereof having one or more amino acid substitutions at a preferred selective mutagenesis position or a hypermutation position, wherein said mutant has a  $k_{off}$  rate no more than 10-fold higher than the antibody comprising a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 5; and

c) comprises a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 2, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 6, or a mutant thereof having one or more amino acid substitutions at a preferred selective mutagenesis position or a hypermutation position, wherein said mutant has a  $k_{off}$  rate no more than 10-fold higher than the antibody comprising a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 2, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 6.

In another aspect the invention features an isolated human antibody, or an antigen-binding portion thereof, which

a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-9}$  M or less;

b) comprises a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 9, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 11 and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 13, or a mutant thereof having one or more amino acid substitutions at a preferred selective mutagenesis position, contact position or a hypermutation position, wherein said mutant has a  $k_{off}$  rate no more than 10-fold higher than the antibody comprising a

- 56 -

heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 9, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 11, and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 13; and

- c) comprises a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 10, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 12, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 14, or a mutant thereof having one or more amino acid substitutions at a preferred selective mutagenesis position, contact position or a hypermutation position, wherein said mutant has a  $k_{off}$  rate no more than 10-fold higher than the antibody comprising a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 10, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 12, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 14.

An ordinarily skilled artisan will also appreciate that additional mutations to the CDR regions of an antibody of the invention, for example in Y61 or in J695, can be made to provide additional anti-IL-12 antibodies of the invention. Such methods of modification can be performed using standard molecular biology techniques, as described above. The functional and kinetic analysis of the modified antibodies can be performed as described in Example 3 and Example 5, respectively. Modifications of individual residues of Y61 that led to the identification of J695 are shown in Figures 2A-2H and are described in Example 2.

Accordingly, in another aspect the invention features an isolated human antibody, or an antigen-binding portion thereof, which

- a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-9}$  M or less;
- b) comprises a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 19 and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 21, or a mutant thereof having one or more amino acid substitutions at a preferred selective mutagenesis position or a hypermutation position, wherein said mutant has a  $k_{off}$  rate no more than 10-fold higher than the antibody comprising a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a heavy chain CDR2



comprising the amino acid sequence of SEQ ID NO: 19, and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 21; and

c) comprises a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 18, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 20, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 22, or a mutant thereof having one or more amino acid substitutions at a preferred selective mutagenesis position or a hypermutation position, wherein said mutant has a  $k_{\text{off}}$  rate no more than 10-fold higher than the antibody comprising a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 18, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 20, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 22.

In another aspect the invention features an isolated human antibody, or an antigen-binding portion thereof, which

a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $\text{IC}_{50}$  of  $1 \times 10^{-9}$  M or less;

b) comprises a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 25, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 27 and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 29, or a mutant thereof having one or more amino acid substitutions at a preferred selective mutagenesis position or a hypermutation position, wherein said mutant has a  $k_{\text{off}}$  rate no more than 10-fold higher than the antibody comprising a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 25, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 29; and

c) comprises a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 26, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30, or a mutant thereof having one or more amino acid substitutions at a preferred selective mutagenesis position or a hypermutation position, wherein said mutant has a  $k_{\text{off}}$  rate no more than 10-fold higher than the antibody comprising a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 26, a light chain CDR2 comprising

the amino acid sequence of SEQ ID NO: 28, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30.

In yet another embodiment, the invention provides isolated human antibodies, or antigen-binding portions thereof, that neutralize the activity of human IL-12, and at least one additional primate IL-12 selected from the group consisting of baboon IL-12, marmoset IL-12, chimpanzee IL-12, cynomolgus IL-12 and rhesus IL-12, but which do not neutralize the activity of the mouse IL-12.

## II Selection of Recombinant Human Antibodies

Recombinant human antibodies of the invention can be isolated by screening of a recombinant combinatorial antibody library, preferably a scFv phage display library, prepared using human VL and VH cDNAs prepared from mRNA derived from human lymphocytes. Methodologies for preparing and screening such libraries are known in the art. In addition to commercially available kits for generating phage display libraries (e.g., the Pharmacia *Recombinant Phage Antibody System*, catalog no. 27-9400-01; and the Stratagene *SurfZAP*<sup>TM</sup> phage display kit, catalog no. 240612), examples of methods and reagents particularly amenable for use in generating and screening antibody display libraries can be found in, for example, Kang *et al.* PCT Publication No. WO 92/18619; Winter *et al.* PCT Publication No. WO 92/20791; Breitling *et al.* PCT Publication No. WO 93/01288; McCafferty *et al.* PCT Publication No. WO 92/01047; Garrard *et al.* PCT Publication No. WO 92/09690; Fuchs *et al.* (1991) *Bio/Technology* 9:1370-1372; Hay *et al.* (1992) *Hum Antibod Hybridomas* 3:81-85; Huse *et al.* (1989) *Science* 246:1275-1281; McCafferty *et al.*, *Nature* (1990) 348:552-554; Griffiths *et al.* (1993) *EMBO J* 12:725-734; Hawkins *et al.* (1992) *J Mol Biol* 226:889-896; Clackson *et al.* (1991) *Nature* 352:624-628; Gram *et al.* (1992) *PNAS* 89:3576-3580, Garrard *et al.* (1991) *Bio/Technology* 9:1373-1377; Hoogenboom *et al.* (1991) *Nuc Acid Res* 19:4133-4137; and Barbas *et al.* (1991) *PNAS* 88:7978-7982.

The antibody libraries used in this method are preferably scFv libraries prepared from human VL and VH cDNAs. The scFv antibody libraries are preferably screened using recombinant human IL-12 as the antigen to select human heavy and light chain sequences having a binding activity toward IL-12. To select for antibodies specific for the p35 subunit of IL-12 or the p70 heterodimer, screening assays were performed in the

5 presence of excess free p40 subunit. Subunit preferences can be determined, for example by, micro-Friguet titration, as described in Example 1.

10 Once initial human VL and VH segments are selected, "mix and match" experiments, in which different pairs of the selected VL and VH segments are screened  
5 for IL-12 binding, are performed to select preferred VL/VH pair combinations (see Example 1). Additionally, to further improve the affinity and/or lower the off rate constant for hIL-12 binding, the VL and VH segments of the preferred VL/VH pair(s)  
15 can be randomly mutated, preferably within the CDR3 region of VH and/or VL, in a process analogous to the *in vivo* somatic mutation process responsible for affinity  
20 maturation of antibodies during a natural immune response. This *in vitro* affinity maturation can be accomplished by amplifying VH and VL regions using PCR primers complimentary to the VH CDR3 or VL CDR3, respectively, which primers have been  
25 "spiked" with a random mixture of the four nucleotide bases at certain positions such that the resultant PCR products encode VH and VL segments into which random  
15 mutations have been introduced into the VH and/or VL CDR3 regions. These randomly mutated VH and VL segments can be rescreened and rescreened for binding to hIL-12 and sequences that exhibit high affinity and a low off rate for IL-12 binding can be  
30 selected. Table 2 (see Appendix A) shows antibodies that displayed altered binding specificity/affinity produced as a result of *in vitro* affinity maturation.

20 Following selection, isolation and screening of an anti-hIL-12 antibody of the invention from a recombinant immunoglobulin display library, nucleic acid encoding the  
35 selected antibody can be recovered from the phage particle(s) (e.g., from the phage genome) and subcloned into other expression vectors by standard recombinant DNA techniques. If desired, the nucleic acid can be further manipulated to create other  
40 antibody forms of the invention (e.g., linked to nucleic acid encoding additional immunoglobulin domains, such as additional constant regions). To express a  
25 recombinant human antibody isolated by screening of a combinatorial library, the DNA encoding the antibody is cloned into a recombinant expression vector and introduced  
45 into a mammalian host cells, as described in further detail in Section IV below.

30 Methods for selecting human IL-12 binding antibodies by phage display technology, and affinity maturation of selected antibodies by random or site-directed mutagenesis of CDR regions are described in further detail in Example 1.

5 As described in Example 1, screening of human VL and VH cDNA libraries identified a series of anti-IL-12 antibodies, of which the Joe 9 antibody was selected for further development. A comparison of the heavy chain variable region of Joe 9 with the heavy chain germline sequences selected from the VBASE database, revealed that Joe 9 was similar to the COS-3 germline sequence. COS-3 belongs to the V<sub>H</sub>3 family of germline sequences.

15 The V<sub>H</sub>3 family is part of the human VH germline repertoire which is grouped into seven families, V<sub>H</sub>1-V<sub>H</sub>7, based on nucleotide sequence homology (Tomlinson *et al.* (1992) *J. Mol. Biol.*, 227, 776-798 and Cook *et al.* (1995) *Immunology Today*, 16, 237-242). The V<sub>H</sub>3 family contains the highest number of members and makes the largest contribution to the germline repertoire. For any given human V<sub>H</sub>3- germline antibody sequence, the amino acid sequence identity within the entire V<sub>H</sub>3 family is high (See e.g., Tomlinson *et al.* (1992) *J. Mol. Biol.*, 227, 776-798 and Cook *et al.* (1995) *Immunology Today*, 16, 237-242). The range of amino acid sequence identity between any two germline VH sequences of the V<sub>H</sub>3 family varies from 69-98 residues out of approximately 100 VH residues, (*i.e.*, 69-98% amino acid sequence homology between any two germline VH sequences). For most pairs of germline sequences there is at least 80 or more identical amino acid residues, (*i.e.*, at least 80% amino acid sequence homology). The high degree of amino acid sequence homology between the V<sub>H</sub>3 family members results in certain amino acid residues being present at key sites in the CDR and framework regions of the VH chain. These amino acid residues confer structural features upon the CDRs.

25 Studies of antibody structures have shown that CDR conformations can be grouped into families of canonical CDR structures based on the key amino acid residues that occupy certain positions in the CDR-and framework regions. Consequently, there are similar local CDR conformations in different antibodies that have canonical structures with identical key amino acid residues (Chothia *et al.* (1987) *J. Mol. Biol.*, 196, 901-917 and Chothia *et al.* (1989) *Nature*, 342, 877-883). Within the V<sub>H</sub>3 family there is a conservation of amino acid residue identity at the key sites for the CDR1 and CDR2 canonical structures (Chothia *et al.* (1992) *J. Mol. Biol.*, 227, 799-817).

5 The COS-3 germline VH gene, is a member of the V<sub>H</sub>3 family and is a variant of  
the 3-30 (DP-49) germline VH allele. COS-3, differs from Joe9 VH amino acid  
sequences at only 5 positions. The high degree of amino acid sequence homology  
10 between Joe9 VH and COS-3, and between Joe9 VH and the other V<sub>H</sub>3 family members  
also confers a high degree of CDR structural homology (Chothia *et al.* (1992) *J. Mol.*  
*Biol.*, 227, 799-817; Chothia *et al.* (1987) *J. Mol. Biol.*, 196, 901-917 and Chothia *et al.*  
15 (1989) *Nature*, 342, 877-883).

The skilled artisan will appreciate that based on the high amino acid sequence  
and canonical structural similarity to Joe 9, other V<sub>H</sub>3 family members could also be  
20 used to generate antibodies that bind to human IL-12. This can be performed, for  
example, by selecting an appropriate VL by chain-shuffling techniques (Winter *et al.*  
(1994) *Annual Rev. Immunol.*, 12, 433-55), or by the grafting of CDRs from a rodent or  
other human antibody including CDRs from antibodies of this invention onto a V<sub>H</sub>3  
family framework.

25 The human V lambda germline repertoire is grouped into 10 families based on  
nucleotide sequence homology (Williams *et al.* (1996) *J. Mol. Biol.*, 264, 220-232). A  
comparison of the light chain variable region of Joe 9 with the light chain germline  
sequences selected from the VBASE database, revealed that Joe 9 was similar to the  
30 DPL8 lambda germline. The Joe9 VL differs from DPL8 sequence at only four  
framework positions, and is highly homologous to the framework sequences of the other  
V<sub>λ</sub>1 family members. Based on the high amino acid sequence homology and canonical  
structural similarity to Joe 9, other V<sub>λ</sub>1 family members may also be used to generate  
antibodies that bind to human IL-12. This can be performed, for example, by selecting  
35 an appropriate VH by chain-shuffling techniques (Winter *et al. Supra*, or by the grafting  
of CDRs from a rodent or other human antibody including CDRs from antibodies of this  
invention onto a V<sub>λ</sub>1 family framework.

The methods of the invention are intended to include recombinant antibodies that  
bind to hIL-12, comprising a heavy chain variable region derived from a member of the  
45 V<sub>H</sub>3 family of germline sequences, and a light chain variable region derived from a  
member of the V<sub>λ</sub>1 family of germline sequences. Moreover, the skilled artisan will  
appreciate that any member of the V<sub>H</sub>3 family heavy chain sequence can be combined  
50 with any member of the V<sub>λ</sub>1 family light chain sequence.

Those skilled in the art will also appreciate that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the germline may exist within a population (e.g., the human population). Such genetic polymorphism in the germline sequences may exist among individuals within a population due to natural allelic variation. Such natural allelic variations can typically result in 1-5 % variance in the nucleotide sequence of the a gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in germline sequences that are the result of natural allelic variation are intended to be within the scope of the invention.

Accordingly, in one aspect, the invention features an isolated human antibody, or an antigen-binding portion thereof, which has the following characteristics:

a) that binds to human IL-12 and dissociates from human IL-12 with a  $k_{off}$  rate constant of  $0.1 \text{ s}^{-1}$  or less, as determined by surface plasmon resonance, or which inhibits phytohemagglutinin blast proliferation in an *in vitro* phytohemagglutinin blast proliferation assay (PHA assay) with an  $IC_{50}$  of  $1 \times 10^{-6} \text{ M}$  or less.

b) has a heavy chain variable region comprising an amino acid sequence selected from a member of the  $V_H3$  germline family, wherein the heavy chain variable region has a mutation at a contact or hypermutation position with an activity enhancing amino acid residue.

c) has a light chain variable region comprising an amino acid sequence selected from a member of the  $V_L1$  germline family, wherein the light chain variable region has a mutation at a preferred selective mutagenesis position, contact or hypermutation position with an activity enhancing amino acid residue.

In a preferred embodiment, the isolated human antibody, or antigen binding has mutation in the heavy chain CDR3.

In another preferred embodiment, the isolated human antibody, or antigen binding has mutation in the light chain CDR3.

In another preferred embodiment, the isolated human antibody, or antigen binding has mutation in the heavy chain CDR2.

In another preferred embodiment, the isolated human antibody, or antigen binding has mutation in the light chain CDR2.

In another preferred embodiment, the isolated human antibody, or antigen binding has mutation in the heavy chain CDR1.

5 In another preferred embodiment, the isolated human antibody, or antigen binding has mutation in the light chain CDR1.

10 An ordinarily skilled artisan will appreciate that based on the high amino acid sequence similarity between members of the  $V_{H3}$  germline family, or between members  
5 of the light chain  $V_{\lambda 1}$  germline family, that mutations to the germlines sequences can provide additional antibodies that bind to human IL-12. Table 1 (see Appendix A) shows the germline sequences of the  $V_{H3}$  family members and demonstrates the  
15 significant sequence homology within the family members. Also shown in Table 1 are the germline sequences for  $V_{\lambda 1}$  family members. The heavy and light chain sequences  
10 of Joe 9 are provided as a comparison. Mutations to the germline sequences of  $V_{H3}$  or  $V_{\lambda 1}$  family members may be made, for example, at the same amino acid positions as  
20 those made in the antibodies of the invention (e.g. mutations in Joe 9). The modifications can be performed using standard molecular biology techniques, such as by  
25 PCR mutagenesis, targeting individual amino acid residues in the germline sequences, followed by kinetic and functional analysis of the modified antibodies as described  
15 herein (e.g., neutralization assays described in Example 3, and by BIAcore analysis, as described in Example 5).

30 Accordingly, in one aspect, the invention features isolated human antibody, or an antigen-binding portion thereof, which has the following characteristics:

- 20 a) has a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 595-667, wherein the heavy chain variable region has a mutation at a preferred selective mutagenesis position, contact or  
35 hypermutation position with an activity enhancing amino acid residue.
- b) has a light chain variable region comprising an amino acid sequence  
40 25 selected from the group consisting of SEQ ID NOs: 669-675, wherein the light chain variable region has a mutation at a preferred selective mutagenesis position, contact or  
hypermutation position with an activity enhancing amino acid residue.

45 An ordinarily skilled artisan will appreciate that based on the high amino acid sequence similarity between Joe 9 and COS-3 heavy chain germline sequence, and  
30 between Joe 9 and DPL8 lambda germline sequence, that other mutations to the CDR regions of these germlines sequences can provide additional antibodies that bind to  
50  
55

human IL-12. Such methods of modification can be performed using standard molecular biology techniques as described above.

Accordingly, in one aspect, the invention features isolated human antibody, or an antigen-binding portion thereof, which has the following characteristics:

a) that binds to human IL-12 and dissociates from human IL-12 with a  $k_{off}$  rate constant of  $0.1 s^{-1}$  or less, as determined by surface plasmon resonance, or which inhibits phytohemagglutinin blast proliferation in an *in vitro* phytohemagglutinin blast proliferation assay (PHA assay) with an  $IC_{50}$  of  $1 \times 10^{-6} M$  or less.

b) has a heavy chain variable region comprising the COS-3 germline amino acid sequence, wherein the heavy chain variable region has a mutation at a preferred selective mutagenesis position, contact or hypermutation position with an activity enhancing amino acid residue.

c) has a light chain variable region comprising the DPL8 germline amino acid sequence, wherein the light chain variable region has a mutation at a preferred selective mutagenesis position, contact or hypermutation position with an activity enhancing amino acid residue.

Due to certain amino acid residues occupying key sites in the CDR and framework regions in the light and heavy chain variable region, structural features are conferred at these regions. In particular, the CDR2 and CDR1 regions are subject to canonical structural classifications. Since there is a high degree of amino acids sequence homology between family members, these canonical features are present between family members. The skilled artisan will appreciate that modifications at the amino acid residues that confer these canonical structures would produce additional antibodies that bind to IL-12. The modifications can be performed using standard molecular biology techniques as described above.

Accordingly, in another aspect, the invention features an isolated human antibody, or an antigen-binding portion thereof, which has the following characteristics:

a) that binds to human IL-12 and dissociates from human IL-12 with a  $k_{off}$  rate constant of  $0.1 s^{-1}$  or less, as determined by surface plasmon resonance, or which inhibits phytohemagglutinin blast proliferation in an *in vitro* phytohemagglutinin blast proliferation assay (PHA assay) with an  $IC_{50}$  of  $1 \times 10^{-6} M$  or less.



b) has a heavy chain variable region comprising an amino acid sequence selected from a member of the  $V_H3$  germline family, wherein the heavy chain variable region comprises a CDR2 that is structurally similar to CDR2s from other  $V_H3$  germline family members, and a CDR1 that is structurally similar to CDR1s from other  $V_H3$  germline family members, and wherein the heavy chain variable region has a mutation at a preferred selective mutagenesis position, contact or hypermutation position with an activity enhancing amino acid residue;

c) has a light chain variable region comprising an amino acid sequence selected from a member of the  $V_L1$  germline family, wherein the light chain variable region comprises a CDR2 that is structurally similar to CDR2s from other  $V_L1$  germline family members, and a CDR1 that is structurally similar to CDR1s from other  $V_L1$  germline family members, and wherein the light chain variable region has a mutation at a preferred selective mutagenesis position, contact or hypermutation position with an activity enhancing amino acid residue.

Recombinant human antibodies of the invention have variable and constant regions which are homologous to human germline immunoglobulin sequences selected from the VBASE database. Mutations to the recombinant human antibodies (e.g., by random mutagenesis or PCR mutagenesis) result in amino acids that are not encoded by human germline immunoglobulin sequences. Also, libraries of recombinant antibodies which were derived from human donors will contain antibody sequences that differ from their corresponding germline sequences due to the normal process of somatic mutation that occurs during B-cell development. It should be noted that if the "germline" sequences obtained by PCR amplification encode amino acid differences in the framework regions from the true germline configuration (*i.e.*, differences in the amplified sequence as compared to the true germline sequence), it may be desirable to change these amino acid differences back to the true germline sequences (*i.e.*, "backmutation" of framework residues to the germline configuration). Thus, the present invention can optionally include a backmutation step. To do this, the amino acid sequences of heavy and light chain encoded by the germline (as found as example in VBASE database) are first compared to the mutated immunoglobulin heavy and light chain framework amino acid sequences to identify amino acid residues in the mutated immunoglobulin framework sequence that differ from the closest germline sequences.

5 Then, the appropriate nucleotides of the mutated immunoglobulin sequence are mutated  
back to correspond to the germline sequence, using the genetic code to determine which  
nucleotide changes should be made. Mutagenesis of the mutated immunoglobulin  
10 framework sequence is carried out by standard methods, such as PCR-mediated  
mutagenesis (in which the mutated nucleotides are incorporated into the PCR primers  
such that the PCR product contains the mutations) or site-directed mutagenesis. The role  
15 of each amino acid identified as candidate for backmutation should be investigated for a  
direct or indirect role in antigen binding and any amino acid found after mutation to  
affect any desirable characteristic of the human antibody should not be included in the  
20 final human antibody; as an example, activity enhancing amino acids identified by the  
selective mutagenesis approach will not be subject to backmutation. Assays to determine  
the characteristics of the antibody resulting from mutagenesis can include ELISA,  
competitive ELISA, *in vitro* and *in vivo* neutralization assays and/or (see e.g. Example  
25 3) immunohistochemistry with tissue sections from various sources (including human,  
primate and/or other species).

To minimize the number of amino acids subject to backmutation those amino  
acid positions found to be different from the closest germline sequence but identical to  
30 the corresponding amino acid in a second germline sequence can remain, provided that  
the second germline sequence is identical and colinear to the sequence of the human  
20 antibody of the invention for at least 10, preferably 12 amino acids, on both sides of the  
amino acid in question. This would assure that any peptide epitope presented to the  
35 immune system by professional antigen presenting cells in a subject treated with the  
human antibody of the invention would not be foreign but identical to a self-antigen, i.e.  
the immunoglobulin encoded by that second germline sequence. Backmutation may  
40 occur at any stage of antibody optimization; preferably, backmutation occurs directly  
before or after the selective mutagenesis approach. More preferably, backmutation  
occurs directly before the selective mutagenesis approach.

### 45 III. Modifications to Preferred Selective Mutagenesis Positions, Contact and/or 30 Hypermutation Positions

Typically, selection of antibodies with improved affinities can be carried out  
50 using phage display methods, as described in section II above. This can be

5 accomplished by randomly mutating combinations of CDR residues and generating large  
libraries containing antibodies of different sequences. However, for these selection  
10 methods to work, the antibody-antigen reaction must tend to equilibrium to allow, over  
time, preferential binding of higher affinity antibodies to the antigen. Selection  
5 conditions that would allow equilibrium to be established could not be determined  
(presumably due to additional non-specific interactions between the antigen and phage  
15 particle) when phage display methods were used to improve the affinity of selected anti-  
IL-12 antibodies, upon attaining a certain level of affinity achieved (*i.e.*, that of antibody  
Y61). Accordingly, antibodies with even higher affinities could not be selected by  
10 phage display methods. Thus, for at least certain antibodies or antigens, phage display  
methods are limiting in their ability to select antibodies with a highly improved binding  
20 specificity/affinity. Accordingly, a method termed Selective Mutagenesis Approach  
which does not require phage display affinity maturation of antibodies, was established  
to overcome this limitation and is provided by the invention. Although this Selective  
25 Mutagenesis Approach was developed to overcome limitations using the phage display  
system, it should be noted that this method can also be used with the phage display  
system. Moreover, the selective mutagenesis approach can be used to improve the  
30 activity of any antibody.

To improve the activity (e.g., affinity or neutralizing activity) of an antibody,  
20 ideally one would like to mutate every CDR position in both the heavy and light chains  
to every other possible amino acid residue. However, since there are, on average, 70  
35 CDR positions within an antibody, such an approach would be very time consuming and  
labor intensive. Accordingly, the method of the invention allows one to improve the  
activity of the antibody by mutating only certain selected residues within the heavy  
40 and/or light chain CDRs. Furthermore, the method of the invention allows improvement  
25 in activity of the antibody without affecting other desirable properties of the antibody.

Determining which amino acid residues of an antibody variable region are in  
45 contact with an antigen cannot be accurately predicted based on primary sequence or  
their positions within the variable region. Nevertheless, alignments of sequences from  
30 antibodies with different specificities conducted by Kabat *et al.* have identified the  
CDRs as local regions within the variable regions which differ significantly among  
50 antibodies (Kabat *et al.* (1971) *Ann. NY Acad. Sci.* 190:382-393, , Kabat, E.A., *et al.*

(1991) *Sequences of Proteins of Immunological Interest, Fifth Edition*, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). Structural studies have shown that the antigen binding surface is formed by amino acid residues present in the CDRs. Other amino acid residues outside the CDR are also known to play structural roles or be directly involved in antigen binding. Therefore, for each antigen-antibody pair, amino acid residues within and outside of the CDRs may be important.

The sequence alignment studies by Tomlison *et al* identified a number of positions in the heavy and light chain CDR1 and CDR2, and in a portion of the kappa chain CDR3 which are frequent sites of somatic mutation. (Tomlison *et al* (1996) *J. Mol. Biol.* 256: 813-817). In particular, positions H31, H31B, H33, H33B, H52B, H56, H58, L30, L31, L31A, L50, L53, L91, L92, L93 and L94 were identified as frequent sites for somatic mutation. However, this analysis excludes the important heavy chain CDR3 regions, and sections of the light chain CDR3 which are known to lie in the center of an antibody binding site, and potentially provide important interactions with an antigen. Furthermore, Tomlison *et al.* propose that somatic diversity alone does not necessarily predict a role of a specific amino acid in antigen binding, and suggest conserved amino acid residues that contact the antigen, and diverse amino acid residues which do not contact the antigen. This conclusion is further supported by mutational studies on the role of somatic mutations to antibody affinity (Sharon, (1990), *PNAS*, 87:4814-7). Nineteen somatic mutations in a high-affinity anti-p-azophenylarsonate (Ars) antibody were simultaneously replaced with their corresponding germline residues, generating a germline version of the anti-Ars antibody which had a two-hundred fold loss in activity. The full affinity of the anti-Ars antibody could be recovered by restoring only three of the nineteen somatic mutations, demonstrating that many somatic mutations may be permitted that do not contribute to antigen binding activity.

The result can be explained in part by the nature of antibody diversity itself. Immature B-cells may produce initially low affinity antibodies that recognize a number of self or non-self antigens. Moreover, antibodies may undergo in the course of affinity maturation sequence variations that may cause self-reactivity. Hypermutation of such low affinity antibodies may serve to abolish self-reactivity ("negative selection") and increase affinity for the foreign antigen. Therefore, the analysis of primary and

5 structural data of a large number of antibodies does not provide a method of predicting  
either (1) the role of somatic hyper-mutation sites in the affinity maturation process  
10 versus the process of decreasing affinity towards unwanted antigens, or (2) how a given  
amino acid contributes to the properties of a specific antigen-antibody pair.

5 Other attempts to address the role of specific amino acid residues in antigen  
recognition were made by analyzing a number of crystal structures of antigen-antibody  
15 complexes (MacCallum *et al.* (1996) *J. Mol. Biol.* 262: 732-745). The potential role of  
positions located within and outside the CDRs was indicated. Positions in CDRs  
involved in antigen binding in more than 10 of 26 analyzed structures included H31,  
10 H33, H50, H52, H53, H54, H56, H58, H95, H96, H97, H98 and H100 in the heavy  
20 chain and L30A, L32, L91, L92, L93, L94, L96 in the light chain. However, the authors  
noted that prediction of antigen contacts using these and other structural data may over  
and under predict contact positions, leading to the speculation that a different strategy  
25 may have to be applied to different antigens.

15 Pini *et al.* describe randomizing multiple residues in antibody CDR sequences in  
a large phage display library to rapidly increase antibody affinity (Pini *et al.* (1998) *J.*  
30 *Biol Chem.* 273: 21769-21776). However, the high affinity antibodies discussed by Pini  
*et al.* had mutations in a total of eight positions, and a reductionary analysis of which  
changes are absolutely required to improve affinity of the antibody becomes impractical  
20 because of the large number of possible combinations to be tested for the smallest  
number of amino acids required.

35 Furthermore, randomizing multiple residues may not necessarily preserve other  
desired properties of the antibody. Desirable properties or characteristics of an antibody  
are art-recognized and include for example, preservation of non-cross reactivity, e.g.,  
40 25 with other proteins or human tissues and preservation of antibody sequences that are  
close to human germline immunoglobulin sequences improvement of neutralization  
potency. Other desirable properties or characteristics include ability to preserve species  
cross reactivity, ability to preserve epitope specificity and ability to preserve high  
45 expression levels of protein in mammalian cells. The desirable properties or  
30 characteristics can be observed or measured using art-recognized techniques including  
but not limited to ELISA, competitive ELISA, *in vitro* and *in vivo* neutralization assays  
50 (see e.g. Example 3), immunohistochemistry with tissue sections from different sources

5 including human, primate or other sources as the need may be, and studies to expression in mammalian cells using transient expression or stable expression.

10 In addition, the method of Pini et al may introduce more changes than the minimal number actually required to improve affinity and may lead to the antibodies triggering anti-human-antibody (HAMA) formation in human subjects.  
15 Further, as discussed elsewhere, the phage display as demonstrated here, or other related method including ribosome display may not work appropriately upon reaching certain affinities between antibody and antigen and the conditions required to reach equilibrium may not be established in a reasonable time frame because of additional interactions  
20 including interactions with other phage or ribosome components and the antigen.

25 The ordinarily skilled artisan may glean interesting scientific information on the origin of antibody diversity from the teachings of the references discussed above. The present invention, however, provides a method for increasing antibody affinity of a specific antigen-antibody pair while preserving other relevant features or desirable  
30 characteristics of the antibody. This is especially important when considering the desirability of imparting a multitude of different characteristics on a specific antibody including antigen binding.

35 If the starting antibody has desirable properties or characteristics which need to be retained, a selective mutagenesis approach can be the best strategy for preserving these desirable properties while improving the activity of the antibody. For example, in  
40 the mutagenesis of Y61, the aim was to increase affinity for hIL-12, and to improve the neutralization potency of the antibody while preserving desired properties. Desired properties of Y61 included (1) preservation of non-cross reactivity with other proteins or human tissues, (2) preservation of fine epitope specificity, i.e. recognizing a p40 epitope  
45 preferably in the context of the p75 (p40/p35) heterodimer, thereby preventing binding interference from free soluble p40; and (3) generation of an antibody with heavy and light chain amino acid sequences that were as close as possible to their respective germline immunoglobulin sequences.

50 In one embodiment, the method of the invention provides a selective mutagenesis approach as a strategy for preserving the desirable properties or characteristics of the antibody while improving the affinity and/or neutralization potency. The term "selective mutagenesis approach" is as defined above and includes a

5 method of individually mutating selected amino acid residues. The amino acid residues  
to be mutated may first be selected from preferred selective mutagenesis positions, then  
from contact positions, and then from hypermutation positions. The individual selected  
10 position can be mutated to at least two other amino acid residue and the effect of the  
5 mutation both on the desired properties of the antibody, and improvement in antibody  
activity is determined.

15 The Selective Mutagenesis approach comprises the steps of:

selecting candidate positions in the order 1) preferred selective mutagenesis  
positions; 2) contact positions; 3) hypermutation positions and ranking the positions  
10 based on the location of the position within the heavy and light chain variable regions of  
an antibody (CDR3 preferred over CDR2 preferred over CDR1);

20 individually mutating candidate preferred selective mutagenesis positions,  
hypermutation and/or contact positions in the order of ranking, to all possible other  
amino acid residues and analyzing the effect of the individual mutations on the activity  
25 of the antibody in order to determine activity enhancing amino acid residues;

if necessary, making stepwise combinations of the individual activity enhancing  
amino acid residues and analyzing the effect of the various combinations on the activity  
30 of the antibodies; selecting mutant antibodies with activity enhancing amino acid  
residues and ranking the mutant antibodies based on the location and identity of the  
20 amino acid substitutions with regard to their immunogenic potential. Highest ranking is  
given to mutant antibodies that comprise an amino acid sequence which nearly identical  
35 to a variable region sequence that is described in a germline database, or has an amino  
acid sequence that is comparable to other human antibodies. Lower ranking is given to  
mutant antibodies containing an amino acid substitution that is rarely encountered in  
40 either germline sequences or the sequences of other human antibodies. The lowest  
ranking is given to mutant antibodies with an amino acid substitution that has not been  
encountered in a germline sequence or the sequence of another human antibody. As set  
45 forth above, mutant antibodies comprising at least one activity enhancing amino acid  
residue located in CDR3 is preferred over CDR2 which is preferred over CDR1. The  
30 CDRs of the heavy chain variable regions are preferred over those of the light chain  
variable region.

5 The mutant antibodies can also be studied for improvement in activity, *e.g.* when compared to their corresponding parental antibody. The improvement in activity of the mutant antibody can be determined for example, by neutralization assays, or binding  
10 specificity/affinity by surface plasmon resonance analysis (see Example 3). Preferably, the improvement in activity can be at least 2-20 fold higher than the parental antibody. The improvement in activity can be at least " $x_1$ " to " $x_2$ " fold higher than the parental antibody wherein " $x_1$ " and " $x_2$ " are integers between and including 2 to 20, including  
15 ranges within the state range, *e.g.* 2-15, *e.g.* 5-10.

The mutant antibodies with the activity enhancing amino acid residue also can be  
10 studied to determine whether at least one other desirable property has been retained after mutation. For example, with anti-hIL-12 antibodies testing for, (1) preservation of non-cross reactivity with other proteins or human tissues, (2) preservation of epitope  
20 recognition, *i.e.* recognizing a p40 epitope preferably in the context of the p70 (p40/p35) heterodimer, thereby preventing binding interference from free soluble p40; and (3)  
25 generation of antibodies with heavy and light chain amino acid sequences that were as close as possible to their respective germline immunoglobulin sequences, and determining which would be least likely to elicit a human immune response based on the  
30 number of differences from the germline sequence. The same observations can be made on an antibody having more than one activity enhancing amino acid residues, *e.g.* at  
20 least two or at least three activity enhancing amino acid residues, to determine whether retention of the desirable property or characteristic has occurred.

35 An example of the use of a "selective mutagenesis approach", in the mutagenesis of Y61 is described below. The individual mutations H31S→E, L50→Y, or L94G→Y each improved neutralization activity of the antibody. However, when combination  
40 clones were tested, the activity of the combined clone H31S→E + L50→Y + L94G→Y was no better than L50→Y + L94G→Y (J695). Therefore, changing the germline amino acid residue Ser to Glu at position 31 of CDR1 was unnecessary for the improved  
45 activity of J695 over Y61. The selective mutagenesis approach therefore, identified the minimal number of changes that contributed to the final activity, thereby reducing the immunogenic potential of the final antibody and preserving other desired properties of  
30 the antibody.



Isolated DNA encoding the VH and VL produced by the selected mutagenesis approach can be converted into full length antibody chain genes, to Fab fragment genes as to a scFV gene, as described in section IV. For expression of VH and VL regions produced by the selected mutagenesis approach, expression vectors encoding the heavy and light chain can be transfected into variety host cells as described in detail in section IV. Preferred host cells include either prokaryotic host cells, for example, *E coli*, or eukaryotic host cells, for example, yeast cells, e.g., *S. cerevisiae*. Most preferred eukaryotic host cells are mammalian host cells, described in detail in section IV.

The selective mutagenesis approach provides a method of producing antibodies with improved activities without prior affinity maturation of the antibody by other means. The selective mutagenesis approach provides a method of producing antibodies with improved affinities which have been subject to back mutations. The selective mutagenesis approach also provides a method of improving the activity of affinity matured antibodies.

The skilled artisan will recognize that the selective mutagenesis approach can be used in standard antibody manipulation techniques known in the art. Examples include, but are not limited to, CDR grafted antibodies, chimeric antibodies, scFV fragments, Fab fragments of a full length antibodies and human antibodies from other sources, e.g., transgenic mice.

Rapid large scale mutational analysis of antibodies include *in vitro* transcription and translation using ribosome display technology (see e.g., Hanes *et al.*, (1997) *Proc. Natl. Acad. Sci.* 94: 4937-4942; Dallacqua *et al.*, (1998) *Curr. Opin. Struc. Biol.* 8: 443-450; He *et al.*, (1997) *Nucleic Acid Res.* 25: 5132-5134), and U.S. Patent Nos. 5,643,768 and 5,658,754 issued to Kawasaki. The selective mutagenesis approach also provides a method of producing antibodies with improved activities that can be selected using ribosomal display techniques.

In the methods of the invention, antibodies or antigen binding portions thereof are further modified by altering individual positions in the CDRs of the HCVR and/or LCVR. Although these modifications can be made in phage-displayed antibodies, the method is advantageous in that it can be performed with antibodies that are expressed in other types of host systems, such as bacterial, yeast or mammalian cell expression

5 systems. The individual positions within the CDRs selected for modification are based on the positions being a contact and/or hypermutation position.

10 Preferred contact positions and hypermutation positions as defined herein are shown in Table 3 (see Appendix A) and their modification in accordance with the method of the invention is described in detail in Example 2. Preferred contact positions are selected from the group consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96. Preferred hypermutation positions are selected from the group consisting of H30, H31, H31B, H32, H52, H56, H58, L30, L31, L32, L53 and L93. More preferred amino acid residues (referred to as "preferred selective mutagenesis positions") are both contact and hypermutation positions and are selected from the group consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93, L94. Particularly preferred contact positions are selected from the group consisting of L50 and L94.

25 Preferred activity enhancing amino acid residues replace amino acid residues located at positions selected from the group consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94, and L96. More preferred activity enhancing amino acid residues replace amino acid residues located at positions H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93, L94. Particularly, preferred activity enhancing amino acid residues replace amino acid residues located at positions selected from the group consisting of L50 and L94.

35 In general, the method of the invention involves selecting a particular preferred selective mutagenesis position, contact and/or hypermutation position within a CDR of the heavy or light chain of a parent antibody of interest, or antigen binding portion thereof, randomly mutagenizing that individual position (e.g., by genetic means using a mutagenic oligonucleotide to generate a "mini-library" of modified antibodies), or mutating a position to specific desired amino acids, to identify activity enhancing amino acid residues expressing, and purifying the modified antibodies (e.g., in a non-phage display host system), measuring the activity of the modified antibodies for antigen (e.g., by measuring  $k_{off}$  rates by BIAcore analysis), repeating these steps for other CDR positions, as necessary, and combining individual mutations shown to have improved

activity and testing whether the combination(s) generate an antibody with even greater activity (e.g., affinity or neutralizing potency) than the parent antibody, or antigen-binding portion thereof.

Accordingly, in one embodiment, the invention provides a method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

- a) providing a parent antibody or antigen-binding portion thereof;
- b) selecting in order a 1) preferred selective mutagenesis position, 2) contact position, or 3) hypermutation position within a complementarity determining region (CDR) for mutation, thereby identifying a selected preferred selective mutagenesis position, contact or hypermutation position;
- c) individually mutating said selected preferred selective mutagenesis position, contact or hypermutation position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof;
- d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof;
- e) optionally, repeating steps a) through d) for at least one other preferred selective mutagenesis position, contact or hypermutation position;
- f) combining, in the parent antibody, or antigen-binding portion thereof, individual mutations shown to have improved activity, to form combination antibodies, or antigen-binding portions thereof; and
- g) evaluating the activity of the combination antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof; until an antibody, or antigen-binding portion thereof, with an improved activity, relative to the parent antibody, or antigen-binding portion thereof, is obtained. Preferably, the selected antibody or antibodies have an improved activity without loss or with retention of at least one desirable characteristic or property of the parental antibody as described above. The desirable characteristic or property can be measured or observed by the ordinarily skilled artisan using art-recognized techniques.

Preferred contact positions are selected from the group consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96. Preferred hypermutation positions are selected from the group consisting of H30, H31, H31B,

- 76 -

5 H32, H52, H56, H58, L30, L31, L32, L53 and L93. More preferred preferred selective  
mutagenesis positions are selected from the group consisting of H30, H31, H31B, H32,  
10 H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93 and L94. Particularly  
preferred contact positions are selected from the group consisting of L50 and L94.

5 In another embodiment, the invention provides a method for improving the  
activity of an antibody, or antigen-binding portion thereof, comprising:

15 a) providing a parent antibody or antigen-binding portion thereof;

b) selecting a preferred selective mutagenesis position, contact or hypermutation  
position within a complementarity determining region (CDR) for mutation;

10 c) individually mutating said selected preferred selective mutagenesis position,  
20 contact or hypermutation position to at least two other amino acid residues to thereby  
create a panel of mutated antibodies, or antigen-binding portions thereof;

d) evaluating the activity of the panel of mutated antibodies, or antigen-binding  
portions thereof, relative to the parent antibody or antigen-binding portion thereof,

25 thereby identifying an activity enhancing amino acid residue;

e) optionally, repeating steps a) through d) for at least one other preferred  
selective mutagenesis position, contact or hypermutation position;

30 f) combining, in the parent antibody, or antigen-binding portion thereof, two  
individual activity enhancing amino acid residues shown to have improved activity, to  
20 form combination antibodies, or antigen-binding portions thereof; and

35 g) evaluating the activity of the combination antibodies, or antigen-binding  
portions thereof with two activity enhancing amino acid residues, relative to the parent  
antibody or antigen-binding portion thereof;

40 until an antibody, or antigen-binding portion thereof, with an improved activity, relative  
25 to the parent antibody, or antigen-binding portion thereof, is obtained.

Preferred contact positions are selected from the group consisting of H30, H31,  
H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98,  
45 H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96. Preferred  
hypermutation positions are selected from the group consisting of H30, H31, H31B,  
30 H32, H52, H56, H58, L30, L31, L32, L53 and L93. More preferred preferred selective  
mutagenesis positions are selected from the group consisting of H30, H31, H31B, H32,

5

10

5

15

10

20

25

15

30

20

35

40

25

45

30

50

55

- 77 -

H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93 and L94. Particularly preferred contact positions are selected from the group consisting of L50 and L94.

In another embodiment, the invention provides a method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

- a) providing a parent antibody or antigen-binding portion thereof;
- b) selecting a preferred selective mutagenesis position, contact or hypermutation position within a complementarity determining region (CDR) for mutation;
- c) individually mutating said selected preferred selective mutagenesis position, contact or hypermutation position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof;
- d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, thereby identifying an activity enhancing amino acid residue;
- e) optionally, repeating steps a) through d) for at least one other preferred selective mutagenesis position, contact or hypermutation position;
- f) combining, in the parent antibody, or antigen-binding portion thereof, three individual activity enhancing amino acid residues shown to have improved activity, to form combination antibodies, or antigen-binding portions thereof; and
- g) evaluating the activity of the combination antibodies, or antigen-binding portions thereof with two activity enhancing amino acid residues, relative to the parent antibody or antigen-binding portion thereof, until an antibody, or antigen-binding portion thereof, with an improved activity, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

Preferably, the activity enhancing amino acid residue replaces amino acid residues located at positions selected from the group consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96.

Following mutagenesis of individual selected positions, mutated clones can be sequenced to identify which amino acid residues have been introduced into the selected position in each clone. A small number of clones (e.g., about 24) can be selected for sequencing, which statistically should yield 10-15 unique antibodies, whereas larger

5 numbers of clones (e.g., greater than 60) can be sequenced to ensure that antibodies with every possible substitution at the selected position are identified.

10 In one embodiment, contact and/or hypermutation positions within the CDR3 regions of the heavy and/or light chains are first selected for mutagenesis. However, for 5 antibodies that have already been affinity matured *in vitro* by random mutagenesis of the CDR3 regions via phage display selection, it may be preferably to first select contact and/or hypermutation positions within CDR1 or CDR2 of the heavy and/or light chain.

15 In a more preferred embodiment, preferred selective mutagenesis positions within the CDR3 regions of the heavy and/or light chains are first selected for 10 mutagenesis. However, for antibodies that have already been affinity matured *in vitro* by random mutagenesis of the CDR3 regions via phage display selection, it may be preferably to first select preferred selective mutagenesis positions within CDR1 or CDR2 of the heavy and/or light chain.

25 In another preferred embodiment, the optimization of a selected antibody by the 15 selective mutagenesis approach is done sequentially as follows: preferred selective mutagenesis positions selected from the group consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93, L94 are mutated first to at 30 least 2 other amino acids each (preferably 5-14 other amino acids) and the resulting antibodies are characterized for increased affinity, neutralization potency (and possibly 20 also for at least one other retained characteristic or property discussed elsewhere). If a mutation of a single preferred selective mutagenesis position does not increase the 35 affinity or neutralization potency at all or sufficiently and if even the combination of multiple activity enhancing amino acids replacing amino acids in preferred selective mutagenesis positions does not result in a combination antibody which meets the target 40 activity (including affinity and/or neutralization potency), additional amino acid residues 25 will be selected for selective mutagenesis from the group consisting of H35, H50, H53, H54, H95, H96, H97, H98, L30A and L96 are mutated to at least 2 other amino acids 45 each (preferably 5-14 other amino acids) and the resulting antibodies are characterized for increased affinity, neutralization potency (and possibly also for at least one other 30 retained characteristic or property discussed elsewhere).

5 If a mutation of a single amino acid residue selected from the group consisting of  
H35, H50, H53, H54, H95, H96, H97, H98, L30A and L96 does not increase the activity  
10 (including affinity and/or neutralization potency) at all or not sufficiently and if even the  
combination of multiple activity enhancing amino acids replacing amino acids in those  
5 positions does not result in an combination antibody which meets the targeted activity  
(including affinity and/or target neutralization potency), additional amino acid residues  
15 will be selected for selective mutagenesis from the group consisting of H33B, H52B,  
L31A and are mutated to at least 2 other amino acids each (preferably 5-14 other amino  
acids) and the resulting antibodies are characterized for increased affinity, neutralization  
10 potency (and possibly also for at least one other retained characteristic or property  
discussed elsewhere).

20 It should be understood that the sequential selective mutagenesis approach may  
end at any of the steps outline above as soon as an antibody with the desired activity  
(including affinity and neutralization potency) has been identified. If mutagenesis of the  
25 preselected positions has identified activity enhancing amino acids residues but the  
combination antibody still do not meet the targets set for activity (including affinity and  
neutralization potency) and/or if the identified activity enhancing amino acids also affect  
30 other desired characteristics and are therefore not acceptable, the remaining CDR  
residues may be subjected to mutagenesis (see section IV).

20 The method of the invention can be used to improve activity of an antibody, or  
antigen binding portion thereof, to reach a predetermined target activity (e.g. a  
35 predetermined affinity and/or neutralization potency, and/or a desired property or  
characteristic).

40 Accordingly, the invention provides a method of improving the activity of an  
25 antibody, or antigen-binding portion thereof, to attain a predetermined target activity,  
comprising:

- a) providing a parent antibody a antigen-binding portion thereof;
- b) selecting a preferred selective mutagenesis position selected from group  
45 consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32, L50, L91,  
30 L92, L93, L94.

- 80 -

5 c) individually mutating the selected preferred selective mutagenesis position to at least two other amino acid residues to hereby create a first panel of mutated antibodies, or antigen binding portions thereof;

10 d) evaluating the activity of the first panel of mutated antibodies, or antigen binding portions thereof to determine if mutation of a single selective mutagenesis position produces an antibody or antigen binding portion thereof with the predetermined target activity or a partial target activity;

15 e) combining in a stepwise fashion, in the parent antibody, or antigen binding portion thereof, individual mutations shown to have an improved activity, to form combination antibodies, or antigen binding portions thereof.

20 f) evaluating the activity of the combination antibodies, or antigen binding portions thereof to determine if the combination antibodies, or antigen binding portions thereof have the predetermined target activity or a partial target activity.

25 g) if steps d) or f) do not result in an antibody or antigen binding portion thereof having the predetermined target activity, or result an antibody with only a partial activity, additional amino acid residues selected from the group consisting of H35, H50, H53, H54, H95, H96, H97, H98, L30A and L96 are mutated to at least two other amino acid residues to thereby create a second panel of mutated antibodies or antigen-binding portions thereof;

30 h) evaluating the activity of the second panel of mutated antibodies or antigen binding portions thereof, to determine if mutation of a single amino acid residue selected from the group consisting of H35, H50, H53, H54, H95, H96, H97, H98, L30A and L96 results an antibody or antigen binding portion thereof, having the predetermined target activity or a partial activity;

35 i) combining in a stepwise fashion in the parent antibody, or antigen-binding portion thereof, individual mutations of step g) shown to have an improved activity, to form combination antibodies, or antigen binding portions thereof;

40 j) evaluating the activity of the combination antibodies or antigen binding portions thereof, to determine if the combination antibodies, or antigen binding portions thereof have the predetermined target activity or a partial target activity;

5

10

15

20

25

30

35

40

45

50

55



5 k) if steps h) or j) do not result in an antibody or antigen binding portion thereof having the predetermined target activity, or result in an antibody with only a partial activity, additional amino acid residues selected from the group consisting of II33B, H52B and L31A are mutated to at least two other amino acid residues to thereby create a  
10 third panel of mutated antibodies or antigen binding portions thereof;

15 l) evaluating the activity of the third panel of mutated antibodies or antigen binding portions thereof, to determine if a mutation of a single amino acid residue selected from the group consisting of II33B, H52B and L31A resulted in an antibody or antigen binding portion thereof, having the predetermined target activity or a partial  
20 activity;

25 m) combining in a stepwise fashion in the parent antibody, or antigen binding portion thereof, individual mutation of step k) shown to have an improved activity, to form combination antibodies, or antigen binding portions, thereof;

30 n) evaluating the activity of the combination antibodies or antigen-binding portions thereof, to determine if the combination antibodies, or antigen binding portions thereof have the predetermined target activity to thereby produce an antibody or antigen binding portion thereof with a predetermined target activity.

35 A number of mutagenesis methods can be used, including PCR assembly, Kunkel (dut-ung-) and thiophosphate (Amersham Sculptor kit) oligonucleotide-directed  
40 mutagenesis.

45 A wide variety of host expression systems can be used to express the mutated antibodies, including bacterial, yeast, baculoviral and mammalian expression systems (as well as phage display expression systems). An example of a suitable bacterial expression vector is pUC119(Sfi). Other antibody expression systems are known in the art and/or are described below in section IV.

50 The modified antibodies, or antigen binding portions thereof, produced by the method of the invention can be identified without the reliance on phage display methods for selection. Accordingly, the method of the invention is particularly advantageous for  
55 improving the activity of a recombinant parent antibody or antigen-binding portion thereof, that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in the phage-display system.

Accordingly, in another embodiment, the invention provides a method for improving the affinity of an antibody, or antigen-binding portion thereof, comprising:

a) providing a recombinant parent antibody or antigen-binding portion thereof; that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in said phage-display system;

b) selecting a preferred selective mutagenesis position, contact or hypermutation position within a complementarity determining region (CDR) for mutation, thereby identifying a selected contact or hypermutation position;

c) individually mutating said selected preferred selective mutagenesis position, contact or hypermutation position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof, and expressing said panel in a non-phage display system;

d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof;

e) optionally repeating steps b) through d) for at least one other preferred selective mutagenesis position, contact or hypermutation position;

f) combining, in the parent antibody, or antigen-binding portion thereof, individual mutations shown to have improved activity, to form combination antibodies, or antigen-binding portions thereof; and

g) evaluating the activity of the combination antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof; until an antibody, or antigen-binding portion thereof, with an improved activity, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

Preferred contact positions are selected from the group consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96. Preferred hypermutation positions are selected from the group consisting of H30, H31, H31B, H32, H52, H56, H58, L30, L31, L32, L53 and L93. More preferred preferred selective mutagenesis positions are selected from the group consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93 and L94. Particularly preferred contact positions are selected from the group consisting of L50 and L94.

5 With available methods it is not possible or it is extremely laborious to derive an  
antibody with increased binding affinity and neutralization potency while retaining other  
properties or characteristics of the antibodies as discussed above. The method of this  
10 invention, however, can readily identify such antibodies. The antibodies subjected to the  
5 method of this invention can come from any source.

Therefore, in another embodiment, the invention provides a method for  
improving the activity of an antibody, or antigen-binding portion thereof, comprising:

- 15 a) providing a recombinant parent antibody or antigen-binding portion thereof;
- b) selecting a preferred selective mutagenesis position, contact or hypermutation  
10 position within a complementarity determining region (CDR) for mutation, thereby  
20 identifying a selected preferred selective mutagenesis position, contact or hypermutation  
position;
- c) individually mutating said selected preferred selective mutagenesis position,  
25 contact or hypermutation position to at least two other amino acid residues to thereby  
15 create a panel of mutated antibodies, or antigen-binding portions thereof and expressing  
said panel in an appropriate expression system;
- d) evaluating the activity of the panel of mutated antibodies, or antigen-binding  
30 portions thereof, relative to the parent antibody or antigen-binding portion thereof,  
thereby identifying an activity enhancing amino acid residue;
- 20 e) evaluating the panel of mutated antibodies, or antigen-binding portions  
thereof, relative to the parent antibody or antigen-binding portion thereof for at least one  
35 other property or characteristics, wherein the property or characteristic is one that needs  
to be retained in the antibody;  
until an antibody, or antigen-binding portion thereof, with an improved activity and at  
40 25 ~~least one retained property or characteristic~~ relative to the parent antibody, or antigen-  
binding portion thereof, is obtained.

In a preferred embodiment, the contact positions are selected from the group  
consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58,  
45 H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93,  
30 L94 and L96 and the other characteristic is selected from 1) preservation of non-  
crossreactivity with other proteins or human tissues, 2) preservation of epitope  
50 recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35

heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence.

In another preferred embodiment, the hypermutation positions are selected from the group consisting of H30, H31, H31B, H32, H52, H56, H58, L30, L31, L32, L53 and L93 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence.

In a more preferred embodiment the residues for selective mutagenesis are selected from the preferred selective mutagenesis positions from the group consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93, L94 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence.

In a more preferred embodiment, the contact positions are selected from the group consisting of L50 and L94 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence.

If therefore, the affinity of an antibody for a specific antigen should be improved, but where the phage display (or related system including ribosome display) method is no longer applicable, and other desirable properties or characteristics should be retained, the method of the invention can be used. Accordingly, in another embodiment, the invention provides a method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

a) providing a recombinant parent antibody or antigen-binding portion thereof; that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in said phage-display system;

5 b) selecting a preferred selective mutagenesis position, contact or hypermutation position within a complementarity determining region (CDR) for mutation, thereby identifying a selected preferred selective mutagenesis position, contact or hypermutation position;

10 c) individually mutating said selected preferred selective mutagenesis position, contact or hypermutation position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof, and expressing said panel in a non-phage display system;

15 d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;

20 e) evaluating the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof for at least one other property or characteristic, wherein the property or characteristic is one that needs to be retained, until an antibody, or antigen-binding portion thereof, with an improved activity and at least one retained property or characteristic, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

25 f) optionally, repeating steps a) through e) for at least one other preferred selective mutagenesis position, contact or hypermutation position;

30 g) combining, in the parent antibody, or antigen-binding portion thereof, at least two individual activity enhancing amino acid residues shown to have improved activity and at least one retained property or characteristic, to form combination antibodies, or antigen-binding portions thereof; and

35 h) evaluating the activity of the combination antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, until an antibody, or antigen-binding portion thereof, with an improved activity and at least one retained other property or characteristic, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

40 In a preferred embodiment, the contact positions are selected from the group consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96 and the other characteristic is selected from 1) preservation of non-

crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence.

5 In another preferred embodiment, the hypermutation positions are selected from the group consisting of H30, H31, H31B, H32, H52, H56, H58, L30, L31, L32, L53 and L93 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence.

10 In a more preferred embodiment the residues for selective mutagenesis are selected from the preferred selective mutagenesis positions from the group consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93, L94 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence.

15 In a more preferred embodiment, the contact positions are selected from the group consisting of L50 and L94 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence.

20 In another embodiment, the invention provides a method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

45 a) providing a recombinant parent antibody or antigen-binding portion thereof; that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in said phage-display system;

5 b) selecting a preferred selective mutagenesis position, contact or hypermutation position within a complementarity determining region (CDR) for mutation, thereby identifying a selected contact or hypermutation position;

10 c) individually mutating said selected preferred selective mutagenesis position, contact or hypermutation position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof, and expressing said panel in a non-phage display system;

15 d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;

20 e) evaluating the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof for at least one other property or characteristic, wherein the property or characteristic is one that needs to be retained, until an antibody, or antigen-binding portion thereof, with an improved activity and at least one retained property or characteristic, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

25 In a preferred embodiment, the contact positions are selected from the group consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence.

30 In another preferred embodiment, the hypermutation positions are selected from the group consisting of H30, H31, H31B, H32, H52, H56, H58, L30, L31, L32, L53 and L93 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence.

5 In a more preferred embodiment the residues for selective mutagenesis are selected from the preferred selective mutagenesis positions from the group consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93, L94  
10 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to  
15 germline immunoglobulin sequence.

In a more preferred embodiment, the contact positions are selected from the  
10 group consisting of L50 and L94 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence.  
20

15 In another embodiment, the invention provides a method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

a) providing a recombinant parent antibody or antigen-binding portion thereof, that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in said phage-display system;  
30

20 b) selecting a preferred selective mutagenesis position, contact or hypermutation position within a complementarity determining region (CDR) for mutation, thereby identifying a selected contact or hypermutation position;

35 c) individually mutating said selected preferred selective mutagenesis positions, contact or hypermutation position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof, and expressing said panel in a non-phage display system;  
40

d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;  
45

30 e) evaluating the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof for at least one other property or characteristic, wherein the property or characteristic is one that needs  
50



to be retained, until an antibody, or antigen-binding portion thereof, with an improved activity and at least one retained characteristic, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

f) optionally, repeating steps a) through c) for at least one other preferred selective mutagenesis position, contact or hypermutation position;

g) combining, in the parent antibody, or antigen-binding portion thereof, at least two individual activity enhancing amino acid residues shown to have improved activity and at least one retained other characteristic, to form combination antibodies, or antigen-binding portions thereof; and

h) evaluating the activity of the combination antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, until an antibody, or antigen-binding portion thereof, with an improved activity and at least one retained property or characteristic, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

In a preferred embodiment, the contact positions are selected from the group consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence.

In another preferred embodiment, the hypermutation positions are selected from the group consisting of H30, H31, H31B, H32, H52, H56, H58, L30, L31, L32, L53 and L93 and the other characteristic is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence.

In a more preferred embodiment the residues for selective mutagenesis are selected from the preferred selective mutagenesis positions from the group consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93, L94

- 90 -

5 and the other characteristic is selected from 1) preservation of non-crossreactivity with  
other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing  
10 p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding  
interference from free, soluble p40 and/or 3) to produce an antibody with a close to  
5 germline immunoglobulin sequence.

In a more preferred embodiment, the contact positions are selected from the  
15 group consisting of L50 and L94 and the other characteristic is selected from 1)  
preservation of non-crossreactivity with other proteins or human tissues, 2) preservation  
of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70  
10 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to  
20 produce an antibody with a close to germline immunoglobulin sequence.

#### IV. Modifications of other CDR residues

25 Ultimately, all CDR residues in a given antibody-antigen pair identified by any  
15 means to be required as activity enhancing amino acid residues and/or required directly  
or indirectly for binding to the antigen and/or for retaining other desirable properties or  
characteristics of the antibody. Such CDR residues are referred to as "preferred  
30 selective mutagenesis positions". It should be noted that in specific circumstances that  
preferred selective mutagenesis residues can be identified also by other means including  
20 co-crystallization of antibody and antigen and molecular modeling.

35 If the preferred attempts to identify activity enhancing amino acids focussing on  
the preferred selective mutagenesis positions, contact or hypermutation positions  
described above are exhausted, or if additional improvements are required, the  
remaining CDR residues may be modified as described below. It should be understood

40 that the antibody could already be modified in any one or more contact or hypermutation  
25 positions according to the embodiments discussed above but may require further  
improvements. Therefore, in another embodiment, the invention provides a method for  
improving the activity of an antibody, or antigen-binding portion thereof, comprising:

- 45 a) providing a parent antibody or antigen-binding portion thereof;  
30 b) selecting an amino acid residue within a complementarity determining region  
(CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A,

5

10

5

15

10

20

25

15

30

20

35

40

25

45

30

50

55

5 H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53,  
L55, L91, L92, L93, L94 and L96;

10 c) individually mutating said selected position e.g., to at least two other amino  
acid residues to thereby create a mutated antibody or a panel of mutated antibodies, or  
5 antigen-binding portions thereof;

15 d) evaluating the activity of the mutated antibody or the panel of mutated  
antibodies, or antigen-binding portions thereof, relative to the parent antibody or  
antigen-binding portion thereof thereby identifying an activity enhancing amino acid  
residue;

20 e) evaluating the mutated antibody or the panel of mutated antibodies, or antigen-  
binding portions thereof, relative to the parent antibody or antigen-binding portion  
thereof, for changes in at least one other property or characteristic until an antibody, or  
antigen-binding portion thereof, with an improved activity, relative to the parent  
25 antibody, or antigen-binding portion thereof, is obtained:

15 Preferably, the other characteristic or property is selected from 1) preservation of  
non-crossreactivity with other proteins or human tissues, 2) preservation of epitope  
recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35  
heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce  
30 an antibody with a close to germline immunoglobulin sequence

20 If mutagenesis of a single residue is not sufficient other residues can be included;  
therefore, in another embodiment, the invention provides a method for improving the  
activity of an antibody, or antigen-binding portion thereof, comprising:

35 a) providing a parent antibody or antigen-binding portion thereof;

40 b) selecting an amino acid residue within a complementarity determining region  
(CDR) for mutation other than H30, H31, H31B, H32, H33, H35; H50, H52, H52A,  
H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53,  
L55, L91, L92, L93, L94 and L96;

45 c) individually mutating said selected position to at least two other amino acid  
residues to thereby create a panel of mutated antibodies, or antigen-binding portions  
30 thereof;

5 d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, thereby identifying an activity enhancing amino acid residue;

10 e) repeating steps b) through d) for at least one other CDR position which is neither the position selected under b) nor a position at H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

15 f) combining, in the parent antibody, or antigen-binding portion thereof, at least two individual activity enhancing amino acid residues shown to have improved activity, to form combination antibodies, or antigen-binding portions thereof; and

20 g) evaluating the activity of the combination antibodies, or antigen-binding portions thereof with two activity enhancing amino acid residues, relative to the parent antibody or antigen-binding portion thereof until an antibody, or antigen-binding portion thereof, with an improved activity, relative to the parent antibody, or antigen-binding  
25 portion thereof, is obtained.

If the preferred attempts to identify activity enhancing amino acids focussing on the contact or hypermutation positions described above are exhausted, or if additional improvements are required, and the antibody in question can not further be optimized by mutagenesis and phage display (or related ribosome display) methods the remaining  
30 CDR residues may be modified as described below. It should be understood that the antibody could already be modified in any one or more preferred selective mutagenesis position, contact or hypermutation positions according to the embodiments discussed above but may require further improvements.

Therefore, in another embodiment, the invention provides a method for  
40 25 improving the activity of an antibody, or antigen-binding portion thereof, comprising:

a) providing a recombinant parent antibody or antigen-binding portion thereof; that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in said phage-display system;

45 b) selecting a selecting an amino acid residue within a complementarity determining region (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and;  
50

5 c) individually mutating said selected contact or hypermutation position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof, and expressing said panel in a non-phage display system;

10 d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;

15 e) evaluating the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, for changes in at least one other property or characteristic, until an antibody, or antigen-binding portion thereof, with an improved activity, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

20 Preferably, the other characteristic or property is selected from 1) preservation of non-crossreactivity with other proteins or human tissues; 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence.

25 If a single mutagenesis is not sufficient to increase the affinity of the antibody other residues may be included in the mutagenesis. Therefore, in another embodiment, the invention provides a method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

30 a) providing a parent antibody or antigen-binding portion thereof that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in said phage-display system;

35 b) selecting an amino acid residue within a complementarity determining region (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

40 c) individually mutating said selected position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof and expression in a non-phage display system;

5 d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;

10 e) repeating steps b) through d) for at least one other position which is neither the position selected under b) nor a position at H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 ;

15 g) combining, in the parent antibody, or antigen-binding portion thereof, at least two individual activity enhancing amino acid residues shown to have improved activity, to form combination antibodies, or antigen-binding portions thereof; and

20 h) evaluating the activity and other property or characteristic of the combination antibodies, or antigen-binding portions thereof with two activity enhancing amino acid residues, relative to the parent antibody or antigen-binding portion thereof; until an antibody, or antigen-binding portion thereof, with an improved activity, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

25 Preferably, the other characteristic or property is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence

30 The preferred attempts to identify activity enhancing amino acids focussing on the preferred selective mutagenesis positions, contact or hypermutation positions described may be exhausted, or additional improvements may be required, and it is important to retain other properties or characteristics of the antibody.

35 Therefore, in another embodiment, the invention provides a method for improving the activity of an antibody, or antigen-binding portion thereof, without affecting other characteristics, comprising:

40 a) providing a parent antibody or antigen-binding portion thereof;

45 b) selecting an amino acid residue within a complementarity determining region (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

5

10

15

20

25

30

35

40

45

50

55

5 c) individually mutating said selected position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof;

10 d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;

15 e) evaluating the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, for changes in at least one other property or characteristic until an antibody, or antigen-binding portion thereof, with an improved activity and retained other property or characteristic, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

20 Preferably, the other characteristic or property is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence.

25 If mutagenesis of a single residue is not sufficient other residues can be included; therefore, in another embodiment, the invention provides a method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

30 a) providing a parent antibody or antigen-binding portion thereof;

35 b) selecting an amino acid residue within a complementarity determining region (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

40 c) individually mutating said selected position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof;

45 d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, thereby identifying an activity enhancing amino acid residue;

50

55

5 c.) evaluating the panel of mutated antibodies or antigen-binding portions thereof, relative to the parent antibody or antigen-portion thereof, for changes in at least one other characteristic or property;

10 e) repeating steps b) through e) for at least one other CDR position which is  
5 neither the position selected under b) nor a position at H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

15 f) combining, in the parent antibody, or antigen-binding portion thereof, at least two individual activity enhancing amino acid residues shown to have improved activity  
10 and not affecting at least one other property or characteristic, to form combination antibodies, or antigen-binding portions thereof; and

20 g) evaluating the activity and the retention of at least one other property or characteristic of the combination antibodies, or antigen-binding portions thereof with two activity enhancing amino acid residues, relative to the parent antibody or antigen-  
25 binding portion thereof until an antibody, or antigen-binding portion thereof, with an improved activity and at least one retained other property or characteristic, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

30 Mutagenesis of the preferred selective mutagenesis position, contact and hypermutation residues may not have increased the affinity of the antibody sufficiently,  
20 and mutagenesis and the phage display method (or related ribosome display method) may no longer be useful and at least one other characteristic or property of the antibody  
35 should be retained.

Therefore, in another embodiment the invention provides a method to improve the affinity of an antibody or antigen-binding portion thereof, comprising:

40 25 a) providing a parent antibody or antigen-binding portion thereof that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in said phage-display system;

45 b) selecting an amino acid residue within a complementarity determining region (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A,  
30 H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;



5 c) individually mutating said selected position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof and expression in a non-phage display system;

10 d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;

15 e) evaluating the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, for changes in at least one other property or characteristic until an antibody, or antigen-binding portion thereof, with an improved activity, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

20 Preferably, the other characteristic or property is selected from 1) preservation of non-crossreactivity with other proteins or human tissues, 2) preservation of epitope recognition, i.e. recognizing p40 epitope preferably in the context of the p70 p40/p35 heterodimer preventing binding interference from free, soluble p40 and/or 3) to produce an antibody with a close to germline immunoglobulin sequence

25 If mutagenesis of a single residue is not sufficient other residues can be included; therefore, in another embodiment, the invention provides a method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

30 a) providing a parent antibody or antigen-binding portion thereof that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in said phage-display system;

35 b) selecting an amino acid residue within a complementarity determining region (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H55, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

40 c) individually mutating said selected position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof and expression in a non-phage display system;

5

10

15

20

25

30

35

40

45

50

55

5 d) evaluating the activity and retention of at least one other property or  
characteristic of the panel of mutated antibodies, or antigen-binding portions thereof,  
relative to the parent antibody or antigen-binding portion thereof, thereby identifying an  
10 activity enhancing amino acid residue;

5 e) repeating steps b) through d) for at least one other CDR position which is  
neither the position selected under b) nor a position at H30, H31, H31B, H32, H33, H35,  
H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32,  
15 L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

f) combining, in the parent antibody, or antigen-binding portion thereof, at least  
10 two individual activity enhancing amino acid residues shown to have improved activity  
and not to affect at least one other property or characteristic, to form combination  
20 antibodies, or antigen-binding portions thereof; and

g) evaluating the activity and retention of at least one property or characteristic  
25 of the combination antibodies, or antigen-binding portions thereof with two activity  
enhancing amino acid residues, relative to the parent antibody or antigen-binding portion  
15 thereof until an antibody, or antigen-binding portion thereof, with an improved activity  
and at least one other retained characteristic or property, relative to the parent antibody,  
30 or antigen-binding portion thereof, is obtained.

## 20 V. Expression of Antibodies

35 An antibody, or antibody portion, of the invention can be prepared by  
recombinant expression of immunoglobulin light and heavy chain genes in a host cell.  
To express an antibody recombinantly, a host cell is transfected with one or more  
recombinant expression vectors carrying DNA fragments encoding the immunoglobulin  
40 25 light and heavy chains of the antibody such that the light and heavy chains are expressed  
in the host cell and, preferably, secreted into the medium in which the host cells are  
cultured, from which medium the antibodies can be recovered. Standard recombinant  
DNA methodologies are used to obtain antibody heavy and light chain genes,  
45 incorporate these genes into recombinant expression vectors and introduce the vectors  
30 into host cells, such as those described in Sambrook, Fritsch and Maniatis (eds),  
*Molecular Cloning: A Laboratory Manual, Second Edition*, Cold Spring Harbor, N.Y.,

(1989), Ausubel, F.M. *et al.* (eds.) *Current Protocols in Molecular Biology*, Greene Publishing Associates, (1989) and in U.S. Patent No. 4,816,397 by Boss *et al.*

To obtain a DNA fragment encoding the heavy chain variable region of Joe 9 wt or a Joe 9 wt-related antibody, antibodies specific for human IL-12 were screened from human libraries and mutated, as described in section II. Once DNA fragments encoding Joe 9 wt or Joe 9 wt-related VH and VL segments are obtained, mutagenesis of these sequences is carried out by standard methods, such as PCR site directed mutagenesis (PCR-mediated mutagenesis in which the mutated nucleotides are incorporated into the PCR primers such that the PCR product contains the mutations) or other site-directed mutagenesis methods. Human IL-12 antibodies that displayed a level of activity and binding specificity/affinity that was desirable, for example J695, were further manipulated by standard recombinant DNA techniques, for example to convert the variable region genes to full-length antibody chain genes, to Fab fragment genes or to a scFv gene. In these manipulations, a VL- or VH-encoding DNA fragment is operatively linked to another DNA fragment encoding another protein, such as an antibody constant region or a flexible linker. The term "operatively linked", as used in this context, is intended to mean that the two DNA fragments are joined such that the amino acid sequences encoded by the two DNA fragments remain in-frame.

The isolated DNA encoding the VH region can be converted to a full-length heavy chain gene by operatively linking the VH-encoding DNA to another DNA molecule encoding heavy chain constant regions (CH1, CH2 and CH3). The sequences of human heavy chain constant region genes are known in the art (see e.g., Kabat, E.A., *et al.* (1991) *Sequences of Proteins of Immunological Interest, Fifth Edition*, U.S. Department of Health and Human Services, NIH Publication No. 91-3242) and DNA fragments encompassing these regions can be obtained by standard PCR amplification. The heavy chain constant region can be an IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM or IgD constant region and any allotypic variant therein as described in Kabat (, Kabat, E.A., *et al.* (1991) *Sequences of Proteins of Immunological Interest, Fifth Edition*, U.S. Department of Health and Human Services, NIH Publication No. 91-3242), but most preferably is an IgG1 or IgG4 constant region. For a Fab fragment heavy chain gene, the VH-encoding DNA can be operatively linked to another DNA molecule encoding only the heavy chain CH1 constant region.

5 The isolated DNA encoding the VL region can be converted to a full-length light chain gene (as well as a Fab light chain gene) by operatively linking the VL-encoding DNA to another DNA molecule encoding the light chain constant region, CL. The sequences of human light chain constant region genes are known in the art (see *e.g.*, Kabat, E.A., *et al.* (1991) *Sequences of Proteins of Immunological Interest, Fifth Edition*, U.S. Department of Health and Human Services, NIH Publication No. 91-3242) and DNA fragments encompassing these regions can be obtained by standard PCR amplification. The light chain constant region can be a kappa or lambda constant region, but most preferably is a lambda constant region.

10 To create a scFv gene, the VH- and VL-encoding DNA fragments are operatively linked to another fragment encoding a flexible linker, *e.g.*, encoding the amino acid sequence (Gly<sub>4</sub>-Ser)<sub>3</sub>, such that the VH and VL sequences can be expressed as a contiguous single-chain protein, with the VL and VH regions joined by the flexible linker (see *e.g.*, Bird *et al.* (1988) *Science* 242:423-426; Huston *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:5879-5883; McCafferty *et al.*, *Nature* (1990) 348:552-554).

15 To express the antibodies, or antibody portions of the invention, DNAs encoding partial or full-length light and heavy chains, obtained as described above, are inserted into expression vectors such that the genes are operatively linked to transcriptional and translational control sequences. In this context, the term "operatively linked" is intended to mean that an antibody gene is ligated into a vector such that transcriptional and translational control sequences within the vector serve their intended function of regulating the transcription and translation of the antibody gene. The expression vector and expression control sequences are chosen to be compatible with the expression host cell used. The antibody light chain gene and the antibody heavy chain gene can be inserted into separate vector or, more typically, both genes are inserted into the same expression vector. The antibody genes are inserted into the expression vector by standard methods (*e.g.*, ligation of complementary restriction sites on the antibody gene fragment and vector, or blunt end ligation if no restriction sites are present). Prior to insertion of the J695 or J695-related light or heavy chain sequences, the expression vector may already carry antibody constant region sequences. For example, one approach to converting the J695 or J695-related VH and VL sequences to full-length antibody genes is to insert them into expression vectors already encoding heavy chain

constant and light chain constant regions, respectively, such that the VH segment is operatively linked to the CH segment(s) within the vector and the VL segment is operatively linked to the CL segment within the vector. Additionally or alternatively, the recombinant expression vector can encode a signal peptide that facilitates secretion of the antibody chain from a host cell. The antibody chain gene can be cloned into the vector such that the signal peptide is linked in-frame to the amino terminus of the antibody chain gene. The signal peptide can be an immunoglobulin signal peptide or a heterologous signal peptide (*i.e.*, a signal peptide from a non-immunoglobulin protein).

In addition to the antibody chain genes, the recombinant expression vectors of the invention carry regulatory sequences that control the expression of the antibody chain genes in a host cell. The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals) that control the transcription or translation of the antibody chain genes. Such regulatory sequences are described, for example, in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). It will be appreciated by those skilled in the art that the design of the expression vector, including the selection of regulatory sequences may depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, *etc.* Preferred regulatory sequences for mammalian host cell expression include viral elements that direct high levels of protein expression in mammalian cells, such as promoters and/or enhancers derived from cytomegalovirus (CMV) (such as the CMV promoter/enhancer), Simian Virus 40 (SV40) (such as the SV40 promoter/enhancer), adenovirus, (*e.g.*, the adenovirus major late promoter (AdMLP)) and polyoma. For further description of viral regulatory elements, and sequences thereof, see *e.g.*, U.S. Patent No. 5,162,062 by Stinski; U.S. Patent No. 4,510,245 by Bell *et al.* and U.S. Patent No. 4,968,615 by Schaffner *et al.*, U.S. Patent No. 5,464,758 by Bujard *et al.* and U.S. Patent No. 5,654,168 by Bujard *et al.*

In addition to the antibody chain genes and regulatory sequences, the recombinant expression vectors of the invention may carry additional sequences, such as sequences that regulate replication of the vector in host cells (*e.g.*, origins of replication) and selectable marker genes. The selectable marker gene facilitates selection of host cells into which the vector has been introduced (see *e.g.*, U.S. Patents Nos. 4,399,216,

5 4,634,665 and 5,179,017, all by Axel *et al.*). For example, typically the selectable  
marker gene confers resistance to drugs, such as G418, hygromycin or methotrexate, on  
10 a host cell into which the vector has been introduced. Preferred selectable marker genes  
include the dihydrofolate reductase (DHFR) gene (for use in dhfr<sup>-</sup> host cells with  
5 methotrexate selection/amplification) and the *neo* gene (for G418 selection).

For expression of the light and heavy chains, the expression vector(s) encoding  
15 the heavy and light chains is transfected into a host cell by standard techniques. The  
various forms of the term "transfection" are intended to encompass a wide variety of  
techniques commonly used for the introduction of exogenous DNA into a prokaryotic or  
10 eukaryotic host cell, *e.g.*, electroporation, calcium-phosphate precipitation, DEAE-  
dextran transfection and the like. Although it is theoretically possible to express the  
20 antibodies of the invention in either prokaryotic or eukaryotic host cells, expression of  
antibodies in eukaryotic cells, and most preferably mammalian host cells, is the most  
preferred because such eukaryotic cells, and in particular mammalian cells, are more  
25 likely than prokaryotic cells to assemble and secrete a properly folded and  
immunologically active antibody. Preferred mammalian host cells for expressing the  
recombinant antibodies of the invention include Chinese Hamster Ovary (CHO cells)  
30 (including dhfr<sup>-</sup> CHO cells, described in Urlaub and Chasin, (1980) *Proc. Natl. Acad. Sci. USA* 77:4216-4220, used with a DHFR selectable marker, *e.g.*, as described in R.J.  
Kaufman and P.A. Sharp (1982) *Mol. Biol.* 159:601-621), NS0 myeloma cells, COS  
20 cells and SP2 cells. When recombinant expression vectors encoding antibody genes are  
introduced into mammalian host cells, the antibodies are produced by culturing the host  
35 cells for a period of time sufficient to allow for expression of the antibody in the host  
cells or, more preferably, secretion of the antibody into the culture medium in which the  
25 host cells are grown. Antibodies can be recovered from the culture medium using  
40 standard protein purification methods.

Host cells can also be used to produce portions of intact antibodies, such as Fab  
45 fragments or scFv molecules. It will be understood that variations on the above  
procedure are within the scope of the present invention. For example, it may be  
30 desirable to transfect a host cell with DNA encoding either the light chain or the heavy  
chain (but not both) of an antibody of this invention. Recombinant DNA technology  
50 may also be used to remove some or all of the DNA encoding either or both of the light

5 and heavy chains that is not necessary for binding to hIL-12. The molecules expressed from such truncated DNA molecules are also encompassed by the antibodies of the invention. In addition, bifunctional antibodies may be produced in which one heavy and  
10 one light chain are an antibody of the invention and the other heavy and light chain are specific for an antigen other than hIL-12 by crosslinking an antibody of the invention to a second antibody by standard chemical crosslinking methods.

15 In a preferred system for recombinant expression of an antibody, or antigen-binding portion thereof, of the invention, a recombinant expression vector encoding both the antibody heavy chain and the antibody light chain is introduced into dhfr- CHO cells by calcium phosphate-mediated transfection. Within the recombinant expression vector,  
20 the antibody heavy and light chain genes are each operatively linked to enhancer/promoter regulatory elements (e.g., derived from SV40, CMV, adenovirus and the like, such as a CMV enhancer/AdMLP promoter regulatory element or an SV40 enhancer/AdMLP promoter regulatory element) to drive high levels of transcription of  
25 the genes. The recombinant expression vector also carries a DHFR gene, which allows for selection of CHO cells that have been transfected with the vector using methotrexate selection/amplification. The selected transformant host cells are cultured to allow for expression of the antibody heavy and light chains and intact antibody is recovered from the culture medium. Standard molecular biology techniques are used to prepare the  
30 recombinant expression vector, transfect the host cells, select for transformants, culture the host cells and recover the antibody from the culture medium. Antibodies or antigen-binding portions thereof of the invention can be expressed in an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see e.g., Taylor, L.D. *et al.* (1992) Nucl. Acids Res. 20: 6287-6295). Plant cells can also be modified to create transgenic  
35 plants that express the antibody or antigen binding portion thereof, of the invention.

40 In view of the foregoing, another aspect of the invention pertains to nucleic acid, vector and host cell compositions that can be used for recombinant expression of the antibodies and antibody portions of the invention. Preferably, the invention features isolated nucleic acids that encode CDRs of J695, or the full heavy and/or light chain  
45 variable region of J695. Accordingly, in one embodiment, the invention features an isolated nucleic acid encoding an antibody heavy chain variable region that encodes the J695 heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 25.  
50  
55

5 Preferably, the nucleic acid encoding the antibody heavy chain variable region further encodes a J695 heavy chain CDR2 which comprises the amino acid sequence of SEQ ID NO: 27. More preferably, the nucleic acid encoding the antibody heavy chain  
10 variable region further encodes a J695 heavy chain CDR1 which comprises the amino acid sequence of SEQ ID NO: 29. Even more preferably, the isolated nucleic acid encodes an antibody heavy chain variable region comprising the amino acid sequence of  
15 SEQ ID NO: 31 (the full VH region of J695).

In other embodiments, the invention features an isolated nucleic acid encoding an antibody light chain variable region that encodes the J695 light chain CDR3  
20 comprising the amino acid sequence of SEQ ID NO: 26. Preferably, the nucleic acid encoding the antibody light chain variable region further encodes a J695 light chain CDR2 which comprises the amino acid sequence of SEQ ID NO: 28. More preferably,  
25 the nucleic acid encoding the antibody light chain variable region further encodes a J695 light chain CDR1 which comprises the amino acid sequence of SEQ ID NO: 30. Even  
15 more preferably, the isolated nucleic acid encodes an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 32 (the full VL region of J695).

30 The invention also provides recombinant expression vectors encoding both an antibody heavy chain and an antibody light chain. For example, in one embodiment, the  
20 invention provides a recombinant expression vector encoding:

- 35 a) an antibody heavy chain having a variable region comprising the amino acid sequence of SEQ ID NO: 31; and  
b) an antibody light chain having a variable region comprising the amino acid sequence of SEQ ID NO: 32.

40 25 The invention also provides host cells into which one or more of the recombinant expression vectors of the invention have been introduced. Preferably, the host cell is a mammalian host cell, more preferably the host cell is a CHO cell, an NS0 cell or a COS cell. Still further the invention provides a method of synthesizing a recombinant human  
45 antibody of the invention by culturing a host cell of the invention in a suitable culture medium until a recombinant human antibody of the invention is synthesized. The  
30 method can further comprise isolating the recombinant human antibody from the culture  
50 medium.



# VI. Pharmaceutical Compositions and Pharmaceutical Administration

The antibodies and antibody-portions of the invention can be incorporated into pharmaceutical compositions suitable for administration to a subject. Typically, the pharmaceutical composition comprises an antibody or antibody portion of the invention and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Examples of pharmaceutically acceptable carriers include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. In many cases, it will be preferable to include isotonic agents, for example: sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Pharmaceutically acceptable carriers may further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the antibody or antibody portion.

The antibodies and antibody-portions of the invention can be incorporated into a pharmaceutical composition suitable for parenteral administration. Preferably, the antibody or antibody-portions will be prepared as an injectable solution containing 0.1-250 mg/ml antibody. The injectable solution can be composed of either a liquid or lyophilized dosage form in a flint or amber vial, ampule or pre-filled syringe. The buffer can be L-histidine (1-50 mM), optimally 5-10mM, at pH 5.0 to 7.0 (optimally pH 6.0). Other suitable buffers include but are not limited to, sodium succinate, sodium citrate, sodium phosphate or potassium phosphate. Sodium chloride can be used to modify the toxicity of the solution at a concentration of 0-300 mM (optimally 150 mM for a liquid dosage form). Cryoprotectants can be included for a lyophilized dosage form, principally 0-10% sucrose (optimally 0.5-1.0%). Other suitable cryoprotectants include trehalose and lactose. Bulking agents can be included for a lyophilized dosage form, principally 1-10% mannitol (optimally 2-4%). Stabilizers can be used in both liquid and lyophilized dosage forms, principally 1-50 mM L-Methionine (optimally 5-10 mM). Other suitable bulking agents include glycine, arginine, can be included as 0-0.05%

5 polysorbate-80 (optimally 0.005-0.01%). Additional surfactants include but are not limited to polysorbate 20 and BRIJ surfactants.

10 In a preferred embodiment, the pharmaceutical composition includes the antibody at a dosage of about 0.01 mg/kg - 10 mg/kg. More preferred dosages of the  
5 antibody include 1 mg/kg administered every other week, or 0.3 mg/kg administered weekly.

15 The compositions of this invention may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (*e.g.*, injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders,  
20 liposomes and suppositories. The preferred form depends on the intended mode of administration and therapeutic application. Typical preferred compositions are in the form of injectable or infusible solutions, such as compositions similar to those used for passive immunization of humans with other antibodies. The preferred mode of  
25 administration is parenteral (*e.g.*, intravenous, subcutaneous, intraperitoneal, intramuscular). In a preferred embodiment, the antibody is administered by intravenous infusion or injection. In another preferred embodiment, the antibody is administered by intramuscular or subcutaneous injection.

30 Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a solution,  
20 microemulsion, dispersion, liposome, or other ordered structure suitable to high drug concentration. Sterile injectable solutions can be prepared by incorporating the active compound (*i.e.*, antibody or antibody portion) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active  
35 compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile, lyophilized powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and spray-drying that yields a powder of the active ingredient plus any  
45 additional desired ingredient from a previously sterile-filtered solution thereof. The proper fluidity of a solution can be maintained, for example, by the use of a coating such  
30 as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prolonged absorption of injectable compositions can be brought  
50

5 about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin.

10 The antibodies and antibody-portions of the present invention can be administered by a variety of methods known in the art, although for many therapeutic applications, the  
5 preferred route/mode of administration is subcutaneous injection, intravenous injection or infusion. As will be appreciated by the skilled artisan, the route and/or mode of  
15 administration will vary depending upon the desired results. In certain embodiments, the active compound may be prepared with a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal  
10 patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid,  
20 collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are patented or generally known to those skilled in the art. See, e.g., *Sustained and Controlled Release Drug Delivery Systems*, J.R. Robinson, ed., Marcel  
25 Dekker, Inc., New York, 1978.

In certain embodiments, an antibody or antibody portion of the invention may be orally administered, for example, with an inert diluent or an assimilable edible carrier.  
30 The compound (and other ingredients, if desired) may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the subject's  
20 diet. For oral therapeutic administration, the compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules,  
35 elixirs, suspensions, syrups, wafers, and the like. To administer a compound of the invention by other than parenteral administration, it may be necessary to coat the compound with, or co-administer the compound with, a material to prevent its  
40 inactivation.

Supplementary active compounds can also be incorporated into the compositions. In certain embodiments, an antibody or antibody portion of the invention  
45 is coformulated with and/or coadministered with one or more additional therapeutic agents that are useful for treating disorders in which IL-12 activity is detrimental. For  
30 example, an anti-IL-12 antibody or antibody portion of the invention may be coformulated and/or coadministered with one or more additional antibodies that bind  
50 other targets (e.g., antibodies that bind other cytokines or that bind cell surface

5 molecules). Furthermore, one or more antibodies of the invention may be used in  
combination with two or more of the foregoing therapeutic agents. Such combination  
10 therapies may advantageously utilize lower dosages of the administered therapeutic  
agents, thus avoiding possible toxicities or complications associated with the various  
5 monotherapies. It will be appreciated by the skilled practitioner that when the antibodies  
of the invention are used as part of a combination therapy, a lower dosage of antibody  
15 may be desirable than when the antibody alone is administered to a subject (e.g., a  
synergistic therapeutic effect may be achieved through the use of combination therapy  
which, in turn, permits use of a lower dose of the antibody to achieve the desired  
10 therapeutic effect).

20 Interleukin 12 plays a critical role in the pathology associated with a variety of  
diseases involving immune and inflammatory elements. These diseases include, but are  
not limited to, rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, Lyme  
25 arthritis, psoriatic arthritis, reactive arthritis, spondyloarthropathy, systemic lupus  
15 erythematosus, Crohn's disease, ulcerative colitis, inflammatory bowel disease, insulin  
dependent diabetes mellitus, thyroiditis, asthma, allergic diseases, psoriasis, dermatitis  
scleroderma, atopic dermatitis, graft versus host disease, organ transplant rejection,  
30 acute or chronic immune disease associated with organ transplantation, sarcoidosis,  
atherosclerosis, disseminated intravascular coagulation, Kawasaki's disease, Grave's  
20 disease, nephrotic syndrome, chronic fatigue syndrome, Wegener's granulomatosis,  
Henoch-Schoenlein purpura, microscopic vasculitis of the kidneys, chronic active  
35 hepatitis, uveitis, septic shock, toxic shock syndrome, sepsis syndrome, cachexia,  
infectious diseases, parasitic diseases, acquired immunodeficiency syndrome, acute  
transverse myelitis, Huntington's chorea, Parkinson's disease, Alzheimer's disease,  
40 25 stroke, primary biliary cirrhosis, hemolytic anemia, malignancies, heart failure,  
myocardial infarction, Addison's disease, sporadic, polyglandular deficiency type I and  
polyglandular deficiency type II, Schmidt's syndrome, adult (acute) respiratory distress  
45 syndrome, alopecia, alopecia areata, seronegative arthropathy, arthropathy, Reiter's  
disease, psoriatic arthropathy, ulcerative colitic arthropathy, enteropathic synovitis,  
30 chlamydia, yersinia and salmonella associated arthropathy, spondyloarthropathy,  
atheromatous disease/arteriosclerosis, atopic allergy, autoimmune bullous disease,  
50 pemphigus vulgaris, pemphigus foliaceus, pemphigoid, linear IgA disease, autoimmune

haemolytic anaemia. Coombs positive haemolytic anaemia, acquired pernicious  
 anaemia, juvenile pernicious anaemia, myalgic encephalitis/Royal Free Disease, chronic  
 mucocutaneous candidiasis, giant cell arteritis, primary sclerosing hepatitis, cryptogenic  
 autoimmune hepatitis, Acquired Immunodeficiency Disease Syndrome, Acquired  
 Immunodeficiency Related Diseases, Hepatitis C, common varied immunodeficiency  
 (common variable hypogammaglobulinaemia), dilated cardiomyopathy, female  
 infertility, ovarian failure, premature ovarian failure, fibrotic lung disease, cryptogenic  
 fibrosing alveolitis, post-inflammatory interstitial lung disease, interstitial pneumonitis,  
 connective tissue disease associated interstitial lung disease, mixed connective tissue  
 disease associated lung disease, systemic sclerosis associated interstitial lung disease,  
 rheumatoid arthritis associated interstitial lung disease, systemic lupus erythematosus  
 associated lung disease, dermatomyositis/polymyositis associated lung disease, Sjögren's  
 disease associated lung disease, ankylosing spondylitis associated lung disease,  
 vasculitic diffuse lung disease, haemosiderosis associated lung disease, drug-induced  
 interstitial lung disease, radiation fibrosis, bronchiolitis obliterans, chronic eosinophilic  
 pneumonia, lymphocytic infiltrative lung disease, postinfectious interstitial lung disease,  
 gouty arthritis, autoimmune hepatitis, type-1 autoimmune hepatitis (classical  
 autoimmune or lupoid hepatitis), type-2 autoimmune hepatitis (anti-LKM antibody  
 hepatitis), autoimmune mediated hypoglycemia, type B insulin resistance with  
 acanthosis nigricans, hypoparathyroidism, acute immune disease associated with organ  
 transplantation, chronic immune disease associated with organ transplantation,  
 osteoarthritis, primary sclerosing cholangitis, idiopathic leucopenia, autoimmune  
 neutropenia, renal disease NOS, glomerulonephritides, microscopic vasculitis of the  
 kidneys, lyme disease, discoid lupus erythematosus, male infertility idiopathic or NOS,  
 sperm-autoimmunity, multiple sclerosis (all subtypes), insulin-dependent diabetes  
 mellitus, sympathetic ophthalmia, pulmonary hypertension secondary to connective  
 tissue disease, Goodpasture's syndrome, pulmonary manifestation of polyarteritis  
 nodosa, acute rheumatic fever, rheumatoid spondylitis, Still's disease, systemic sclerosis,  
 Takayasu's disease/arteritis, autoimmune thrombocytopenia, idiopathic  
 thrombocytopenia, autoimmune thyroid disease, hyperthyroidism, goitrous autoimmune  
 hypothyroidism (Hashimoto's disease), atrophic autoimmune hypothyroidism, primary  
 myxoedema, phacogenic uveitis, primary vasculitis and vitiligo. The human antibodies,

5 and antibody portions of the invention can be used to treat autoimmune diseases, in particular those associated with inflammation, including, rheumatoid spondylitis, allergy, autoimmune diabetes, autoimmune uveitis.

10 Preferably, the antibodies of the invention or antigen-binding portions thereof, are used to treat rheumatoid arthritis, Crohn's disease, multiple sclerosis, insulin dependent diabetes mellitus and psoriasis, as described in more detail in section VII.

15 A human antibody, or antibody portion, of the invention also can be administered with one or more additional therapeutic agents useful in the treatment of autoimmune and inflammatory diseases.

20 Antibodies of the invention, or antigen binding portions thereof can be used alone or in combination to treat such diseases. It should be understood that the antibodies of the invention or antigen binding portion thereof can be used alone or in combination with an additional agent, e.g., a therapeutic agent, said additional agent being selected by the skilled artisan for its intended purpose. For example, the additional agent can be a therapeutic agent art-recognized as being useful to treat the disease or condition being treated by the antibody of the present invention. The additional agent also can be an agent which imparts a beneficial attribute to the therapeutic composition e.g., an agent which effects the viscosity of the composition.

25 It should further be understood that the combinations which are to be included within this invention are those combinations useful for their intended purpose. The agents set forth below are illustrative for purposes and not intended to be limited. The combinations which are part of this invention can be the antibodies of the present invention and at least one additional agent selected from the lists below. The combination can also include more than one additional agent, e.g., two or three additional agents if the combination is such that the formed composition can perform its intended function.

30 Preferred combinations are non-steroidal anti-inflammatory drug(s) also referred to as NSAIDS which include drugs like ibuprofen. Other preferred combinations are corticosteroids including prednisolone; the well known side-effects of steroid use can be reduced or even eliminated by tapering the steroid dose required when treating patients in combination with the anti-IL-12 antibodies of this invention. Non-limiting examples of therapeutic agents for rheumatoid arthritis with which an antibody, or antibody

- 111 -

5 portion, of the invention can be combined include the following: cytokine suppressive  
anti-inflammatory drug(s) (CSAIDs); antibodies to or antagonists of other human  
10 cytokines or growth factors. for example, TNF, LT, IL-1, IL-2, IL-6, IL-7, IL-8, IL-15,  
IL-16, IL-18, EMAP-II, GM-CSF, FGF, and PDGF. Antibodies of the invention, or  
5 antigen binding portions thereof, can be combined with antibodies to cell surface  
molecules such as CD2, CD3, CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69,  
CD80 (B7.1), CD86 (B7.2), CD90, or their ligands including CD154 (gp39 or CD40L).

15 Preferred combinations of therapeutic agents may interfere at different points in  
the autoimmune and subsequent inflammatory cascade; preferred examples include TNF  
10 antagonists like chimeric, humanized or human TNF antibodies, D2E7, (U.S. application  
serial number 08/599,226 filed February 9, 1996), cA2 (Remicade™), CDP 571, anti-  
20 TNF antibody fragments (e.g., CDP870), and soluble p55 or p75 TNF receptors,  
derivatives thereof, (p75TNFR1gG (Enbrel™) or p55TNFR1gG (Lenercept)), soluble IL-  
25 13 receptor (sIL-13), and also TNF $\alpha$  converting enzyme (TACE) inhibitors; similarly  
IL-1 inhibitors (e.g., Interleukin-1-converting enzyme inhibitors, such as Vx740, or IL-  
15 1RA etc.) may be effective for the same reason. Other preferred combinations include  
Interleukin 11, anti-P7s and p-selectin glycoprotein ligand (PSGL). Yet another  
30 preferred combination are other key players of the autoimmune response which may act  
parallel to, dependent on or in concert with IL-12 function; especially preferred are IL-  
20 18 antagonists including IL-18 antibodies or soluble IL-18 receptors, or IL-18 binding  
proteins. It has been shown that IL-12 and IL-18 have overlapping but distinct functions  
35 and a combination of antagonists to both may be most effective. Yet another preferred  
combination are non-depleting anti-CD4 inhibitors. Yet other preferred combinations  
include antagonists of the co-stimulatory pathway CD80 (B7.1) or CD86 (B7.2)  
40 25 including antibodies, soluble receptors or antagonistic ligands.

The antibodies of the invention, or antigen binding portions thereof, may also be  
combined with agents, such as methotrexate, 6-MP, azathioprine sulphasalazine,  
45 mesalazine, olsalazine chloroquine/hydroxychloroquine, pencillamine, aurothiomalate  
(intramuscular and oral), azathioprine, cochlincine, corticosteroids (oral, inhaled and local  
30 injection), beta-2 adrenoreceptor agonists (salbutamol, terbutaline, salmeteral), xanthines  
(theophylline, aminophylline), cromoglycate, nedocromil, ketotifen, ipratropium and  
50 oxitropium, cyclosporin, FK506, rapamycin, mycophenolate mofetil, leflunomide,

NSAIDs, for example, ibuprofen, corticosteroids such as prednisolone, phosphodiesterase inhibitors, adenosine agonists, antithrombotic agents, complement inhibitors, adrenergic agents, agents which interfere with signalling by proinflammatory cytokines such as TNF $\alpha$  or IL-1 (e.g. IRAK, NIK, IKK, p38 or MAP kinase inhibitors), IL-1 $\beta$  converting enzyme inhibitors (e.g., Vx740), anti-P7s, p-selectin glycoprotein ligand (PSGL), TNF $\alpha$  converting enzyme (TACE) inhibitors, T-cell signalling inhibitors such as kinase inhibitors, metalloproteinase inhibitors, sulfasalazine, azathioprine, 6-mercaptopurines, angiotensin converting enzyme inhibitors, soluble cytokine receptors and derivatives thereof (e.g. soluble p55 or p75 TNF receptors and the derivatives p75TNFRIgG (Enbrel<sup>TM</sup>) and p55TNFRIgG (Lenercept), sIL-1RI, sIL-1RII, sIL-6R, soluble IL-13 receptor (sIL-13)) and antiinflammatory cytokines (e.g. IL-4, IL-10, IL-11, IL-13 and TGF $\beta$ ). Preferred combinations include methotrexate or leflunomide and in moderate or severe rheumatoid arthritis cases, cyclosporine.

Non-limiting examples of therapeutic agents for inflammatory bowel disease with which an antibody, or antibody portion, of the invention can be combined include the following: budenoside; epidermal growth factor; corticosteroids; cyclosporin, sulfasalazine; aminosalicylates; 6-mercaptopurine; azathioprine; metronidazole; lipoxygenase inhibitors; mesalamine; olsalazine; balsalazide; antioxidants; thromboxane inhibitors; IL-1 receptor antagonists; anti-IL-1 $\beta$  monoclonal antibodies; anti-IL-6 monoclonal antibodies; growth factors; elastase inhibitors; pyridinyl-imidazole compounds; antibodies to or antagonists of other human cytokines or growth factors, for example, TNF, LT, IL-1, IL-2, IL-6, IL-7, IL-8, IL-15, IL-16, IL-18, EMAP-II, GM-CSF, FGF, and PDGF. Antibodies of the invention, or antigen binding portions thereof, can be combined with antibodies to cell surface molecules such as CD2, CD3, CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD90 or their ligands. The antibodies of the invention, or antigen binding portions thereof, may also be combined with agents, such as methotrexate, cyclosporin, FK506, rapamycin, mycophenolate mofetil, leflunomide, NSAIDs, for example, ibuprofen, corticosteroids such as prednisolone, phosphodiesterase inhibitors, adenosine agonists, antithrombotic agents, complement inhibitors, adrenergic agents, agents which interfere with signalling by proinflammatory cytokines such as TNF $\alpha$  or IL-1 (e.g. IRAK, NIK, IKK, p38 or MAP kinase inhibitors), IL-1 $\beta$  converting enzyme inhibitors (e.g., Vx740), anti-P7s, p-selectin glycoprotein



ligand (PSGL), TNF $\alpha$  converting enzyme inhibitors, T-cell signalling inhibitors such as kinase inhibitors, metalloproteinase inhibitors, sulfasalazine, azathioprine, 6-mercaptapurines, angiotensin converting enzyme inhibitors, soluble cytokine receptors and derivatives thereof (e.g. soluble p55 or p75 TNF receptors, sIL-1RI, sIL-1RII, sIL-6R, soluble IL-13 receptor (sIL-13)) and antiinflammatory cytokines (e.g. IL-4, IL-10, IL-11, IL-13 and TGF $\beta$ ).

Preferred examples of therapeutic agents for Crohn's disease in which an antibody or an antigen binding portion can be combined include the following: TNF antagonists, for example, anti-TNF antibodies, D2E7 (U.S. application serial number 08/599,226, filed February 9, 1996), cA2 (Remicade<sup>TM</sup>), CDP 571, anti-TNF antibody fragments (e.g., CDP870), TNFR-Ig constructs (p75TNFR-IgG (Enbrel<sup>TM</sup>) and p55TNFR-IgG (Lenercept)), anti-P7s, p-selectin glycoprotein ligand (PSGL), soluble IL-13 receptor (sIL-13), and PDE4 inhibitors. Antibodies of the invention or antigen binding portions thereof, can be combined with corticosteroids, for example, budesonide and dexamethasone. Antibodies of the invention or antigen binding portions thereof, may also be combined with agents such as sulfasalazine, 5-aminosalicylic acid and olsalazine, and agents which interfere with synthesis or action of proinflammatory cytokines such as IL-1, for example, IL-1 $\beta$  converting enzyme inhibitors (e.g., Vx740) and IL-1ra. Antibodies of the invention or antigen binding portion thereof may also be used with T cell signaling inhibitors, for example, tyrosine kinase inhibitors 6-mercaptapurines. Antibodies of the invention or antigen binding portions thereof, can be combined with IL-11.

Non-limiting examples of therapeutic agents for multiple sclerosis with which an antibody, or antibody portion, of the invention can be combined include the following: corticosteroids; prednisolone; methylprednisolone; azathioprine; cyclophosphamide; cyclosporine; methotrexate; 4-aminopyridine; tizanidine; interferon- $\beta$ 1a (Avonex; Biogen); interferon- $\beta$ 1b (Betaseron; Chiron/Berlex); Copolymer 1 (Cop-1; Copaxone; Teva Pharmaceutical Industries, Inc.); hyperbaric oxygen; intravenous immunoglobulin; clabribinc; antibodies to or antagonists of other human cytokines or growth factors, for example, TNF, LT, IL-1, IL-2, IL-6, IL-7, IL-8, IL-15, IL-16, IL-18, EMAP-II, GM-CSF, FGF, and PDGF. Antibodies of the invention, or antigen binding portions thereof, can be combined with antibodies to cell surface molecules such as CD2, CD3, CD4,

CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD80, CD86, CD90 or their ligands. The antibodies of the invention, or antigen binding portions thereof, may also be combined with agents, such as methotrexate, cyclosporine, FK506, rapamycin, mycophenolate mofetil, leflunomide, NSAIDs, for example, ibuprofen, corticosteroids such as prednisolone, phosphodiesterase inhibitors, adenosine agonists, antithrombotic agents, complement inhibitors, adrenergic agents, agents which interfere with signalling by proinflammatory cytokines such as TNF $\alpha$  or IL-1 (e.g. IRAK, NIK, IKK, p38 or MAP kinase inhibitors), IL-1 $\beta$  converting enzyme inhibitors (e.g., Vx740), anti-P7s, p-selectin glycoprotein ligand (PSGL), TACE inhibitors, T-cell signalling inhibitors such as kinase inhibitors, metalloproteinase inhibitors, sulfasalazine, azathioprine, 6-mercaptopurines, angiotensin converting enzyme inhibitors, soluble cytokine receptors and derivatives thereof (e.g. soluble p55 or p75 TNF receptors, sIL-1RI, sIL-1RII, sIL-6R, soluble IL-13 receptor (sIL-13)) and antiinflammatory cytokines (e.g. IL-4, IL-10, IL-13 and TGF $\beta$ ).

Preferred examples of therapeutic agents for multiple sclerosis in which the antibody or antigen binding portion thereof can be combined to include interferon- $\beta$ , for example, IFN $\beta$ 1a and IFN $\beta$ 1b; copaxone, corticosteroids, IL-1 inhibitors, TNF inhibitors, and antibodies to CD40 ligand and CD80.

The pharmaceutical compositions of the invention may include a "therapeutically effective amount" or a "prophylactically effective amount" of an antibody or antibody portion of the invention. A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of the antibody or antibody portion may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the antibody or antibody portion to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the antibody or antibody portion are outweighed by the therapeutically beneficial effects. A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.

5 Dosage regimens may be adjusted to provide the optimum desired response (*e.g.*,  
a therapeutic or prophylactic response). For example, a single bolus may be  
administered, several divided doses may be administered over time or the dose may be  
10 proportionally reduced or increased as indicated by the exigencies of the therapeutic  
situation. It is especially advantageous to formulate parenteral compositions in dosage  
unit form for ease of administration and uniformity of dosage. Dosage unit form as used  
15 herein refers to physically discrete units suited as unitary dosages for the mammalian  
subjects to be treated; each unit containing a predetermined quantity of active compound  
calculated to produce the desired therapeutic effect in association with the required  
10 pharmaceutical carrier. The specification for the dosage unit forms of the invention are  
dictated by and directly dependent on (a) the unique characteristics of the active  
compound and the particular therapeutic or prophylactic effect to be achieved, and (b)  
the limitations inherent in the art of compounding such an active compound for the  
treatment of sensitivity in individuals.

25 An exemplary, non-limiting range for a therapeutically or prophylactically  
effective amount of an antibody or antibody portion of the invention is 0.01-20 mg/kg,  
more preferably 1-10 mg/kg, even more preferably 0.3-1 mg/kg. It is to be noted that  
dosage values may vary with the type and severity of the condition to be alleviated. It is  
30 to be further understood that for any particular subject, specific dosage regimens should  
be adjusted over time according to the individual need and the professional judgment of  
the person administering or supervising the administration of the compositions, and that  
dosage ranges set forth herein are exemplary only and are not intended to limit the scope  
or practice of the claimed composition.

#### 40 25 VII. Uses of the Antibodies of the Invention

Given their ability to bind to hIL-12, the anti-hIL-12 antibodies, or portions  
thereof, of the invention can be used to detect hIL-12 (*e.g.*, in a biological sample, such  
as serum or plasma), using a conventional immunoassay, such as an enzyme linked  
45 immunosorbent assays (ELISA), an radioimmunoassay (RIA) or tissue  
immunohistochemistry. The invention provides a method for detecting hIL-12 in a  
30 biological sample comprising contacting a biological sample with an antibody, or  
antibody portion, of the invention and detecting either the antibody (or antibody portion)

5 bound to hIL-12 or unbound antibody (or antibody portion), to thereby detect hIL-12 in  
the biological sample. The antibody is directly or indirectly labeled with a detectable  
substance to facilitate detection of the bound or unbound antibody. Suitable detectable  
10 substances include various enzymes, prosthetic groups, fluorescent materials,  
luminescent materials and radioactive materials. Examples of suitable enzymes include  
horseradish peroxidase, alkaline phosphatase,  $\beta$ -galactosidase, or acetylcholinesterase;  
15 examples of suitable prosthetic group complexes include streptavidin/biotin and  
avidin/biotin; examples of suitable fluorescent materials include umbelliferone,  
fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein,  
20 dansyl chloride or phycoerythrin; an example of a luminescent material includes  
luminol; and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$  or  $^3\text{H}$ .

Alternative to labeling the antibody, hIL-12 can be assayed in biological fluids  
by a competition immunoassay utilizing rhIL-12 standards labeled with a detectable  
substance and an unlabeled anti-hIL-12 antibody. In this assay, the biological sample,  
25 the labeled rhIL-12 standards and the anti-hIL-12 antibody are combined and the amount  
of labeled rhIL-12 standard bound to the unlabeled antibody is determined. The amount  
of hIL-12 in the biological sample is inversely proportional to the amount of labeled  
30 rhIL-12 standard bound to the anti-hIL-12 antibody.

The Y61 and J695 antibodies of the invention can also be used to detect IL-12  
20 from species other than humans, in particular IL-12 from primates. For example, Y61  
can be used to detect IL-12 in the cynomolgus monkey and the rhesus monkey. J695  
35 can be used to detect IL-12 in the cynomolgus monkey, rhesus monkey, and baboon.  
However, neither antibody cross reacts with mouse or rat IL-12 (see Example 3,  
subsection F).

40 25 The antibodies and antibody portions of the invention are capable of neutralizing  
hIL-12 activity *in vitro* (see Example 3) and *in vivo* (see Example 4). Accordingly, the  
antibodies and antibody portions of the invention can be used to inhibit IL-12 activity,  
45 e.g., in a cell culture containing hIL-12, in human subjects or in other mammalian  
subjects having IL-12 with which an antibody of the invention cross-reacts (e.g.  
30 primates such as baboon, cynomolgus and rhesus). In a preferred embodiment, the  
invention provides an isolated human antibody, or antigen-binding portion thereof, that  
50 neutralizes the activity of human IL-12, and at least one additional primate IL-12

5 selected from the group consisting of baboon IL-12, marmoset IL-12, chimpanzee IL-12, cynomolgus IL-12 and rhesus IL-12, but which does not neutralize the activity of the mouse IL-12. Preferably, the IL-12 is human IL-12. For example, in a cell culture  
10 containing, or suspected of containing hIL-12, an antibody or antibody portion of the invention can be added to the culture medium to inhibit hIL-12 activity in the culture.

In another embodiment, the invention provides a method for inhibiting IL-12  
15 activity in a subject suffering from a disorder in which IL-12 activity is detrimental. IL-12 has been implicated in the pathophysiology of a wide variety of disorders (Windhagen *et al.*, (1995) *J. Exp. Med.* 182: 1985-1996; Morita *et al.* (1998) *Arthritis and Rheumatism*. 41: 306-314; Bucht *et al.*, (1996) *Clin. Exp. Immunol.* 103: 347-367;  
20 Fais *et al.* (1994) *J. Interferon Res.* 14:235-238; Parronchi *et al.*, (1997) *Am. J. Path.* 150:823-832; Montelconc *et al.*, (1997) *Gastroenterology*. 112:1169-1178, and Berrebi *et al.*, (1998) *Am. J. Path.* 152:667-672; Parronchi *et al.* (1997) *Am. J. Path.* 150:823-832). The invention provides methods for inhibiting IL-12 activity in a subject suffering  
25 from such a disorder, which method comprises administering to the subject an antibody or antibody portion of the invention such that IL-12 activity in the subject is inhibited. Preferably, the IL-12 is human IL-12 and the subject is a human subject. Alternatively, the subject can be a mammal expressing a IL-12 with which an antibody of the invention cross-reacts. Still further the subject can be a mammal into which has been introduced  
30 hIL-12 (*e.g.*, by administration of hIL-12 or by expression of an hIL-12 transgene). An antibody of the invention can be administered to a human subject for therapeutic purposes (discussed further below). Moreover, an antibody of the invention can be administered to a non-human mammal expressing a IL-12 with which the antibody cross-reacts for veterinary purposes or as an animal model of human disease. Regarding  
35 the latter, such animal models may be useful for evaluating the therapeutic efficacy of antibodies of the invention (*e.g.*, testing of dosages and time courses of administration).

As used herein, the phrase "a disorder in which IL-12 activity is detrimental" is intended to include diseases and other disorders in which the presence of IL-12 in a  
45 subject suffering from the disorder has been shown to be or is suspected of being either responsible for the pathophysiology of the disorder or a factor that contributes to a worsening of the disorder. Accordingly, a disorder in which IL-12 activity is  
50 detrimental is a disorder in which inhibition of IL-12 activity is expected to alleviate the

5 symptoms and/or progression of the disorder. Such disorders may be evidenced, for example, by an increase in the concentration of IL-12 in a biological fluid of a subject suffering from the disorder (*e.g.*, an increase in the concentration of IL-12 in serum, plasma, synovial fluid, *etc.* of the subject), which can be detected, for example, using an anti-IL-12 antibody as described above. There are numerous examples of disorders in which IL-12 activity is detrimental. In one embodiment, the antibodies or antigen binding portions thereof, can be used in therapy to treat the diseases or disorders described herein. In another embodiment, the antibodies or antigen binding portions thereof, can be used for the manufacture of a medicine for treating the diseases or disorders described herein. The use of the antibodies and antibody portions of the invention in the treatment of a few non-limiting specific disorders is discussed further below:

25 A. *Rheumatoid Arthritis:*

15 Interleukin-12 has been implicated in playing a role in inflammatory diseases such as rheumatoid arthritis. Inducible IL-12p40 message has been detected in synovia from rheumatoid arthritis patients and IL-12 has been shown to be present in the synovial fluids from patients with rheumatoid arthritis (see *e.g.*, Morita *et al.*, (1998) *Arthritis and Rheumatism* 41: 306-314). IL-12 positive cells have been found to be present in the sublining layer of the rheumatoid arthritis synovium. The human antibodies, and antibody portions of the invention can be used to treat, for example, rheumatoid arthritis, juvenile rheumatoid arthritis, Lyme arthritis, rheumatoid spondylitis, osteoarthritis and gouty arthritis. Typically, the antibody, or antibody portion, is administered systemically, although for certain disorders, local administration of the antibody or antibody portion may be beneficial. An antibody, or antibody portion, of the invention also can be administered with one or more additional therapeutic agents useful in the treatment of autoimmune diseases.

45 In the collagen induced arthritis (CIA) murine model for rheumatoid arthritis, treatment of mice with an anti-IL-12 mAb (rat anti-mouse IL-12 monoclonal antibody, C17.15) prior to arthritis profoundly suppressed the onset, and reduced the incidence and severity of disease. Treatment with the anti-IL-12 mAb early after onset of arthritis

reduced severity, but later treatment of the mice with the anti-IL-12 mAb after the onset of disease had minimal effect on disease severity.

#### B. Crohn's Disease

Interleukin-12 also plays a role in the inflammatory bowel disease, Crohn's disease. Increased expression of IFN- $\gamma$  and IL-12 occurs in the intestinal mucosa of patients with Crohn's disease (see e.g., Fais *et al.*, (1994) *J. Interferon Res.* 14: 235-238; Parronchi *et al.*, (1997) *Amer. J. Pathol.* 150: 823-832; Monteleone *et al.*, (1997) *Gastroenterology* 112: 1169-1178; Berrebi *et al.*, (1998) *Amer. J. Pathol.* 152: 667-672). Anti-IL-12 antibodies have been shown to suppress disease in mouse models of colitis, e.g., TNBS induced colitis IL-12 knockout mice, and recently in IL-10 knockout mice. Accordingly, the antibodies, and antibody portions, of the invention, can be used in the treatment of inflammatory bowel diseases.

#### C. Multiple Sclerosis

Interleukin-12 has been implicated as a key mediator of multiple sclerosis. Expression of the inducible IL-12 p40 message or IL-12 itself can be demonstrated in lesions of patients with multiple sclerosis (Windhagen *et al.*, (1995) *J. Exp. Med.* 182: 1985-1996; Drulovic *et al.*, (1997) *J. Neurol. Sci.* 147: 145-150). Chronic progressive patients with multiple sclerosis have elevated circulating levels of IL-12. Investigations with T-cells and antigen presenting cells (APCs) from patients with multiple sclerosis revealed a self-perpetuating series of immune interactions as the basis of progressive multiple sclerosis leading to a Th1-type immune response. Increased secretion of IFN- $\gamma$  from the T cells led to increased IL-12 production by APCs, which perpetuated the cycle leading to a chronic state of a Th1-type immune activation and disease (Balashov *et al.*, (1997) *Proc. Natl. Acad. Sci.* 94: 599-603). The role of IL-12 in multiple sclerosis has been investigated using mouse and rat experimental allergic encephalomyelitis (EAE) models of multiple sclerosis. In a relapsing-remitting EAE model of multiple sclerosis in mice, pretreatment with anti-IL-12 mAb delayed paralysis and reduced clinical scores. Treatment with anti-IL-12 mAb at the peak of paralysis or during the subsequent remission period reduced clinical

5 scores. Accordingly, the antibodies or antigen binding portions thereof of the invention  
may serve to alleviate symptoms associated with multiple sclerosis in humans.

10 D. *Insulin-Dependent Diabetes Mellitus*

5 Interleukin-12 has been implicated as an important mediator of insulin-  
dependent diabetes mellitus (IDDM). IDDM was induced in NOD mice by  
administration of IL-12, and anti-IL-12 antibodies were protective in an adoptive  
15 transfer model of IDDM. Early onset IDDM patients often experience a so-called  
"honeymoon period" during which some residual islet cell function is maintained. These  
10 residual islet cells produce insulin and regulate blood glucose levels better than  
administered insulin. Treatment of these early onset patients with an anti-IL-12  
20 antibody may prevent further destruction of islet cells, thereby maintaining an  
endogenous source of insulin.

25 E. *Psoriasis*

Interleukin-12 has been implicated as a key mediator in psoriasis.  
Psoriasis involves acute and chronic skin lesions that are associated with a TH1-type  
30 cytokine expression profile. (Hamid et al. (1996) J. Allergy Clin. Immunol. 1:225-231;  
Turka et al. (1995) Mol. Med. 1:690-699). IL-12 p35 and p40 mRNAs were detected in  
20 diseased human skin samples. Accordingly, the antibodies or antigen binding portions  
thereof of the invention may serve to alleviate chronic skin disorders such psoriasis.

35 The present invention is further illustrated by the following examples which  
should not be construed as limiting in any way. The contents of all cited references,  
including literature references, issued patents, and published patent applications, as cited  
40 throughout this application are hereby expressly incorporated by reference. It should  
further be understood that the contents of all the tables attached hereto (see Appendix A)  
are incorporated by reference.



## APPENDIX A

121

Table 1 VH3 Family Germline Amino Acid Sequences Numbering according to Kabat (Joe9 VH included for comparison)

SEQ ID	germline	CDR H1	CDR H2
574	VH		
575	DP-29	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
576	DP-30	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
577	DP-31	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
578	DP-32	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
579	DP-33	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
580	DP-34	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
581	DP-35	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
582	DP-36	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
583	DP-37	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
584	DP-38	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
585	DP-39	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
586	DP-40	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
587	DP-41	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
588	DP-42	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
589	DP-43	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
590	DP-44	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
591	DP-45	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
592	DP-46	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
593	DP-47	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
594	DP-48	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
595	DP-49	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
596	DP-50	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
597	DP-51	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
598	DP-52	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
599	DP-53	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
600	DP-54	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
601	DP-55	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
602	DP-56	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
603	DP-57	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
604	DP-58	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
605	DP-59	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
606	DP-60	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
607	DP-61	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
608	DP-62	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
609	DP-63	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
610	DP-64	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
611	DP-65	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
612	DP-66	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
613	DP-67	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
614	DP-68	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
615	DP-69	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
616	DP-70	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
617	DP-71	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
618	DP-72	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
619	DP-73	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
620	DP-74	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
621	DP-75	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
622	DP-76	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
623	DP-77	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
624	DP-78	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
625	DP-79	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
626	DP-80	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
627	DP-81	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
628	DP-82	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
629	DP-83	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
630	DP-84	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
631	DP-85	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
632	DP-86	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
633	DP-87	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
634	DP-88	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
635	DP-89	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
636	DP-90	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
637	DP-91	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
638	DP-92	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG
639	DP-93	EVQLVESGGGLVQPGGSLRLSCAASGTF	RTSRKNSVITTYAASVSG

## 122

Table 1

[illegible]

APPENDIX A

123

Table 1 V $\alpha$ 1 Family Germline Amino Acid Sequences  
Numbering according to Kabat.  
(Joe9 VL included for comparison)

SEQ ID	Gene*	VL	CDR L1	CDR L2	CDR L3
668	1b	DPL3	QSVLTQPPSVSAAPGKQVTISC	SGSSNIGNNT	GIQDFSGSKSGTSATLCTGLTQDEADYIC
669	1d	DPL4	QSVLTQPPSVSAAPGKQVTISC	SGSSDMGNYA	GIQDFSGSKSGTSATLCTGLTQDEADYIC
670	1c	DPL2	QSVLTQPPSVASGTPGQVTISC	SGSSDMGNYA	GIQDFSGSKSGTSATLCTGLTQDEADYIC
671	1g	DPL3	QSVLTQPPSVASGTPGQVTISC	SGSSNIGSNT	GVDPFSGSKSGTSATLCTGLTQDEADYIC
672	1a	DPL1	QSVLTQPPSVSEAPRQVTISC	SGSSNIGNNT	GVDPFSGSKSGTSATLCTGLTQDEADYIC
673	1f	DPL9	QSVLTQPPSVSEAPRQVTISC	SGSSNIGNNT	GVDPFSGSKSGTSATLCTGLTQDEADYIC
674	1e	DPL6	QSVLTQPPSVSEAPRQVTISC	SGSSNIGNNT	GVDPFSGSKSGTSATLCTGLTQDEADYIC
675		Joe9 VL	QSVLTQPPSVSEAPRQVTISC	SGSSNIGSNT	GVDPFSGSKSGTSATLCTGLTQDEADYIC

\*Williams, JMB, 1996, 264, 220-232

## APPENDIX A

124

Table 2

Clone	H3 SEQ ID NO:	H3	L3 SEQ ID NO:	L3	koff	RB assay IC50 (M)	PHA assay IC50 (M)	IFN gamma IC50 (M)
Joe9 wt	77	SGSYDY	110	QSYDSSLRGSRV	1.00E-01	1.50E-06	1.00E-06	
Joe9 wt IgG1	77	SGSYDY	110	QSYDSSLRGSRV	1.34 e-2		5.00E-07	
70-1	78	HGSHDN	110	Joe9 wt			2.00E-07	
70-1 IgG1	78	HGSHDN	110	Joe9 wt	3.30E-02		2.00E-07	
70-2	79	HGSHDY	110	Joe9 wt	1.29E-01		3-5.0E-7	
70-7	80	RRRSNY	110	Joe9 wt	7.20E-02		3-5.0E-7	
70-13	81	SGSIDY	110	Joe9 wt	1.64 e-2	2.00E-07	6.00E-07	
78-34	77	wt	111	QSYDRGFTGSRV				
78-25	77	wt	112	QSYDSSLRGSRV	5.00E-02			
78-28	77	wt	112	QSYDSSLRGSRV	4.66E-02			
78-35	77	wt	113	QSYDSSLTGSRV	4.99E-02	4.00E-07		
79-1	77	wt	114	QSYDSSLRGSRV		2.00E-07	6.00E-07	
101-14	79	70-2	111	78-34	7.52E-03			
101-9	79	70-2	113	78-35	8.54E-03			
101-19	81	70-13	111	78-34	4.56E-02			
101-8	81	70-13	111	78-34	1.01E-02			
101-4	81	70-13	113	78-35	9.76E-03			
101-5	81	70-13	113	78-35	4.45E-02			
101-11 (12)	78	70-1	111	78-34	4.5 e-3		3.00E-08	
101-11 IgG1	78	70-1	111	78-34		1.60E-09		
26-1 (2,3)	78	70-1	114	79-1	7.4 e-3		6.00E-08	
136-9	112	HGSHDD	115	QTYDISESGSRV	3.20E-03			
136-10	82	HGSHDD	116	QSYDRGFTGSRV	1.40E-03	2.00E-09		
136-14	63	HGSHDN	117	QTYDRGFTGSRV	1.10E-03	3.00E-10	1.00E-07	
136-15	83	HGSHDN	118	QTYDKGFTGSSV	7.4 e-4	1.00E-10	2.00E-09	
136-15 germline	83	HGSHDN	118	QTYDKGFTGSSV	4.60E-04		6.00E-09	
136-16	83	HGSHDN	119	QSYDRRFTGSRV	6.10E-04	3.00E-10	5.00E-09	
136-17	83	HGSHDN	120	QSYDRNFTGSRV	2.90E-05	2.00E-09	7.00E-09	
136-18	83	HGSHDN	121	QSYDRGFTGSRV	1.10E-03	8.00E-10		
136-21	83	HGSHDN	122	QSYDRGFTGSRV	4.20E-04	2.00E-09		
136-24	83	HGSHDN	123	QSYDNAVTASKV	8.90E-04	1.00E-09		

## APPENDIX A

125

**Table 2**

Clone	H3 SEQ ID NO:	H3	L3 SEQ ID NO:	L3	koff	RB assay IC50 (M)	PHA assay IC50 (M)	IFN gamma IC50 (M)
101-11	84	TT HGSHDN HGCG	124	QSYDRGFTGSRV	4.5x10-3	2x10-9	2.00E-08	
136-15M1	85	AK	124	QSYDRGFTGSRV		4.00E-10		
149-4	86	..S..	124	..S..	1.37x10-3	8x10-11	3.00E-09	
149-5	87	..T..	125	QSYDSSLGTRV	1.02x10-3	1.2x10-10	3.00E-09	
149-6	84	..	124	..	2.73x10-3	6x10-10	2.00E-09	
149-7	84	..	126	..D..	1.13x10-3	9x10-10	3.00E-09	
149-8	88	K.		2.33x10-3	3x10-9			
149-9	89	K.	127	..E..M.	3.54x10-3	1.8x10-10		
149-11	90	..S..	128	..N..A..	1.43x10-2	2x10-10	4.00E-09	
149-12	84	..			3.73x10-3	neutralising		
149-13	84	..			2.22x10-3	5x10-10		
149-14	91	..R..N..				1.5x10-10	6.00E-09	
156-1	92	TT HGSHDN	124	QSYDRGFTGSRV				
156-2	93	..T..	126	..D..	5.00E-03			
156-3	93	..T..	129	..R..				
156-4	93	..T..	128	..N..A..	9.00E-03			
156-5	93	..T..	127	..E..SM.				
156-6	92	..T..	130	..T..K..S.				
156-7	92	..	126	..D..	3.00E-03			
156-8	92	..	129	..R..				
156-9	92	..	128	..N..A..				
156-10	92	..	127	..E..SM.				
156-11	94	..K..	130	..T..K..S.				
156-12	94	..K..	126	..D..				
156-13	94	..K..	129	..R..				
156-14	94	..K..	128	..N..A..				
156-15	94	..K..	127	..E..SM.				
156-16	93	..T..	130	..T..K..S.				
156-17	92	..	124	..				
156-18	93	..T..	125	..SSLM..T..	6.00E-03			
			125	..SSLM..T..				

APPENDIX A

126

Table 2

Clone	H3 SPQ ID NO:	H3	L3 SEQ ID NO:	L3	koff	RB assay IC50 (M)	PHA assay IC50 (M)	IFN gamma IC50 (M)
103-1	92	TT HGSHDN	124	QSYDRGFTGSRV	2.9x10 <sup>-3</sup>			
103-2	95	.. Q.R...	124	.....				
103-3	96	K. R.R...	130	.T..K.....S.	7.3x10 <sup>-4</sup>	7.00E-11	1.00E-09	
103-6	97	.....K	124	.....	2.5x10 <sup>-3</sup>			
103-7	98	.....D	131	.....D...T..	4.5x10 <sup>-4</sup>			
103-8	99	K. ....	130	.T..K.....S.	3.3x10 <sup>-4</sup>	1.40E-10	1.00E-09	
103-14 & 9	100	KT HGSHDN	132	QSYDRGFTGSMV	6.7 e-4	6.00E-11	1.50E-09	
103-8 & 2	100	KT HGSHDN	133	QSYDRGFTGSSV	5.3 e-4	4.00E-11	1.20E-09	
103-4	101	TT HGSHDN	134	QSYDRGFTGARV	1.6 e-4	8.60E-11	1.50E-09	
103-152	101	TT HGSHDN	135	QSYERGTGARV		8.60E-11	9.00E-10	
170-1	102	TT SGSDYX	136	QSYDRGFTGSRVF				
170-2	102	.. .....	137	.....FK..	2.35E-03			
170-3	102	.. .....	138	.....VSAY..	8.80E-04			
170-4	102	.. .....	139	.....L.VTK..	1.11E-03			
170-7	102	.. .....	140	.....Y.A....	8.11E-04			
170-11	102	.. .....	141	.....K....	5.30E-04			
170-13	102	.. .....	142	.....L.F....	4.40E-04			
170-15	102	.. .....	143	.....YK..	1.59E-03			
170-19	102	.. H..H.N	144	.....L.Y.L.	4.43E-03			
170-21	102	.. H..Q.N	145	.....DYK..	1.00E-03			
170-22	102	.. .....	146	.....P.L.	3.89E-03			
170-23	102	.. H..H.N	147	.....L.....	5.60E-04			
170-24	102	.. H..Q.N	148	.....A..M	1.00E-03	2.00E-10		
170-35	102	A. H..Q.N	149	.....Y...	2.80E-04	5.00E-10		
170-38	102	.. .....	150	.....P....	1.00E-03			
170-39	102	.. .....	151	.....M.S....	2.10E-04			
170-36	83	HGSHDN	152	QSYDRGFTGSRVF	2.79E-03			
170-25	106	HGSDT	153	QSYDSLRGSRVF	5.00E-04	2.00E-10		

## APPENDIX A

127

**Table 2**

Clone	H3 SEQ ID NO:	H3	L3 SEQ ID NO:	L3	koff	RB assay IC50 (M)	PHA assay IC50 (M)	IFN gamma IC50 (M)
73-B1	106	SGSYDY	136	QBYDRGEGSRVE				
73-B2	107	SGSYDY	154	H...SD.....	3.25E-03	>1E-8		
73-B6	107	SGSYDY	155	H.SES.....	2.07E-03			
73-C1	107	SGSYDY	156	H...NR.....	2.51E-03	>1E-8		
73-C2	107	SGSYDY	157	H...SR.....	2.71E-03	>1E-8		
73-C6	107	SGSYDY	158	....SE.....	3.79E-03			
73-D1	107	SGSYDY	159	....T.....	3.96E-03			
73-D2	107	SGSYDY	160	H...S.....	3.99E-03			
73-D4	107	SGSYDY	161	....T.....	3.56E-03			
73-D5	107	SGSYDY	162	H...TK.....	5.36E-03			
73-E3	107	SGSYDY	163	H.S.S.....	3.57E-03			
73-E6	107	SGSYDY	164	....SD.....	4.98E-03			
73-F3	107	SGSYDY	165	H...ES.....	4.17E-03			
73-F5	107	SGSYDY	166	....APWS.....	7.08E-03			
73-G2	107	SGSYDY	167	....DSD....K..	3.74E-03			
73-G3	107	SGSYDY	168	HTN.S.....	3.98E-03			
73-G4	107	SGSYDY	169	H...TR.....	3.50E-03			
73-G5	107	SGSYDY	170	....MR.....	6.58E-02			
73-G6	107	SGSYDY	171	H.S.SDS.....	6.01E-03			
73-H2	107	SGSYDY	172	....NTD.....	6.30E-03			
73-F6	107	SGSYDY	173	....S.....	5.93E-03			
73-H3	107	SGSYDY	174	H...M.....	5.87E-03			
73-C5	107	SGSYDY	175	H...N.....	6.85E-03			
73-B7	108	HGSDN	176	H.R..D.....	4.84E-03			
			177	QSYDSSLRGSRV	2.50E-03	7.00E-09		

## APPENDIX A

128

Table 2

Clone	H3 SEQ ID NO:	H3	L3 SEQ ID NO:	L3	koff	HB assay IC50 (M)	PHA assay IC50 (M)	IFN gamma IC50 (M)
M2 A2	83	HGSHDN	136	OSYDRGFTGSRVE				
M2 A4	83	HGSHDN	178	.....IH.....	4.00E-02			
M2 A5	83	HGSHDN	179	.....S..P.....	8.49E-03			
M2 B1	83	HGSHDN	180	.....I..S.....	4.01E-02			
M2 B3	83	HGSHDN	181	.....S..L.....	7.97E-03			
M2 B4	83	HGSHDN	182	.....I..M.....	4.60E-02			
M2 B5	83	HGSHDN	183	.....I..L.....	4.42E-02			
M2 B6	83	HGSHDN	184	.....S..V.....	8.38E-03			
M2 C2	83	HGSHDN	185	.....L..A....	2.81E-02			
M2 C3	83	HGSHDN	186	.....T..L.....	4.62E-02			
M2 C4	83	HGSHDN	187	.....S..L.....	8.16E-03			
M2 C5	83	HGSHDN	188	.....TAL.....	4.71E-02			
M2 D1	83	HGSHDN	189	.....IR.....	3.71E-02			
M2 D2	83	HGSHDN	190	.....IRS.....	3.85E-02			
M2 D3	83	HGSHDN	191	.....NRL.....	3.33E-02			
M2 D4	83	HGSHDN	192	.....ETS.....	5.81E-02			
M2 D5	83	HGSHDN	193	.....SSS.....	5.18E-02			
M2 D6	83	HGSHDN	194	.....S...A....	5.01E-02			
M2 E1	83	HGSHDN	195	.....T..K....S..	5.32E-02			
M2 E2	83	HGSHDN	196	.....N.....	4.77E-02			
M2 E6	83	HGSHDN	197	.....T...K....	9.77E-03			
M2 F1	83	HGSHDN	198	.....SDV.....	6.16E-02			
M2 H5	83	HGSHDN	199	.....A.....	9.90E-03			



## APPENDIX A

129

Table 2

Clone	H3 SEQ ID NO:	H3	L3 SEQ ID NO:	L3	koff	RB assay IC50 (M)	PHA assay IC50 (M)	IFN gamma IC50 (M)
A5	83	HGSHDN	124	OSTDRGTGSRV				
A12	83	HGSHDN	199	.....TFPSML	1.12E-03			
A4	83	HGSHDN	200	.....ITPRPM	1.43E-03			
A6	83	HGSHDN	201	.....RNPALT	1.47E-03			
A10	83	HGSHDN	202	.....TPEMLH	1.87E-03			
A11	83	HGSHDN	203	.....NSPATV	1.87E-03			
C2	83	HGSHDN	204	.....TFPSPO	2.07E-03			
A8	83	HGSHDN	205	.....LNPST	2.23E-03			
B8	83	HGSHDN	206	.....KSNKML	2.37E-03			
C6	83	HGSHDN	207	.....HTAHLV	2.40E-03			
A3	83	HGSHDN	208	.....OTPSIT	2.42E-03			
B11	83	HGSHDN	209	.....YPRNLT	2.51E-03			
B5	83	HGSHDN	210	.....ITPGLA	2.95E-03			
C10	83	HGSHDN	211	.....QPHAVL	3.04E-03			
C4	83	HGSHDN	212	.....NSPIPT	3.10E-03			
C3	83	HGSHDN	213	.....TPNNSF	3.23E-03			
B2	83	HGSHDN	214	.....S.VDPGPF	3.34E-03			
A2	83	HGSHDN	215	.....RPRHAL	3.61E-03			
C5	83	HGSHDN	216	.....PYHPDR	3.80E-03			
A7	83	HGSHDN	217	.....PHQOPT	3.91E-03			
C9	83	HGSHDN	218	.....RNNFSP	3.95E-03			
B3	83	HGSHDN	219	.....PTHLPH	3.97E-03			
C8	83	HGSHDN	220	.....TFSTPT	4.12E-03			
B7	83	HGSHDN	221	.....S.TSNLLP	5.16E-03			
A1	83	HGSHDN	222	.....DSNDDL	5.45E-03			
C7	83	HGSHDN	223	.....LPRLTH	5.66E-03			
C12	83	HGSHDN	224	.....IPTSYL	5.83E-03			
B10	83	HGSHDN	225	.....LRVQAP	5.85E-03			
B6	83	HGSHDN	226	.....LSDGPI	6.04E-03			
A9	83	HGSHDN	227	.....S.SLRRL	7.58E-03			
B9	83	HGSHDN	228	.....PARTSP	7.98E-03			
			229	.....RAHPQ	8.66E-03			

## APPENDIX A

130

Table 2

Clone	H3 SEQ ID NO:	H3	L3 SEQ ID NO:	L3	koff	RB assay IC50 (M)	PHA assay IC50 (M)	IFN gamma IC50 (M)
			124	QSYDRGEGSRV				
177-D7	83	HGSHDN	230	.....TQPABI	4.07E-04			
177-G6	83	HGSHDN	231	.....THPTMI	5.50E-04			
177-D9	83	HGSHDN	232	.....RIPABT	6.32E-04			
177-C6	83	HGSHDN	233	.....THPVPA	7.94E-04			
177-H5	83	HGSHDN	234	.....SBPIPA	1.32E-03			
177-H9	83	HGSHDN	235	.....THPVPA	1.58E-03			
177-H10	83	HGSHDN	236	.....THPTMY	3.44E-03			
144-F1	83	HGSHDN	237	.....HHYTFE	5.80E-04			
43-E3	83	HGSHDN	238	.....SHPAAE	8.00E-04			
43-E9	83	HGSHDN	239	.....TIPSIE	8.00E-04			
43-G2	83	HGSHDN	240	.....SSPAIM	7.00E-04			
43-G3	83	HGSHDN	241	.....IWFNLN	9.00E-04			
31-A6	83	HGSHDN	242	.....THPNLN	5.00E-04			
31-B5	83	HGSHDN	243	.....THPSTS	5.00E-04			
			124	QSYDRGEGSRV				
Y17	83	HGSHDN	244	QSYDRGSAFMIN	8.90E-05	4.50E-10	>1E-8	
Y19	83	HGSHDN	245	QSYDRGHHPAMS	2.26E-04	3.00E-11	>1E-8	
Y38	83	HGSHDN	246	.....THPSIT	5.08E-04	5.50E-11	2.60E-09	
Y45	83	HGSHDN	247	.....TDPRAIV	6.17E-04	4.00E-11	4.30E-09	
Y61	83	HGSHDN	248	.....THPALL	2.75 e-4	4E-11	1.40E-10	
Y61 IgG	83	HGSHDN	248	.....THPALL	1.50E-04	1.60E-11	1.30E-10	
Y61 IgG germline	83	HGSHDN	248	.....THPALL	1.50E-04	1.60E-11	1.30E-10	
Y139	83	HGSHDN	249	.....SHPALT	5.92E-04	3E-11	4.50E-10	1.60E-10
Y139 IgG1	83	HGSHDN	249	.....SHPALT			1.00E-09	
Y174	83	HGSHDN	250	.....TTPAPE	7.55E-04	6E-11	2.00E-09	
Y177	83	HGSHDN	251	.....SHPALI	6.61E-04	5E-11	1.00E-09	
A5	83	HGSHDN	252	.....THPSML	4.50E-04	6.60E-11		
A12	83	HGSHDN	253	.....TTPRPM	5.57E-04	2.50E-10		
D9	83	HGSHDN	254	.....RLPAOT	8.21E-04	3.5E-09		
G6	83	HGSHDN	255	.....THPLTI	5.08E-04	1E-10	>>	
G6 IgG1	83	HGSHDN	255	.....THPLTI			1.00E-09	
C6	83	HGSHDN	256	QSYDRGOTPSIT	1.07E-03	3.5E-10	1.00E-09	
Y55	83	HGSHDN	257	QSYDRGTHFQMY	1.06E-03	1.40E-10	1.00E-08	>1E-8

## APPENDIX A

131

Table 2

Clone	H3 SEQ ID NO:	H3	L3 SEQ ID NO:	L3	koff	RB assay IC50 (M)	PHA assay IC50 (M)	IFN gamma IC50 (M)
A4	83	HGSHDN	258	QSYDRGNPALT	6.30E-04	2.50E-10		
A03	83	HGSHDN	259	QSYDRGTHPLTM	3.04E-04	3.00E-11	4.00E-10	
A03 IgG1	83	HGSHDN	260	QSYDRGTHPLTM	3.04E-04	2.90E-11	3.80E-10	
A03 IgG germline	83	HGSHDN	260	QSYDRGTHPLTM	2.50E-04	3.50E-11	1.75E-10	
99-B11	83	HGSHDN	261	QSYDSGYTGSRV	5.40E-03			
99-C11	83	HGSHDN	262	QSYDSGFTGSRV	5.70E-03			
99-H4	83	HGSHDN	263	QSYDSRFTGSRV	4.80E-03			
99-E9	83	HGSHDN	262	QSYDSGFTGSRV	5.40E-03			
99-H7	83	HGSHDN	264	QSYDPGTASRV	3.30E-03			
99-H11	83	HGSHDN	265	QSYSTHMPISRV	4.90E-03			
99-F6	83	HGSHDN	266	QSYDSGSTGSRV	4.90E-03			
99-F7	83	HGSHDN	267	QSYNSYPLSRV	4.00E-03			
99-F8	83	HGSHDN	268	QSYTRAPQOV	3.70E-03			
99-F11	83	HGSHDN	262	QSYDSGFTGSRV	5.40E-03			
99-G7	83	HGSHDN	269	QSYLSRAFSRV	4.80E-03			
99-G11	83	HGSHDN	270	QSYDSRFTGSRV	4.30E-03			
L3.3R3M-B1	83	HGSHDN	124	QSYDRGFTGSRV				
L3.3R3M-B3	83	HGSHDN	271	.....FTGSMV	5.46E+00			
L3.3R3M-C6	83	HGSHDN	272	.....FTGSMV	5.51E+00			
L3.3R3M-E9	83	HGSHDN	273	.....FTGFDG	6.17E+00			
L3.3R3M-G8	83	HGSHDN	274	.....TAPALS	4.95E+00			
L3.3R3M-H6	83	HGSHDN	275	.....SYPALR	5.55E+00			
L3.3R3M-H10	83	HGSHDN	276	.....NWPNSN	5.69E+00			
L3.3R3M-A3	83	HGSHDN	277	.....TAPSLI	5.35E+00			
L3.3R3M-F8	83	HGSHDN	278	.....FTGSMV	5.37E+00			
L3.3R3M-G1	83	HGSHDN	279	.....TTPRIR	4.99E+00			
L3.3R3M-G7	83	HGSHDN	280	.....FTGSMV	4.21E+00			
L3.3R3M-H11	83	HGSHDN	281	.....FTGSMV	4.24E+00			
		HGSHDN	282	.....MIPALT	3.95E+00			

## APPENDIX A

132

Table 2

Clone	H3 SEQ ID NO:	H3	L3 SEQ ID NO:	L3	koff	RB assay IC50 (M)	PRA assay IC50 (M)	IFN gamma IC50 (M)
Y61-L94N	109	CKT HGSHDN	283	QSYDRNTHPALL			8.00E-11	
Y61-L94F	109	CKT HGSHDN	284	QSYDRFTHPALL			6.00E-11	
Y61-L94Y	109	CKT HGSHDN	285	QSYDRYTHPALL		2.00E-11	2.00E-11	
Y61-L94Y IgG	109	CKT HGSHDN	285	QSYDRYTHPALL	1.27E-04	6.00E-11	5.00E-11	4.00E-11
Y61-L50Y	109	CKT HGSHDN	286	QSYDRGTHPALL		2.00E-11		
Y61-L50Y* IgG	109	CKT HGSHDN	286	QSYDRGTHPALL	6.98E-05		2.00E-11	3.00E-11
Y61-L50Y-H31E** IgG	109	CKT HGSHDN	286	QSYDRGTHPALL	2.99E-05		6.00E-11	2.00E-11
Y61-L50Y-H31E-L94Y** IgG	109	CKT HGSHDN	287	QSYDRYTHPALL	4.64E-05		1.00E-11	1.00E-11
J695 (Y61-L94Y-L50Y IgG*)	109	CKT HGSHDN	287	QSYDRYTHPALL	5.14E-05	5.00E-11	1.00E-11	5.00E-12

\*CDR L2: L50G to Y  
\*\*CDR L2: L50G to Y; CDR H1: H31S to E

## APPENDIX A

133

Table 3

Kabat Number	CDR H1				CDR H2				CDR H3			
	Y61 VH	Y61 VH	Y61 VH	Y61 VH	Y61 VH	Y61 VH	Y61 VH	Y61 VH	Y61 VH	Y61 VH	Y61 VH	Y61 VH
Contact Positions	FTFSYGMH	FTFSYGMH	FTFSYGMH	FTFSYGMH	FTFSYGMH	FTFSYGMH	FTFSYGMH	FTFSYGMH	FTFSYGMH	FTFSYGMH	FTFSYGMH	FTFSYGMH
Hypermutation Positions	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX
Kabat number	CDR L1				CDR L2				CDR L3			
	Y61 VL	Y61 VL	Y61 VL	Y61 VL	Y61 VL	Y61 VL	Y61 VL	Y61 VL	Y61 VL	Y61 VL	Y61 VL	Y61 VL
Contact Positions	SGGRSNI	SGGRSNI	SGGRSNI	SGGRSNI	SGGRSNI	SGGRSNI	SGGRSNI	SGGRSNI	SGGRSNI	SGGRSNI	SGGRSNI	SGGRSNI
Hypermutation Positions	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX

x contact and/or hypermutation position  
 x contact and/or hypermutation position mutated in Y61

## APPENDIX A

134

Table 4. Neutralization Activity in the Presence of Excess Free IL-12 p40

SEQ ID NO:	Clone	PHA assay IC50 (M) p70:p40 1:0	PHA assay IC50 (M) p70:p40 1:20	PHA assay IC50 (M) p70:p40 1:50
VH: 47	136-15	2.00E-09	5.00E-09	4.00E-09
VL: 48				
VH: 51	149-5	6.50E-09	7.00E-09	4.00E-09
VL: 52				
VH: 53	149-6	9.00E-10	1.00E-09	1.00E-09
VL: 54				
VH: 84	149-7	3.50E-09	2.50E-09	4.00E-09
VL: 1:6				
VH: 23	Y61 IgG	1.80E-10		1.80E-10
VL: 24				
VH: 65	AO3 IgG1	2.50E-10		2.50E-10
VL: 66				
VH: 31	J695	1.00E-11		3.50E-11
VL: 32				

## EXAMPLES

### EXAMPLE 1: Isolation of Anti-IL-12 Antibodies

#### A. Screening for IL-12 binding antibodies

Antibodies to hIL-12 were isolated by screening three separate scFv phage display libraries prepared using human VL and VH cDNAs from mRNA derived from human tonsils (referred to as scFv 1), tonsil and peripheral blood lymphocytes (PBL) (referred to as scFv 2), and bone marrow-derived lymphocytes (referred to as BMDL). Construction of the library and methods for selection are described in Vaughan et al. (1996) Nature Biotech. 14: 309-314.

The libraries were screened using the antigens, human IL-12 p70 subunit, human IL-12 p40 subunit, chimaeric IL-12 (mouse p40/human p35), mouse IL-12, biotinylated human IL-12 and biotinylated chimaeric IL-12. IL-12 specific antibodies were selected by coating the antigen onto immunotubes using standard procedures (Marks et al., (1991) J. Mol. Biol. 222: 581-597). The scFv library 2 was screened using either IL-12, or biotinylated-IL-12, and generated a significant number of IL-12 specific binders. Five different clonotypes were selected, determined by BstNI enzymatic digestion patterns, and confirmed by DNA sequencing. The main clonotypes were VHDP58/VLDPL11, VHDP77/VLDPK31, VHDP47/VL and VHDP77/VLDPK31, all of which recognized the p40 subunit of IL-12.

Screening of the BMDL library with IL-12 p70 generated 3 different clonotypes. Two of these were found to be cross-reactive clones. The dominant clone was sequenced and consisted of VHDP35/VLDP. This clone recognizes the p40 subunit of IL-12. Screening of the scFv library 1, using IL-12 p70, did not produce specific IL-12 antibodies.

In order to identify IL-12 antibodies which preferentially bind to the p70 heterodimer or the p35 subunit of IL-12, rather than the p40 subunit, the combined scFv 1 + 2 library, and the BMDL library were used. To select IL-12 antibodies that recognized the p70 heterodimer or p35 subunit, phage libraries were preincubated and selected in the presence of free p40. Sequencing of isolated clones revealed 9 different antibody lineages. Subunit preferences were further analyzed by 'micro-Friguet'

titration. The supernatant containing scFv was titrated on biotin-captured IL-12 in an ELISA and the ED<sub>50</sub> determined. The concentration of scFv producing 50% ED was preincubated with increasing concentrations of free p70 or p40 (inhibitors). A decrease in the ELISA signal on biotin-IL-12 coated plates was measured and plotted against the concentration of free p70 or p40. This provided the IC<sub>50</sub> for each clone with respect to p70 and p40. If the titrations for both subunits overlaps, then the scFv binds to both p40 and p70. Any variation from this gives the degree of preference of p70 over p40.

#### B. Affinity Maturation of Antibody Lineage Specific for IL-12 (Joe 9)

The clones were tested for their ability to inhibit IL-12 binding to its receptor in an IL-12 receptor binding assay (referred to as RBA), and for their ability to inhibit IL-12 induced proliferation of PHA stimulated human blast cells (PHA assay), described in Example 3. Clone Joe 9 had the lowest IC<sub>50</sub> value in both the RBA and the PHA assay, with an IC<sub>50</sub> value of  $1 \times 10^{-6}$  M in both assays. In addition the heavy chain variable region (VH) of Joe 9 had the least number of changes compared to the closest germline sequence COS-3, identified from the VBASE database. Table 1 (see Appendix A) shows the V<sub>H</sub>3 family of germline sequences, of which COS-3 is a member, as well as members of V<sub>H</sub>1 family of germline sequences. Therefore, Joe 9 was selected for affinity maturation. The amino acids sequences of VH and VL of the Joe9 wild type (Joe9 wt) antibody are shown in Figure 1A-1D.

In order to increase the affinity of Joe 9, various mutations of the complementarity determining region 3 (CDR3) of both the heavy and light chains were made. The CDR3 variants were created by site-directed PCR mutagenesis using degenerate oligonucleotides specific for either the heavy chain CDR3 (referred to as "H3") or the light chain CDR3 (referred to as "L3"), with an average of three base substitutions in each CDR3 (referred to as "spike"). PCR mutagenesis of the heavy chain CDR3 was performed using the degenerate heavy chain oligonucleotide containing a random mixture of all four nucleotides,

5'TGTCCCTTGGCCCCA(G)(T)(A)(G)(T)(C)(A)(T)(A)(G)(C)(T)(C)(C)(C)(A)(C)(T)

GGTCGTACAGTAATA 3' (SEQ ID NO: 580), and oligonucleotide pUC Reverse Tag

GAC ACC TCG ATC AGC GGA TAA CAA TTTCAC ACA GG (SEQ ID NO: 581)



to generate a repertoire of heavy chain CDR3 mutants. The parent light chain was amplified using Joe 9 reverse oligonucleotide (5'TGG GGC CAA GGG ACA3' (SEQ ID NO:582) and the fdteteseq 24+21 oligonucleotide (5'-ATT CGT CCT ATA CCG TTC TAC TTT GTC GTC TTT CCA GAC GTT AGT-3' (SEQ ID NO: 583).

Complementarity between the two PCR products was used to drive annealing of the two fragments in a PCR assembly reaction and the full length recombined scFv library was amplified with pUC Reverse Tag (SEQ ID NO: 581) and fdTag 5'-ATT CGT CCT ATA CCG TTC-3' (SEQ ID NO: 584). PCR mutagenesis of the light chain was performed using the light chain oligonucleotide containing a mixture of all four

nucleotides

5'GGTCCCAGTTCGGAAGACCCCTCGAACC(C)(C)(T)(C)(A)(G)(G)(C)(T)(G)(C)(T)(G)(T)(C)ATA'GACTGGCAGTAATAGTCAGC 3' (SEQ ID NO: 585), and Joe 9 reverse oligonucleotide 5'TGG GGC CAA GGG ACA3' (SEQ ID NO: 586)

to produce a repertoire of light chain CDR3 mutants. The parent heavy chain was amplified with pUC Reverse Tag (SEQ ID NO: 581) and HuJH3FOR oligonucleotide 5'TGAAGAGACGGT'GACCATTGTCCC3' (SEQ ID NO: 587). Complementarity between the two PCR products was used to drive annealing of the two fragments in a PCR assembly reaction and the full length recombined scFv library was amplified with Reverse Tag GAC ACC TCG ATC AGC G (SEQ ID NO: 588) and HuJL 2-3 FOR NOT oligonucleotide 5'GAG TCA TTC TCG ACT TGC GGC CGC ACC TAG GAC GGT CAG CTT GGT CCC 3' (SEQ ID NO: 589).

Heavy chain CDR3 mutants were selected using 1 nM biotinylated IL-12, and washed for 1 h at room temperature in PBS containing free IL-12 or p40 at a concentration of 7 nM. Clones were analyzed by phage ELISA and those that bound to IL-12 were tested in BIAcore kinetic binding studies using a low density IL-12 chip (see procedure for BIAcore analysis in Example 5). Generally, BIAcore analysis measures real-time binding interactions between ligand (recombinant human IL-12 immobilized on a biosensor matrix) and analyte (antibodies in solution) by surface plasmon resonance (SPR) using the BIAcore system (Pharmacia Biosensor, Piscataway, NJ). The system utilizes the optical properties of SPR to detect alterations in protein concentrations within a dextran biosensor matrix. Proteins are covalently bound to the dextran matrix at known concentrations. Antibodies are injected through the dextran matrix and

specific binding between injected antibodies and immobilized ligand results in an increased matrix protein concentration and resultant change in the SPR signal. These changes in SPR signal are recorded as resonance units (RU) and are displayed with respect to time along the y-axis of a sensorgram. To determine the off rate ( $k_{off}$ ), on rate ( $k_{on}$ ), association rate ( $K_a$ ) and dissociation rate ( $K_d$ ) constants, BIAcore kinetic evaluation software (version 2.1) was used. Clones that demonstrated an improvement in the  $k_{off}$  rate were analyzed by neutralization assays which included inhibition by antibody of IL-12 binding to its receptor (RBA assay), inhibition of IL-12-induced proliferation in PHA stimulated human blast cells (PHA assay), and inhibition of IL-12-induced interferon gamma production by human blast cells (IFN gamma assay). A summary of the dissociation rates and/or  $IC_{50}$  values from neutralization assays of heavy chain CDR3 spiked clones 70-1 through 70-13 is presented in Table 2 (see Appendix A). Clone 70-1 displayed a  $k_{off}$  rate that was better than the parent Joe 9 clone, and had the lowest  $IC_{50}$  value of  $2.0 \times 10^{-7}$  M. Therefore clone 70-1 was selected for conversion to complete IgG1.

Light chain CDR3 mutants were selected using 1 nM biotin-IL-12 and washed with PBS containing 7 nM free p40. Clones were screened in phage ELISA and those that bound to IL-12 were tested in BIAcore binding analysis using low density IL-12 chips. Clones that displayed an off rate which was better than the parent Joe 9 clone were tested in neutralization assays which measured either, inhibition of IL-12 receptor binding, or inhibition of PHA blast cell proliferation. A summary of the dissociation rates and/or  $IC_{50}$  values from neutralization assays of light chain CDR3 mutant clones, 78-34 through 79-1, is presented in Table 2 (see Appendix A).

Based on the  $k_{off}$  rate, clones 78-34 and 78-35 displayed an improved  $k_{off}$  rate compared to the parent Joe 9. Both of these clones were selected for combination analysis with heavy chain mutants.

#### C. Combination Clones

Mutant light and heavy chain clones that exhibited the best binding characteristics were used for combination and assembly of scFvs. Mutant clones with improved potency characteristics were combined by PCR overlap extension and pull-

through of the mutated VII and VL segments as described above. Clones 101-14 through 26-1, shown in Table 2 (see Appendix A), were produced from the combination of heavy chain mutants (70-2, 70-13 and 70-1) with light chain mutants (78-34, 78-35 and 79-1). The  $k_{off}$  rates and/or  $IC_{50}$  values from neutralization assays for these clones are presented in Table 2.

BIAcore binding analysis identified clone 101-11, produced from the combination of the heavy chain CDR3 mutant clone 70-1 with the light chain CDR3 mutant clone 78-34, as having an off rate of  $0.0045 s^{-1}$ . This  $k_{off}$  rate was a significant improvement compared to the  $k_{off}$  rates for either the heavy chain CDR3 mutant clone 70-1 ( $0.0134 s^{-1}$ ), or for the light chain CDR3 mutant clone 78-34 ( $0.0164 s^{-1}$ ) alone. Furthermore, clone 101-11 showed a significant improvement in neutralization assays. Accordingly, clone 101-11 was selected for affinity maturation as described below.

#### D. Affinity maturation of clone 101-11

Further affinity maturation of clone 101-11 consisted of repeat cycles of PCR mutagenesis of both the heavy and light chain CDR3s of 101-11 using spiked oligonucleotide primers. The clones were selected with decreasing concentrations of biotinylated IL-12 (bio-IL-12). The binding characteristics of the mutated clones was assessed by BIAcore binding analysis and RBA, PHA neutralization assays. The  $k_{off}$  rates and/or  $IC_{50}$  values for clones 136-9 through 170-25 are presented in Table 2 (see Appendix A). Clone 103-14 demonstrated an improved  $IC_{50}$  value in both the receptor binding assay and the PHA blast assay. Clone 103-14 also demonstrated a low  $k_{off}$  rate, and accordingly was selected for further affinity maturation.

#### E. Generation and Selection of Randomized Libraries of Clone 103-14 Light CDR3

The light chain CDR3 of clone 103-14 (QSYDRGFTGSMV (SEQ ID NO: 590)) was systematically randomized in 3 segments using 3 different libraries as outlined below, where X is encoded by a randomized codon of sequence NNS with N being any nucleotide and S being either deoxycytosine or deoxyguanine.

L3.1=XXXXXXFTGSMV (SEQ ID NO: 591)

L3.2= QSYXXXXXXSMV (SEQ ID NO: 592)

- 140 -

L3.3=QSYDRGXXXXXX (SEQ ID NO: 593)

Randomized mutagenesis of all three light chain CDRs (referred to as L3.1, L3.2, and L3.3) of clone 103-14 was performed. The heavy chain CDR3 (referred to as H3) of clone 103-14 was not mutated. Four randomized libraries based on clone 103-14 (H3 and L3.1, L3.2 & L3.3) were constructed and subjected to a large variety of selection conditions that involved using limiting antigen concentration and the presence or absence of excess free antigen (p40 and p70). The outputs from selections (clones 73-B1 through 99-G11) were screened primarily by BIAcore, and on occasion with RBA and are shown in Table 2 (see Appendix A).

Random mutagenesis of the light chain CDR of 103-14 generated clone Y61, which exhibited a significant improvement in  $IC_{50}$  value compared to the parent clone 103-14. Y61 was selected for conversion to a whole IgG1. Whole Y61-IgG1 has an  $IC_{50}$  value of approximately 130 pM determined by the PHA assay. The  $IC_{50}$  value was not affected by a 50 fold molar excess of free p40, demonstrating that free p40 did not cross-react with Y61 anti-IL-12 antibody to thereby decrease the antibody binding to the heterodimer. The full length sequences of Y61 heavy chain variable region and light chain variable region are shown below.

#### Y61 Heavy Chain Variable Region Peptide Sequence

##### CDR H1

QVQLVESGGGVVQPGRSLRLSCAASFTFS SYGMH WVRQAPGKGLEWVA

##### CDR H2

FIRYDGSNKYYADSVKG RFTISRDN SKNTLYLQMNSLRAEDTAVYYCKT

##### CDR H3

HGSHDN WGQGTMTVTSS (SEQ ID NO: 23)

#### Y61 Light Chain Variable Region Peptide Sequence

- 141 -

**CDR L1**

QSVLTQPPSVSGAPGQRVTISC SGGRSNIGSNTVK WYQQLPGTAPKLLIY

**CDR L2**

GNDQRPS GVPDRFSGSKSGTSASLAITGLQAEDEADYYC

**CDR L3**

QSYDRGTHPALL FGTGTKVTVLG (SEQ ID NO:24)

CDR residues are assigned according to the Kabat definitions.

**EXAMPLE 2: Mutation of Y61 at Hypermutation and Contact Positions**

Typically selection of recombinant antibodies with improved affinities can be carried out using phage display methods. This is accomplished by randomly mutating combinations of CDR residues to generate large libraries containing single-chain antibodies of different sequences. Typically, antibodies with improved affinities are selected based on their ability to reach an equilibrium in an antibody-antigen reaction. However, when Y61 scFv was expressed on phage surface and incubated with IL-12, selection conditions could not be found that would allow the system to reach normal antibody-antigen equilibrium. The scFv-phage remained bound to IL-12, presumably due to a non-specific interaction, since purified Y61 scFv exhibits normal dissociation kinetics. Since the usual methods of phage-display affinity maturation to Y61 (i.e. library generation and selections by mutagenesis of multiple CDR residues) could not be utilized, a new strategy was developed in which individual CDR positions were mutated.

This strategy involves selection of appropriate CDR positions for mutation and is based on identification and selection of amino acids that are preferred selective mutagenesis positions, contact positions, and/or hypermutation positions. Contact positions are defined as residues that have a high probability of contact with an antigen when the antigen interacts with the antibody, while hypermutation positions are defined as residues considered to have a high probability for somatic hypermutation during *in vivo* affinity maturation of the antibody. Preferred selective mutagenesis positions are CDR positions that are both contact and hypermutation positions. The Y61 antibody

5 was already optimized in the CDR3 regions using the procedure described in Example 1, therefore it was difficult to further improve the area which lies at the center of the antibody binding site using phage-display selection methods. Greater improvements in activity were obtained by mutation of potential contact positions outside the CDR3 regions by either removing a detrimental antigen-antibody contact or, engineering a new contact.

15 Amino acids residues of Y61 which were considered contact points with antigen, and those CDR positions which are sites of somatic hypermutations during *in vivo* affinity maturation, are shown in Table 3 (see Appendix A). For Y61 affinity maturation, 15 residues outside CDR3, 3 residues within the L3 loop, and 5 residues in the H3 loop were selected for PCR mutagenesis.

20 Y61 scFv gene was cloned into the pUC119(Sfi) plasmid vector for mutagenesis. Oligonucleotides were designed and synthesized with randomized codons to mutate each selected position. Following PCR mutagenesis, a small number of clones (~24) were sequenced and expressed in a host cell, for example, in a bacterial, yeast or mammalian host cell. The expressed antibody was purified and the  $k_{off}$  measured using the BIAcore system. Clones with improved off-rates, as compared to Y61, were then tested in neutralization assays. This procedure was repeated for other CDR positions. Individual mutations shown to have improved neutralization activity were combined to generate an antibody with even greater neutralization potency.

35 The Y61 CDR positions that were mutated in order to improve neutralization potency, and the respective amino-acid substitutions at each position are shown in Figures 2A-2H. Off-rates, as determined by BIAcore analysis, are given. These off rates are also shown in the histograms to the right of each table.

40 25 Results of these substitutions at positions H30, H32, H33, H50, H53, H54, H58, H95, H97, H101, L50, L92, L93, demonstrated that all amino-acid substitutions examined resulted in antibodies with poorer off-rates than Y61. At positions H52, L32, and L50, only a one amino acid substitution was found to improve the off-rate of Y61, all other changes adversely affected activity. For L50, this single Gly→Tyr change significantly (5-10 times) improved the neutralization potency of Y61. The results demonstrated the importance of these positions to Y61 activity, and suggest that in most cases phage-display was able to select for the optimal residues. However, at positions

5

10

5

15

10

20

25

15

30

20

35

40

25

45

30

50

55

- 143 -

H31, H56, L30, and L94, several substitutions were found to improve Y61 off-rate, suggesting that these positions were also important for antigen binding, although the phage display approach did not allow selection of the optimal residues.

Selective mutation of contact and hypermutation positions of Y61 identified amino acid residue L50 in the light chain CDR2, and residue L94 of the light chain CDR3, which improved the neutralization ability of Y61. A combination of these mutations produced an additive effect, generating an antibody, J695, that exhibited a significant increase in neutralization ability. The full length sequence of J695 heavy and light chain variable region sequences is shown below.

J695 Heavy Chain Variable Region Peptide Sequence

**CDR H1**

QVQLVESGGGVVQPGRSLRLSCAASGFTFS SYGMH WVRQAPGKGLEWVA

**CDR H2**

FIRYDGSNKYYADSVKG RFTISRDN SKNTLYLQMNSLRAEDTAVYYCKT

**CDR H3**

HGSHDN WGQGTMTVTVSS (SEQ ID NO: 31)

J695 Light Chain Variable Region Peptide Sequence

**CDR L1**

QSVLTQPPSVSGAPGQRVTISC SGSRSNIGSNTVK WYQQEPGTAPKLLIY

**CDR L2**

YNDQRPS GVPDRFSGSKSGTSASLAITGLQAEDEADYYC

**CDR L3**

QSYDRYTHPALL FGTGTVTVLG (SEQ ID NO: 32)

CDR residues are assigned according to the Kabat definitions.

A summary of the heavy and light chain variable region sequence alignments showing the lineage development of clones that were on the path from Joe9 to J695 is shown in Figures 1A-1D. The CDRs and residue numbering are according to Kabat.

### EXAMPLE 3: Functional Activity of Anti-hIL-12 Antibodies

To examine the functional activity of the human anti-human IL-12 antibodies of the invention, the antibodies were used in several assays that measure the ability of an antibody to inhibit IL-12 activity.

#### A. Preparation of Human PHA-activated Lymphoblasts

Human peripheral blood mononuclear cells (PBMC) were isolated from a leukopac collected from a healthy donor by Ficoll-Hypaque gradient centrifugation for 45 minutes at 1500 rpm as described in Current Protocols in Immunology, Unit 7.1. PBMC at the interface of the aqueous blood solution and the lymphocyte separation medium were collected and washed three times with phosphate-buffered saline (PBS) by centrifugation for 15 minutes at 1500 rpm to remove Ficoll-Paque particles.

The PBMC were then activated to form lymphoblasts as described in Current Protocols in Immunology, Unit 6.16. The washed PBMC were resuspended at  $0.5 \times 10^6$  cells/ml in RPMI complete medium (RPMI 1640 medium, 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100  $\mu$ g/ml streptomycin), supplemented with 0.2% (v/v) PHA-P (Difco, Detroit, MI) and cultured for four days at 37°C in a 5% CO<sub>2</sub> atmosphere. After four days, cell cultures were split 1:1 by volume in RPMI complete medium, plus 0.2% (v/v) PHA-P and 50 U/ml recombinant human IL-2. Recombinant human IL-2 was produced by transfection of an expression vector carrying the human IL-2 cDNA into COS cells (see Kaufman *et al.*, (1991) *Nucleic Acids Res.* 19, 4484-4490), and purified as described in PCT/US96/01382. Cell cultures were then incubated for an additional one to three days. PHA blast cells were harvested, washed twice with RPMI complete medium and frozen in 95% FBS, 5% DMSO at  $10 \times 10^6$  cells/ml.



PHA blast cells to be used for the IL-12 receptor binding assay (see section B) were collected after one day culture in the presence of IL-2, whereas PHA blast cells to be used for the PHA blast proliferation assay (see section C) and the interferon-gamma induction assay (see section D) were collected after three day culture in the presence of IL-2.

#### B. IL-12 Receptor Binding Assay

The ability of anti-IL-12 antibodies to inhibit binding of radiolabelled IL-12 to IL-12 receptors on PHA blasts were analyzed as follows. Various concentrations of anti-IL-12 antibody were preincubated for 1 hour at 37°C with 50-100 pM <sup>125</sup>I-hIL-12 (iodinated hIL-12 was prepared using the Bolton-Hunter labeling method to a specific activity of 20-40mCi/mg from NEN-Dupont) in binding buffer (RPMI 1640, 5% FBS, 25 mM Hepes pH 7.4). PHA blast cells isolated as described above, were washed once and resuspended in binding buffer to a cell density of 2x10<sup>7</sup> cells/ml. PHA blasts (1x10<sup>6</sup> cells) were added to the antibody <sup>125</sup>I-hIL-12 mixture and incubated for two hours at room temperature. Cell bound radioactivity was separated from free <sup>125</sup>I-hIL-12 by centrifugation of the assay mixture for 30 seconds at room temperature, aspiration of the liquid and a wash with 0.1ml binding buffer, followed by centrifugation at 4°C for 4 min at 10,000 x g. The cell pellet was examined for cell bound radioactivity using a gamma counter. Total binding was determined in the absence of antibody and non-specific binding was determined by inclusion of 25 nM unlabeled IL-12 in the assay. Incubations were carried out in duplicate.

In the IL-12 receptor binding assay using the Y61 and J695 human anti-IL-12 antibodies, both antibodies demonstrated a comparable inhibition of IL-12 receptor binding. Y61 inhibited IL-12 receptor binding with an IC<sub>50</sub> value of approximately 1.6 x 10<sup>-11</sup>M, while J695 had an IC<sub>50</sub> value of approximately 1.1 x 10<sup>-11</sup>M.

C. Human PHA Blast Proliferation Assay

Anti-IL-12 antibodies were evaluated for their ability to inhibit PHA blast proliferation (which proliferation is stimulated by IL-12). Serial dilutions of anti-IL-12 antibody were preincubated for 1 hour at 37°C, 5% CO<sub>2</sub> with 230 pg/ml hIL-12 in 100 ml RPMI complete medium in a microtiter plate (U-bottom, 96-well, Costar, Cambridge, MA). PHA blast cells isolated as described above, were washed once and resuspended in RPMI complete medium to a cell density of  $3 \times 10^5$  cells/ml. PHA blasts (100 ml,  $3 \times 10^4$  cells) were added to the antibody/hIL-12 mixture, incubated for 3 days at 37°C, 5% CO<sub>2</sub> and labeled for 4-6 hours with 0.5 mCi/well (3H)-Thymidine (Amersham, Arlington Heights, IL). The culture contents were harvested onto glass fiber filters by means of a cell harvester (Tomtec, Orange, CT) and (3H)-Thymidine incorporation into cellular DNA was measured by liquid scintillation counting. All samples were assayed in duplicate.

The results of neutralization in the presence of varying concentrations of p70:p40 (i.e. the ratio of IL-12 heterodimer to free p40 subunit) is shown in Table 4 (see Appendix A).

Analysis of the Y61 human anti-IL-12 antibody in the PHA blast proliferation assay demonstrated that the antibody inhibited PHA blast proliferation with an IC<sub>50</sub> value of approximately  $1.8 \times 10^{-10}$  M in the presence of IL-12 p70 alone, without any excess p40 (p70:p40 ratio of 1:0). In the presence of a 50-fold excess of free p40 (p70:p40 at a ratio of 1:50), the Y61 antibody inhibited PHA blast proliferation with an IC<sub>50</sub> value of approximately  $1.8 \times 10^{-10}$  M. This result demonstrates that the ability of Y61 to inhibit blast proliferation is not compromised by the presence of excess p40.

The human anti-IL-12 antibody, J695 inhibited PHA blast proliferation with an IC<sub>50</sub> value of approximately  $1.0 \times 10^{-11}$  M in the presence of p70:p40 at a ratio of 1:0. In the presence of a p70:p40 ratio of 1:50, this antibody inhibited PHA blast proliferation with an IC<sub>50</sub> value of approximately  $5.8 \pm 2.8 \times 10^{-12}$  M (n=2), demonstrating that the excess p40 had only a slight inhibitory effect on the antibody. Overall results demonstrate the improved neutralization activity of J695 in comparison with Y61 due to the mutations at L50 and L94.

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

D. Interferon-gamma Induction Assay

The ability of anti-IL-12 antibodies to inhibit the production of IFN $\gamma$  by PHA blasts (which production is stimulated by IL-12) was analyzed as follows. Various concentrations of anti-IL-12 antibody were preincubated for 1 hour at 37°C, 5% CO<sub>2</sub> with 200-400 pg/ml hIL-12 in 100  $\mu$ l RPMI complete medium in a microtiter plate (U-bottom, 96-well, Costar). PHA blast cells isolated as described above, were washed once and resuspended in RPMI complete medium to a cell density of  $1 \times 10^7$  cells/ml. PHA blasts (100  $\mu$ l of  $1 \times 10^6$  cells) were added to the antibody/hIL-12 mixture and incubated for 18 hours at 37°C and 5% CO<sub>2</sub>. After incubation, 150  $\mu$ l of cell free supernatant was withdrawn from each well and the level of human IFN $\gamma$  produced was measured by ELISA (Endogen Interferon gamma ELISA, Endogen, Cambridge, MA). Each supernatant was assayed in duplicate.

Analysis of human anti-hIL-12 antibody, Y61 in this assay demonstrated that Y61 inhibited human IFN $\gamma$  production with an IC<sub>50</sub> value of approximately  $1.6 \times 10^{-10}$  M, while the human anti-IL-12 antibody, J695, inhibited human IFN $\gamma$  production with an IC<sub>50</sub> value of approximately  $5.0 \pm 2.3 \times 10^{-12}$  M (n=3). The result demonstrates the substantial improvement in the affinity of J695 as a result of the modifications at L50 and L94.

E. Induction of Non-human IL-12 from Isolated PBMC

To examine the cross-reactivity of the human anti-hIL-12 antibodies with IL-12 from other species, non-human IL-12 was produced as follows. PBMC were separated from fresh heparinized blood by density gradient centrifugation as described above using lymphoprep (Nycomed, Oslo, Norway) for cynomolgus monkey, baboon, and dog, PBMC, Accu-paque (Accurate Chemical & Sci. Corp., Westbury, NY) for dog PBMC or Lympholyte-rat (Accurate Chemical & Sci. Corp., Westbury, NY) for rat PBMC.

The PBMC were then induced to produce IL-12 as described (D'Andrea *et al.*, (1992) *J. Exp. Med.* 176, 1387-1398, Villinger *et al.*, (1995) *J. Immunol.* 155, 3946-3954, Buettner *et al.*, (1998) *Cytokine* 10, 241-248). The washed PBMC were resuspended at  $1 \times 10^6$  cells/ml in RPMI complete medium, supplemented with 0.0075% (wt/vol) of SAC (Pansorbin; Calbiochem-Behring Co., La Jolla, CA) or 1-5 mg/ml

ConA (Sigma Chemical Co., St. Louis, MO) plus 0.0075% SAC and incubated for 18 hours at 37°C in a 5% CO<sub>2</sub> atmosphere. Cell-free and SAC-free medium was collected by centrifugation and filtering through 0.2 mm filters.

IL-12 from the rhesus monkey was obtained as recombinant rhesus IL-12 from Emory University School of Medicine, Atlanta, GA.

F. Murine 2D6 Cell Proliferation Assay

The murine T cell clone 2D6 proliferates in response to murine IL-2, IL-4, IL-7 and IL-12 (Maruo *et al.*, (1997) *J. Leukocyte Biol.* 61, 346-352). A significant proliferation was also detected in response to rat PBMC supernatants containing rat IL-12. The cells do not respond to dog, cynomolgus, baboon or human IL-12. Murine 2D6 cells were propagated in RPMI complete medium supplemented with 50 mM beta-mercaptoethanol (βME) and 30 ng/ml murine IL-12. One day prior to the assay, the murine IL-12 was washed out and the cells were incubated overnight in RPMI complete medium plus βME.

Serial dilutions of anti-IL-12 antibody were preincubated for 1 hour at 37°C, 5% CO<sub>2</sub> with 40 pg/ml murine IL-12 in 100 ml RPMI complete medium plus βME in a microtiter plate (U-bottom, 96-well, Costar). 2D6 cells were washed once and resuspended in RPMI complete medium containing βME to a cell density of  $1 \times 10^5$  cells/ml. 2D6 cells (100 μl,  $1 \times 10^4$  cells) were added to the antibody/hIL-12 mixture, incubated for 3 days at 37°C, 5% CO<sub>2</sub> and labeled for 4-6 hours with 0.5 mCi/well (3H)-Thymidine. The culture contents were harvested and counted by liquid scintillation counting. All samples were assayed in duplicate.

G. Species Cross-reactivity of J695 with Non-Human IL-12

Species cross-reactivity of J695 with non-human IL-12 was analyzed using PBMC's isolated from several non-human species. The presence of non-human IL-12 activity in the rat, dog, cynomolgus and baboon PBMC supernatants was confirmed using several bioassays described above, such as the murine 2D6 cell proliferation assay, the human PHA blast proliferation assay and the interferon-gamma induction assay by blocking the non-human PBMC induced responses with rabbit and/or sheep polyclonal

antibodies to murine and/or human IL-12. Cross-reactivity of the human anti-hIL-12 antibodies Y61 and J695 with non-human IL-12 in PBMC supernatants or purified murine and rhesus IL-12 was then assessed in the same bioassay(s) by determining the J695 antibody concentration at which 50% inhibition of the response was observed. The species cross-reactivity results are summarized in Table 5. The results demonstrate that Y61 and J695 are each able to recognize IL-12 from monkeys (e.g, cynomolgus and rhesus IL-12 for Y61, and cynomolgus, rhesus and baboon for J695) and that J695 is approximately 35 fold less active on dog IL-12; neither Y61 nor J695 cross reacts with mouse or rat IL-12.

#### H. Human cytokine specificity of J695

The specificity of J695 was tested in a competition ELISA in which a panel of human cytokines was tested for their ability to interfere with the binding of soluble J695 to immobilized human IL-12. The panel of human cytokines included IL-1 $\alpha$  and IL-1 $\beta$  (Genzyme, Boston, MA), IL-2 (Endogen), IL-4, IL-10, IL-17, IFN-gamma, and TGF- $\beta$ 1 (R&D, Minneapolis, MN) IL-8 (Calbiochem), PDGF, IGF-I, and IGF-II (Boehringer Mannheim Corp., Indianapolis, IN), TNF $\alpha$  and lymphotoxin, IL-6, soluble IL-6 receptor, IL-11, IL-12 p70, IL-12 p40, M-CSF, and LIF. EBI-3, an IL-12 p40 related protein that is induced by Epstein-Barr virus infection in B lymphocytes (Devergne *et*

Table 5 Species Cross Reactivity Data

Antibody		IC <sub>50</sub> (M)						
		Mouse IL-12	Rat IL-12	Dog IL-12	Cyno IL-12	Rhesus IL-12	Baboon IL-12	Human IL-12
Name	Specificity	Purified	PBMC sup	PBMC sup	PBMC sup	Purified	PBMC sup	Purified
C17.15	rat- $\alpha$ mulL12	$3.0 \times 10^{-11}$						
R03B03	rabbit- $\alpha$ mulL12	$1.5 \times 10^{-10}$	$6.0 \times 10^{-10}$					
C8.6.2	mouse- $\alpha$ huIL12				$1.2 \times 10^{-10}$	$1.0 \times 10^{-10}$	$2.0 \times 10^{-10}$	$5.0 \times 10^{-11}$
Y61	human- $\alpha$ huIL12	Non-neutralizing			$2.2 \times 10^{-10}$	$1.0 \times 10^{-10}$		$1.7 \times 10^{-10}$
J695	human- $\alpha$ huIL12	Non-neutralizing	Non-neutralizing	$3.5 \times 10^{-10}$	$1.0 \times 10^{-11}$	$1.0 \times 10^{-11}$	$1.5 \times 10^{-11}$	$5.0 \times 10^{-12}$

- 151 -

5 *al.*, (1996) *J. Virol.* 70, 1143-1153 ) was expressed as a human IgG-Fc chimera (EBI-3/Fc). Single-stranded salmon sperm DNA (Sigma) was also tested.

10 Flat-bottom ELISA immunoassay microtiter plates (96 well, high binding, Costar) were coated overnight at 4°C with 0.1 ml human IL-12 (2 µg/ml in 0.1 M carbonate coating buffer (4 volumes 0.1 M NaHCO<sub>3</sub> plus 8.5 volumes 0.1 M NaHCO<sub>3</sub>)).  
15 The plates were washed twice with PBS containing 0.05 % Tween 20 (PBS-T), blocked with 200µl of 1 mg/ml bovine serum albumin (BSA, Sigma) in PBS-T for 1 hour at room temperature, and again washed twice with PBS-T. Samples (100 µl) containing IL-12 antibody J695 (100 ng/ml) and each cytokine (2nM) in PBS-T containing 50  
20 µg/ml BSA (PBS-T/BSA) were added and incubated for 2 h at room temperature. The plates were washed 4 times and incubated for 1h at room temperature with 100 µl mouse anti-human lambda-IIRP (1:500 in PBS-T/BSA, Southern Biotech. Ass. Inc., Birmingham, AL). The plates were washed 4 times and developed with ABTS (Kirkcgaard & Perry Lab., Gaithersburg, MD) for 20-30 minutes in the dark. The  
25 OD<sub>450nm</sub> was read using a microplate reader (Molecular Devices, Menlo Park, CA). Percent binding was determined relative to J695 binding to the IL-12 coated plate in the absence of any soluble cytokine.

30 The results demonstrated that J695 binding to immobilized human IL-12 was blocked only by human IL-12 p70 and to a lesser extent, by human IL-12 p40 and not by  
20 any of the other cytokines tested.

#### 35 I. Binding to a Novel IL-12 Molecule

An alternative IL-12 heterodimer has been described, in which the p35 subunit is replaced by a novel p19 molecule. P19 was identified using 3D homology searching for  
40 IL-6/IL-12 family members, and is synthesized by activated dendritic cells. P19 binds to p40 to form a p19/p40 dimer, which has IL-12 -like activity, but is not as potent as the p35/p40 heterodimer in IFN $\gamma$  induction. Antibodies which recognize p40 alone, but  
45 preferably in the context of a p70 molecule (e.g., J695 and Y61, see Example 3H) are expected to also neutralize both the p35/p40 molecules and the p19/p40 molecules.

30

50

55

**EXAMPLE 4: In vivo Activity of Anti-hIL-12 Antibodies**

The *in vivo* effects of IL-12 antibodies on IL-12 induced responses were examined in a model modified from one used by Bree *et al.* to study the effect of human IL-12 on peripheral hematology in cynomolgus monkey Bree *et al.*, (1994) *Biochem Biophys Res. Comm.* 204: 1150-1157. In those previous studies, administration of human IL-12 at 1 µg/kg/day for a period of 5 days resulted in a decrease in white blood cell count (WBC), especially in the lymphocyte and monocyte subsets after 24 hours. A decrease in the platelet count was observed at 72 hours. Levels of plasma neopterin, a marker of monocyte activation in response to IFN-γ, began to elevate at 24 hours and were the highest at 72 hours.

In the first study with human anti-hIL-12 antibodies, fifteen healthy cynomolgus monkeys with an average weight of 5kg. were sedated and divided into 5 groups (n=3). Group 1 received an intravenous (IV) administration of 10 mg/kg human intravenous immunoglobulin (IVIG, Miles, Eckhart, IN, purified using protein A Sepharose). Group 2 received an intravenous administration of 1 mg/kg C8.6.2 (neutralizing mouse anti-human IL-12 monoclonal antibody). Group 3 received an intravenous administration of 10 mg/kg C8.6.2. Group 4 received an intravenous administration of 1 mg/kg Y61 (human anti-human IL-12 antibody, purified from CHO cell conditioned medium). Group 5 received an intravenous administration of 10 mg/kg Y61.

One hour after the antibody administration all animals received a single subcutaneous (SC) injection of human IL-12 (1 µg/kg). Blood samples were taken at the following time points: baseline, 8, 24, 48, 96 and 216 hours, and analyzed for complete blood cell counts with differentials and serum chemistry. Serum human IL-12, C8.6.2 antibody, Y61 antibody, monkey IFN-gamma, monkey IL-10, monkey IL-6 and plasma neopterin levels were also measured.

Animals treated with IL-12 plus IVIG control antibody (Group 1) showed many of the expected hematological changes, including decreases in WBC, platelets, lymphocyte count and monocyte count. These decreases were not seen or were less pronounced in the animals treated with either the C8.6.2 or Y61 antibody at 1 or 10 mg/kg (Groups 2-5).



Serum or plasma samples were analyzed by ELISA specific for monkey IFN-gamma and monkey IL-10 (Biosource International, Camarillo, CA), monkey IL-6 (Endogen) and plasma neopterin (ICN Pharmaceuticals, Orangeburg, NY). IFN-gamma, IL-10 or IL-6 were not detected in any of the IL-12 treated animals including the control animals treated with IL-12 plus IVIG. This was probably due to the low level exposure to IL-12 (only 1 dose of 1 µg/kg). Nevertheless, plasma neopterin levels increased about three fold in the IL-12 plus IVIG treated animals but did not change in all C8.6.2 or Y61 treated animals, including the lower dose (1 mg/kg) Y61 treated animals, indicating that Y61 was effective *in vivo* in blocking this sensitive response to IL-12.

In a second study, *in vivo* activity and pharmacodynamics (PD) of J695 in cynomolgous monkeys were studied by administering exogenous rhIL-12 and determining if J695 could block or reduce the responses normally associated with rhIL-12 administration. Male cynomolgus monkeys (n=3 per group) were administered a single dose of 0.05, 0.2, or 1.0 mg/kg J695 or 1 mg/kg intravenous immunoglobulin (IVIG) as a bolus intravenous (IV) injection via a saphenous vein or subcutaneously (SC) in the dorsal skin. One hour following the administration of J695 or IVIG, all animals received a single SC dose of 1 µg/kg rhIL-12 in the dorsal skin. Blood samples were collected via the femoral vein up to 28 days after J695 administration. Serum was acquired from each blood sample and assayed for IL-12, J695, IFN-γ, and anti-J695 antibodies by ELISA. Neopterin was assayed by reverse-phase high performance liquid chromatography.

The levels of neopterin, normalized with respect to the levels of neopterin that were measured before administration of J695 or rhIL-12, are shown in Figure 3. To compare the suppression of neopterin between groups, the area under the curve (AUC) normalized for neopterin levels was calculated for each animal (Table 6). Neopterin exposure (AUC) was suppressed in a dose-dependent manner between approximately 71 and 93% in the IV groups and between 71 and 100% in SC groups, relative to the IVIG control groups. These results suggest that the dose of J695 necessary for 50% inhibition of the neopterin response (ED<sub>50</sub>) was less than 0.05 mg/kg when administered by either the IV or SC route.

Table 6: Dose-Dependent Suppression of IL-12 Induced Neopterin by J695 in Cynomolgus Monkeys

Route of dosing IVIG or J695 and rhIL-12	J695 Dose (mg/kg)	IVIG Dose (mg/kg)	AUC of Normalized Neopterin Levels	% Reduction of Neopterin AUC Compared with Control
Single IV injection followed 1 hr later by a dose of 1 µg/kg human IL-12 given SC	-	1.0	1745 ± 845	0
	0.05	-	502 ± 135	71.3
	0.2	-	199 ± 316	88.6
	1.0	-	128 ± 292	92.7
Single SC injection followed 1 hour later by a dose of 1 µg/kg human IL-12 given SC	-	1.0	1480 ± 604	0
	0.05	-	426 ± 108	71.2
	0.2	-	395 ± 45.9	73.3
	1.0	-	0 ± 109	100

Treatment with J695 also prevented or reduced the changes in hematology normally associated with rhIL-12 administration (leukopenia and thrombocytopenia). At 24 hours after rhIL-12 administration lymphocyte counts were reduced by approximately 50% when compared to baseline values in the control IV and SC IVIG treated groups. Administration of J695 either SC or IV at all three dose levels prevented this reduction, resulting in lymphocyte counts at 24 hours approximately the same as baseline values. At 48 hours after IL-12 administration, platelet counts in the groups treated with IV and SC IVIG were reduced by approximately 25% when compared to baseline values.

An example dose schedule targeted to maintain serum levels above the 90% effect level would be 1 mg/kg IV and SC given approximately every other week, or 0.3 mg/kg given approximately every week, assuming slight accumulation during repeated dosing. This study demonstrates that antibody can be given safely to monkeys at such dosages. In independent toxicity studies, it was further found that up to 100 mg/kg of the antibody can be given safely to monkeys.

J695 was also effective in preventing IFN-γ production in mice treated with a chimeric IL-12, a molecule which combines the murine p35 subunit with the human IL-12 p40 subunit. In contrast to human IL-12 which is biologically inactive in mice, this

- 155 -

chimeric IL-12 retains biological function in mice, including induction of IFN- $\gamma$ . In addition, the human p40 subunit allows the molecule to be bound and neutralized by J695. Chimeric IL-12 at a dose of 0.05 mg/kg i.p. was administered to female C3H/HeJ mice (10/experimental group) in five daily doses on days 0, 1, 2, 3, and 4. J695 was given on days 0, 2 and 4 at doses of 0.05, 0.01, 0.002, 0.0004, 0.00008, and 0.000016 mg/kg i.p., 30' prior to the IL-12 injections. The control hulgG1 $\gamma$  was given IP. at a dose of 0.05 mg/kg on days 0, 2, and 4. The mice were bled on day 5, and serum IFN- $\gamma$  levels were determined by ELISA. The results demonstrated that J695 caused dose-dependent inhibition of IFN- $\gamma$  production with an ED<sub>50</sub> of approximately 0.001 mg/kg. Collectively, these results demonstrate that J695 is a potent inhibitor of IL-12 activity *in vivo*.

**EXAMPLE 5: Kinetic Analysis of Binding of Human Antibodies to Recombinant human IL-12 (rhIL-12)**

Real-time binding interactions between captured ligand (human anti-rhIL-12 antibody J695, captured on a biosensor matrix) and analyte (rhIL-12 in solution) were measured by surface plasmon resonance (SPR) using the BIAcore system (Biacore AB, Uppsala, Sweden). The system utilizes the optical properties of SPR to detect alterations in protein concentration within a dextran biosensor matrix. Proteins are covalently bound to the dextran matrix at known concentrations. Antibodies are injected through the dextran matrix and specific binding between injected antibodies and immobilized ligand results in an increased matrix protein concentration and resultant change in the SPR signal. These changes in SPR signal are recorded as resonance units (RU) and are displayed with respect to time along the y-axis of a sensorgram.

To facilitate immobilization of goat anti-human IgG (Southern Biotechnology Associates, Cat. No. 2040-01, Birmingham, AL) on the biosensor matrix, goat anti-human IgG is covalently linked via free amine groups to the dextran matrix by first activating carboxyl groups on the matrix with 100 mM N-hydroxysuccinimide (NHS) and 400 mM N-Ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC). Next, goat anti-human IgG is injected across the activated matrix. Thirty-five microliters of goat anti-human IgG (25  $\mu$ g/ml), diluted in sodium acetate, pH 4.5, is

- 156 -

injected across the activated biosensor and free amines on the protein are bound directly to the activated carboxyl groups. Unreacted matrix EDC-esters are deactivated by an injection of 1 M ethanolamine. Standard amine coupling kits were commercially available (Biacore AB, Cat. No. BR-1000-50, Uppsala, Sweden).

J695 was diluted in HBS running buffer (Biacore AB, Cat. No. BR-1001-88, Uppsala, Sweden) to be captured on the matrix via goat anti-human IgG. To determine the capacity of rhIL12-specific antibodies to bind immobilized goat anti-human IgG, a binding assay was conducted as follows. Aliquots of J695 (25 µg/ml; 25 µl aliquots) were injected through the goat anti-human IgG polyclonal antibody coupled dextran matrix at a flow rate of 5 µl/min. Before injection of the protein and immediately afterward, HBS buffer alone flowed through each flow cell. The net difference in signal between the baseline and the point corresponding to approximately 30 seconds after completion of J695 injection was taken to represent the amount of IgG1 J695 bound (approximately 1200 RU's). Direct rhIL12 specific antibody binding to soluble rhIL12 was measured. Cytokines were diluted in HBS running buffer and 50 µl aliquots were injected through the immobilized protein matrices at a flow rate of 5 µl/min. The concentrations of rhIL-12 employed were 10, 20, 25, 40, 50, 80, 100, 150 and 200 nM. Prior to injection of rhIL-12, and immediately afterwards, HBS buffer alone flowed through each flow cell. The net difference in baseline signal and signal after completion of cytokine injection was taken to represent the binding value of the particular sample. Biosensor matrices were regenerated using 100 mM HCl before injection of the next sample. To determine the dissociation constant (off-rate), association constant (on-rate), BIACore kinetic evaluation software (version 2.1) was used.

Representative results of CHO derived J695 binding to rhIL-12 as compared to the COS derived J695, are shown in Table 7.

Table 7: Binding of CHO or COS derived J695 to rhIL-12.

Source	rhIL12, nM	rhIL12 bound, RU's	Ab, bound, RU's	rhIL12/AB
CHO	200	1112	1613	1.48
CHO	150	1033	1525	1.45
CHO	100	994	1490	1.43

- 157 -

CHO	80	955	1457	1.40
CHO	50	912	1434	1.36
CHO	40	877	1413	1.33
CHO	25	818	1398	1.25
CHO	20	773	1382	1.20
CHO	10	627	1371	0.98
Source	rhIL12, nM	rhIL12 bound, RU's	Ab, bound, RU's	rhIL12/AB
COS	200	1172	1690	1.49
COS	150	1084	1586	1.46
COS	100	1024	1524	1.44
COS	80	985	1489	1.42
COS	50	932	1457	1.37
COS	40	894	1431	1.34
COS	25	833	1409	1.27
COS	20	783	1394	1.20
COS	10	642	1377	1.00

Molecular kinetic interactions between captured J695 and soluble rhIL-12 were quantitatively analyzed using BIAcore technology. Several independent experiments were performed and the results were analyzed by the available BIAcore mathematical analysis software to derive kinetic rate constants, as shown in Table 8.

Table 8: Apparent kinetic rate and affinity constants of J695 for rhIL-12.

Antibody	Source	On-rate (M <sup>-1</sup> s <sup>-1</sup> ), Avg.	Off-rate (s <sup>-1</sup> ), Avg.	Kd (M), Avg.
J695	CHO	3.52E+05	4.72E-05	1.34E-10
J695	COS	3.40E+05	2.61E-05	9.74E-11

There was a small difference between the calculated apparent constant (Kd) for the interaction between CHO derived J695 (Kd = 1.34·10<sup>-10</sup>M<sup>-1</sup>) and COS derived J695 (Kd = 9.74 x 10<sup>-11</sup>M<sup>-1</sup>) antibodies. The apparent dissociation constant (Kd) between J695 and rhIL12 was estimated from the observed rate constants by the formula: Kd = off-rate/ on-rate.

To determine the apparent association and dissociation rate constant for the interaction between J695 and rhIL-12, several binding reactions were performed using a fixed amount of J695 (2 µg/ml) and varying concentrations of rhIL-12. Real-time binding interaction sensorgrams between captured J695 and soluble rhIL-12 showed that both forms of antibody were very similar for both the association and dissociation phase.

To further evaluate the capacity of captured IgG1 J695 mAb to bind soluble recombinant cytokine, a direct BIAcore method was used. In this method, goat anti-human IgG (25 µg/ml) coupled carboxymethyl dextran sensor surface was coated with IgG1 J695 (2 µg/ml) and recombinant cytokine was then added. When soluble rhIL-12 was injected across a biosensor surface captured with CHO or COS derived IgG1 J695, the amount of signal increased as the concentration of cytokine in the solution increased. No binding was observed with mIL-12 (R&D Systems, Cat. No. 419-MI., Minneapolis, MN) or rh IL-12 any concentration tested up to 1000 nM. These results support the conclusion that IgG1 J695 antibodies recognize a distinct determinant on rhIL-12.

Table 9 shows the results of an experiment using BIAcore to demonstrate human IgG1 J695 mAb binding to only soluble rhIL-12 and none of the other recombinant cytokines.

Table 9: Epitope mapping of J695 using BIAcore technology.

	Captured ligand COS J695	Captured ligand CHO J695
Soluble analyte		
rec. human IL12	Positive	Positive
rec. murine IL12	Negative	Negative

#### EXAMPLE 6: Further Studies of J695 Affinity for IL-12

Molecular kinetic interactions between J695 antibody and human IL-12 were quantitatively analyzed using BIAcore plasmon resonance technology, and apparent kinetic rate constants were derived.

5 BIAcore technology was used to measure the binding of soluble rhIL-12 to solid  
phase captured J695. A goat anti-human IgG antibody was immobilized on the  
biosensor chips, then a fixed amount of J695 was injected and captured on the surface.  
10 Varying concentrations of rhIL-12 were applied, and the binding of IL-12 at different  
5 concentrations to J695 was measured as a function of time. Apparent dissociation and  
association rate constants were calculated, assuming zero-order dissociation and first  
15 order association kinetics, as well as a simple one-to-one molecular interaction between  
J695 and IL-12. Three independent experiments were performed, and the values shown  
are averages for the three experiments. From these measurements, the apparent  
10 dissociation ( $k_d$ ) and association ( $k_a$ ) rate constants were derived and used to calculate a  
20  $K_d$  value for the interaction (see Table 10). The results indicated that J695 has a high  
affinity for rhIL-12.

25 Table 10: Kinetic Parameters for the Interaction Between J695 and Human IL-12

Kinetic Parameter	Value
$k_d$	$3.71 \pm 0.40 \times 10^{-3} \text{ s}^{-1}$
$k_a$	$3.81 \pm 0.48 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$
$K_d$	$9.74 \times 10^{-11} \text{ M (14 ng/mL)}$

35 **EXAMPLE 7: Characteristics and Neutralization Activity of C17.15, a Rat  
Monoclonal Antibody to Murine Interleukin-12**

20 To assess the relevance of IL-12 treatment studies in mouse models of inflammation  
and autoimmunity using monoclonal antibodies specific for murine IL-12 to similar  
40 approaches in human disease, the interaction of C17.15, a rat anti-murine IL-12  
monoclonal antibody with murine IL-12, was examined. The ability of C17.15 to  
45 neutralize murine IL-12 activity in a PHA blast proliferation assay, and to block murine  
25 IL-12 binding to cell surface receptors, was assessed, as were the kinetics of the C17.15-  
murine IL-12 binding interaction.

In a human PHA blast proliferation assay (See Example 3), serial dilutions of C17.15 or rat IgG2a (a control antibody) were preincubated with 230 pg/mL murine IL-12 for 1 hr at 37 °C. PHA-stimulated blast cells were added to the antibody-IL-12 mixtures and incubated for 3 days at 37 °C. The cells were subsequently labeled for 6 h with 1  $\mu$ Ci/well [ $^3$ H]-thymidine. The cultures were harvested and [ $^3$ H]-thymidine incorporation was measured. Background non-specific proliferation was measured in the absence of added murine IL-12. All samples were assayed in duplicate. The IC<sub>50</sub> (M) of C17.15 for recombinant murine IL-12 in this assay was found to be  $1.4 \times 10^{-11}$ , as compared to the IC<sub>50</sub> value of  $5.8 \times 10^{-12}$  observed for J695 for recombinant human IL-12 under the same conditions (see Table 11).

Table 11: Comparison of the properties of anti-human IL-12 monoclonal antibody J695 and the rat anti-mouse IL-12 monoclonal antibody C17.15

Antibody	Epitope	Biomolecular Interaction Assay			Receptor Binding Assay	PHA blast Assay
		$k_{on}$ , on-rate ( $M^{-1}s^{-1}$ )	$k_{off}$ , off-rate ( $s^{-1}$ )	$K_d$ (M)	IC <sub>50</sub> (M)	IC <sub>50</sub> (M)
J695	Hu p40	$3.81 \times 10^3$	$3.71 \times 10^{-3}$	$9.74 \times 10^{-11}$	$1.1 \times 10^{-11}$	$5.8 \times 10^{-12}$
C17.15	Mu p40	$3.80 \times 10^3$	$1.84 \times 10^{-3}$	$4.80 \times 10^{-10}$	$1.5 \times 10^{-10}$	$1.4 \times 10^{-11}$

The ability of C17.15 to inhibit the binding of murine IL-12 to cellular receptors was also measured. Serial dilutions of C17.15 were pre-incubated for 1 hr at 37 °C with 100 pM [ $^{125}$ I]-murine IL-12 in binding buffer. The 2D6 cells ( $2 \times 10^6$ ) were added to the antibody/[ $^{125}$ I]-murine IL-12 mixture and incubated for 2 hours at room temperature. Cell-bound radioactivity was separated from free [ $^{125}$ I]-IL-12, and the remaining cell-bound radioactivity was determined. Total binding of the labeled murine IL-12 to receptors on 2D6 cells was determined in the absence of antibody, and non-specific binding was determined by the inclusion of 25 nM unlabelled murine IL-12 in the assay. Specific binding was calculated as the total binding minus the non-specific binding. Incubations were carried out in duplicate. The results showed that C17.15 has an IC<sub>50</sub> (M) of  $1.5 \times 10^{-10}$  for inhibition of binding of murine IL-12 to cellular receptors.



5 The affinity of C17.15 for recombinant murine IL-12 was assessed by biomolecular interaction analysis. A goat anti-rat IgG antibody was immobilized on the biosensor chips, followed by an injection of a fixed amount of the C17.15 antibody, resulting in  
10 capture of C17.15 on the surface of the chip. Varying concentrations of recombinant murine IL-12 were applied to the C17.15 surface, and the binding of murine IL-12 to the immobilized C17.15 was measured as a function of time. Apparent dissociation and  
15 association rate constants were calculated, assuming a zero order dissociation and first order association kinetics as well as a simple one to one molecular interaction between the immobilized C17.15 and murine IL-12. From these measurements, the apparent  
20 dissociation ( $k_d$ , off-rate) and association ( $k_a$ , on-rate) rate constants were calculated. These results were used to calculate a  $K_d$  value for the interaction. An on-rate of  $3.8 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$ , an off-rate of  $1.84 \times 10^{-4} \text{ s}^{-1}$ , and a  $K_d$  of  $4.8 \times 10^{-10}$  was observed for the recombinant murine IL-12-C17.15 interaction.

25 The observed activities of C17.15 in neutralizing murine IL-12 activity and binding to cell surface receptors, as well as the kinetics of binding of C17.15 to murine IL-12 correlate with similar measurements for the J695-rhIL-12 interaction. This indicates  
30 that the modes of action of the rat anti-mouse IL-12 antibody C17.15 and anti-human IL-12 antibody J695 are nearly identical based upon on-rate, off-rate,  $K_d$ ,  $\text{IC}_{50}$ , and the PHA blast assay. Therefore, C17.15 was used as a homologous antibody to J695 in  
20 murine models of inflammation and autoimmune disease to study the effects of IL-12 blockade on the initiation or progression of disease in these model animals (see Example  
35 8).

40 **EXAMPLE 8: Treatment of Autoimmune or Inflammation-Based Diseases in Mice by  $\alpha$ -Murine IL-12 Antibody Administration**

45 **A. Suppression of Collagen-Induced Arthritis in Mice by the  $\alpha$ -IL-12 antibody C17.15**

50 A correlation between IL-12 levels and rheumatoid arthritis (RA) has been demonstrated. For example, elevated levels of IL-12 p70 have been detected in the  
55 synovia of RA patients compared with healthy controls (Morita et al (1998) *Arthritis and Rheumatism*, 41: 306-314). Therefore, the ability of C17.15, a rat anti-mouse IL-12 antibody, to suppress collagen-induced arthritis in mice was assessed.

- 162 -

Male DBA/1 mice (10/group) were immunized with type II collagen on Day 0 and treated with C17.15, or control rat IgG, at 10 mg/kg intraperitoneally on alternate days from Day -1 (1 day prior to collagen immunization) to Day 12. The animals were monitored clinically for the development of arthritis in the paws until Day 90. The arthritis was graded as: 0- normal; 1- arthritis localized to one joint; 2- more than one joint involved but not whole paw; 3- whole paw involved; 4- deformity of paw; 5- ankylosis of involved joints. The arthritis score of a mouse was the sum of the arthritic grades in each individual paw of the mouse (max = 20). The results are expressed as mean  $\pm$  SEM in each group.

The results, as shown in Figure 4, indicate that an arthritic score was measurable in the C17.15-treated mice only after day 50 post-treatment, and that the peak mean arthritic score obtained with the C17.15-treated mice was at least 5-fold lower than that measured in the IgG-treated mice. This demonstrated that the rat anti-mouse IL-12 antibody C17.15 prevented the development of collagen-induced arthritis in mice.

#### B. Suppression of Colitis in Mice by the Rat $\alpha$ -Murine IL-12 Antibody C17.15

IL-12 has also been demonstrated to play a role in the development/pathology of colitis. For example, anti-IL-12 antibodies have been shown to suppress disease in mouse models of colitis, e.g., TNBS induced colitis IL-2 knockout mice (Simpson et al. (1998) *J. Exp. Med.* 187(8): 1225-34). Similarly, anti-IL-2 antibodies have been demonstrated to suppress colitis formation in IL-10 knock-out mice. The ability of the rat anti-mouse IL-12 antibody, C17.15, to suppress TNBS colitis in mice was assessed in two studies (Davidson et al. (1998) *J. Immunol.* 161(6): 3143-9).

In the first study, colitis was induced in pathogen free SJL mice by the administration of a 150  $\mu$ L 50% ethanol solution containing 2.0 mg TNBS delivered via a pediatric umbilical artery catheter into the rectum. Control animals were treated with a 150  $\mu$ L 50% ethanol solution only. A single dose of 0.75, 0.5, 0.25, or 0.1 mg C17.15 or 0.75 mg control rat IgG2a was given intravenously via the tail vein at day 11, and the therapeutic effect of the treatment was assessed by weighing the animals on days 11 and 17, and histological scoring at day 17. The weight of the mice treated with C17.15 increased within 48 hours of antibody treatment and normalized on day 6 after treatment. The effect of treatment with C17.15 was confirmed histologically. Further,

assessments of IFN- $\gamma$  secretion by CD4<sup>+</sup> T-cells from spleen and colon of the treated mice, as well as IL-12 levels from spleen or colon-derived macrophages from the treated mice were also made (see Table 12).

In the second study, the dosing was optimized and the mice were treated with a total dose of 0.1 mg or 0.5 mg C17.15 or 0.1 mg control IgG2a, respectively, split between days 12 and 14. It was found that the administration of C17.15 in a single dose at the dosage of 0.1 mg/mouse or 0.25 mg/mouse led to only partial improvement in TNBS-induced colitis and did not result in a significant reduction in the CD4<sup>+</sup> T cell production of IFN- $\gamma$  *in vitro*, but did result in a significant decrease in secretion of IL-12, compared to untreated controls. At a single dose of 0.5 mg/mouse or greater a response was observed. Taking the lowest dose of antibody tested and administering it in two divided injections (at days 12 and 14) improved the dosing regimen, indicating that multiple low doses can be more effective than a single bolus dose. The data obtained are shown in Table 12.

Table 12: Anti-mouse IL-12 mAb C17.15 Suppresses Established Colitis in Mice

Disease Induction Day 0	Treatment Day 11	Weight (g)		IFN- $\gamma$ spleen CD4 <sup>+</sup> cells (U/mL)	IL-12 spleen macrophages (pg/ml)
		Day 11	Day 17		
TNBS + Ethanol	Control IgG2a 0.75 mg	16.0	15.26	3326	300
TNBS + Ethanol	C17.15 0.75 mg	16.0	20.21	1732	0
TNBS + Ethanol	C17.15 0.5 mg	16.36	19.94	1723	0
TNBS + Ethanol	C17.15 0.25 mg	16.28	17.7	3618	7
TNBS + Ethanol	C17.15 0.1 mg	16.2	17.98	3489	22
Ethanol control	-	20.76	21.16	1135	0

Administration of C17.15 monoclonal anti-IL-12 in two divided doses spaced one day apart totaling 0.1 mg/mouse or 0.05 mg/mouse led to complete reversal of colitis as assessed by wasting and macroscopic appearance of the colon. In addition, this dose schedule led to significant down-regulation of lamina propria T-cell production of IFN- $\gamma$  and macrophage production of IL-12, so that the latter were comparable to

levels seen in control ethanol-treated mice without TNBS-colitis. Thus, C17.15 administration to mouse models for TNBS colitis reversed the progression of the disease in a dose-dependent manner.

C. Suppression of Experimental Autoimmune Encephalomyelitis (EAE) in Mice by  $\alpha$ -IL-12 Antibodies

It is commonly believed that IL-12 plays a role in the pathogenesis of multiple sclerosis (MS). The inducible IL-12 p40 message has been shown to be expressed in acute plaques of MS patients but not in inflammatory brain infarct lesions (Windhagen, A. *et al.* (1995) *J. Exp. Med.* 182: 1985-1996). T cells from MS patients (but not control T cells) stimulate IL-12 production from antigen-presenting cells through unregulated CD40L expression (Balashov, K.E. *et al.* (1997) *Proc. Natl. Acad. Sci. USA* 94: 599-603). MS patients have enhanced IFN- $\gamma$  secretion that can be blocked with  $\alpha$ -IL-12 antibodies *in vitro* (Balashov, K.E. *et al.* (1997) *Proc. Natl. Acad. Sci. USA* 94: 599-603). Elevated levels of serum IL-12 are detected in MS patients, but not in other neurological diseases (Nicoletti, F. *et al.* (1996) *J. Neuroimmunol.* 70: 87-90). Increased IL-12 production has been shown to correlate with disease activity in MS patients (Cormabella, M. *et al.* (1998) *J. Clin. Invest.* 102: 671-678). The role of IL-12 in the pathogenesis of a murine model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), has been studied (Leonard, J.P. *et al.* (1995) *J. Exp. Med.* 181: 281-386; Banerjee, S. *et al.* (1998) *Arthritis Rheum.* (1998) 41: S33; and Segal, B.M. *et al.* (1998) *J. Exp. Med.* 187: 537-546). The disease in this model is known to be induced by T cells of the TH<sub>1</sub> subset. Therefore, the ability of  $\alpha$ -IL-12 antibodies to prevent the onset of acute EAE was assessed.

An  $\alpha$ -IL-12 antibody was found to be able to inhibit the onset of acute EAE, to suppress the disease after onset, and to decrease the severity of relapses in mice immunized with the autoantigen, myelin basic protein (Banerjee, S. *et al.* (1998) *Arthritis Rheum.* (1998) 41: S33). The beneficial effects of  $\alpha$ -IL-12 antibody treatment in the mice persisted for over two months after stopping treatment. It has also been demonstrated that anti-IL-12 antibodies suppress the disease in mice that are recipients of encephalitogenic T cells by adoptive transfer (Leonard, J.P. *et al.* (1995) *J. Exp. Med.* 181: 281-386).

**EXAMPLE 9: Clinical Pharmacology of J695**

In a double blind, crossover study, 64 healthy, human male subjects were administered ascending doses of J695 or placebo. Measurement of complement fragment C3a prior to and 0.25 h after dosing did not demonstrate activation of the complement system. CRP and fibrinogen levels were only increased in subjects in whom symptoms of concurrent infections were observed.

All subjects survived and the overall tolerability of J695 was very good. In no case did treatment have to be stopped because of adverse events (AEs). The most commonly observed AEs were headache and common cold/bronchitis, neither of which were categorized as severe.

One of the study subjects, a 33-year-old single male, was suffering from psoriasis guttata at the start of the study. According to the randomized study design, this subject by chance received 5mg/kg J695 by SC administration. Ten days prior to administration of the antibody, the subject showed only small discrete papular lesions on the arms and legs. At the time of the antibody administration, the subject displayed increased reddening, thickness of the erythematous plaques, and increased hyperkeratosis. One week after J695 administration, the subject reported an improvement in skin condition, including flattening of the lesions and a decrease in scaling. Shortly after the second administration of J695 (5 mg/kg IV), the subject's skin was totally cleared of psoriatic lesions, in the absence of any local treatment. Erythematous plaques covered with white scales reappeared concomitant with the expected clearance of J695 after the second administration of antibody.

**EXAMPLE 10: Comparison of J695 Produced by Two CHO Cell Lines**

For recombinant expression of J695, a recombinant expression vector encoding both the antibody heavy chain and the antibody light chain is introduced into dhfr- CHO cells (Urlaub, G. and Chasin, L.A. (1980) *Proc. Natl. Acad. Sci. USA* 77:4216-4220) by calcium phosphate-mediated transfection. Within the recombinant expression vector, the antibody heavy and light chain genes are each operatively linked to enhancer/promoter regulatory elements (e.g., derived from SV40, CMV, adenovirus and

the like, such as a CMV enhancer/AdMLP promoter regulatory element or an SV40 enhancer/AdMLP promoter regulatory element) to drive high levels of transcription of the genes. The recombinant expression vector also carries a DHFR gene, which allows for selection of CHO cells that have been transfected with the vector using methotrexate selection/amplification.

One hundred and fifty micrograms of an expression vector encoding the peptide sequences of the human antibody J695 were dissolved in 2.7 ml water in a 50 ml conical tube. Three hundred  $\mu$ L of 2.5 M  $\text{CaCl}_2$  were added and this DNA mixture was added dropwise to 3 ml of 2 x HEPES buffered saline in a 50 ml conical tube. After vortexing for 5 sec and incubating at room temperature for 20 min, 1 mL was distributed evenly over each plate (still in F12 medium), and the plates were incubated at 37 °C for 4 h. Liquid was removed by aspiration and 2 ml of 10% DMSO in F12 were added to each plate. The DMSO shock continued for 1 min, after which the DMSO was diluted by the addition of 5 ml PBS to each plate. Plates were washed twice in PBS, followed by the addition of 10 ml of alpha MEM, supplemented with H/T and 5% FBS (selective for cells expressing DHFR) and overnight incubation at 37 °C. Cells were seeded into 96-well plates at a density of 100 cells per well, and plates were incubated at 37 °C, 5%  $\text{CO}_2$  for two weeks, with one change of medium per week.

Five days after the final medium change, culture supernatants were diluted 1:50 and tested using an ELISA specific for human IgG gamma chain. The clones yielding the highest ELISA signal were transferred from the 96-well plates to 12-well plates in 1.5 ml/well of Alpha MEM + 5% dialyzed serum. After 3 days, another ELISA specific for human IgG gamma chain was performed, and the 12 clones with the greatest activity were split into the alpha MEM + 5% dialyzed serum and 20 nM MTX. Cell line 031898 218 grew in the presence of 20 nM MTX without any apparent cell death or reduction in growth rate, produced 1.8  $\mu$ g/ml hIgG in a three-day assay. T-25 cultures of 031898 218, growing in medium containing MTX, produced an average of 11.9  $\mu$ g/ml of J695. The line, designated ALP903, was adapted to growth in suspension under serum-free conditions, where it produced 7.5 pg J695/cell/24h.

ALP903 cells, after initial selection in alpha MEM/5% FBS/20 nM MTX medium, were passed again in 20 nM MTX. The cells were cultured under 100 nM MTX selection, followed by passaging in 500 nM MTX twice in the next 30 days. At

that time the culture was producing 32  $\mu\text{g}$  J695/mL/24 h. The culture was subcloned by limiting dilution. Subclone 218-22 produced 16.5  $\mu\text{g}$ /mL in a 96-well plate in 2 days and 50.3  $\mu\text{g}$ /mL of J695 in a 12-well dish in 2 days. Clone 218-22 was cultured in alpha MEM/5% dialyzed FBS/500 nM MTX for 38 days, followed by adaptation to serum-free spinner culture, as above. The average cell-specific productivity of the serum-free suspension culture, designated ALP 905, was 58 pg/cell/24h.

The first cell line used to produce J695 (ALP 903) resulted in lower yields of the antibody from culture than a second cell line, ALP 905. To assure that the ALP 905-produced J695 was functionally identical to that produced from ALP 903, both batches of antibodies were assessed for IL-12 affinity, for the ability to block IL-12 binding to cellular receptors, for the ability to inhibit IFN- $\gamma$  induction by IL-12, and for the ability to inhibit IL-12-mediated PHA blast proliferation.

The affinities of J695 batches ALP 903 and ALP 905 for IL-12 were determined by measuring the kinetic rate constants of binding to IL-12 by surface plasmon resonance studies (BIAcore analyses). The off-rate constant ( $k_d$ ) and the on-rate constant ( $k_a$ ) of antibody batches ALP903 and ALP905 for binding to rhIL-12 were determined in three experiments (as described in Example 3). The affinity,  $K_d$ , of binding to IL-12 was calculated by dividing the off-rate constant by the on-rate constant.  $K_d$  was calculated for each separate experiment and then averaged. The results showed that the determined kinetic parameters and affinity of binding to rhIL-12 were very similar for J695 batches ALP 903 and ALP 905: the calculated  $K_d$  was  $1.19 \pm 0.22 \times 10^{-10}$  M for batch ALP 903 and  $1.49 \pm 0.47 \times 10^{-10}$  M for batch ALP 905 (see Table 13).

The ability of J695 derived from both ALP 903 and ALP 905 to block binding of rhIL-12 to IL-12 receptors on human PHA-activated T-lymphoblasts was assessed (see Example 3). Each sample of J695 was tested at a starting concentration of  $1 \times 10^{-8}$  with 10-fold serial dilutions. The antibody was preincubated for 1 hour at 37 °C with 50 pM [ $^{125}\text{I}$ ]-human IL-12 in binding buffer. PHA blast cells were added to the antibody/[ $^{125}\text{I}$ ]-human IL-12 mixture and incubated for 2 h at room temperature. Cell bound radioactivity was separated from free [ $^{125}\text{I}$ ]-IL-12 by centrifugation and washing steps, and % inhibition was calculated. The  $\text{IC}_{50}$  values for J695 were determined from the inhibition curves using 4-parameter curve fitting and were confirmed by two

independent experiments. Incubations were carried out in duplicate. The results for the two batches of J695 were very similar (see Table 13).

The ability of J695 from both ALP 903 and ALP 905 cells to inhibit rhIL-12-induced IFN- $\gamma$  production by human PHA-activated lymphoblasts *in vitro* was assessed. Serial dilutions of J695 were preincubated with 200 pg/mL rhIL-12 for 1 h at 37 °C. PHA lymphoblast cells were added and incubated for 18 hours at 37 °C. After incubation, cell free supernatant was withdrawn and the level of human IFN- $\gamma$  determined by ELISA. The IC<sub>50</sub> values from the inhibition curves were plotted against the antibody concentration using 4-parameter curve fitting. The results demonstrate that the ability of the two batches to inhibit IFN- $\gamma$  production is very similar.

The *in vitro* PHA blast cell proliferation assay was used to measure the neutralization capacity of ALP 903 and ALP 905 J695 for rhIL-12. Serial dilutions of J695 of each type were preincubated with 230 pg/mL human IL-12 for 1 h at 37 °C. Next PHA blast cells were added and incubated for 3 days at 37 °C. The cells were then labeled for 6 hours with 1  $\gamma$ Ci/well [<sup>3</sup>H]-thymidine. The cultures were harvested and [<sup>3</sup>H]-thymidine incorporation measured. Non-specific proliferation (background) was measured in the absence of rhIL-12. The IC<sub>50</sub> values for ALP 903 and ALP 905 J695 were found to be very similar and are set forth in Table 13.

The activity of the J695 antibodies in neutralizing rhIL-12 activity, in blocking IL-12 binding to cell surface receptors, and in binding to rhIL-12 did not significantly differ from batch ALP 903 to batch ALP 905, and thus the antibodies produced from these two different cell types were equivalent.

Table 13: Comparison of the Properties of J695 lots ALP 903 and ALP 905

Antibody	k <sub>on</sub> , On-rate (M <sup>-1</sup> , s <sup>-1</sup> )	k <sub>off</sub> , Off-rate (s <sup>-1</sup> )	K <sub>d</sub> (M)	RB assay IC <sub>50</sub> (M)	PHA blast Assay IC <sub>50</sub> (M)	IFN- $\gamma$ Assay IC <sub>50</sub> (M)
J695 ALP 903	3.75 x 10 <sup>5</sup>	4.46 x 10 <sup>-3</sup>	1.19 x 10 <sup>-10</sup>	3.4 x 10 <sup>-11</sup>	5.5 x 10 <sup>-12</sup>	5.8 x 10 <sup>-12</sup>
J695 ALP 905	3.91 x 10 <sup>5</sup>	5.59 x 10 <sup>-3</sup>	1.49 x 10 <sup>-10</sup>	3.0 x 10 <sup>-11</sup>	4.4 x 10 <sup>-12</sup>	4.3 x 10 <sup>-12</sup>



5

EQUIVALENTS

10

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

15

20

25

30

35

40

45

50

55

**CLAIMS**

1. An isolated human antibody, or an antigen-binding portion thereof, that binds to human IL-12, wherein said human antibody is a neutralizing antibody.

2. A selectively mutated human IL-12 antibody, comprising:  
a human antibody or antigen-binding portion thereof, selectively mutated at a preferred selective mutagenesis, contact or hypermutation position with an activity enhancing amino acid residue such that it binds to human IL-12.

3. A selectively mutated human IL-12 antibody, comprising:  
a human antibody or antigen-binding portion thereof, selectively mutated at a preferred selective mutagenesis position with an activity enhancing amino acid residue such that it binds to human IL-12.

4. The selectively mutated human IL-12 antibody of claim 2, wherein the human antibody or antigen-binding portion thereof is selectively mutated at more than one preferred selective mutagenesis, contact or hypermutation positions with an activity enhancing amino acid residue.

5. The selectively mutated human IL-12 antibody of claim 4, wherein the human antibody or antigen-binding portion thereof is selectively mutated at no more than three preferred selective mutagenesis, contact or hypermutation positions.

6. The selectively mutated human IL-12 antibody of claim 4, wherein the human antibody or antigen-binding portion thereof is selectively mutated at no more than two preferred selective mutagenesis, contact or hypermutation positions.

- 171 -

7. The selectively mutated human IL-12 antibody of claim 2, wherein the human antibody or antigen-binding portion thereof, is selectively mutated such that a target specificity affinity level is attained, said target level being improved over that attainable when selecting for an antibody against the same antigen using phage display technology.

8. The selectively mutated human IL-12 antibody of claim 7, wherein the selectively mutated human antibody further retains at least one desirable property or characteristic.

9. An isolated human antibody, or antigen-binding portion thereof, that binds to human IL-12 and dissociates from human IL-12 with a  $k_{\text{off}}$  rate constant of  $0.1 \text{ s}^{-1}$  or less, as determined by surface plasmon resonance, or which inhibits phytohemagglutinin blast proliferation in an *in vitro* phytohemagglutinin blast proliferation assay (PHA assay) with an  $\text{IC}_{50}$  of  $1 \times 10^{-6} \text{ M}$  or less.

10. The isolated human antibody of claim 9, or an antigen-binding portion thereof, which dissociates from human IL-12 with a  $k_{\text{off}}$  rate constant of  $1 \times 10^{-2} \text{ s}^{-1}$  or less, as determined by surface plasmon resonance, or which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $\text{IC}_{50}$  of  $1 \times 10^{-7} \text{ M}$  or less.

11. The isolated human antibody of claim 9, or an antigen-binding portion thereof, which dissociates from human IL-12 with a  $k_{\text{off}}$  rate constant of  $1 \times 10^{-3} \text{ s}^{-1}$  or less, as determined by surface plasmon resonance, or which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $\text{IC}_{50}$  of  $1 \times 10^{-8} \text{ M}$  or less.

12. The isolated human antibody of claim 9, or an antigen-binding portion thereof, which dissociates from human IL-12 with a  $k_{\text{off}}$  rate constant of  $1 \times 10^{-4} \text{ s}^{-1}$  or less, as determined by surface plasmon resonance, or which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $\text{IC}_{50}$  of  $1 \times 10^{-9} \text{ M}$  or less.

5  
10  
13. The isolated human antibody of claim 9, or an antigen-binding portion thereof, which dissociates from human IL-12 with a  $k_{off}$  rate constant of  $1 \times 10^{-5} s^{-1}$  or less, as determined by surface plasmon resonance, or which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-10} M$  or less.

5  
15  
14. The isolated human antibody of claim 9, or an antigen-binding portion thereof, which dissociates from human IL-12 with a  $k_{off}$  rate constant of  $1 \times 10^{-5} s^{-1}$  or less, as determined by surface plasmon resonance, or which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-11} M$  or less.

10  
20  
15. An isolated human antibody, or an antigen-binding portion thereof, which has the following characteristics:

- 25  
26  
a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-6} M$  or less;  
15  
27  
b) has a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 1; and  
30  
28  
c) has a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 2.

20  
35  
16. The isolated human antibody of claim 15, or an antigen-binding portion thereof, which further has a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 3; and has a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 4.

40  
25  
45  
17. The isolated human antibody of claim 15, or an antigen-binding portion thereof, which further has a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 5; and has a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 6.

5 18. The isolated human antibody, or antigen binding portion thereof of claim  
16, which has a heavy chain variable region comprising the amino acid sequence of SEQ  
10 ID NO: 7; and has a light chain variable region comprising the amino acid sequence of  
SEQ ID NO: 8.

5 19. An isolated human antibody, or an antigen-binding portion thereof, which  
has the following characteristics:

15 a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay  
with an  $IC_{50}$  of  $1 \times 10^{-9}M$  or less;

10 b) has a heavy chain CDR3 comprising the amino acid sequence of SEQ ID  
20 NO: 9; and

c) has a light chain CDR3 comprising the amino acid sequence of SEQ ID  
NO: 10.

25 20. The isolated human antibody of claim 19, or an antigen-binding portion  
thereof, which further has a heavy chain CDR2 comprising the amino acid sequence of  
SEQ ID NO: 11; and has a light chain CDR2 comprising the amino acid sequence of  
30 SEQ ID NO: 12.

20 21. The isolated human antibody of claim 19, or an antigen-binding portion  
thereof, which further has a heavy chain CDR1 comprising the amino acid sequence of  
35 SEQ ID NO: 13; and has a light chain CDR1 comprising the amino acid sequence of  
SEQ ID NO: 14.

40 22. The isolated human antibody of claim 19, which has a heavy chain  
variable region comprising the amino acid sequence of SEQ ID NO: 15; and has a light  
chain variable region comprising the amino acid sequence of SEQ ID NO: 16.

23. An isolated human antibody, or an antigen-binding portion thereof, which  
a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay  
with an  $IC_{50}$  of  $1 \times 10^{-9}$ M or less;

b) has a heavy chain CDR3 comprising the amino acid sequence of SEQ ID  
NO: 17; and  
c) has a light chain CDR3 comprising the amino acid sequence of SEQ ID  
NO: 18.

24. The isolated human antibody, or an antigen-binding portion thereof, of  
claim 23 which further has a heavy chain CDR2 comprising the amino acid sequence of  
SEQ ID NO: 19; and a light chain CDR2 comprising the amino acid sequence of SEQ  
ID NO: 20.

25. The isolated human antibody, or an antigen-binding portion thereof, of  
claim 23 which further has a heavy chain CDR1 comprising the amino acid sequence of  
SEQ ID NO: 21; and a light chain CDR1 comprising the amino acid sequence of SEQ  
ID NO: 22.

26. An isolated human antibody, or an antigen-binding portion thereof,  
having a heavy chain variable region comprising the amino acid sequence of SEQ ID  
NO: 23, and a light chain variable region comprising the amino acid sequence of SEQ  
ID NO: 24.

27. The isolated human antibody of claim 26, comprising a heavy chain  
constant region selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA  
and IgE constant regions.

28. The isolated human antibody of claim 27, wherein the antibody heavy  
chain constant region is IgG1.

29. The isolated human antibody of claim 26, which is a Fab fragment.

30. The isolated human antibody of claim 26, which is a F(ab')<sub>2</sub> fragment.

31. The isolated human antibody of claim 26, which is a single chain Fv fragment.

32. An isolated human antibody, or an antigen-binding portion thereof, which

a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC<sub>50</sub> of  $1 \times 10^{-9}$ M or less;

b) has a heavy chain CDR3 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 404-SEQ ID NO: 469; or

c) has a light chain CDR3 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 534-SEQ ID NO: 579.

33. The isolated human antibody, or an antigen-binding portion thereof, of claim 32 which further has a heavy chain CDR2 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 335-SEQ ID NO: 403; or a light chain CDR2 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 506-SEQ ID NO: 533.

34. The isolated human antibody, or an antigen-binding portion thereof, of claim 32 which further has a heavy chain CDR1 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 288-SEQ ID NO: 334; or a light chain CDR1 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 470-SEQ ID NO: 505.

35. An isolated human antibody, or an antigen-binding portion thereof, having a the heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 23, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 24.

- 176 -

36. The isolated human antibody of claim 35, comprising a heavy chain constant region selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA and IgE constant regions.

37. The isolated human antibody of claim 36, wherein the antibody heavy chain constant region is IgG1.

38. The isolated human antibody of claim 35, which is a Fab fragment.

39. The isolated human antibody of claim 35, which is a F(ab')<sub>2</sub> fragment.

40. The isolated human antibody of claim 35, which is a single chain Fv fragment.

41. An isolated human antibody, or an antigen-binding portion thereof, which  
a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC<sub>50</sub> of  $1 \times 10^{-9}$ M or less;

b) has a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 25; and

c) has a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 26.

42. The isolated human antibody, or an antigen-binding portion thereof, of claim 41 which further has a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 27; and a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28.

43. The isolated human antibody, or an antigen-binding portion thereof, of claim 41 which further has a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 29; and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30.



- 177 -

44. An isolated human antibody, or an antigen-binding portion thereof, having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 31, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 32.

45. The isolated human antibody of claim 44, comprising a heavy chain constant region selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA and IgE constant regions.

46. The isolated human antibody of claim 45, wherein the antibody heavy chain constant region is IgG1.

47. The isolated human antibody of claim 44, which is a Fab fragment.

48. The isolated human antibody of claim 44, which is a F(ab')<sub>2</sub> fragment.

49. The isolated human antibody of claim 44, which is a single chain Fv fragment.

50. An isolated human antibody, or an antigen-binding portion thereof, which  
a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC<sub>50</sub> of 1 x 10<sup>-6</sup>M or less;

b) comprises a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 3 and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 5, or a mutant thereof having one or more amino acid substitutions at a contact position or a hypermutation position, wherein said mutant has a k<sub>off</sub> rate no more than 10-fold higher than the antibody comprising a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 5; and

- 178 -

c) comprises a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 2, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 6, or a mutant thereof having one or more amino acid substitutions at a contact position or a hypermutation position, wherein said mutant has a  $k_{off}$  rate no more than 10-fold higher than the antibody comprising a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 2, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 6.

51. An isolated human antibody, or an antigen-binding portion thereof, which

a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PIIA assay with an  $IC_{50}$  of  $1 \times 10^{-9}$ M or less;

b) comprises a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 9, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 11 and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 13, or a mutant thereof having one or more amino acid substitutions at a contact position or a hypermutation position, wherein said mutant has a  $k_{off}$  rate no more than 10-fold higher than the antibody comprising a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 9, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 11, and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 13; and

c) comprises a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 10, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 12, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 14, or a mutant thereof having one or more amino acid substitutions at a contact position or a hypermutation position, wherein said mutant has a  $k_{off}$  rate no more than 10-fold higher than the antibody comprising a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 10, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 12, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 14.

52. An isolated human antibody, or an antigen-binding portion thereof, which

a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC<sub>50</sub> of  $1 \times 10^{-9}$ M or less;

b) comprises a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 19 and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 21, or a mutant thereof having one or more amino acid substitutions at a contact position or a hypermutation position, wherein said mutant has a  $k_{off}$  rate no more than 10-fold higher than the antibody comprising a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 21; and

c) comprises a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 18, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 20, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 22, or a mutant thereof having one or more amino acid substitutions at a contact position or a hypermutation position, wherein said mutant has a  $k_{off}$  rate no more than 10-fold higher than the antibody comprising a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 18, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 20, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 22.

53. An isolated nucleic acid encoding the heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 17.

54. The isolated nucleic acid of claim 53, which encodes an antibody heavy chain variable region.

55. The isolated nucleic acid of claim 54, wherein the CDR2 of the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 19.

- 180 -

56. The isolated nucleic acid of claim 54, wherein the CDR1 of the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 21.

57. The isolated nucleic acid of claim 56, which encodes an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 23.

58. An isolated nucleic acid encoding the light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 18.

59. The isolated nucleic acid of claim 58, which encodes an antibody light chain variable region.

60. The isolated nucleic acid of claim 59, wherein the CDR2 of the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO: 20.

61. The isolated nucleic acid of claim 59, wherein the CDR1 of the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO: 22.

62. The isolated nucleic acid of claim 61, which encodes an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 24.

63. An isolated human antibody, or an antigen-binding portion thereof, which

a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an  $IC_{50}$  of  $1 \times 10^{-9}M$  or less;

b) comprises a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 25, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 27 and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 29, or a mutant thereof having one or more amino acid substitutions at a contact position or a hypermutation position, wherein said mutant has a  $k_{off}$  rate no more than 10-fold higher than the antibody comprising a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 25, a heavy chain CDR2 comprising the amino acid sequence

of SEQ ID NO: 27, and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 29; and

c) comprises a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 26, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30, or a mutant thereof having one or more amino acid substitutions at a contact position or a hypermutation position, wherein said mutant has a  $k_{off}$  rate no more than 10-fold higher than the antibody comprising a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 26, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30.

64. An isolated nucleic acid encoding the heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 25.

65. The isolated nucleic acid of claim 64, which encodes an antibody heavy chain variable region.

66. The isolated nucleic acid of claim 65, wherein the CDR2 of the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 27.

67. The isolated nucleic acid of claim 65, wherein the CDR1 of the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 29.

68. The isolated nucleic acid of claim 67, which encodes an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 31.

69. An isolated nucleic acid encoding the light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 26.

70. The isolated nucleic acid of claim 69, which encodes an antibody light chain variable region.

5  
10 71. The isolated nucleic acid of claim 70, wherein the CDR2 of the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO: 28.

5 72. The isolated nucleic acid of claim 70, wherein the CDR1 of the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO: 30.

15 73. The isolated nucleic acid of claim 72, which encodes an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 32.

20 74. An isolated human antibody, or an antigen-binding portion thereof, which has the following characteristics:

25 a) that binds to human IL-12 and dissociates from human IL-12 with a  $k_{off}$  rate constant of  $0.1 \text{ s}^{-1}$  or less, as determined by surface plasmon resonance, or which inhibits phytohemagglutinin blast proliferation in an *in vitro* phytohemagglutinin blast proliferation assay (PIIA assay) with an  $IC_{50}$  of  $1 \times 10^{-6} \text{ M}$  or less.

30 b) has a heavy chain variable region comprising an amino acid sequence selected from a member of the VH3 germline family, wherein the heavy chain variable region has a mutation at a contact or hypermutation position with an activity enhancing amino acid residue.

35 c) has a light chain variable region comprising an amino acid sequence selected from a member of the VL1 germline family, wherein the light chain variable region has a mutation at a contact or hypermutation position with an activity enhancing amino acid residue.

40 25

45

50

55

5  
75. An isolated human antibody, or an antigen-binding portion thereof, which has the following characteristics:

10 a) that binds to human IL-12 and dissociates from human IL-12 with a  $k_{\text{off}}$  rate constant of  $0.1 \text{ s}^{-1}$  or less, as determined by surface plasmon resonance, or which  
5 inhibits phytohemagglutinin blast proliferation in an *in vitro* phytohemagglutinin blast proliferation assay (PHA assay) with an  $\text{IC}_{50}$  of  $1 \times 10^{-6} \text{ M}$  or less.

15 b) has a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 595-667, wherein the heavy chain variable region has a mutation at a contact or hypermutation position with  
10 an activity enhancing amino acid residue.

20 c) has a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 669-675, wherein the light chain variable region has a mutation at a contact or hypermutation position with an activity  
25 enhancing amino acid residue.

15  
76. An isolated human antibody, or an antigen-binding portion thereof, which has the following characteristics:

30 a) that binds to human IL-12 and dissociates from human IL-12 with a  $k_{\text{off}}$  rate constant of  $0.1 \text{ s}^{-1}$  or less, as determined by surface plasmon resonance, or which  
20 inhibits phytohemagglutinin blast proliferation in an *in vitro* phytohemagglutinin blast proliferation assay (PHA assay) with an  $\text{IC}_{50}$  of  $1 \times 10^{-6} \text{ M}$  or less.

35 b) has a heavy chain variable region comprising the COS-3 germline amino acid sequence, wherein the heavy chain variable region has a mutation at a contact or hypermutation position with an activity enhancing amino acid residue.

40  
25 c) has a light chain variable region comprising the DPL8 germline amino acid sequence, wherein the light chain variable region has a mutation at a contact or hypermutation position with an activity enhancing amino acid residue.

5 77. An isolated human antibody, or an antigen-binding portion thereof, which has the following characteristics:

10 a) that binds to human IL-12 and dissociates from human IL-12 with a  $k_{\text{off}}$  rate constant of  $0.1 \text{ s}^{-1}$  or less, as determined by surface plasmon resonance, or which  
5 inhibits phytohemagglutinin blast proliferation in an *in vitro* phytohemagglutinin blast proliferation assay (PHA assay) with an  $\text{IC}_{50}$  of  $1 \times 10^{-6} \text{ M}$  or less.

15 b) has a heavy chain variable region comprising an amino acid sequence selected from a member of the VH3 germline family, wherein the heavy chain variable region comprises a CDR2 that is structurally similar to CDR2s from other VH3 germline  
10 family members, and a CDR1 that is structurally similar to CDR1s from other VH3 germline family members, and wherein the heavy chain variable region has a mutation at a contact or hypermutation position with an activity enhancing amino acid residue;

20 c) has a light chain variable region comprising an amino acid sequence selected from a member of the V $\lambda$ 1 germline family, wherein the light chain variable  
25 region comprises a CDR2 that is structurally similar to CDR2s from other V $\lambda$ 1 germline family members, and a CDR1 that is structurally similar to CDR1s from other V $\lambda$ 1 germline family members, and wherein the light chain variable region has a mutation at  
30 a contact or hypermutation position with an activity enhancing amino acid residue.

20 78. The isolated human antibody, or antigen binding portion thereof, of  
35 claims 74, 75, 76, or 77, wherein the mutation is in the heavy chain CDR3.

40 79. The isolated human antibody, or antigen binding portion thereof, of  
25 claims 74, 75, 76, or 77, wherein the mutation is in the light chain CDR3.

45 80. The isolated human antibody, or antigen binding portion thereof, of  
claims 74, 75, 76, or 77, wherein the mutation is in the heavy chain CDR2.

50 81. The isolated human antibody, or antigen binding portion thereof, of  
30 claims 74, 75, 76, or 77, wherein the mutation is in the light chain CDR2.



82. The isolated human antibody, or antigen binding portion thereof, of claims 74, 75, 76, or 77, wherein the mutation is in the heavy chain CDR1.

83. The isolated human antibody, or antigen binding portion thereof, of claims 74, 75, 76, or 77, wherein the mutation is in the light chain CDR1.

84. A recombinant expression vector encoding:  
a) an antibody heavy chain having a variable region comprising the amino acid sequence of SEQ ID NO: 31; and  
b) an antibody light chain having a variable region comprising the amino acid sequence of SEQ ID NO: 32.

85. A host cell into which the recombinant expression vector of claim 84 has been introduced.

86. A method of synthesizing a human antibody that binds human IL-12, comprising culturing the host cell of claim 85 in a culture medium until a human antibody that binds human IL-12 is synthesized by the cell.

87. An isolated human antibody, or antigen-binding portion thereof, that neutralizes the activity of human IL-12, and at least one additional primate IL-12 selected from the group consisting of baboon IL-12, marmoset IL-12, chimpanzee IL-12, cynomolgus IL-12 and rhesus IL-12, but which does not neutralize the activity of the mouse IL-12.

88. A pharmaceutical composition comprising the antibody or an antigen binding portion thereof, of any one of claims 1-52, 74-83 and 87 and a pharmaceutically acceptable carrier.

89. A composition comprising the antibody or an antigen binding portion thereof, of any one of claims 1-52, 74-83 and 87 and an additional agent.

5 90. The composition of claim 89, wherein the additional agent is a therapeutic agent.

10 91. The composition of claim 90, wherein the therapeutic agent is selected  
5 from the group consisting of budenoside, epidermal growth factor, corticosteroids, cyclosporin, sulfasalazine, aminosalicylates, 6-mercaptopurine, azathioprine, metronidazole, lipoxygenase inhibitors, mesalamine, olsalazine, balsalazide,  
15 antioxidants, thromboxane inhibitors, IL-1 receptor antagonists, anti-IL-1 $\beta$  monoclonal antibodies, anti-IL-6 monoclonal antibodies, growth factors, elastase inhibitors, pyridinyl-imidazole compounds, antibodies or agonists of TNF, LT, IL-1, IL-2, IL-6, IL-  
20 7, IL-8, IL-15, IL-16, IL-18, EMAP-II, GM-CSF, FGF, and PDGF, antibodies of CD2, CD3, CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD90 or their ligands, methotrexate, cyclosporin, FK506, rapamycin, mycophenolate mofetil, leflunomide, NSAIDs, ibuprofen, corticosteroids, prednisolone, phosphodiesterase inhibitors,  
25 adenosine agonists, antithrombotic agents, complement inhibitors, adrenergic agents, IRAK, NIK, IKK, p38, MAP kinase inhibitors, IL-1 $\beta$  converting enzyme inhibitors, TNF $\alpha$  converting enzyme inhibitors, T-cell signalling inhibitors, metalloproteinase inhibitors, sulfasalazine, azathioprine, 6-mercaptopurines, angiotensin converting  
30 enzyme inhibitors, soluble cytokine receptors, soluble p55 TNF receptor, soluble p75 TNF receptor, sIL-1RI, sIL-1RII, sIL-6R, antiinflammatory cytokines, IL-4, IL-10, IL-  
20 11, IL-13 and TGF $\beta$ .

35 92. The therapeutic composition of claim 90, wherein the therapeutic agent is selected from the group consisting of anti-TNF antibodies and antibody fragments  
40 thereof, TNFR-Ig constructs, TACE inhibitors, PDE4 inhibitors, corticosteroids, budenoside, dexamethasone, sulfasalazine, 5-aminosalicylic acid, olsalazine, IL-1 $\beta$  converting enzyme inhibitors, IL-1ra, tyrosine kinase inhibitors, 6-mercaptopurines and  
45 IL-11.

50 93. The therapeutic composition of claim 90, wherein the therapeutic agent is selected from the group consisting of corticosteroids, prednisolone, methylprednisolone, azathioprine, cyclophosphamide, cyclosporine, methotrexate, 4-aminopyridine,  
55

tizanidine, interferon- $\beta$ 1a, interferon- $\beta$ 1b, Copolymer 1, hyperbaric oxygen, intravenous immunoglobulin, clabribinc, antibodies or agonists of TNF, LT, IL-1, IL-2, IL-6, IL-7, IL-8, IL-15, IL-16, IL-18, EMAP-II, GM-CSF, FGF, PDGF, antibodies to CD2, CD3, CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD80, CD86, CD90 or their ligands, methotrexate, cyclosporine, FK506, rapamycin, mycophenolate mofetil, leflunomide, NSAIDs, ibuprofen, corticosteroids, prednisolone, phosphodiesterase inhibitors, adenosine agonists, antithrombotic agents, complement inhibitors, adrenergic agents, IRAK, NIK, IKK, p38 or MAP kinase inhibitors, IL-1 $\beta$  converting enzyme inhibitors, TACE inhibitors, T-cell signalling inhibitors, kinase inhibitors, metalloproteinase inhibitors, sulfasalazine, azathioprine, 6-mercaptopurines, angiotensin converting enzyme inhibitors, soluble cytokine receptors, soluble p55 TNF receptor, soluble p75 TNF receptor, sIL-1RI, sIL-1RII, sIL-6R, sIL-13R, anti-P7s, p-selectin glycoprotein ligand (PSGL), antiinflammatory cytokines, IL-4, IL-10, IL-13 and TGF $\beta$ .

94. A method for inhibiting human IL-12 activity comprising contacting human IL-12 with the antibody of claim 44 such that human IL-12 activity is inhibited.

95. A method for inhibiting human IL-12 activity in a human subject suffering from a disorder in which IL-12 activity is detrimental, comprising administering to the human subject the antibody of claim 44 such that human IL-12 activity in the human subject is inhibited.

96. The method of claim 95, wherein the disorder is selected from the group consisting of rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, Lyme arthritis, psoriatic arthritis, reactive arthritis, spondyloarthropathy, ankylosing spondylitis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, inflammatory bowel disease, multiple sclerosis, insulin dependent diabetes mellitus, thyroiditis, asthma, allergic diseases, psoriasis, dermatitis scleroderma, thyroiditis, graft versus host disease, organ transplant rejection, acute or chronic immune disease associated with organ transplantation, sarcoidosis, atherosclerosis, disseminated intravascular coagulation, Kawasaki's disease, Grave's disease, nephrotic syndrome, chronic fatigue syndrome, polyarteritis nodosa, Wegener's granulomatosis, Henoch-

- 188 -

Schonlein purpura, microscopic vasculitis of the kidneys, chronic active hepatitis, Sjogren's syndrome, uveitis, sepsis, septic shock, sepsis syndrome, adult respiratory distress syndrome, cachexia, infectious diseases, parasitic diseases, acquired immunodeficiency syndrome, acute transverse myelitis, myasthenia gravis, Huntington's chorea, Parkinson's disease, Alzheimer's disease, stroke, primary biliary cirrhosis, fibrotic lung diseases, hemolytic anemia, malignancies, heart failure and myocardial infarction.

97. The method of claim 95, wherein the disorder is Crohn's disease.

98. The method of claim 95, wherein the disorder is multiple sclerosis.

99. The method of claim 95, wherein the disorder is rheumatoid arthritis.

100. A method for improving the activity of an antibody, or antigen-binding portion thereof, to attain a predetermined target activity, comprising:

a) providing a parent antibody a antigen-binding portion thereof;

b) selecting a preferred selective mutagenesis position selected from group consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93, L94.

c) individually mutating the selected preferred selective mutagenesis position to at least two other amino acid residues to hereby create a first panel of mutated antibodies, or antigen binding portions thereof;

d) evaluating the activity of the first panel of mutated antibodies, or antigen binding portions thereof to determine if mutation of a single selective mutagenesis position produces an antibody or antigen binding portion thereof with the predetermined target activity or a partial target activity;

e) combining in a stepwise fashion, in the parent antibody, or antigen binding portion thereof, individual mutations shown to have an improved activity, to form combination antibodies, or antigen binding portions thereof.

- 189 -

f) evaluating the activity of the combination antibodies, or antigen binding portions thereof to determined if the combination antibodies, or antigen binding portions thereof have the predetermined target activity or a partial target activity.

g) if steps d) or f) do not result in an antibody or antigen binding portion thereof having the predetermined target activity, or result an antibody with only a partial activity, the method further comprising mutating additional amino acid residues selected from the group consisting of H35, H50, H53, H54, H95, H96, H97, H98, L30A and L96 to at least two other amino acid residues to thereby create a second panel of mutated antibodies or antigen-binding portions thereof;

h) evaluating the activity of the second panel of mutated antibodies or antigen binding portions thereof, to determined if mutation of a single amino acid residue selected from the group consisting of H35, H50, H53, H54, H95, H96, H97, H98, L30A and L96 results an antibody or antigen binding portion thereof, having the predetermined target activity or a partial activity;

i) combining in stepwise fashion in the parent antibody, or antigen-binding portion thereof, individual mutations of step g) shown to have an improved activity, to form combination antibodies, or antigen binding portions thereof;

j) evaluating the activity of the combination antibodies or antigen binding portions thereof, to determined if the combination antibodies, or antigen binding portions thereof have the predetermined target activity or a partial target activity;

k) if steps h) or j) do not result in an antibody or antigen binding portion thereof having the predetermined target activity, or result in an antibody with only a partial activity, the method further comprising mutating additional amino acid residues selected from the group consisting of H33B, H52B and L31A to at least two other amino acid residues to thereby create a third panel of mutated antibodies or antigen binding portions thereof;

l) evaluating the activity of the third panel of mutated antibodies or antigen binding portions thereof, to determine if a mutation of a single amino acid residue selected from the group consisting of H33B, H52B and L31A resulted in an antibody or antigen binding portion thereof, having the predetermined target activity or a partial activity;

- 190 -

m) combining in a stepwise fashion in the parent antibody, or antigen binding portion thereof, individual mutation of step k) shown to have an improved activity, to form combination antibodies, or antigen binding portions, thereof;

n) evaluating the activity of the combination antibodies or antigen-binding portions thereof, to determine if the combination antibodies, or antigen binding portions thereof have the predetermined target activity to thereby produce an antibody or antigen binding portion thereof with a predetermined target activity.

101. A method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

a) providing a parent antibody or antigen-binding portion thereof;

b) selecting a preferred selective mutagenesis position, contact or hypermutation position within a complementarity determining region (CDR) for mutation, thereby identifying a selected preferred selective mutagenesis position, contact or hypermutation position;

c) individually mutating said preferred selective mutagenesis position, contact or hypermutation position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof;

d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof;

e) repeating steps b) through d) for at least one other preferred selective mutagenesis position, contact or hypermutation position if the desired antibody activity is not obtained;

f) combining in a stepwise fashion, in the parent antibody, or antigen-binding portion thereof, individual mutations shown to have improved activity, to form combination antibodies, or antigen-binding portions thereof; and

g) evaluating the activity of the combination antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, until an antibody, or antigen-binding portion thereof, with an improved activity, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

- 191 -

102. The method of claim 101, wherein contact positions are selected from the group consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96.

103. The method of claim 101, wherein hypermutation positions are selected from the group consisting of H30, H31, H31B, H32, H52, H56, H58, L30, L31, L32, L53 and L93.

104. The method of claim 101, wherein the preferred positions are selected from the group consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93, L94.

105. The method of claim 101, wherein the contact positions are selected from the group consisting of L50 and L94.

106. A method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

a) providing a recombinant parent antibody or antigen-binding portion thereof; that was obtained by selection in a phage-display system but whose activity is not further improved by mutagenesis in said phage-display system;

b) selecting a preferred selective mutagenesis position, contact or hypermutation position within a complementarity determining region (CDR) for mutation, thereby identifying a selected preferred selective mutagenesis position, contact or hypermutation position;

c) individually mutating said selected preferred selective mutagenesis position, contact or hypermutation position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof, and expressing said panel in a non-phage display system;

d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof;

- 192 -

e) repeating steps b) through d) for at least one other preferred selective mutagenesis position, contact or hypermutation position if the desired antibody activity is not obtained;

f) combining, in the parent antibody, or antigen-binding portion thereof, individual mutations shown to have improved activity, to form combination antibodies, or antigen-binding portions thereof; and

g) evaluating the activity of the combination antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof; until an antibody, or antigen-binding portion thereof, with an improved activity, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

107. The method of claim 106, wherein contact positions are selected from the group consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96.

108. The method of claim 106, wherein hypermutation positions are selected from the group consisting of H30, H31, H31B, H32, H52, H56, H58, L30, L31, L32, L53 and L93.

109. The method of claim 106, wherein preferred selective mutagenesis positions are selected from the group consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93, L94

110. The method of claim 106, wherein the contact positions are selected from the group consisting of L50 and L94.



- 193 -

111. A method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

a) providing a recombinant parent antibody or antigen-binding portion thereof ;

b) selecting a preferred selective mutagenesis position, contact or hypermutation position within a complementarity determining region (CDR) for mutation, thereby identifying a selected preferred selective mutagenesis position, contact or hypermutation position;

c) individually mutating said selected preferred selective mutagenesis position, contact or hypermutation position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof and expressing said panel in an appropriate expression system;

d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;

e) evaluating the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, for at least one other property or characteristic, wherein the property or characteristic is one that needs to be retained in the antibody; until an antibody, or antigen-binding portion thereof, with an improved activity and at least one retained property or characteristic, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

112. The method of claim 111, wherein contact positions are selected from the group consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96, and wherein the other property or characteristic is selected from the group consisting of preservation of non-crossreactivity with other proteins, preservation of non-crossreactivity with other human tissues, preservation of epitope recognition and an antibody with a close to germline immunoglobulin sequence.

30

5

10

15

20

25

30

35

40

45

50

55

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

113. The method of claim 111, wherein the hypermutation positions are selected from the group consisting of H30, H31, H31B, H32, H52, H56, H58, L30, L31, L32, L53 and L93, and wherein the other property or characteristic is selected from the group consisting of preservation of non-crossreactivity with other proteins, preservation of non-crossreactivity with other human tissues, preservation of epitope recognition and an antibody with a close to germline immunoglobulin sequence.

114. The method of claim 111, wherein the preferred selective mutagenesis positions are selected from the group consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93 and L94, and wherein the other property or characteristic is selected from the group consisting of preservation of non-crossreactivity with other proteins, preservation of non-crossreactivity with other human tissues, preservation of epitope recognition and an antibody with a close to germline immunoglobulin sequence.

115. The method of claim 111, wherein the contact positions are selected from the group consisting of L50 and L94, and wherein the other property or characteristic is selected from the group consisting of preservation of non-crossreactivity with other proteins, preservation of non-crossreactivity with other human tissues, preservation of epitope recognition and an antibody with a close to germline immunoglobulin sequence.

116. A method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

a) providing a recombinant parent antibody or antigen-binding portion thereof; that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in said phage-display system;

b) selecting a preferred selective mutagenesis position, contact or hypermutation position within a complementarity determining region (CDR) for mutation, thereby identifying a selected preferred selective mutagenesis position, contact or hypermutation position;

- 195 -

c) individually mutating said selected preferred selective mutagenesis position, contact or hypermutation position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof, and expressing said panel in a non-phage display system;

d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;

e) evaluating the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof for at least one other property or characteristic, wherein the property or characteristic is one that needs to be retained, until an antibody, or antigen-binding portion thereof, with an improved activity and at least one retained property or characteristic, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

f) repeating steps a) through e) for at least one other preferred selective mutagenesis position, contact or hypermutation position;

g) combining, in the parent antibody, or antigen-binding portion thereof, at least two individual activity enhancing amino acid residues shown to have improved activity and at least one retained property or characteristic, to form combination antibodies, or antigen-binding portions thereof; and

h) evaluating the activity of the combination antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof; until an antibody, or antigen-binding portion thereof, with an improved activity and at least one retained property or characteristic, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

117. The method of claim 116, wherein contact positions are selected from the group consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96, and wherein the other property or characteristic is selected from the group consisting of preservation of non-crossreactivity with other proteins, preservation of non-crossreactivity with other human tissues, preservation of epitope recognition and an antibody with a close to germline immunoglobulin sequence.

5  
10  
15  
118. The method of claim 116, wherein the hypermutation positions are selected from the group consisting of H30, H31, H31B, H32, H52, H56, H58, L30, L31, L32, L53 and L93, and wherein the other property or characteristic is selected from the group consisting of preservation of non-crossreactivity with other proteins, preservation of non-crossreactivity with other human tissues, preservation of epitope recognition and an antibody with a close to germline immunoglobulin sequence.

20  
25  
119. The method of claim 116 wherein the preferred selective mutagenesis positions are selected from the group consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93 and L94, and wherein the other property or characteristic is selected from the group consisting of preservation of non-crossreactivity with other proteins, preservation of non-crossreactivity with other human tissues, preservation of epitope recognition and an antibody with a close to germline immunoglobulin sequence.

30  
35  
120. The method of claim 116, wherein the contact positions are selected from the group consisting of L50 and L94, and wherein the other property or characteristic is selected from the group consisting of preservation of non-crossreactivity with other proteins, preservation of non-crossreactivity with other human tissues, preservation of epitope recognition and an antibody with a close to germline immunoglobulin sequence.

40  
121. A method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

45  
25 a) providing a recombinant parent antibody or antigen-binding portion thereof; that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in said phage-display system;

50  
30 b) selecting a contact or hypermutation position within a complementarity determining region (CDR) for mutation, thereby identifying a selected contact or hypermutation position;

55  
c) individually mutating said selected contact or hypermutation position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or

antigen-binding portions thereof, and expressing said panel in a non-phage display system;

d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;

e) evaluating the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof for at least one additional property or characteristic, wherein the property or characteristic is one that needs to be retained,

until an antibody, or antigen-binding portion thereof, with an improved activity and at least one retained property or characteristic relative to the parent antibody, or antigen-binding portion thereof, is obtained.

122. The method of claim 121, wherein contact positions are selected from the group consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96, and wherein the other property or characteristic is selected from the group consisting of preservation of non-crossreactivity with other proteins, preservation of non-crossreactivity with other human tissues, preservation of epitope recognition and an antibody with a close to germline immunoglobulin sequence.

123. The method of claim 121, wherein the hypermutation positions are selected from the group consisting of H30, H31, H31B, H32, H52, H56, H58, L30, L31, L32, L53 and L93, and wherein the other property or characteristic is selected from the group consisting of preservation of non-crossreactivity with other proteins, preservation of non-crossreactivity with other human tissues, preservation of epitope recognition and an antibody with a close to germline immunoglobulin sequence.

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

124. The method of claim 121, wherein the contact positions are selected from the group consisting of L50 and L94, and wherein the other property or characteristic is selected from the group consisting of preservation of non-crossreactivity with other proteins, preservation of non-crossreactivity with other human tissues, preservation of epitope recognition and an antibody with a close to germline immunoglobulin sequence.

125. A method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

a) providing a recombinant parent antibody or antigen-binding portion thereof; that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in said phage-display system;

b) selecting a preferred selective mutagenesis position, contact or hypermutation position within a complementarity determining region (CDR) for mutation, thereby identifying a selected preferred selective mutagenesis position contact or hypermutation position;

c) individually mutating said selected preferred selective mutagenesis position, contact or hypermutation position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof, and expressing said panel in a non-phage display system;

d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;

e) evaluating the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof for at least one other property or characteristic, wherein the property or characteristic is one that needs to be retained, until an antibody, or antigen-binding portion thereof, with an improved activity and at least one retained property or characteristic relative to the parent antibody, or antigen-binding portion thereof, is obtained.

f) repeating steps a) through e) for at least one other preferred selective mutagenesis position, contact or hypermutation position;

g) combining, in the parent antibody, or antigen-binding portion thereof, at least two individual activity enhancing amino acid residues shown to have improved activity

5 and at least one retained property or characteristic, to form combination antibodies, or antigen-binding portions thereof; and

10 h) evaluating the activity of the combination antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof;  
5 until an antibody, or antigen-binding portion thereof, with an improved activity and at least one retained property or characteristic relative to the parent antibody, or antigen-binding portion thereof, is obtained.  
15

126. The method of claim 125, wherein contact positions are selected from the  
10 group consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96, and wherein the other property or characteristic is selected from  
20 the group consisting of preservation of non-crossreactivity with other proteins, preservation of non-crossreactivity with other human tissues, preservation of epitope  
25 recognition and an antibody with a close to germline immunoglobulin sequence.  
15

127. The method of claim 125, wherein the hypermutation positions are  
30 selected from the group consisting of H30, H31, H31B, H32, H52, H56, H58, L30, L31, L32, L53 and L93, and wherein the other property or characteristic is selected from the  
20 group consisting of preservation of non-crossreactivity with other proteins, preservation of non-crossreactivity with other human tissues, preservation of epitope recognition and  
35 an antibody with a close to germline immunoglobulin sequence.

128. The method of claim 125 wherein the preferred selective mutagenesis  
40 positions are selected from the group consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93 and L94, and wherein the other property or characteristic is selected from the group consisting of preservation of non-  
45 crossreactivity with other proteins, preservation of non-crossreactivity with other human tissues, preservation of epitope recognition and an antibody with a close to germline  
30 immunoglobulin sequence.

5

10

15

20

25

30

35

40

45

50

55

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

129. The method of claim 125, wherein the contact positions are selected from the group consisting of L50 and L94, and wherein the other property or characteristic is selected from the group consisting of preservation of non-crossreactivity with other proteins, preservation of non-crossreactivity with other human tissues, preservation of epitope recognition and an antibody with a close to germline immunoglobulin sequence.

130. A method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

a) providing a parent antibody or antigen-binding portion thereof;

b) selecting a amino acid residue within a complementarity determining region (CDR) for mutation at a position other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

c) individually mutating said selected position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof;

d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;

e) evaluating the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, for changes in at least one other property or characteristic; until an antibody, or antigen-binding portion thereof, with an improved activity, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

131. A method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

a) providing a parent antibody or antigen-binding portion thereof;

b) selecting a amino acid residue within a complementarity determining region (CDR) for mutation at a position other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;



- 201 -

5 c) individually mutating said selected position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof;

10 d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, thereby identifying an activity enhancing amino acid residue;

15 e) repeating steps b) through d) for at least one other position within the CDR which is neither the position selected under b) nor a position at H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

20 f) combining, in the parent antibody, or antigen-binding portion thereof, at least two individual activity enhancing amino acid residues shown to have improved activity, to form combination antibodies, or antigen-binding portions thereof; and

25 g) evaluating the activity of the combination antibodies, or antigen-binding portions thereof with two activity enhancing amino acid residues, relative to the parent antibody or antigen-binding portion thereof until an antibody, or antigen-binding portion thereof, with an improved activity, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

30 132. A method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

35 a) providing a recombinant parent antibody or antigen-binding portion thereof; that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in said phage-display system;

40 b) selecting a selecting an amino acid residue within a complementarity determining region (CDR) for mutation at a position other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and;

45 c) individually mutating said selected contact or hypermutation position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof, and expressing said panel in a non-phage display system;

50

55

5 d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;

10 e) evaluating the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, for changes in at least one other property or characteristic, until an antibody, or antigen-binding portion thereof, with an improved activity, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

15 133. A method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

20 a) providing a parent antibody or antigen-binding portion thereof that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in said phage-display system;

25 b) selecting an amino acid residue within a complementarity determining region (CDR) for mutation at a position other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

30 c) individually mutating said selected position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof and expression in a non-phage display system;

35 d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;

40 e) repeating steps b) through d) for at least one other position within the CDR which is neither the position selected under b) nor a position at H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 ;

45 f) combining, in the parent antibody, or antigen-binding portion thereof, at least two individual activity enhancing amino acid residues shown to have improved activity, to form combination antibodies, or antigen-binding portions thereof; and

50

55

5 g) evaluating the activity and other property or characteristics of the combination  
antibodies, or antigen-binding portions thereof, with two activity enhancing amino acid  
10 residues, relative to the parent antibody or antigen-binding portion thereof;  
until an antibody, or antigen-binding portion thereof, with an improved activity, relative  
5 to the parent antibody, or antigen-binding portion thereof, is obtained.

15 134. A method for improving the activity of an antibody, or antigen-binding  
portion thereof, without affecting other properties, comprising:

a) providing a parent antibody or antigen-binding portion thereof;

10 b) selecting an amino acid residue within a complementarity determining region  
(CDR) for mutation at a position other than H30, H31, H31B, H32, H33, H35, H50,  
20 H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34,  
L50, L52, L53, L55, L91, L92, L93, L94 and L96;

25 c) individually mutating said selected position to at least two other amino acid  
15 residues to thereby create a panel of mutated antibodies, or antigen-binding portions  
thereof;

30 d) evaluating the activity of the panel of mutated antibodies, or antigen-binding  
portions thereof, relative to the parent antibody or antigen-binding portion thereof  
thereby identifying an activity enhancing amino acid residue;

20 e) evaluating the panel of mutated antibodies, or antigen-binding portions  
thereof, relative to the parent antibody or antigen-binding portion thereof, for changes in  
35 at least one other property or characteristic, wherein the property or characteristic needs  
to be retained, until an antibody, or antigen-binding portion thereof, with an improved  
activity and retained property, or characteristic relative to the parent antibody, or  
40 25 antigen-binding portion thereof, is obtained.

45 135. A method for improving the activity of an antibody, or antigen-binding  
portion thereof, comprising:

a) providing a parent antibody or antigen-binding portion thereof;

30 b) selecting an amino acid residue within a complementarity determining region  
(CDR) for mutation at a position other than H30, H31, H31B, H32, H33, H35, H50,

- 204 -

H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

c) individually mutating said selected position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof;

d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, thereby identifying an activity enhancing amino acid residue;

e) evaluating the panel of mutated antibodies or antigen-binding portions thereof, relative to the parent antibody or antigen-portion thereof, for changes in at least one other property or characteristic;

f) repeating steps b) through e) for at least one other CDR position which is neither the position selected under b) nor a position at H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

g) combining, in the parent antibody, or antigen-binding portion thereof, at least two individual activity enhancing amino acid residues shown to have improved activity but not affecting at least one other property or characteristic, to form combination antibodies, or antigen-binding portions thereof with at least one retained property or characteristic; and

h) evaluating the activity and the retention of at least one property or characteristic of the combination antibodies, or antigen-binding portions thereof with two activity enhancing amino acid residues, relative to the parent antibody or antigen-binding portion thereof until an antibody, or antigen-binding portion thereof, with an improved activity and at least one retained property or characteristic, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

136. A method to improve the affinity of an antibody or antigen-binding portion thereof, comprising:

a) providing a parent antibody or antigen-binding portion thereof that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in said phage-display system;

5 b) selecting an amino acid residue within a complementarity determining region (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

10 c) individually mutating said selected position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof and expression in a non-phage display system;

15 d) evaluating the activity of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof thereby identifying an activity enhancing amino acid residue;

20 e) evaluating the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, for changes in at least one other property or characteristic until an antibody, or antigen-binding portion thereof, with an improved activity, relative to the parent antibody, or antigen-binding portion thereof, is obtained.

25 137. A method for improving the activity of an antibody, or antigen-binding portion thereof, comprising:

30 a) providing a parent antibody or antigen-binding portion thereof that was obtained by selection in a phage-display system but whose activity cannot be further improved by mutagenesis in said phage-display system;

35 b) selecting an amino acid residue within a complementarity determining region (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

40 c) individually mutating said selected position to at least two other amino acid residues to thereby create a panel of mutated antibodies, or antigen-binding portions thereof and expression in a non-phage display system;

45 d) evaluating the activity and retention of at least one other property or characteristic of the panel of mutated antibodies, or antigen-binding portions thereof, relative to the parent antibody or antigen-binding portion thereof, thereby identifying an activity enhancing amino acid residue;

5 e) repeating steps b) through d) for at least one other CDR position which is  
neither the position selected under b) nor a position at H30, H31, H31B, H32, H33,  
10 H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31,  
L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

5 f) combining, in the parent antibody, or antigen-binding portion thereof, at least  
two individual activity enhancing amino acid residues shown to have improved activity  
15 and not to affect at least one other property or characteristic, to form combination  
antibodies, or antigen-binding portions thereof; and

g) evaluating the activity and retention of at least one other property or  
10 characteristic of the combination antibodies, or antigen-binding portions thereof with  
two activity enhancing amino acid residues, relative to the parent antibody or antigen-  
binding portion thereof until an antibody, or antigen-binding portion thereof, with an  
20 improved activity and at least one other retained property or characteristic, relative to  
the parent antibody, or antigen-binding portion thereof, is obtained.

15 138. The method of claims 130, 131, 132, 133, 134, 135, 136 or 137, wherein  
the other property or characteristic is selected from the group consisting of preservation  
30 of non-crossreactivity with other proteins, preservation of non-cross reactivity with other  
human tissues, preservation of epitope recognition and an antibody with a close to  
20 germline immunoglobulin sequence.

35 139. A method for detecting human IL-12 comprising contacting human IL-12  
with the antibody, or antigen-binding portion thereof, of any of claims 1-52, 74-83 and  
87 such that human IL-12 is detected.

40 25 140. The method of claim 139, wherein human IL-12 is detected *in vitro*.

45 141. The method of claim 139, wherein human IL-12 is detected in a  
biological sample for diagnostic purposes.

30 142. Use of the antibody, or antigen-binding portion thereof, of any of claims  
50 1-52, 74-83 and 87 in therapy.

5  
10  
143. Use of the antibody, or antigen-binding portion thereof, of any of claims 1-52, 74-83 and 87 in the manufacture of a medicament for the treatment of a disorder in which IL-12 activity is detrimental.

5  
15  
144. The use of claim 143, wherein the disorder is selected from the group consisting of rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, Lyme arthritis, psoriatic arthritis, reactive arthritis, spondyloarthropathy, ankylosing  
20  
25  
inflammatory bowel disease, multiple sclerosis, insulin dependent diabetes mellitus, thyroiditis, asthma, allergic diseases, psoriasis, dermatitis, scleroderma, thyroiditis, graft  
30  
versus host disease, organ transplant rejection, acute or chronic immune disease associated with organ transplantation, sarcoidosis, atherosclerosis, disseminated  
35  
intravascular coagulation, Kawasaki's disease, Grave's disease, nephrotic syndrome, chronic fatigue syndrome, polyarteritis nodosa, Wegener's granulomatosis, Henoch-Schönlein  
40  
45  
purpura, microscopic vasculitis of the kidneys, chronic active hepatitis, Sjögren's syndrome, uveitis, sepsis, septic shock, sepsis syndrome, adult respiratory distress syndrome, cachexia, infectious diseases, parasitic diseases, acquired  
50  
immunodeficiency syndrome, acute transverse myelitis, myasthenia gravis, Huntington's  
55  
chorea, Parkinson's disease, Alzheimer's disease, stroke, primary biliary cirrhosis, fibrotic lung diseases, hemolytic anemia, malignancies, heart failure and myocardial infarction.

40  
145. The use of claim 143, wherein the disorder is Crohn's disease.

45  
146. The use of claim 143, wherein the disorder is multiple sclerosis.

50  
147. The use of claim 143, wherein the disorder is rheumatoid arthritis.

1/14

Figure 1A. Heavy Chain Variable Region Sequences

SEQ ID NO:	Kabat number	CDR H1	CDR H2
33	JOE9wt VH	31 32 33 34 35	50 51 52 53 54 55 56
35	Cos-3/Jr3 VH	QVQLVQSGG	QVQLVQSGG
37	70-1 VH	.....G	.....
39	78-34 VH	.....	.....
41	79-1 VH	.....	.....
43	101-11 VH	.....	.....
45	26-1 VH	.....	.....
47	136-15 VH	.....	.....
49	136-15 VH germline	.....E	.....
51	149-5 VH	.....	.....
53	149-6 VH	.....	.....
55	103-4 VH	.....	.....
57	103-8 VH	.....	.....
59	103-14 VH	.....	.....
61	G6 VH	.....	.....
63	Y139 VH	.....	.....
65	AO3 VH	.....	.....
67	AO3 VH germline	.....E	.....
23	Y61 VH	.....	.....
69	Y61 VH germline	.....E	.....
71	Y61-H31E VH	.....E	.....
73	Y61 L50Y VH	.....	.....
75	Y61-L94Y VH	.....	.....
31	J695	.....E	.....



Figure 1B. Heavy Chain Variable Region Sequences

SEQ ID NO:	Kabat number	CDR H2	CDR H3
33	JOE9wt VH	53 54 55 56 57 58 59 60 61 62 63 64 65 KYYADSVKGRFTISRDNKNTLYLQMKSLRAEDTAVYYCTTAK	103 104 105 106 107 108 109 110 111 112 113 WGQGTMTVSS
35	Cos-3/Jn3 VH		
37	70-1 VH		
39	78-34 VH		
41	79-1 VH		
43	101-11 VH		
45	26-1 VH		
47	136-15 VH		
49	136-15 VH germline		
51	149-5 VH		
53	149-6 VH		
55	103-4 VH		
57	103-8 VH		
59	103-14 VH		
61	G6 VH		
63	Y139 VH		
65	A03 VH		
67	A03 VH germline		
23	Y61 VH		
69	Y61 VH germline		
71	Y61-H31E VH		
73	Y61 L50Y VH		
75	Y61-L94Y VH		
31	J695		

3/14

Figure 1C. Light Chain Variable Region Sequences

SEQ ID NO:	Kabat number	CDR L1	CDR L2
34	Joe9 VL wt		
36	Dp18 Lx1042/JA1		
38	70-1 VL		
40	78-34 VL		
42	79-1 VL		
44	101-11 VL		
46	26-1 VL		
48	136-15 VL		
50	136-15 VL germline		
52	149-5 VL		
54	149-6 VL		
56	103-4 VL		
58	103-8 VL		
60	103-14 VL		
62	G6 VL		
64	Y139 VL		
66	AO3 VL		
68	AO3 VL germline		
70	Y61 VL		
72	Y61 VL germline		
74	Y61-H31E VL		
76	Y61-L50Y VL		
78	Y61-L94Y VL		
80	J695 VL		
82			
84			
86			
88			
90			
92			
94			
96			
98			
100			
102			
104			
106			
108			
110			
112			
114			
116			
118			
120			
122			
124			
126			
128			
130			
132			
134			
136			
138			
140			
142			
144			
146			
148			
150			
152			
154			
156			
158			
160			
162			
164			
166			
168			
170			
172			
174			
176			
178			
180			
182			
184			
186			
188			
190			
192			
194			
196			
198			
200			
202			
204			
206			
208			
210			
212			
214			
216			
218			
220			
222			
224			
226			
228			
230			
232			
234			
236			
238			
240			
242			
244			
246			
248			
250			
252			
254			
256			
258			
260			
262			
264			
266			
268			
270			
272			
274			
276			
278			
280			
282			
284			
286			
288			
290			
292			
294			
296			
298			
300			
302			
304			
306			
308			
310			
312			
314			
316			
318			
320			
322			
324			
326			
328			
330			
332			
334			
336			
338			
340			
342			
344			
346			
348			
350			
352			
354			
356			
358			
360			
362			
364			
366			
368			
370			
372			
374			
376			
378			
380			
382			
384			
386			
388			
390			
392			
394			
396			
398			
400			
402			
404			
406			
408			
410			
412			
414			
416			
418			
420			
422			
424			
426			
428			
430			
432			
434			
436			
438			
440			
442			
444			
446			
448			
450			
452			
454			
456			
458			
460			
462			
464			
466			
468			
470			
472			
474			
476			
478			
480			
482			
484			
486			
488			
490			
492			
494			
496			
498			
500			
502			
504			
506			
508			
510			
512			
514			
516			
518			
520			
522			
524			
526			
528			
530			
532			
534			
536			
538			
540			
542			
544			
546			
548			
550			
552			
554			
556			
558			
560			
562			
564			
566			
568			
570			
572			
574			
576			
578			
580			
582			
584			
586			
588			
590			
592			
594			
596			
598			
600			
602			
604			
606			
608			
610			
612			
614			
616			
618			
620			
622			
624			
626			
628			
630			
632			
634			
636			
638			
640			
642			
644			
646			
648			
650			
652			
654			
656			
658			
660			
662			
664			
666			
668			
670			
672			
674			
676			
678			
680			
682			
684			
686			
688			
690			
692			
694			
696			
698			
700			
702			
704			
706			
708			
710			
712			
714			
716			
718			
720			
722			
724			
726			
728			
730			
732			
734			
736			
738			
740			
742			
744			
746			
748			
750			
752			
754			
756			
758			
760			
762			
764			
766			
768			
770			
772			
774			
776			
778			
780			
782			
784			
786			
788			
790			
792			
794			
796			
798			
800			
802			
804			
806			
808			
810			
812			
814			
816			
818			
820			
822			
824			
826			
828			
830			
832			
834			
836			
838			
840			
842			
844			
846			
848			
850			
852			
854			
856			
858			
860			
862			
864			
866			
868			
870			
872			
874			
876			
878			
880			
882			
884			
886			
888			
890			
892			
894			
896			
898			
900			
902			
904			
906			
908			
910			
912			
914			
916			
918			
920			
922			
924			
926			
928			
930			
932			
934			
936			
938			
940			
942			
944			
946			
948			
950			
952			
954			
956			

4/14





Figure 1D. Light Chain Variable Region Sequences

SEQ ID NO:	Kabat number	CDR L3
34	Joe9 VL wt	
36	Dp18 L-1042/JL1	
38	70-1 VL	
40	78-34 VL	
42	79-1 VL	
44	101-11 VL	
46	26-1 VL	
48	136-15 VL	
50	136-15 VL germline	
52	149-5 VL	
54	149-6 VL	
56	103-4 VL	
58	103-8 VL	
60	103-14 VL	
62	G6 VL	
64	Y139 VL	
66	AO3 VL	
68	AO3 VL germline	
70	Y61 VL	
72	Y61 VL germline	
74	Y61-H31E VL	
76	Y61-L50Y VL	
78	Y61-L94Y VL	
80	J695 VL	
100		GVPRFSGSKSGTSASLAITGVQAEDEADYYC QSYDSSLRGSRV FGTGTVTLG
101		.....L.....S.....
102		.....RGFT.....
103		.....W.....
104		.....RGFT.....
105		.....W.....
106		.....T..KGFT..S..
107		.....T..KGFT..S..
108		.....W.T.....
109		.....RGFT.....
110		.....RGFT.A..
111		.....T..KGFT..S..
112		.....ERGFT..M..
113		.....RGTHPLTI
114		.....EGSHPALT
115		.....RGTHPLTM
116		.....RGTHPLTM
117		.....RGTHPALL
118		.....RGTHPALL
119		.....RGTHPALL
120		.....RGTHPALL
121		.....RGTHPALL
122		.....RGTHPALL
123		.....RGTHPALL
124		.....RGTHPALL
125		.....RGTHPALL
126		.....RGTHPALL
127		.....RGTHPALL
128		.....RGTHPALL
129		.....RGTHPALL
130		.....RGTHPALL
131		.....RGTHPALL
132		.....RGTHPALL
133		.....RGTHPALL
134		.....RGTHPALL
135		.....RGTHPALL
136		.....RGTHPALL
137		.....RGTHPALL
138		.....RGTHPALL
139		.....RGTHPALL
140		.....RGTHPALL
141		.....RGTHPALL
142		.....RGTHPALL
143		.....RGTHPALL
144		.....RGTHPALL
145		.....RGTHPALL
146		.....RGTHPALL
147		.....RGTHPALL
148		.....RGTHPALL
149		.....RGTHPALL
150		.....RGTHPALL
151		.....RGTHPALL
152		.....RGTHPALL
153		.....RGTHPALL
154		.....RGTHPALL
155		.....RGTHPALL
156		.....RGTHPALL
157		.....RGTHPALL
158		.....RGTHPALL
159		.....RGTHPALL
160		.....RGTHPALL
161		.....RGTHPALL
162		.....RGTHPALL
163		.....RGTHPALL
164		.....RGTHPALL
165		.....RGTHPALL
166		.....RGTHPALL
167		.....RGTHPALL
168		.....RGTHPALL
169		.....RGTHPALL
170		.....RGTHPALL
171		.....RGTHPALL
172		.....RGTHPALL
173		.....RGTHPALL
174		.....RGTHPALL
175		.....RGTHPALL
176		.....RGTHPALL
177		.....RGTHPALL
178		.....RGTHPALL
179		.....RGTHPALL
180		.....RGTHPALL
181		.....RGTHPALL
182		.....RGTHPALL
183		.....RGTHPALL
184		.....RGTHPALL
185		.....RGTHPALL
186		.....RGTHPALL
187		.....RGTHPALL
188		.....RGTHPALL
189		.....RGTHPALL
190		.....RGTHPALL
191		.....RGTHPALL
192		.....RGTHPALL
193		.....RGTHPALL
194		.....RGTHPALL
195		.....RGTHPALL
196		.....RGTHPALL
197		.....RGTHPALL
198		.....RGTHPALL
199		.....RGTHPALL
200		.....RGTHPALL

5/14

Figure 2A. Y61 Heavy Chain CDR H1 Mutagenesis





SEQ ID NO:	Y61	CDR H1								$k_{off}$ ( $\times 10^3$ )
		27	28	29	30	31	32	33	34	
21	Y61	F	T	F	S	S	Y	G	M	H
288		.	.	.	E	.	.	.	.	22.8
289		.	.	.	S	.	.	.	.	16.8
290		.	.	.	Y	.	.	.	.	31.9
291		.	.	.	H	.	.	.	.	29.6
292		.	.	.	K	.	.	.	.	22.5
293		.	.	.	R	.	.	.	.	24.5
294		.	.	.	N	.	.	.	.	30.1
295		.	.	.	T	.	.	.	.	32.0
296		.	.	.	G	.	.	.	.	23.3
297		.	.	.	V	.	.	.	.	39.9
298		.	.	.	I	.	.	.	.	20.7
299		.	.	.	W	.	.	.	.	21.6
300		.	.	.	E	.	.	.	.	21.9
301		.	.	.	C	.	.	.	.	12.0
302		.	.	.	S	.	.	.	.	24.9
303		.	.	.	Y	.	.	.	.	39.8
304		.	.	.	H	.	.	.	.	30.9
305		.	.	.	R	.	.	.	.	66.4
306		.	.	.	N	.	.	.	.	19.1
307		.	.	.	Q	.	.	.	.	15.2
308		.	.	.	T	.	.	.	.	71.6
309		.	.	.	A	.	.	.	.	20.5
310		.	.	.	I	.	.	.	.	33.4
311		.	.	.	E	.	.	.	.	229.0
312		.	.	.	C	.	.	.	.	383.0
313		.	.	.	S	.	.	.	.	157.5
314		.	.	.	Y	.	.	.	.	33.7
315		.	.	.	H	.	.	.	.	46.1
316		.	.	.	R	.	.	.	.	448.5
317		.	.	.	N	.	.	.	.	297.0
318		.	.	.	T	.	.	.	.	148.0
319		.	.	.	A	.	.	.	.	165.5
320		.	.	.	V	.	.	.	.	133.5
321		.	.	.	L	.	.	.	.	226.0
322		.	.	.	I	.	.	.	.	160.5
323		.	.	.	D	.	.	.	.	152.0
324		.	.	.	E	.	.	.	.	189.0
325		.	.	.	C	.	.	.	.	286.5
326		.	.	.	S	.	.	.	.	39.9
327		.	.	.	Y	.	.	.	.	250.5
328		.	.	.	N	.	.	.	.	30.8
329		.	.	.	G	.	.	.	.	17.8
330		.	.	.	A	.	.	.	.	27.3
331		.	.	.	V	.	.	.	.	191.0
332		.	.	.	M	.	.	.	.	21.5
333		.	.	.	I	.	.	.	.	250.0
334		.	.	.	P	.	.	.	.	159.5



6/14

Figure 2B. Y61 Heavy Chain CDR H2 Mutagenesis



		CDR H2																	
SEQ ID NO:		50	51	52	52A	53	54	55	56	57	58	59	60	61	62	63	64	65	K <sub>ref</sub> (x 10 <sup>3</sup> )
19	Y61	F	I	R	Y	D	G	S	N	K	Y	Y	A	D	S	I	V	KIG	34.7
335		E	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	28.5
336		C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	23.0
337		Y	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	30.9
338		H	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	61.2
339		K	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	34.4
340		N	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	42.0
341		Q	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	20.5
342		T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	44.0
343		L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	20.4
344		F	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	31.8
345		E	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	29.2
346		S	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	29.8
347		Y	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	40.7
348		H	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	26.2
349		K	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	20.6
350		R	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	28.5
351		Q	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	37.4
352		T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	32.1
353		G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	17.1
354		A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	31.7
355		V	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	34.7
356		L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	35.1
357		W	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	15.1
358		D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	39.9
359		E	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	36.8
360		S	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	61.1
361		Y	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	158.0
362		K	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	166.5
363		R	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	72.7
364		N	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	79.2
365		Q	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	50.0
366		T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	40.4
367		A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	44.0
368		V	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	109.5
369		L	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	94.4
370		I	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	168.5
371		F	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	45.5
372		D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	35.1
373		E	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	37.3
374		S	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	64.6
375		Y	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	40.7
376		K	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2.5
377		R	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	44.7
378		N	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	31.6
379		Q	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	64.4
380		T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	17.8
381		G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	43.5
382		V	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	



7/14

Figure 2C. Y61 Heavy Chain CDR H2 Mutagenesis

SEQ ID NO:	CDR H2																	$k_{eff}$ ( $\times 10^3$ )	
	Y61	F	I	R	Y	D	G	S	N	K	Y	Y	A	D	S	V	K		G
19	Y61	F	I	R	Y	D	G	S	N	K	Y	Y	A	D	S	V	K	G	
383		.	.	.	.	.	F	.	.	.	.	.	.	.	.	.	.	.	66.3
384		.	.	.	.	.	.	S	.	.	.	.	.	.	.	.	.	.	62.4
385		.	.	.	.	.	.	.	Y	.	.	.	.	.	.	.	.	.	39.0
386		.	.	.	.	.	.	.	H	.	.	.	.	.	.	.	.	.	42.0
387		.	.	.	.	.	.	.	N	.	.	.	.	.	.	.	.	.	38.5
388		.	.	.	.	.	.	.	T	.	.	.	.	.	.	.	.	.	23.5
389		.	.	.	.	.	.	.	G	.	.	.	.	.	.	.	.	.	27.2
390		.	.	.	.	.	.	.	M	.	.	.	.	.	.	.	.	.	38.3
391		.	.	.	.	.	.	.	L	.	.	.	.	.	.	.	.	.	26.4
392		.	.	.	.	.	.	.	I	.	.	.	.	.	.	.	.	.	16.9
393		.	.	.	.	.	.	.	P	.	.	.	.	.	.	.	.	.	29.9
394		.	.	.	.	.	.	.	F	.	.	.	.	.	.	.	.	.	34.5
395		.	.	.	.	.	.	.	.	E	.	.	.	.	.	.	.	.	41.5
396		.	.	.	.	.	.	.	.	S	.	.	.	.	.	.	.	.	94.1
397		.	.	.	.	.	.	.	.	Y	.	.	.	.	.	.	.	.	31.0
398		.	.	.	.	.	.	.	.	N	.	.	.	.	.	.	.	.	83.1
399		.	.	.	.	.	.	.	.	V	.	.	.	.	.	.	.	.	52.4
400		.	.	.	.	.	.	.	.	L	.	.	.	.	.	.	.	.	73.0
401		.	.	.	.	.	.	.	.	I	.	.	.	.	.	.	.	.	65.7
402		.	.	.	.	.	.	.	.	P	.	.	.	.	.	.	.	.	62.8
403		.	.	.	.	.	.	.	.	F	.	.	.	.	.	.	.	.	79.4



8/14

Figure 2D. Y61 Heavy Chain CDR H3 Mutagenesis

SEQ ID NO:	Y61	CDR H3						$K_{off}$ ( $\times 10^3$ )
		95	96	97	98	101	102	
17	Y61	H	G	S	H	D	N	
404		E	.	.	.	.	.	231.5
405		S	.	.	.	.	.	193.0
406		H	.	.	.	.	.	28.7
407		K	.	.	.	.	.	227.5
408		Q	.	.	.	.	.	85.9
409		T	.	.	.	.	.	202.0
410		A	.	.	.	.	.	150.0
411		L	.	.	.	.	.	147.5
412		P	.	.	.	.	.	471.0
413		F	.	.	.	.	.	514.0
414		.	D	.	.	.	.	223.5
415		.	C	.	.	.	.	24.2
416		.	H	.	.	.	.	23.7
417		.	R	.	.	.	.	96.2
418		.	T	.	.	.	.	186.0
419		.	G	.	.	.	.	39.7
420		.	V	.	.	.	.	38.2
421		.	M	.	.	.	.	204.5
422		.	L	.	.	.	.	261.0
423		.	I	.	.	.	.	207.5
424		.	P	.	.	.	.	129.0
425		.	W	.	.	.	.	197.0
426		.	.	D	.	.	.	202.0
427		.	.	S	.	.	.	37.5
428		.	.	Y	.	.	.	273.0
429		.	.	H	.	.	.	190.5
430		.	.	R	.	.	.	224.0
431		.	.	N	.	.	.	221.5
432		.	.	T	.	.	.	58.8
433		.	.	G	.	.	.	229.0
434		.	.	A	.	.	.	143.0
435		.	.	I	.	.	.	208.0
436		.	.	P	.	.	.	300.0
437		.	.	W	.	.	.	239.0
438		.	.	F	.	.	.	180.5
439		.	.	.	H	.	.	25.5
440		.	.	.	R	.	.	34.0
441		.	.	.	T	.	.	22.7
442		.	.	.	A	.	.	67.3
443		.	.	.	V	.	.	29.3
444		.	.	.	L	.	.	59.8
445		.	.	.	I	.	.	34.3
446		.	.	.	F	.	.	68.8
447		.	.	.	D	.	.	14.4
448		.	.	.	S	.	.	44.9
449		.	.	.	Y	.	.	465.0
450		.	.	.	H	.	.	327.0
451		.	.	.	R	.	.	110.0

Y61 Mutagenesis: H95



Y61 Mutagenesis: H96



Y61 Mutagenesis: H97





Y61 Mutagenesis: H98



9/14

Figure 2E. Y61 Heavy Chain CDR H3 Mutagenesis

SEQ ID NO:		CDR H3						$K_{off}$ ( $\times 10^5$ )
		95	96	97	98	101	102	
17	Y61	H	G	S	H	D	N	
452		.	.	.	.	N	.	223.0
453		.	.	.	.	G	.	375.0
454		.	.	.	.	A	.	106.5
455		.	.	.	.	V	.	163.0
456		.	.	.	.	I	.	162.5
457		.	.	.	.	.	S	32.5
458		.	.	.	.	.	H	18.0
459		.	.	.	.	.	K	40.5
460		.	.	.	.	.	R	57.5
461		.	.	.	.	.	N	40.3
462		.	.	.	.	.	T	33.3
463		.	.	.	.	.	G	69.2
464		.	.	.	.	.	A	38.2
465		.	.	.	.	.	L	95.6
466		.	.	.	.	.	I	99.6
467		.	.	.	.	.	P	181.5
468		.	.	.	.	.	W	23.5
469		.	.	.	.	.	F	31.8








10/14

Figure 2F. Y61 Light Chain CDR L1 Mutagenesis



SEQ ID NO:	CDR L1													$k_{off}$ ( $\times 10^3$ )
	24	25	26	27	27A	27B	28	29	30	31	32	33	34	
22	Y61	S	G	G	R	S	N	I	G	S	N	T	V	K
470		.	.	.	.	.	.	.	D	.	.	.	.	22.0
471		.	.	.	.	.	.	.	C	.	.	.	.	18.6
472		.	.	.	.	.	.	.	S	.	.	.	.	21.1
473		.	.	.	.	.	.	.	Y	.	.	.	.	48.3
474		.	.	.	.	.	.	.	K	.	.	.	.	34.6
475		.	.	.	.	.	.	.	R	.	.	.	.	18.2
476		.	.	.	.	.	.	.	N	.	.	.	.	16.6
477		.	.	.	.	.	.	.	T	.	.	.	.	22.6
478		.	.	.	.	.	.	.	P	.	.	.	.	25.0
479		.	.	.	.	.	.	.	D	.	.	.	.	58.0
480		.	.	.	.	.	.	.	E	.	.	.	.	38.4
481		.	.	.	.	.	.	.	S	.	.	.	.	39.2
482		.	.	.	.	.	.	.	Y	.	.	.	.	35.7
483		.	.	.	.	.	.	.	H	.	.	.	.	31.5
484		.	.	.	.	.	.	.	K	.	.	.	.	33.1
485		.	.	.	.	.	.	.	N	.	.	.	.	22.9
486		.	.	.	.	.	.	.	Q	.	.	.	.	29.2
487		.	.	.	.	.	.	.	T	.	.	.	.	30.9
488		.	.	.	.	.	.	.	G	.	.	.	.	36.6
489		.	.	.	.	.	.	.	M	.	.	.	.	17.4
490		.	.	.	.	.	.	.	I	.	.	.	.	9.7
491		.	.	.	.	.	.	.	D	.	.	.	.	25.2
492		.	.	.	.	.	.	.	C	.	.	.	.	381.5
493		.	.	.	.	.	.	.	S	.	.	.	.	191.0
494		.	.	.	.	.	.	.	Y	.	.	.	.	21.3
495		.	.	.	.	.	.	.	H	.	.	.	.	26.0
496		.	.	.	.	.	.	.	K	.	.	.	.	31.8
497		.	.	.	.	.	.	.	R	.	.	.	.	690.0
498		.	.	.	.	.	.	.	N	.	.	.	.	196.5
499		.	.	.	.	.	.	.	Q	.	.	.	.	247.0
500		.	.	.	.	.	.	.	T	.	.	.	.	24.1
501		.	.	.	.	.	.	.	A	.	.	.	.	190.5
502		.	.	.	.	.	.	.	V	.	.	.	.	164.5
503		.	.	.	.	.	.	.	L	.	.	.	.	215.5
504		.	.	.	.	.	.	.	I	.	.	.	.	154.0
505		.	.	.	.	.	.	.	P	.	.	.	.	42.4



11/14

Figure 2G. Y61 Light Chain CDR L2 Mutagenesis




SEQ ID NO:		CDR L2							$K_{off}$ ( $\times 10^5$ )
		S0	S1	S2	S3	S4	S5	S6	
20	Y61	G	N	D	Q	R	P	S	
506		D	.	.	.	.	.	.	34.8
507		E	.	.	.	.	.	.	61.7
508		C	.	.	.	.	.	.	46.7
509		S	.	.	.	.	.	.	28.6
510		Y	.	.	.	.	.	.	17.4
511		H	.	.	.	.	.	.	76.1
512		K	.	.	.	.	.	.	242.5
513		R	.	.	.	.	.	.	44.4
514		N	.	.	.	.	.	.	30.5
515		Q	.	.	.	.	.	.	34.8
516		T	.	.	.	.	.	.	27.2
517		G	.	.	.	.	.	.	21.5
518		A	.	.	.	.	.	.	37.2
519		V	.	.	.	.	.	.	38.5
520		M	.	.	.	.	.	.	95.3
521		L	.	.	.	.	.	.	61.6
522		I	.	.	.	.	.	.	120.5
523		P	.	.	.	.	.	.	41.0
524		W	.	.	.	.	.	.	38.2
525		F	.	.	.	.	.	.	3,476.7
526		.	.	.	S	.	.	.	86.6
527		.	.	.	Y	.	.	.	73.3
528		.	.	.	R	.	.	.	61.4
529		.	.	.	Q	.	.	.	29.7
530		.	.	.	T	.	.	.	83.4
531		.	.	.	A	.	.	.	55.4
532		.	.	.	I	.	.	.	85.5
533		.	.	.	P	.	.	.	97.4



12/14


Figure 2H. Y61 Light Chain CDR L3 Mutagenesis

		CDR L3												
SEQ ID NO:		89	90	91	92	93	94	95	95A	95B	95C	96	97	$k_{off}$ ( $\times 10^3$ )
18	Y61	Q	S	Y	D	R	G	T	H	P	A	L	L	
534		.	.	.	D	.	.	.	.	.	.	.	.	25.9
535		.	.	.	C	.	.	.	.	.	.	.	.	45.3
536		.	.	.	S	.	.	.	.	.	.	.	.	30.7
537		.	.	.	Y	.	.	.	.	.	.	.	.	51.1
538		.	.	.	N	.	.	.	.	.	.	.	.	34.7
539		.	.	.	Q	.	.	.	.	.	.	.	.	42.7
540		.	.	.	T	.	.	.	.	.	.	.	.	40.8
541		.	.	.	G	.	.	.	.	.	.	.	.	34.9
542		.	.	.	A	.	.	.	.	.	.	.	.	35.7
543		.	.	.	L	.	.	.	.	.	.	.	.	72.8
544		.	.	.	I	.	.	.	.	.	.	.	.	61.8
545		.	.	.	W	.	.	.	.	.	.	.	.	72.0
546		.	.	.	F	.	.	.	.	.	.	.	.	44.9
547		.	.	.	D	.	.	.	.	.	.	.	.	34.3
548		.	.	.	C	.	.	.	.	.	.	.	.	32.0
549		.	.	.	S	.	.	.	.	.	.	.	.	34.1
550		.	.	.	Y	.	.	.	.	.	.	.	.	33.5
551		.	.	.	R	.	.	.	.	.	.	.	.	19.9
552		.	.	.	N	.	.	.	.	.	.	.	.	31.6
553		.	.	.	Q	.	.	.	.	.	.	.	.	30.0
554		.	.	.	T	.	.	.	.	.	.	.	.	31.6
555		.	.	.	G	.	.	.	.	.	.	.	.	39.2
556		.	.	.	A	.	.	.	.	.	.	.	.	31.0
557		.	.	.	V	.	.	.	.	.	.	.	.	26.9
558		.	.	.	M	.	.	.	.	.	.	.	.	27.5
559		.	.	.	L	.	.	.	.	.	.	.	.	30.0
560		.	.	.	I	.	.	.	.	.	.	.	.	29.5
561		.	.	.	P	.	.	.	.	.	.	.	.	34.9
562		.	.	.	W	.	.	.	.	.	.	.	.	34.9
563		.	.	.		D	.	.	.	.	.	.	.	25.3
564		.	.	.		C	.	.	.	.	.	.	.	52.0
565		.	.	.		S	.	.	.	.	.	.	.	28.7
566		.	.	.		Y	.	.	.	.	.	.	.	13.1
567		.	.	.		H	.	.	.	.	.	.	.	18.7
568		.	.	.		R	.	.	.	.	.	.	.	23.1
569		.	.	.		N	.	.	.	.	.	.	.	13.7
570		.	.	.		Q	.	.	.	.	.	.	.	25.0
571		.	.	.		T	.	.	.	.	.	.	.	30.5
572		.	.	.		G	.	.	.	.	.	.	.	25.6
573		.	.	.		A	.	.	.	.	.	.	.	52.6
574		.	.	.		V	.	.	.	.	.	.	.	35.1
575		.	.	.		L	.	.	.	.	.	.	.	24.4
576		.	.	.		I	.	.	.	.	.	.	.	27.6
577		.	.	.		P	.	.	.	.	.	.	.	33.2
578		.	.	.		W	.	.	.	.	.	.	.	29.3
579		.	.	.		F	.	.	.	.	.	.	.	23.6



13/14

**Figure 3: *In vivo* efficacy of J695 in cynomolgus monkeys**



14/14




FIGURE 4

- 1 -

## SEQUENCE LISTING

<110> Jochen, Salfeld et al.  
<120> Human Antibodies That Bind Human IL-12 And Methods For Producing  
<130> BRI-093CPPC  
<140>  
<141>  
  
<150> 60/126,603  
<151> March 25, 1999  
  
<160> 675  
  
<170> PatentIn Ver. 2.0  
  
<210> 1  
<211> 6  
<212> PRT  
<213> Homo sapiens  
  
<220>  
<223> Xaa at position 1 could be either His or Ser  
  
<220>  
<223> Xaa at position 4 could be either Tyr or His  
  
<220>  
<223> Xaa at position 6 could be either Tyr, Asn or Thr  
  
<400> 1  
Xaa Gly Ser Xaa Asp Xaa  
1 5  
  
<210> 2  
<211> 12  
<212> PRT  
<213> Homo sapiens  
  
<220>  
<223> Xaa at position 2 could be either Ser or Thr  
  
<220>  
<223> Xaa at position 4 could be either Asp or Glu  
  
<220>  
<223> Xaa at position 5 could be either Ser, Arg or Lys  
  
<220>  
<223> Xaa at position 6 could be either Ser, Gly or Tyr  
  
<220>  
<223> Xaa at position 7 could be either Leu, Phe, Thr or Ser  
  
<220>  
<223> Xaa at position 8 could be either Arg, Ser, Thr, Trp or His  
  
<220>  
<223> Xaa at position 9 could be either Gly or Pro  
  
<220>

- 2 -

<223> Xaa at position 10 could be either Ser, Thr, Ala  
or Leu

<220>  
<223> Xaa at position 11 could be either Arg, Ser, Met,  
Thr or Leu

<220>  
<223> Xaa at position 12 could be either Val, Ile, Thr,  
Met or Leu

<400> 2  
Gln Xaa Tyr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1 5 10

<210> 3  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 3  
Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 4  
<211> 7  
<212> PRT  
<213> Homo sapiens

<220>  
<223> Xaa at position 1 could be either Gly or Tyr  
  
<220>  
<223> Xaa at position 3 could be either Asp or Ser  
  
<220>  
<223> Xaa at position 4 could be either Gln or Asn

<400> 4  
Xaa Asn Xaa Xaa Arg Pro Ser  
1 5

<210> 5  
<211> 9  
<212> PRT  
<213> Homo sapiens

<220>  
<223> Xaa represents either Ser or Glu

<400> 5  
Phe Thr Phe Ser Xaa Tyr Gly Met His  
1 5

<210> 6  
<211> 13  
<212> PRT  
<213> Homo sapiens

- 3 -

<220>  
 <223> Xaa at position 1 could be either Ser or Thr  
  
 <220>  
 <223> Xaa at position 3 could be either Ser or Gly  
  
 <220>  
 <223> Xaa at position 4 could be either Arg or Ser  
  
 <220>  
 <223> Xaa at position 8 could be either Gly or Val  
  
 <220>  
 <223> Xaa at position 9 could be either Ser or Ala  
  
 <220>  
 <223> Xaa at position 10 could be either Asn, Gly or Tyr  
  
 <220>  
 <223> Xaa at position 11 could be either Thr or Asp  
  
 <220>  
 <223> Xaa at position 13 could be either Lys or His  
  
 <400> 6  
 Xaa Gly Xaa Xaa Ser Asn Ile Xaa Xaa Xaa Val Xaa  
           1                  5                  10

<210> 7  
 <211> 115  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <223> Xaa at position 6 could be either Gln or Glu  
  
 <220>  
 <223> Xaa at position 16 could be either Arg or Gly  
  
 <220>  
 <223> Xaa at position 31 could be either Ser or Glu  
  
 <220>  
 <223> Xaa at position 84 could be either Lys or Asn  
  
 <220>  
 <223> Xaa at position 97 could be either Thr, Ala or Lys  
  
 <220>  
 <223> Xaa at position 98 could be either Phe or Lys  
  
 <220>  
 <223> Xaa at position 99 could be either Ser or His  
  
 <220>  
 <223> Xaa at position 102 could be either Tyr or His  
  
 <220>  
 <223> Xaa at position 104 could be either Tyr, Asn or Thr

<400> 7  
 Gln Val Gln Leu Val Xaa Ser Gly Gly Gly Val Val Gln Pro Gly Xaa  
           1                  5                  10                  15



- 4 -

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Xaa Tyr  
                   20                  25                  30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
                   35                  40                  45  
 Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Asx  
                   50                  55                  60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
                   65                  70                  75                  80  
 Leu Gln Met Xaa Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
                   85                  90                  95  
 Xaa Xaa Xaa Gly Ser Xaa Asp Xaa Trp Gly Gln Gly Thr Met Val Thr  
                   100                  105                  110  
 Val Ser Ser  
                   115

<210> 8  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <223> Xaa at position 1 could be either Ser or Gln  
  
 <220>  
 <223> Xaa at position 2 could be either Tyr or Ser  
  
 <220>  
 <223> Xaa at position 13 could be either Thr or Ala  
  
 <220>  
 <223> Xaa at position 23 and 91 could be either Ser or Thr  
  
 <220>  
 <223> Xaa at position 25 could be either Gly or Ser  
  
 <220>  
 <223> Xaa at position 26 could be either Arg or Ser  
  
 <220>  
 <223> Xaa at position 30 could be either Gly or Val  
  
 <220>  
 <223> Xaa at position 41 could be either Ser or Ala  
  
 <220>  
 <223> Xaa at position 35 could be either Lys or His  
  
 <220>  
 <223> Xaa at position 51 could be either Gly or Lys  
  
 <220>  
 <223> Xaa at position 54 could be either Gln or Asn  
  
 <220>  
 <223> Xaa at position 79 could be either Val or Leu  
  
 <220>  
 <223> Xaa at position 93 could be either Asp or Glu

- 5 -

<220>  
 <223> Xaa at position 94 could be either Ser, Arg or Lys  
  
 <220>  
 <223> Xaa at position 95 could be either Ser, Gly or Tyr  
  
 <220>  
 <223> Xaa at position 96 could be either Leu, Phe, Thr  
 or Ser  
  
 <220>  
 <223> Xaa at position 97 could be either Arg, Ser, Thr,  
 Trp or His  
  
 <220>  
 <223> Xaa at position 98 could be either Gly or Pro  
  
 <220>  
 <223> Xaa at position 99 could be either Ser, Thr, Ala  
 or Leu  
  
 <220>  
 <223> Xaa at position 100 could be either Arg, Ser, Met,  
 Thr or Leu  
  
 <220>  
 <223> Xaa at position 101 could be either Val, Ile, Thr,  
 Met or Leu  
  
 <220>  
 <223> Xaa at position 32 could be either Asn, Gly or Tyr  
  
 <220>  
 <223> Xaa at position 33 could be either Thr or Asp  
  
 <220>  
 <223> Xaa at position 53 could be either Asp or Ser  
  
 <400> 8  
 Xaa Xaa Val Leu Thr Gln Pro Pro Ser Val Ser Gly Xaa Pro Gly Gln  
   1                  5                  10                  15  
 Arg Val Thr Ile Ser Cys Xaa Gly Xaa Xaa Ser Asn Ile Xaa Xaa Xaa  
           20                  25                  30  
 Xaa Val Xaa Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
           35                  40                  45  
 Ile Tyr Xaa Asn Xaa Xaa Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
   50                  55                  60  
 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Xaa Gln  
   65                  70                  75                  80  
 Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Xaa Tyr Xaa Xaa Xaa  
           85                  90                  95  
 Xaa Xaa Xaa Xaa Xaa Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
           100                  105                  110

&lt;210&gt; 9

```

<211> 6
<212> PRT
<213> Homo sapiens

<220>
<223> Xaa at position 2 could be either Gly, Val, Cys or
His

<220>
<223> Xaa at position 3 could be either Ser or Thr

<220>
<223> Xaa at position 4 could be either His, Thr, Val, Arg, or Ile

<220>
<223> Xaa at position 5 could be either Asp or Ser

<220>
<223> Xaa at position 6 could be either Asn, Lys, Ala,
Thr, Ser, Phe, Trp, or His

<400> 9
His Xaa Xaa Xaa Xaa Xaa
1 5

<210> 10
<211> 12
<212> PRT
<213> Homo sapiens

<220>
<223> Xaa at position 4 could be either Asp or Ser

<220>
<223> Xaa at position 5 represents any amino acid

<220>
<223> Xaa at position 6 could be either Gly, Asp, Gln,
Leu, Phe, Arg, His, Asn or Tyr

<400> 10
Gln Ser Tyr Xaa Xaa Xaa Thr His Pro Ala Leu Leu
1 5 10

<210> 11
<211> 17
<212> PRT
<213> Homo sapiens

<220>
<223> Xaa at position 1 could be either Phe, Thr or Tyr

<220>
<223> Xaa at position 3 could be either Arg or Ala

<220>
<223> Xaa at position 5 could be either Asp, Ser, Glu or
Ala

<220>
<223> Xaa at position 6 could be either Gly or Arg

<220>
<223> Xaa at position 8 represents any amino acid

```

- 7 -

<220>  
 <223> Xaa at position 10 could be either Tyr or Glu  
 <400> 11  
 Xaa Ile Xaa Tyr Xaa Xaa Ser Xaa Lys Xaa Tyr Ala Asp Ser Val Lys  
 1 5 10 15

Gly.

<210> 12  
 <211> 7  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <223> Xaa at position 1 could be either Gly, Tyr, Ser,  
 Thr, Asn or Gln

<400> 12  
 Xaa Asn Asp Gln Arg Pro Ser  
 1 5

<210> 13  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <223> Xaa at position 4 and 5 represents any amino acid

<220>  
 <223> Xaa at position 6 could be either Tyr or His

<220>  
 <223> Xaa at position 7 could be either Gly, Met, Ala,  
 Asn or Ser

<400> 13  
 Phe Thr Phe Xaa Xaa Xaa Xaa Met His  
 1 5

<210> 14  
 <211> 13  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <223> Xaa at position 9 could be either Ser, Cys, Arg,  
 Asn, Asp or Thr

<220>  
 <223> Xaa at position 10 could be either Asn, Met or Ile

<220>  
 <223> Xaa at position 11 could be either Thr, Tyr, Asp,  
 His, Lys or Pro

<400> 14  
 Ser Gly Gly Arg Ser Asn Ile Gly Xaa Xaa Val Lys  
 1 5 10

- 8 -

<210> 15  
 <211> 114  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <223> Xaa at position 30 could be Ser or Glu

<220>  
 <223> Xaa at position 83 could be Lys or Asn

<220>  
 <223> Xaa at position 5 could be either Gln or Glu

<400> 15  
 Gln Val Gln Val Xaa Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser  
           1                  5                  10                  15  
 Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Xaa Tyr Gly  
           20                  25                  30  
 Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gln Trp Val Ala  
           35                  40                  45  
 Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
           50                  55                  60  
 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu  
           65                  70                  75                  80  
 Gln Met Xaa Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Lys  
           85                  90                  95  
 Thr His Gly Ser His Asp Asn Trp Gly Gln Gly Thr Met Val Thr Val  
           100                  105                  110  
 Ser Ser

<210> 16  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <223> Xaa at position 1 could be either Ser or Gln

<220>  
 <223> Xaa at position 2 could be Tyr or Ser

<220>  
 <223> Xaa at position 13 could be either Thr or Ala

<220>  
 <223> Xaa at position 25 could be either Gly or Ser

<220>  
 <223> Xaa at position 51 and 95 could be either Gly or Tyr

<220>  
 <223> Xaa at position 79 could be either Val or Leu

<400> 16

- 9 -

Xaa Xaa Val Leu Thr Gln Pro Pro Ser Val Ser Gly Xaa Pro Gly Gln  
 1 5 10 15  
 Arg Val Thr Ile Ser Cys Ser Gly Xaa Arg Ser Asn Ile Gly Ser Asn  
 20 25 30  
 Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45  
 Ile Tyr Xaa Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60  
 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Xaa Gln  
 65 70 75 80  
 Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Arg Xaa Thr  
 85 90 95  
 His Pro Ala Leu Leu Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
 100 105 110

<210> 17  
 <211> 6  
 <212> PRT  
 <213> Homo sapiens

<400> 17  
 His Gly Ser His Asp Asn  
 1 5

<210> 18  
 <211> 12  
 <212> PRT  
 <213> Homo sapiens

<400> 18  
 Gln Ser Tyr Asp Arg Gly Thr His Pro Ala Leu Leu  
 1 5 10

<210> 19  
 <211> 17  
 <212> PRT  
 <213> Homo sapiens

<400> 19  
 Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
 1 5 10 15

Gly

<210> 20  
 <211> 7  
 <212> PRT  
 <213> Homo sapiens

<400> 20  
 Gly Asn Asp Gln Arg Pro Ser  
 1 5

<210> 21  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens

<400> 21  
 Phe Thr Phe Ser Ser Tyr Gly Met His  
 1 5

<210> 22  
 <211> 13  
 <212> PRT  
 <213> Homo sapiens

<400> 22  
 Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn Thr Val Lys  
 1 5 10

<210> 23  
 <211> 115  
 <212> PRT  
 <213> Homo sapiens

<400> 23  
 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Lys Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Lys Thr His Gly Ser His Asp Asn Trp Gly Gln Gly Thr Met Val Thr  
 100 105 110  
 Val Ser Ser  
 115

<210> 24  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 24  
 Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln  
 1 5 10 15  
 Arg Val Thr Ile Ser Cys Ser Gly Gly Arg Ser Trp Ile Gly Ser Asn  
 20 25 30  
 Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

- 11 -

```

          35          40          45
Ile Tyr Gly Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
   50          55          60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Val Gln
   65          70          75          80

Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Arg Gly Thr
          85          90          95

His Pro Ala Leu Leu Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly
          100          105          110

```

<210> 25  
 <211> 6  
 <212> PRT  
 <213> Homo sapiens

<400> 25  
 His Gly Ser His Asp Asn  
   1                  5

<210> 26  
 <211> 12  
 <212> PRT  
 <213> Homo sapiens

<400> 26  
 Gln Ser Tyr Asp Arg Tyr Thr His Pro Ala Leu Leu  
   1                  5                  10

<210> 27  
 <211> 17  
 <212> PRT  
 <213> Homo sapiens

<400> 27  
 Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
   1                  5                  10                  15

Gly

<210> 28  
 <211> 7  
 <212> PRT  
 <213> Homo sapiens

<400> 28  
 Tyr Asn Asp Gln Arg Pro Ser  
   1                  5

<210> 29  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens



&lt;400&gt; 29

Phe Thr Phe Ser Ser Tyr Gly Met His  
1 5

&lt;210&gt; 30

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 30

Ser Gly Ser Arg Ser Asn Ile Gly Ser Asn Thr Val Lys  
1 5 10

&lt;210&gt; 31

&lt;211&gt; 115

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 31

Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
20 25 30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
35 40 45Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95Lys Thr His Gly Ser His Asp Asn Trp Gly Gln Gly Thr Met Val Thr  
100 105 110Val Ser Ser  
115

&lt;210&gt; 32

&lt;211&gt; 112

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 32

Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln  
1 5 10 15Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly Ser Asn  
20 25 30Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
35 40 45Ile Tyr Tyr Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
50 55 60Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln  
65 70 75 80

- 13 -

Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Arg Tyr Thr  
                     85                    90                    95  
 His Pro Ala Leu Leu Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
                     100                    105                    110

<210> 33  
 <211> .115  
 <212> PRT  
 <213> Homo sapiens

<400> 33  
 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
   1                    5                    10                    15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
                     20                    25                    30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
                     35                    40                    45  
 Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
                     50                    55                    60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
                     65                    70                    75                    80  
 Leu Gln Met Lys Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
                     85                    90                    95  
 Thr Thr Ser Gly Ser Tyr Asp Tyr Trp Gly Gln Gly Thr Met Val Thr  
                     100                    105                    110  
 Val Ser Ser  
                     115

<210> 34  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 34  
 Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln  
   1                    5                    10                    15  
 Arg Val Thr Ile Ser Cys Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn  
                     20                    25                    30  
 Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
                     35                    40                    45  
 Ile Tyr Gly Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
                     50                    55                    60  
 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Val Gln  
                     65                    70                    75                    80  
 Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu  
                     85                    90                    95

- 14 -

Arg Gly Ser Arg Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
 100 105 110

<210> 35  
 <211> 115  
 <212> PRT  
 <213> Homo sapiens

<400> 35  
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Lys Ser Gly Ser Tyr Asp Tyr Trp Gly Gln Gly Thr Met Val Thr  
 100 105 110  
 Val Ser Ser  
 115

<210> 36  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <223> Xaa at position 32 represents either Gly or Tyr  
 <400> 36  
 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln  
 1 5 10 15  
 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Xaa  
 20 25 30  
 Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45  
 Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60  
 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln  
 65 70 75 80  
 Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu  
 85 90 95  
 Ser Gly Ser Arg Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly

100

105

110

<210> 37  
 <211> 115  
 <212> PRT  
 <213> Homo sapiens

<400> 37  
 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Lys Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Thr Thr His Gly Ser His Asp Asn Trp Gly Gln Gly Thr Met Val Thr  
 100 105 110  
 Val Ser Ser  
 115

<210> 38  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 38  
 Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln  
 1 5 10 15  
 Arg Val Thr Ile Ser Cys Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn  
 20 25 30  
 Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45  
 Ile Tyr Gly Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60  
 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Val Gln  
 65 70 75 80  
 Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu  
 85 90 95  
 Arg Gly Ser Arg Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
 100 105 110

- 16 -

<210> 39  
 <211> 115  
 <212> PRT  
 <213> Homo sapiens

<400> 39  
 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Lys Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Thr Thr Ser Gly Ser Tyr Asp Tyr Trp Gly Gln Gly Thr Met Val Thr  
 100 105 110  
 Val Ser Ser  
 115

<210> 40  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 40  
 Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln  
 1 5 10 15  
 Arg Val Thr Ile Ser Cys Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn  
 20 25 30  
 Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45  
 Ile Tyr Gly Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60  
 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Val Gln  
 65 70 75 80  
 Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Arg Gly Phe  
 85 90 95  
 Thr Gly Ser Arg Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
 100 105 110

<210> 41  
 <211> 115

- 17 -

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 41

Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45

Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80

Leu Gln Met Lys Ser Leu Arg Ala Gln Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Thr Thr Ser Gly Ser Tyr Asp Tyr Trp Gly Gln Gly Thr Met Val Thr  
 100 105 110

Val Ser Ser  
 115

&lt;210&gt; 42

&lt;211&gt; 112

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 42

Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln  
 1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn  
 20 25 30

Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45

Ile Tyr Gly Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Val Gln  
 65 70 75 80

Ala Gln Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu  
 85 90 95

Trp Gly Ser Arg Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
 100 105 110

&lt;210&gt; 43

&lt;211&gt; 115

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 43

- 18 -

Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Lys Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Thr Thr His Gly Ser His Asp Asn Trp Gly Gln Gly Thr Met Val Thr  
 100 105 110  
 Val Ser Ser  
 115

<210> 44  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 44  
 Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln  
 1 5 10 15  
 Arg Val Thr Ile Ser Cys Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn  
 20 25 30  
 Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45  
 Ile Tyr Gly Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60  
 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Val Gln  
 65 70 75 80  
 Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Arg Gly Phe  
 85 90 95  
 Thr Gly Ser Arg Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
 100 105 110

<210> 45  
 <211> 115  
 <212> PRT  
 <213> Homo sapiens

<400> 45  
 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

- 19 -

20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Lys Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Thr Thr His Gly Ser His Asp Asn Trp Gly Gln Gly Thr Met Val Thr  
 100 105 110  
 Val Ser Ser  
 115

<210> 46  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 46  
 Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln  
 1 5 10 15  
 Arg Val Thr Ile Ser Cys Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn  
 20 25 30  
 Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45  
 Ile Tyr Gly Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60  
 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Val Gln  
 65 70 75 80  
 Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu  
 85 90 95  
 Trp Gly Ser Arg Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
 100 105 110

<210> 47  
 <211> 115  
 <212> PRT  
 <213> Homo sapiens

<400> 47  
 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45



- 20 -

Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80

Leu Gln Met Lys Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Lys Thr His Gly Ser His Asp Asn Trp Gly Gln Gly Thr Met Val Thr  
 100 105 110

Val Ser Ser  
 115

<210> 48  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 48  
 Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln  
 1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly Ser Asn  
 20 25 30

Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45

Ile Tyr Gly Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Val Gln  
 65 70 75 80

Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Thr Tyr Asp Lys Gly Phe  
 85 90 95

Thr Gly Ser Ser Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
 100 105 110

<210> 49  
 <211> 115  
 <212> PRT  
 <213> Homo sapiens

<400> 49  
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45

Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60

- 21 -

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Lys Thr His Gly Ser His Asp Asn Trp Gly Gln Gly Thr Met Val Thr  
 100 105 110  
 Val Ser Ser  
 115

<210> 50  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 50  
 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln  
 1 5 10 15  
 Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly Ser Asn  
 20 25 30  
 Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45  
 Ile Tyr Gly Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60  
 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln  
 65 70 75 80  
 Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Thr Tyr Asp Lys Gly Phe  
 85 90 95  
 Thr Gly Ser Ser Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
 100 105 110

<210> 51  
 <211> 115  
 <212> PRT  
 <213> Homo sapiens

<400> 51  
 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Lys Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

- 22 -

85 90 95

Thr Thr His Gly Ser His Asp Thr Trp Gly Gln Gly Thr Met Val Thr  
100 105 110

Val Ser Ser  
115

<210> 52  
<211> 112  
<212> PRT  
<213> Homo sapiens

<400> 52  
Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln  
1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn  
20 25 30

Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
35 40 45

Ile Tyr Gly Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Val Gln  
65 70 75 80

Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu  
85 90 95

Trp Gly Thr Arg Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
100 105 110

<210> 53  
<211> 115  
<212> PRT  
<213> Homo sapiens

<400> 53  
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
35 40 45

Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
65 70 75 80

Leu Gln Met Lys Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Thr Thr His Gly Ser His Asp Asn Trp Gly Gln Gly Thr Met Val Thr  
100 105 110

Val Ser Ser  
115

<210> 54  
<211> 112  
<212> PRT  
<213> Homo sapiens

<400> 54  
Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln  
1 5 10 15  
Arg Val Thr Ile Ser Cys Ser Gly Gly Arg Ser Asn Ile Val Ser Asn  
20 25 30  
Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
35 40 45  
Ile Tyr Gly Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
50 55 60  
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Val Gln  
65 70 75 80  
Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Arg Gly Phe  
85 90 95  
Thr Gly Ser Arg Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
100 105 110

<210> 55  
<211> 115  
<212> PRT  
<213> Homo sapiens

<400> 55  
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
1 5 10 15  
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
20 25 30  
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
35 40 45  
Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
50 55 60  
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
65 70 75 80  
Leu Gln Met Lys Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95  
Thr Thr His Gly Ser His Asp Asn Trp Gly Gln Gly Thr Met Val Thr  
100 105 110  
Val Ser Ser  
115

-24-

<210> 56  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 56  
 Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln  
 1 5 10 15  
 Arg Val Thr Ile Ser Cys Ser Gly Gly Arg Ser Asn Ile Val Ser Asn  
 20 25 30  
 Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45  
 Ile Tyr Gly Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60  
 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Val Gln  
 65 70 75 80  
 Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Arg Gly Phe  
 85 90 95  
 Thr Gly Ala Arg Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
 100 105 110

<210> 57  
 <211> 115  
 <212> PRT  
 <213> Homo sapiens

<400> 57  
 Gln Val Gln Leu Val Cln Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Lys Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Lys Thr His Gly Ser His Asp Asn Trp Gly Gln Gly Thr Met Val Thr  
 100 105 110  
 Val Ser Ser  
 115

<210> 58  
 <211> 112  
 <212> PRT

- 25 -

&lt;213&gt; Homo sapiens

&lt;400&gt; 58

Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln  
 1 5 10 15  
 Arg Val Thr Ile Ser Cys Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn  
 20 25 30  
 Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45  
 Ile Tyr Gly Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60  
 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Val Gln  
 65 70 75 80  
 Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Thr Tyr Asp Lys Gly Phe  
 85 90 95  
 Thr Gly Ser Ser Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
 100 105 110

&lt;210&gt; 59

&lt;211&gt; 115

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 59

Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Lys Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Lys Thr His Gly Ser His Asp Asn Trp Gly Gln Gly Thr Met Val Thr  
 100 105 110  
 Val Ser Ser  
 115

&lt;210&gt; 60

&lt;211&gt; 112

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 60

Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln

- 26 -

```

      1           5           10           15
Arg Val Thr Ile Ser Cys Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn
      20           25           30
Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
      35           40           45
Ile Tyr Gly Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
      50           55           60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Val Gln
      65           70           75           80
Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Gln Arg Gly Phe
      85           90           95
Thr Gly Ser Met Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly
      100          105          110

```

<210> 61  
 <211> 115  
 <212> PRT  
 <213> Homo sapiens

```

<400> 61
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg
      1           5           10           15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
      20           25           30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
      35           40           45
Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
      50           55           60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
      65           70           75           80
Leu Gln Met Lys Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
      85           90           95
Lys Thr His Gly Ser His Asp Asn Trp Gly Gln Gly Thr Met Val Thr
      100          105          110
Val Ser Ser
      115

```

<210> 62  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

```

<400> 62
Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
      1           5           10           15
Arg Val Thr Ile Ser Cys Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn
      20           25           30

```

- 27 -

Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45  
 Ile Tyr Gly Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60  
 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Val Gln  
 65 70 75 80  
 Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Arg Gly Thr  
 85 90 95  
 His Pro Leu Thr Ile Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
 100 105 110

<210> 63  
 <211> 115  
 <212> PRT  
 <213> Homo sapiens

<400> 63  
 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Lys Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Lys Thr His Gly Ser His Asp Asn Trp Gly Gln Gly Thr Met Val Thr  
 100 105 110  
 Val Ser Ser  
 115

<210> 64  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 64  
 Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln  
 1 5 10 15  
 Arg Val Thr Ile Ser Cys Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn  
 20 25 30  
 Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45



- 28 -

Ile Tyr Gly Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60  
 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Val Gln  
 65 70 75 80  
 Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Arg Gly Ser  
 85 90 95  
 His Pro Ala Leu Thr Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
 100 105 110

<210> 65  
 <211> 115  
 <212> PRT  
 <213> Homo sapiens

<400> 65  
 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Cln Met Lys Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Lys Thr His Gly Ser His Asp Asn Trp Gly Gln Gly Thr Met Val Thr  
 100 105 110  
 Val Ser Ser  
 115

<210> 66  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 66  
 Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln  
 1 5 10 15  
 Arg Val Thr Ile Ser Cys Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn  
 20 25 30  
 Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45  
 Ile Tyr Gly Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60  
 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Val Gln

```

<400> 67
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
  1          5          10
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
      20          25          30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
      35          40          45
Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
      50          55          60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
      65          70          75          80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
      85          90          95
Lys Thr His Gly Ser His Asp Asn Trp Gly Gln Gly Thr Met Val Thr
      100          105          110
Val Ser Ser
      115

```

```

<400> 68
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
  1              5              10              15
Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly Ser Asn
              20              25              30
Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
              35              40              45
Ile Tyr Gly Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
  50              55              60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln
  65              70              75              80
Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Arg Gly Thr
              85              90              95

```

- 30 -

His Pro Leu Thr Met Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
 100 105 110

<210> 69  
 <211> 115  
 <212> PRT  
 <213> Homo sapiens

<400> 69  
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Phe Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Lys Thr His Gly Ser His Asp Asn Trp Gly Gln Gly Thr Met Val Thr  
 100 105 110  
 Val Ser Ser  
 115

<210> 70  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 70  
 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln  
 1 5 10 15  
 Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly Ser Asn  
 20 25 30  
 Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45  
 Ile Tyr Gly Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60  
 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln  
 65 70 75 80  
 Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Arg Gly Thr  
 85 90 95  
 His Pro Ala Leu Leu Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
 100 105 110

<210> 71  
 <211> 115  
 <212> PRT  
 <213> Homo sapiens

<400> 71  
 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Glu Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Lys Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Lys Thr His Gly Ser His Asp Asn Trp Gly Gln Gly Thr Met Val Thr  
 100 105 110  
 Val Ser Ser  
 115

<210> 72  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 72  
 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln  
 1 5 10 15  
 Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly Ser Asn  
 20 25 30  
 Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45  
 Ile Tyr Gly Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60  
 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln  
 65 70 75 80  
 Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Arg Gly Thr  
 85 90 95  
 His Pro Ala Leu Leu Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
 100 105 110

<210> 73  
 <211> 115  
 <212> PRT  
 <213> Homo sapiens

<400> 73  
 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Lys Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Lys  
 85 90 95  
 Lys Thr His Gly Ser His Asp Asn Trp Gly Gln Gly Thr Met Val Thr  
 100 105 110  
 Val Ser Ser  
 115

<210> 74  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 74  
 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln  
 1 5 10 15  
 Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly Ser Asn  
 20 25 30  
 Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45  
 Ile Tyr Tyr Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60  
 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln  
 65 70 75 80  
 Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Arg Gly Thr  
 85 90 95  
 His Pro Ala Leu Leu Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
 100 105 110

<210> 75  
 <211> 115  
 <212> PRT  
 <213> Homo sapiens

- 33 -

&lt;400&gt; 75

Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Lys Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Lys Thr His Gly Ser His Asp Asn Trp Gly Gln Gly Thr Met Val Thr  
 100 105 110  
 Val Ser Ser  
 115

&lt;210&gt; 76

&lt;211&gt; 112

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 76

Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln  
 1 5 10 15  
 Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly Ser Asn  
 20 25 30  
 Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45  
 Ile Tyr Gly Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60  
 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln  
 65 70 75 80  
 Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Arg Tyr Thr  
 85 90 95  
 His Pro Ala Leu Leu Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
 100 105 110

&lt;210&gt; 77

&lt;211&gt; 6

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 77

Ser Gly Ser Tyr Asp Tyr  
 1 5

<210> 78  
<211> 6  
<212> PRT  
<213> Homo sapiens  
  
<400> 78  
His Gly Ser His Asp Asn  
1 5

<210> 79  
<211> 6  
<212> PRT  
<213> Homo sapiens  
  
<400> 79  
His Gly Ser Tyr Asp Tyr  
1 5

<210> 80  
<211> 6  
<212> PRT  
<213> Homo sapiens  
  
<400> 80  
Arg Arg Arg Ser Asn Tyr  
1 5

<210> 81  
<211> 6  
<212> PRT  
<213> Homo sapiens  
  
<400> 81  
Ser Gly Ser Ile Asp Tyr  
1 5

<210> 82  
<211> 6  
<212> PRT  
<213> Homo sapiens  
  
<400> 82  
His Gly Ser His Asp Asp  
1 5

<210> 83  
<211> 6  
<212> PRT  
<213> Homo sapiens  
  
<400> 83  
His Gly Ser His Asp Asn  
1 5

<210> 84  
<211> 12  
<212> PRT  
<213> Homo sapiens

- 35 -

<400> 84  
Thr Thr His Gly Ser His Asp Asn Trp Gly Gln Gly  
1 5 10

<210> 85  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 85  
Ala Lys His Gly Ser His Asp Asn Trp Gly Gln Gly  
1 5 10

<210> 86  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 86  
Thr Thr His Gly Ser His Asp Asn Trp Ser Gln Gly  
1 5 10

<210> 87  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 87  
Thr Thr His Gly Ser His Asp Thr Trp Gly Gln Gly  
1 5 10

<210> 88  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 88  
Lys Thr His Gly Ser His Asp Asn Trp Gly Gln Gly  
1 5 10

<210> 89  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 89  
Lys Thr His Gly Ser His Asp Asn Trp Gly His Gly  
1 5 10

<210> 90  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 90  
Thr Thr His Gly Ser His Asp Asn Trp Ser Gln Gly  
1 5 10



- 36 -

<210> 91  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 91  
Thr Thr His Arg Ser His Asn Asn Trp Gly Gln Gly  
1 5 10

<210> 92  
<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 92  
Thr Thr His Gly Ser His Asp Asn  
1 5

<210> 93  
<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 93  
Thr Thr His Gly Ser His Asp Thr  
1 5

<210> 94  
<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 94  
Thr Lys His Gly Ser His Asp Asn  
1 5

<210> 95  
<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 95  
Thr Thr Gln Gly Arg His Asp Asn  
1 5

<210> 96  
<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 96  
Lys Thr Arg Gly Arg His Asp Asn  
1 5

<210> 97  
<211> 8  
<212> PRT  
<213> Homo sapiens

- 37 -

<400> 97  
Thr Thr His Gly Ser His Asp Lys  
1 5

<210> 98  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 98  
Thr Thr His Gly Ser His Asp Asp  
1 5

<210> 99  
<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 99  
Lys Thr His Gly Ser His Asp Asn  
1 5

<210> 100  
<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 100  
Lys Thr His Gly Ser His Asp Asn  
1 5

<210> 101  
<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 101  
Thr Thr His Gly Ser His Asp Asn  
1 5

<210> 102  
<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 102  
Thr Thr Ser Gly Ser Tyr Asp Tyr  
1 5

<210> 103  
<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 103  
Thr Thr His Gly Ser His Asp Asn  
1 5

<210> 104

- 38 -

<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 104  
Thr Thr His Gly Ser Gln Asp Asn  
1 5

<210> 105  
<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 105  
Ala Thr His Gly Ser Gln Asp Asn  
1 5

<210> 106  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 106  
His Gly Ser Gln Asp Thr  
1 5

<210> 107  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 107  
Ser Gly Ser Tyr Asp Tyr  
1 5

<210> 108  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 108  
His Gly Ser Gln Asp Asn  
1 5

<210> 109  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 109  
Cys Lys Thr His Gly Ser His Asp Asn  
1 5

<210> 110  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 110  
Gln Ser Tyr Asp Ser Ser Leu Arg Gly Ser Arg Val

- 39 -

1 5 10

<210> 111  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 111  
Gln Ser Tyr Asp Arg Gly Phe Thr Gly Ser Arg Val  
1 5 10

<210> 112  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 112  
Gln Ser Tyr Asp Ser Ser Leu Arg Gly Ser Arg Val  
1 5 10

<210> 113  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 113  
Gln Ser Tyr Asp Ser Ser Leu Thr Gly Ser Arg Val  
1 5 10

<210> 114  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 114  
Gln Ser Tyr Asp Ser Ser Leu Trp Gly Ser Arg Val  
1 5 10

<210> 115  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 115  
Gln Thr Tyr Asp Ile Ser Glu Ser Gly Ser Arg Val  
1 5 10

<210> 116  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 116  
Gln Ser Tyr Asp Arg Gly Phe Thr Gly Ser Arg Val  
1 5 10

<210> 117  
<211> 12  
<212> PRT

- 40 -

&lt;213&gt; Homo sapiens

&lt;400&gt; 117

Gln	Thr	Tyr	Asp	Arg	Gly	Phe	Thr	Gly	Ser	Arg	Val
1					5					10	

&lt;210&gt; 118

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 118

Gln	Thr	Tyr	Asp	Lys	Gly	Phe	Thr	Gly	Ser	Ser	Val
1				5						10	

&lt;210&gt; 119

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 119

Gln	Ser	Tyr	Asp	Arg	Arg	Phe	Thr	Gly	Ser	Arg	Val
1				5						10	

&lt;210&gt; 120

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 120

Gln	Ser	Tyr	Asp	Trp	Asn	Phe	Thr	Gly	Ser	Arg	Val
1				5						10	

&lt;210&gt; 121

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 121

Gln	Ser	Tyr	Asp	Arg	Gly	Phe	Thr	Gly	Ser	Arg	Val
1				5						10	

&lt;210&gt; 122

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 122

Gln	Ser	Tyr	Asp	Asn	Gly	Phe	Thr	Gly	Ser	Arg	Val
1				5						10	

&lt;210&gt; 123

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 123

Gln	Ser	Tyr	Asp	Asn	Ala	Val	Thr	Ala	Ser	Lys	Val
1				5						10	

- 41 -

<210> 124  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 124  
Gln Ser Tyr Asp Arg Gly Phe Thr Gly Ser Arg Val  
1 5 10

<210> 125  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 125  
Gln Ser Tyr Asp Ser Ser Leu Trp Gly Thr Arg Val  
1 5 10

<210> 126  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 126  
Gln Ser Tyr Asp Arg Asp Phe Thr Gly Ser Arg Val  
1 5 10

<210> 127  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 127  
Gln Ser Tyr Glu Arg Gly Phe Thr Gly Ser Met Val  
1 5 10

<210> 128  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 128  
Gln Ser Tyr Asp Asn Gly Phe Thr Gly Ala Arg Val  
1 5 10

<210> 129  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 129  
Gln Ser Tyr Asp Arg Arg Phe Thr Gly Ser Arg Val  
1 5 10

<210> 130  
<211> 12  
<212> PRT

- 42 -

&lt;213&gt; Homo sapiens

&lt;400&gt; 130

Gln Thr Tyr Asp Lys Gly Phe Thr Gly Ser Ser Val  
1 5 10

&lt;210&gt; 131

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 131

Gln Ser Tyr Asp Arg Asp Phe Thr Gly Thr Arg Val  
1 5 10

&lt;210&gt; 132

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 132

Gln Ser Tyr Asp Arg Gly Phe Tyr Gly Ser Met Val  
1 5 10

&lt;210&gt; 133

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 133

Gln Thr Tyr Asp Lys Gly Phe Thr Gly Ser Ser Val  
1 5 10

&lt;210&gt; 134

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 134

Gln Ser Tyr Asp Arg Gly Phe Thr Gly Ala Arg Val  
1 5 10

&lt;210&gt; 135

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 135

Gln Ser Tyr Glu Arg Gly Phe Thr Gly Ala Arg Val  
1 5 10

&lt;210&gt; 136

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 136

Gln Ser Tyr Asp Arg Gly Phe Thr Gly Ser Arg Val Phe  
1 5 10

&lt;210&gt; 137

- 43 -

<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 137  
Gln Ser Tyr Asp Arg Gly Phe Thr Gly Phe Lys Val Phe  
1 5 10

<210> 138  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 138  
Gln Ser Tyr Asp Arg Gly Phe Val Ser Ala Tyr Val Phe  
1 5 10

<210> 139  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 139  
Gln Ser Tyr Asp Arg Gly Leu Thr Val Thr Lys Val Phe  
1 5 10

<210> 140  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 140  
Gln Ser Tyr Asp Arg Gly Tyr Thr Ala Ser Arg Val Phe  
1 5 10

<210> 141  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 141  
Gln Ser Tyr Asp Arg Gly Phe Thr Gly Ser Lys Val Phe  
1 5 10

<210> 142  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 142  
Gln Ser Tyr Asp Arg Gly Leu Thr Gly Phe Arg Val Phe  
1 5 10

<210> 143  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 143  
Gln Ser Tyr Asp Arg Gly Phe Thr Gly Tyr Lys Val Phe



- 44 -

1 5 10

<210> 144  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 144  
Gln Ser Tyr Asp Arg Gly Leu Thr Gly Tyr Arg Leu Phe  
1 5 10

<210> 145  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 145  
Gln Ser Tyr Asp Arg Gly Phe Thr Asp Tyr Lys Val Phe  
1 5 10

<210> 146  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 146  
Gln Ser Tyr Asp Arg Gly Phe Thr Gly Pro Arg Leu Phe  
1 5 10

<210> 147  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 147  
Gln Ser Tyr Asp Arg Gly Leu Thr Gly Ser Arg Val Phe  
1 5 10

<210> 148  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 148  
Gln Ser Tyr Asp Arg Gly Phe Thr Gly Ala Arg Val Trp  
1 5 10

<210> 149  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 149  
Gln Ser Tyr Asp Arg Gly Phe Thr Gly Tyr Arg Val Phe  
1 5 10

<210> 150  
<211> 13  
<212> PRT

- 45 -

&lt;213&gt; Homo sapiens

&lt;400&gt; 150

Gln Ser Tyr Asp Arg Gly Phe Thr Gly Pro Arg Val Phe  
1 5 10

&lt;210&gt; 151

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 151

Gln Ser Tyr Asp Arg Gly Met Thr Ser Ser Arg Val Phe  
1 5 10

&lt;210&gt; 152

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 152

Gln Ser Tyr Asp Arg Asp Ser Thr Gly Ser Arg Val Phe  
1 5 10

&lt;210&gt; 153

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 153

Gln Ser Tyr Asp Ser Ser Leu Arg Gly Ser Arg Val Phe  
1 5 10

&lt;210&gt; 154

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 154

His Ser Tyr Asp Ser Asp Phe Thr Gly Ser Arg Val Phe  
1 5 10

&lt;210&gt; 155

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 155

His Ser Ser Glu Ser Gly Phe Thr Gly Ser Arg Val Phe  
1 5 10

&lt;210&gt; 156

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 156

His Ser Tyr Asp Asn Arg Phe Thr Gly Ser Arg Val Phe  
1 5 10

- 46 -

<210> 157  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 157  
His Ser Tyr Asp Ser Arg Phe Thr Gly Ser Arg Val Phe  
1 5 10

<210> 158  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 158  
Gln Ser Tyr Asp Ser Glu Phe Thr Gly Ser Arg Val Phe  
1 5 10

<210> 159  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 159  
Gln Ser Tyr Asp Thr Gly Phe Thr Gly Ser Arg Val Phe  
1 5 10

<210> 160  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 160  
His Ser Tyr Asp Ser Gly Phe Thr Gly Ser Arg Val Phe  
1 5 10

<210> 161  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 161  
Gln Ser Tyr Asp Thr Gly Phe Thr Gly Ser Arg Val Phe  
1 5 10

<210> 162  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 162  
His Ser Tyr Asp Thr Lys Phe Thr Gly Ser Arg Val Phe  
1 5 10

<210> 163  
<211> 13  
<212> PRT  
<213> Homo sapiens

- 47 -

<400> 163  
His Ser Ser Asp Ser Gly Phe Thr Gly Ser Arg Val Phe  
1 5 10

<210> 164  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 164  
Gln Ser Tyr Asp Ser Asp Phe Thr Gly Ser Arg Val Phe  
1 5 10

<210> 165  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 165  
His Ser Tyr Glu Ser Gly Phe Thr Gly Ser Arg Val Phe  
1 5 10

<210> 166  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 166  
Gln Ser Tyr Asp Ala Pro Trp Ser Gly Ser Arg Val Phe  
1 5 10

<210> 167  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 167  
Gln Ser Tyr Asp Ser Asp Phe Thr Gly Ser Lys Val Phe  
1 5 10

<210> 168  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 168  
His Thr Asn Asp Ser Gly Phe Thr Gly Ser Arg Val Phe  
1 5 10

<210> 169  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 169  
His Ser Tyr Asp Thr Arg Phe Thr Gly Ser Arg Val Phe  
1 5 10

<210> 170

- 48 -

<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 170  
Gln Ser Tyr Asp Met Arg Phe Thr Gly Ser Arg Val Phe  
1 5 10

<210> 171  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 171  
His Ser Ser Asp Ser Asp Ser Thr Gly Ser Arg Val Phe  
1 5 10

<210> 172  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 172  
Gln Ser Tyr Asn Thr Asp Phe Thr Gly Ser Arg Val Phe  
1 5 10

<210> 173  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 173  
Gln Ser Tyr Asp Ser Gly Phe Thr Gly Ser Arg Val Phe  
1 5 10

<210> 174  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 174  
His Ser Tyr Asp Met Gly Phe Thr Gly Ser Arg Val Phe  
1 5 10

<210> 175  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 175  
His Ser Tyr Asp Asn Gly Phe Thr Gly Ser Arg Val Phe  
1 5 10

<210> 176  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 176  
His Ser His Asp Arg Asp Phe Thr Gly Ser Arg Val Phe

- 49 -

1 5 10

<210> 177  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 177  
Gln Ser Tyr Asp Ser Ser Leu Arg Gly Ser Arg Val  
1 5 10

<210> 178  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 178  
Gln Ser Tyr Asp Arg Gly Ile His Gly Ser Arg Val Phe  
1 5 10

<210> 179  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 179  
Gln Ser Tyr Asp Ser Gly Phe Pro Gly Ser Arg Val Phe  
1 5 10

<210> 180  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 180  
Gln Ser Tyr Asp Ile Gly Ser Thr Gly Ser Arg Val Phe  
1 5 10

<210> 181  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 181  
Gln Ser Tyr Asp Ser Gly Leu Thr Gly Ser Arg Val Phe  
1 5 10

<210> 182  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 182  
Gln Ser Tyr Asp Ile Gly Met Thr Gly Ser Arg Val Phe  
1 5 10

<210> 183  
<211> 13  
<212> PRT

- 50 -

&lt;213&gt; Homo sapiens

&lt;400&gt; 183

Gln Ser Tyr Asp Ile Gly Leu Thr Gly Ser Arg Val Phe  
1 5 10

&lt;210&gt; 184

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 184

Gln Ser Tyr Asp Ser Gly Val Thr Gly Ser Arg Val Phe  
1 5 10

&lt;210&gt; 185

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 185

Gln Ser Tyr Asp Arg Gly Leu Thr Ala Ser Arg Val Phe  
1 5 10

&lt;210&gt; 186

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 186

Gln Ser Tyr Asp Thr Gly Leu Thr Gly Ser Arg Val Phe  
1 5 10

&lt;210&gt; 187

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 187

Gln Ser Tyr Asp Thr Ala Leu Thr Gly Ser Arg Val Phe  
1 5 10

&lt;210&gt; 188

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 188

Gln Ser Tyr Asp Ile Arg Phe Thr Gly Ser Arg Val Phe  
1 5 10

&lt;210&gt; 189

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 189

Gln Ser Tyr Asp Ile Arg Ser Thr Gly Ser Arg Val Phe  
1 5 10

<210> 190  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 190  
Gln Ser Tyr Asp Asn Arg Leu Thr Gly Ser Arg Val Phe  
1 5 10

<210> 191  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 191  
Gln Ser Tyr Glu Thr Ser Phe Thr Gly Ser Arg Val Phe  
1 5 10

<210> 192  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 192  
Gln Ser Tyr Asp Ser Ser Ser Thr Gly Ser Arg Val Phe  
1 5 10

<210> 193  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 193  
Gln Ser Tyr Asp Ser Gly Phe Thr Ala Ser Arg Val Phe  
1 5 10

<210> 194  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 194  
Gln Thr Tyr Asp Lys Gly Phe Thr Gly Ser Ser Val Phe  
1 5 10

<210> 195  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 195  
Gln Ser Tyr Asp Asn Gly Phe Thr Gly Ser Arg Val Phe  
1 5 10

<210> 196  
<211> 13  
<212> PRT  
<213> Homo sapiens



- 52 -

<400> 196  
Gln Ser Tyr Asp Thr Gly Phe Thr Lys Ser Arg Val Phe  
1 5 10

<210> 197  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 197  
Gln Ser Tyr Asp Ser Asp Val Thr Gly Ser Arg Val Phe  
1 5 10

<210> 198  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 198  
Gln Ser Tyr Asp Ala Gly Phe Thr Gly Ser Arg Val Phe  
1 5 10

<210> 199  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 199  
Gln Ser Tyr Asp Arg Gly Thr His Pro Ser Met Leu  
1 5 10

<210> 200  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 200  
Gln Ser Tyr Asp Arg Gly Thr Thr Pro Arg Pro Met  
1 5 10

<210> 201  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 201  
Gln Ser Tyr Asp Arg Gly Arg Asn Pro Ala Leu Thr  
1 5 10

<210> 202  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 202  
Gln Ser Tyr Asp Arg Gly Thr His Pro Trp Leu His  
1 5 10

<210> 203

- 53 -

<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 203  
Gln Ser Tyr Asp Arg Gly Asn Ser Pro Ala Thr Val  
1 5 10

<210> 204  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 204  
Gln Ser Tyr Asp Arg Gly Thr Phe Pro Ser Pro Gln  
1 5 10

<210> 205  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 205  
Gln Ser Tyr Asp Arg Gly Leu Asn Pro Ser Ala Thr  
1 5 10

<210> 206  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 206  
Gln Ser Tyr Asp Arg Gly Lys Ser Asn Lys Met Leu  
1 5 10

<210> 207  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 207  
Gln Ser Tyr Asp Arg Gly His Thr Ala His Leu Tyr  
1 5 10

<210> 208  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 208  
Gln Ser Tyr Asp Arg Gly Gln Thr Pro Ser Ile Thr  
1 5 10

<210> 209  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 209  
Gln Ser Tyr Asp Arg Gly Tyr Pro Arg Asn Ile Leu

- 54 -

1 5 10

<210> 210  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 210  
Gln Ser Tyr Asp Arg Gly Ile Thr Pro Gly Leu Ala  
1 5 10

<210> 211  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 211  
Gln Ser Tyr Asp Arg Gly Gln Pro His Ala Val Leu  
1 5 10

<210> 212  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 212  
Gln Ser Tyr Asp Arg Gly Asn Ser Pro Ile Pro Thr  
1 5 10

<210> 213  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 213  
Gln Ser Tyr Asp Arg Gly Thr Pro Asn Asn Ser Phe  
1 5 10

<210> 214  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 214  
Gln Ser Tyr Asp Ser Gly Val Asp Pro Gly Pro Tyr  
1 5 10

<210> 215  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 215  
Gln Ser Tyr Asp Arg Gly Arg Pro Arg His Ala Leu  
1 5 10

<210> 216  
<211> 12  
<212> PRT

- 55 -

&lt;213&gt; Homo sapiens

&lt;400&gt; 216

Gln Ser Tyr Asp Arg Gly Pro Tyr His Pro Ile Arg  
1 5 10

&lt;210&gt; 217

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 217

Gln Ser Tyr Asp Arg Gly Pro His Thr Gln Pro Thr  
1 5 10

&lt;210&gt; 218

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 218

Gln Ser Tyr Asp Arg Gly His Asn Asn Phe Ser Pro  
1 5 10

&lt;210&gt; 219

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 219

Gln Ser Tyr Asp Arg Gly Pro Thr His Leu Pro His  
1 5 10

&lt;210&gt; 220

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 220

Gln Ser Tyr Asp Arg Gly Thr Pro Ser Tyr Pro Thr  
1 5 10

&lt;210&gt; 221

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 221

Gln Ser Tyr Asp Ser Gly Thr Ser Asn Leu Leu Pro  
1 5 10

&lt;210&gt; 222

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 222

Gln Ser Tyr Asp Arg Gly Asp Ser Asn His Asp Leu  
1 5 10

<210> 223  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 223  
Gln Ser Tyr Asp Arg Gly Leu Pro Arg Leu Thr His  
1 5 10

<210> 224  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 224  
Gln Ser Tyr Asp Arg Gly Ile Pro Thr Ser Tyr Leu  
1 5 10

<210> 225  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 225  
Gln Ser Tyr Asp Arg Gly Leu Arg Val Gln Ala Pro  
1 5 10

<210> 226  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 226  
Gln Ser Tyr Asp Arg Gly Leu Ser Asp Ser Pro Leu  
1 5 10

<210> 227  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 227  
Gln Ser Tyr Asp Ser Gly Ser Leu Arg Arg Ile Leu  
1 5 10

<210> 228  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 228  
Gln Ser Tyr Asp Arg Gly Pro Ala Arg Thr Ser Pro  
1 5 10

<210> 229  
<211> 12  
<212> PRT  
<213> Homo sapiens

- 57 -

<400> 229  
Gln Ser Tyr Asp Arg Gly Arg Ala Ala His Pro Gln  
1 5 10

<210> 230  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 230  
Gln Ser Tyr Asp Arg Gly Thr Gln Pro Ala Asx Ile  
1 5 10

<210> 231  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 231  
Gln Ser Tyr Asp Arg Gly Thr His Pro Thr Met Ile  
1 5 10

<210> 232  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 232  
Gln Ser Tyr Asp Arg Gly Arg Ile Pro Ala Asx Thr  
1 5 10

<210> 233  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 233  
Gln Ser Tyr Asp Arg Gly Thr His Pro Val Pro Ala  
1 5 10

<210> 234  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 234  
Gln Ser Tyr Asp Arg Gly Ser Asx Pro Ile Pro Ala  
1 5 10

<210> 235  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 235  
Gln Ser Tyr Asp Arg Gly Thr His Pro Val Pro Ala  
1 5 10

<210> 236

- 58 -

<211> 12  
<212> PRT  
<213> Homo sapiens  
  
<400> 236  
Gln Ser Tyr Asp Arg Gly Thr His Pro Thr Met Tyr  
1 5 10

<210> 237  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 237  
Gln Ser Tyr Asp Arg Gly His His Tyr Thr Thr Phe  
1 5 10

<210> 238  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 238  
Gln Ser Tyr Asp Arg Gly Ser His Pro Ala Ala Glu  
1 5 10

<210> 239  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 239  
Gln Ser Tyr Asp Arg Gly Thr Ile Pro Ser Ile Glu  
1 5 10

<210> 240  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 240  
Gln Ser Tyr Asp Arg Gly Ser Ser Pro Ala Ile Met  
1 5 10

<210> 241  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 241  
Gln Ser Tyr Asp Arg Gly Ile Trp Pro Asn Leu Asn  
1 5 10

<210> 242  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 242  
Gln Ser Tyr Asp Arg Gly Thr His Pro Asn Leu Asn

- 59 -

1 5 10

<210> 243  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 243  
Gln Ser Tyr Asp Arg Gly Thr His Pro Ser Ile Ser  
1 5 10

<210> 244  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 244  
Gln Ser Tyr Asp Arg Gly Ser Ala Pro Met Ile Asn  
1 5 10

<210> 245  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 245  
Gln Ser Tyr Asp Arg Gly His His Pro Ala Met Ser  
1 5 10

<210> 246  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 246  
Gln Ser Tyr Asp Arg Gly Thr His Pro Ser Ile Thr  
1 5 10

<210> 247  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 247  
Gln Ser Tyr Asp Arg Gly Thr Asp Pro Ala Ile Val  
1 5 10

<210> 248  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 248  
Gln Ser Tyr Asp Arg Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 249  
<211> 12  
<212> PRT



- 60 -

&lt;213&gt; Homo sapiens

&lt;400&gt; 249

Gln	Ser	Tyr	Asp	Arg	Gly	Ser	His	Pro	Ala	Leu	Thr
1					5					10	

&lt;210&gt; 250

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 250

Gln	Ser	Tyr	Asp	Arg	Gly	Thr	Thr	Pro	Ala	Pro	Glu
1					5					10	

&lt;210&gt; 251

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 251

Gln	Ser	Tyr	Asp	Arg	Gly	Ser	His	Pro	Thr	Leu	Ile
1					5					10	

&lt;210&gt; 252

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 252

Gln	Ser	Tyr	Asp	Arg	Gly	Thr	His	Pro	Ser	Met	Leu
1					5					10	

&lt;210&gt; 253

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 253

Gln	Ser	Tyr	Asp	Arg	Gly	Thr	Thr	Pro	Arg	Pro	Met
1					5					10	

&lt;210&gt; 254

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 254

Gln	Ser	Tyr	Asp	Arg	Gly	Arg	Leu	Pro	Ala	Gln	Thr
1					5					10	

&lt;210&gt; 255

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 255

Gln	Ser	Tyr	Asp	Arg	Gly	Thr	His	Pro	Leu	Thr	Ile
1					5					10	

- 61 -

<210> 256  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 256  
Gln Ser Tyr Asp Arg Gly Gln Thr Pro Ser Ile Thr  
1 5 10

<210> 257  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 257  
Gln Ser Tyr Asp Arg Gly Thr His Phe Gln Met Tyr  
1 5 10

<210> 258  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 258  
Gln Ser Tyr Asp Arg Gly Arg Asn Pro Ala Leu Thr  
1 5 10

<210> 259  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 259  
Gln Ser Tyr Asp Arg Gly Thr His Pro Leu Thr Met  
1 5 10

<210> 260  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 260  
Gln Ser Tyr Asp Arg Gly Thr His Pro Leu Thr Met  
1 5 10

<210> 261  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 261  
Gln Ser Tyr Asp Ser Gly Tyr Thr Gly Ser Arg Val  
1 5 10

<210> 262  
<211> 12  
<212> PRT  
<213> Homo sapiens

- 62 -

<400> 262  
Gln Ser Tyr Asp Ser Gly Phe Thr Gly Ser Arg Val  
1 5 10

<210> 263  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 263  
Gln Ser Tyr Asp Ser Arg Phe Thr Gly Ser Arg Val  
1 5 10

<210> 264  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 264  
Gln Ser Tyr Pro Asp Gly Thr Pro Ala Ser Arg Val  
1 5 10

<210> 265  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 265  
Gln Ser Tyr Ser Thr His Met Pro Ile Ser Arg Val  
1 5 10

<210> 266  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 266  
Gln Ser Tyr Asp Ser Gly Ser Thr Gly Ser Arg Val  
1 5 10

<210> 267  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 267  
Gln Ser Tyr Pro Asn Ser Tyr Pro Ile Ser Arg Val  
1 5 10

<210> 268  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 268  
Gln Ser Tyr Ile Arg Ala Pro Gln Gln Val  
1 5 10

<210> 269

- 63 -

<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 269  
Gln Ser Tyr Leu Lys Ser Arg Ala Phe Ser Arg Val  
1 5 10

<210> 270  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 270  
Gln Ser Tyr Asp Ser Arg Phe Thr Gly Ser Arg Val  
1 5 10

<210> 271  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 271  
Gln Ser Tyr Asp Arg Gly Phe Thr Gly Ser Met Val  
1 5 10

<210> 272  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 272  
Gln Ser Tyr Asp Arg Gly Phe Thr Gly Ser Met Val  
1 5 10

<210> 273  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 273  
Gln Ser Tyr Asp Arg Gly Phe Thr Gly Phe Asp Gly  
1 5 10

<210> 274  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 274  
Gln Ser Tyr Asp Arg Gly Thr Ala Pro Ala Leu Ser  
1 5 10

<210> 275  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 275  
Gln Ser Tyr Asp Arg Gly Ser Tyr Pro Ala Leu Arg

- 64 -

1 5 10

<210> 276  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 276  
Gln Ser Tyr Asp Arg Gly Asn Trp Pro Asn Ser Asn  
1 5 10

<210> 277  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 277  
Gln Ser Tyr Asp Arg Gly Thr Ala Pro Ser Leu Leu  
1 5 10

<210> 278  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 278  
Gln Ser Tyr Asp Arg Gly Phe Thr Gly Ser Met Val  
1 5 10

<210> 279  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 279  
Gln Ser Tyr Asp Arg Gly Thr Thr Pro Arg Ile Arg  
1 5 10

<210> 280  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 280  
Gln Ser Tyr Asp Arg Gly Phe Thr Gly Ser Met Val  
1 5 10

<210> 281  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 281  
Gln Ser Tyr Asp Arg Gly Phe Thr Gly Ser Met Val  
1 5 10

<210> 282  
<211> 12  
<212> PRT

- 65 -

&lt;213&gt; Homo sapiens

&lt;400&gt; 282

Gln Ser Tyr Asp Arg Gly Met Ile Pro Ala Leu Thr  
1 5 10

&lt;210&gt; 283

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 283

Gln Ser Tyr Asp Arg Asn Thr His Pro Ala Leu Leu  
1 5 10

&lt;210&gt; 284

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 284

Gln Ser Tyr Asp Arg Phe Thr His Pro Ala Leu Leu  
1 5 10

&lt;210&gt; 285

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 285

Gln Ser Tyr Asp Arg Tyr Thr His Pro Ala Leu Leu  
1 5 10

&lt;210&gt; 286

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 286

Gln Ser Tyr Asp Arg Gly Thr His Pro Ala Leu Leu  
1 5 10

&lt;210&gt; 287

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 287

Gln Ser Tyr Asp Arg Tyr Thr His Pro Ala Leu Leu  
1 5 10

&lt;210&gt; 288

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 288

Phe Thr Phe Glu Ser Tyr Gly Met His  
1 5

- 66 -

<210> 289  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 289  
Phe Thr Phe Ser Ser Tyr Gly Met His  
1 5

<210> 290  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 290  
Phe Thr Phe Tyr Ser Tyr Gly Met His  
1 5

<210> 291  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 291  
Phe Thr Phe His Ser Tyr Gly Met His  
1 5

<210> 292  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 292  
Phe Thr Phe Lys Ser Tyr Gly Met His  
1 5

<210> 293  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 293  
Phe Thr Phe Arg Ser Tyr Gly Met His  
1 5

<210> 294  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 294  
Phe Thr Phe Asn Ser Tyr Gly Met His  
1 5

<210> 295  
<211> 9  
<212> PRT  
<213> Homo sapiens

- 67 -

<400> 295  
Phe Thr Phe Thr Ser Tyr Gly Met His  
1 5

<210> 296  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 296  
Phe Thr Phe Gly Ser Tyr Gly Met His  
1 5

<210> 297  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 297  
Phe Thr Phe Val Ser Tyr Gly Met His  
1 5

<210> 298  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 298  
Phe Thr Phe Ile Ser Tyr Gly Met His  
1 5

<210> 299  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 299  
Phe Thr Phe Trp Ser Tyr Gly Met His  
1 5

<210> 300  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 300  
Phe Thr Phe Ser Glu Tyr Gly Met His  
1 5

<210> 301  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 301  
Phe Thr Phe Ser Cys Tyr Gly Met His  
1 5

<210> 302



- 68 -

<211> 9  
<212> PRT  
<213> Homo sapiens  
  
<400> 302  
Phe Thr Phe Ser Ser Tyr Gly Met His  
1 5

<210> 303  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 303  
Phe Thr Phe Ser Tyr Tyr Gly Met His  
1 5

<210> 304  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 304  
Phe Thr Phe Ser His Tyr Gly Met His  
1 5

<210> 305  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 305  
Phe Thr Phe Ser Arg Tyr Gly Met His  
1 5

<210> 306  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 306  
Phe Thr Phe Ser Asn Tyr Gly Met His  
1 5

<210> 307  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 307  
Phe Thr Phe Ser Gln Tyr Gly Met His  
1 5

<210> 308  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 308  
Phe Thr Phe Ser Thr Tyr Gly Met His

1 5

<210> 309  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 309  
Phe Thr Phe Ser Ala Tyr Gly Met His  
1 5

<210> 310  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 310  
Phe Thr Phe Ser Ile Tyr Gly Met His  
1 5

<210> 311  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 311  
Phe Thr Phe Ser Ser Glu Gly Met His  
1 5

<210> 312  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 312  
Phe Thr Phe Ser Ser Cys Gly Met His  
1 5

<210> 313  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 313  
Phe Thr Phe Ser Ser Ser Gly Met His  
1 5

<210> 314  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 314  
Phe Thr Phe Ser Ser Tyr Gly Met His  
1 5

<210> 315  
<211> 9  
<212> PRT

- 70 -

&lt;213&gt; Homo sapiens

&lt;400&gt; 315

Phe Thr Phe Ser Ser His Gly Met His  
1 5

&lt;210&gt; 316

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 316

Phe Thr Phe Ser Ser Arg Gly Met His  
1 5

&lt;210&gt; 317

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 317

Phe Thr Phe Ser Ser Asn Gly Met His  
1 5

&lt;210&gt; 318

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 318

Phe Thr Phe Ser Ser Thr Gly Met His  
1 5

&lt;210&gt; 319

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 319

Phe Thr Phe Ser Ser Ala Gly Met His  
1 5

&lt;210&gt; 320

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 320

Phe Thr Phe Ser Ser Val Gly Met His  
1 5

&lt;210&gt; 321

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 321

Phe Thr Phe Ser Ser Leu Gly Met His  
1 5

- 71 -

<210> 322  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 322  
Phe Thr Phe Ser Ser Ile Gly Met His  
1 5

<210> 323  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 323  
Phe Thr Phe Ser Ser Tyr Asp Met His  
1 5

<210> 324  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 324  
Phe Thr Phe Ser Ser Tyr Glu Met His  
1 5

<210> 325  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 325  
Phe Thr Phe Ser Ser Tyr Cys Met His  
1 5

<210> 326  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 326  
Phe Thr Phe Ser Ser Tyr Ser Met His  
1 5

<210> 327  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 327  
Phe Thr Phe Ser Ser Tyr Tyr Met His  
1 5

<210> 328  
<211> 9  
<212> PRT  
<213> Homo sapiens

- 72 -

<400> 328  
Phe Thr Phe Ser Ser Tyr Asn Met His  
1 5

<210> 328  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 329  
Phe Thr Phe Ser Ser Tyr Gly Met His  
1 5

<210> 329  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 330  
Phe Thr Phe Ser Ser Tyr Ala Met His  
1 5

<210> 331  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 331  
Phe Thr Phe Ser Ser Tyr Val Met His  
1 5

<210> 332  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 332  
Phe Thr Phe Ser Ser Tyr Met Met His  
1 5

<210> 333  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 333  
Phe Thr Phe Ser Ser Tyr Ile Met His  
1 5

<210> 334  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 334  
Phe Thr Phe Ser Ser Tyr Pro Met His  
1 5

<210> 335

- 73 -

<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 335  
Glu Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 336  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 336  
Cys Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 337  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 337  
Tyr Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 338  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 338  
His Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 339  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 339  
Lys Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 340  
<211> 17

- 74 -

<212> PRT  
<213> Homo sapiens

<400> 340  
Asn Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 341  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 341  
Gln Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 342  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 342  
Thr Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 343  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 343  
Leu Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 344  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 344  
Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 345  
<211> 17  
<212> PRT

- 75 -

&lt;213&gt; Homo sapiens

&lt;400&gt; 345

Phe Ile Glu Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

&lt;210&gt; 346

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 346

Phe Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

&lt;210&gt; 347

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 347

Phe Ile Tyr Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

&lt;210&gt; 348

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 348

Phe Ile His Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

&lt;210&gt; 349

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 349

Phe Ile Lys Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

&lt;210&gt; 350

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens



- 76 -

&lt;400&gt; 350

Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

&lt;210&gt; 351

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 351

Phe Ile Gln Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

&lt;210&gt; 352

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 352

Phe Ile Thr Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

&lt;210&gt; 353

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 353

Phe Ile Gly Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

&lt;210&gt; 354

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 354

Phe Ile Ala Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

&lt;210&gt; 355

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

- 77 -

&lt;400&gt; 355

Phe Ile Val Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

&lt;210&gt; 356

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 356

Phe Ile Leu Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

&lt;210&gt; 357

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 357

Phe Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

&lt;210&gt; 358

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 358

Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

&lt;210&gt; 359

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 359

Phe Ile Arg Tyr Glu Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

&lt;210&gt; 360

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 360

- 78 -

Phe Ile Arg Tyr Ser Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 361  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 361  
Phe Ile Arg Tyr Tyr Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 362  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 362  
Phe Ile Arg Tyr Lys Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 363  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 363  
Phe Ile Arg Tyr Arg Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 364  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 364  
Phe Ile Arg Tyr Asn Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 365  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 365  
Phe Ile Arg Tyr Gln Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys

- 79 -

1                    5                    10                    15  
Gly

<210> 366  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 366  
Phe Ile Arg Tyr Thr Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1                    5                    10                    15

Gly

<210> 367  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 367  
Phe Ile Arg Tyr Ala Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1                    5                    10                    15

Gly

<210> 368  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 368  
Phe Ile Arg Tyr Val Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1                    5                    10                    15

Gly

<210> 369  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 369  
Phe Ile Arg Tyr Leu Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1                    5                    10                    15

Gly

<210> 370  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 370  
Phe Ile Arg Tyr Ile Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1                    5                    10                    15

- 80 -

Gly

<210> 371  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 371  
Phe Ile Arg Tyr Phe Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 372  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 372  
Phe Ile Arg Tyr Asp Asp Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 373  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 373  
Phe Ile Arg Tyr Asp Glu Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 374  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 374  
Phe Ile Arg Tyr Asp Ser Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 375  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 375  
Phe Ile Arg Tyr Asp Tyr Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

- 81 -

Gly

<210> 376  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 376  
Phe Ile Arg Tyr Asp Lys Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 377  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 377  
Phe Ile Arg Tyr Asp Arg Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 378  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 378  
Phe Ile Arg Tyr Asp Asn Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 379  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 379  
Phe Ile Arg Tyr Asp Gln Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 380  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 380  
Phe Ile Arg Tyr Asp Thr Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 381  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 381  
Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 382  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 382  
Phe Ile Arg Tyr Asp Val Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 383  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 383  
Phe Ile Arg Tyr Asp Phe Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 384  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 384  
Phe Ile Arg Tyr Asp Gly Ser Ser Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 385  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 385  
Phe Ile Arg Tyr Asp Gly Ser Tyr Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 386  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 386  
Phe Ile Arg Tyr Asp Gly Ser His Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 387  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 387  
Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 388  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 388  
Phe Ile Arg Tyr Asp Gly Ser Thr Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 389  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 389  
Phe Ile Arg Tyr Asp Gly Ser Gly Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 390  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 390  
Phe Ile Arg Tyr Asp Gly Ser Met Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly



<210> 391  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 391  
Phe Ile Arg Tyr Asp Gly Ser Leu Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 392  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 392  
Phe Ile Arg Tyr Asp Gly Ser Ile Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 393  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 393  
Phe Ile Arg Tyr Asp Gly Ser Pro Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 394  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 394  
Phe Ile Arg Tyr Asp Gly Ser Phe Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 395  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 395  
Phe Ile Arg Tyr Asp Gly Ser Asn Lys Glu Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

- 85 -

<210> 396  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 396  
Phe Ile Arg Tyr Asp Gly Ser Asn Lys Ser Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 397  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 397  
Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 398  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 398  
Phe Ile Arg Tyr Asp Gly Ser Asn Lys Asn Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 399  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 399  
Phe Ile Arg Tyr Asp Gly Ser Asn Lys Val Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 400  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 400  
Phe Ile Arg Tyr Asp Gly Ser Asn Lys Leu Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 401

- 86 -

<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 401  
Phe Ile Arg Tyr Asp Gly Ser Asn Lys Ile Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 402  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 402  
Phe Ile Arg Tyr Asp Gly Ser Asn Lys Pro Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 403  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 403  
Phe Ile Arg Tyr Asp Gly Ser Asn Lys Phe Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 404  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 404  
Glu Gly Ser His Asp Asn  
1 5

<210> 405  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 405  
Ser Gly Ser His Asp Asn  
1 5

<210> 406  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 406  
His Gly Ser His Asp Asn  
1 5

<210> 407  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 407  
Lys Gly Ser His Asp Asn  
1 5

<210> 408  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 408  
Gln Gly Ser His Asp Asn  
1 5

<210> 409  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 409  
Thr Gly Ser His Asp Asn  
1 5

<210> 410  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 410  
Ala Gly Ser His Asp Asn  
1 5

<210> 411  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 411  
Leu Gly Ser His Asp Asn  
1 5

<210> 412  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 412  
Pro Gly Ser His Asp Asn  
1 5

<210> 413  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 413  
Phe Gly Ser His Asp Asn  
1 5

<210> 414  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 414  
His Asp Ser His Asp Asn  
1 5

<210> 415  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 415  
His Cys Ser His Asp Asn  
1 5

<210> 416  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 416  
His His Ser His Asp Asn  
1 5

<210> 417  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 417  
His Arg Ser His Asp Asn  
1 5

<210> 418  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 418  
His Thr Ser His Asp Asn  
1 5

<210> 419  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 419  
His Gly Ser His Asp Asn  
1 5

- 89 -

<210> 420  
<211> 6  
<212> PRT  
<213> Homo sapiens  
  
<400> 420  
His Val Ser His Asp Asn  
1 5

<210> 421  
<211> 6  
<212> PRT  
<213> Homo sapiens  
  
<400> 421  
His Met Ser His Asp Asn  
1 5

<210> 422  
<211> 6  
<212> PRT  
<213> Homo sapiens  
  
<400> 422  
His Leu Ser His Asp Asn  
1 5

<210> 423  
<211> 6  
<212> PRT  
<213> Homo sapiens  
  
<400> 423  
His Ile Ser His Asp Asn  
1 5

<210> 424  
<211> 6  
<212> PRT  
<213> Homo sapiens  
  
<400> 424  
His Pro Ser His Asp Asn  
1 5

<210> 425  
<211> 6  
<212> PRT  
<213> Homo sapiens  
  
<400> 425  
His Trp Ser His Asp Asn  
1 5

<210> 426  
<211> 6  
<212> PRT  
<213> Homo sapiens  
  
<400> 426

- 90 -

His Gly Asp His Asp Asn  
1 5

<210> 427  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 427  
His Gly Ser His Asp Asn  
1 5

<210> 428  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 428  
His Gly Tyr His Asp Asn  
1 5

<210> 429  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 429  
His Gly His His Asp Asn  
1 5

<210> 430  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 430  
His Gly Arg His Asp Asn  
1 5

<210> 431  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 431  
His Gly Asn His Asp Asn  
1 5

<210> 432  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 432  
His Gly Thr His Asp Asn  
1 5

<210> 433  
<211> 6

- 91 -

<212> PRT  
<213> Homo sapiens  
  
<400> 433  
His Gly Gly His Asp Asn  
1 5

<210> 434  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 434  
His Gly Ala His Asp Asn  
1 5

<210> 435  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 435  
His Gly Ile His Asp Asn  
1 5

<210> 436  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 436  
His Gly Pro His Asp Asn  
1 5

<210> 437  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 437  
His Gly Trp His Asp Asn  
1 5

<210> 438  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 438  
His Gly Phe His Asp Asn  
1 5

<210> 439  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 439  
His Gly Ser His Asp Asn  
1 5



<210> 440  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 440  
His Gly Ser Arg Asp Asn  
1 5

<210> 441  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 441  
His Gly Ser Thr Asp Asn  
1 5

<210> 442  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 442  
His Gly Ser Ala Asp Asn  
1 5

<210> 443  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 443  
His Gly Ser Val Asp Asn  
1 5

<210> 444  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 444  
His Gly Ser Leu Asp Asn  
1 5

<210> 445  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 445  
His Gly Ser Ile Asp Asn  
1 5

<210> 446  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 446  
His Gly Ser Phe Asp Asn  
1 5

<210> 447  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 447  
His Gly Ser His Asp Asn  
1 5

<210> 448  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 448  
His Gly Ser His Ser Asn  
1 5

<210> 449  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 449  
His Gly Ser His Tyr Asn  
1 5

<210> 450  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 450  
His Gly Ser His His Asn  
1 5

<210> 451  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 451  
His Gly Ser His Arg Asn  
1 5

<210> 452  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 452  
His Gly Ser His Asn Asn  
1 5

- 94 -

<210> 453  
<211> 6  
<212> PRT  
<213> Homo sapiens  
  
<400> 453  
His Gly Ser His Gly Asn  
1 5

<210> 454  
<211> 6  
<212> PRT  
<213> Homo sapiens  
  
<400> 454  
His Gly Ser His Ala Asn  
1 5

<210> 455  
<211> 6  
<212> PRT  
<213> Homo sapiens  
  
<400> 455  
His Gly Ser His Val Asn  
1 5

<210> 456  
<211> 6  
<212> PRT  
<213> Homo sapiens  
  
<400> 456  
His Gly Ser His Ile Asn  
1 5

<210> 457  
<211> 6  
<212> PRT  
<213> Homo sapiens  
  
<400> 457  
His Gly Ser His Asp Ser  
1 5

<210> 458  
<211> 6  
<212> PRT  
<213> Homo sapiens  
  
<400> 458  
His Gly Ser His Asp His  
1 5

<210> 459  
<211> 6  
<212> PRT  
<213> Homo sapiens  
  
<400> 459

- 95 -

His Gly Ser His Asp Lys  
1 5

<210> 460  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 460  
His Gly Ser His Asp Arg  
1 5

<210> 461  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 461  
His Gly Ser His Asp Asn  
1 5

<210> 462  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 462  
His Gly Ser His Asp Thr  
1 5

<210> 463  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 463  
His Gly Ser His Asp Gly  
1 5

<210> 464  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 464  
His Gly Ser His Asp Ala  
1 5

<210> 465  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 465  
His Gly Ser His Asp Leu  
1 5

<210> 466  
<211> 6

- 96 -

<212> PRT  
<213> Homo sapiens

<400> 466  
His Gly Ser His Asp Ile  
1 5

<210> 467  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 467  
His Gly Ser His Asp Pro  
1 5

<210> 468  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 468  
His Gly Ser His Asp Trp  
1 5

<210> 469  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 469  
His Gly Ser His Asp Phe  
1 5

<210> 470  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 470  
Ser Gly Gly Arg Ser Asn Ile Gly Asp Asn Thr Val Lys  
1 5 10

<210> 471  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 471  
Ser Gly Gly Arg Ser Asn Ile Gly Cys Asn Thr Val Lys  
1 5 10

<210> 472  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 472  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn Thr Val Lys  
1 5 10

- 97 -

<210> 473  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 473  
Ser Gly Gly Arg Ser Asn Ile Gly Tyr Asn Thr Val Lys  
1 5 10

<210> 474  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 474  
Ser Gly Gly Arg Ser Asn Ile Gly Lys Asn Thr Val Lys  
1 5 10

<210> 475  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 475  
Ser Gly Gly Arg Ser Asn Ile Gly Arg Asn Thr Val Lys  
1 5 10

<210> 476  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 476  
Ser Gly Gly Arg Ser Asn Ile Gly Asn Asn Thr Val Lys  
1 5 10

<210> 477  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 477  
Ser Gly Gly Arg Ser Asn Ile Gly Thr Asn Thr Val Lys  
1 5 10

<210> 478  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 478  
Ser Gly Gly Arg Ser Asn Ile Gly Pro Asn Thr Val Lys  
1 5 10

<210> 479  
<211> 13  
<212> PRT  
<213> Homo sapiens

- 98 -

<400> 479  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Asp Thr Val Lys  
1 5 10

<210> 480  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 480  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Glu Thr Val Lys  
1 5 10

<210> 481  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 481  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Ser Thr Val Lys  
1 5 10

<210> 482  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 482  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Tyr Thr Val Lys  
1 5 10

<210> 483  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 483  
Ser Gly Gly Arg Ser Asn Ile Gly Ser His Thr Val Lys  
1 5 10

<210> 484  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 484  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Lys Thr Val Lys  
1 5 10

<210> 485  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 485  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn Thr Val Lys  
1 5 10

- 99 -

<210> 486  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 486  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Gln Thr Val Lys  
1 5 10

<210> 487  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 487  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Thr Thr Val Lys  
1 5 10

<210> 488  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 488  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Gly Thr Val Lys  
1 5 10

<210> 489  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 489  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Met Thr Val Lys  
1 5 10

<210> 490  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 490  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Ile Thr Val Lys  
1 5 10

<210> 491  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 491  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn Asp Val Lys  
1 5 10

<210> 492  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 492



- 100 -

Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn Cys Val Lys  
1 5 10

<210> 493  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 493  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn Ser Val Lys  
1 5 10

<210> 494  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 494  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn Tyr Val Lys  
1 5 10

<210> 495  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 495  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn His Val Lys  
1 5 10

<210> 496  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 496  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn Lys Val Lys  
1 5 10

<210> 497  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 497  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn Arg Val Lys  
1 5 10

<210> 498  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 498  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn Asn Val Lys  
1 5 10

<210> 499  
<211> 13

- 101 -

<212> PRT  
<213> Homo sapiens

<400> 499  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn Gln Val Lys  
1 5 10

<210> 500  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 500  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn Thr Val Lys  
1 5 10

<210> 501  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 501  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn Ala Val Lys  
1 5 10

<210> 502  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 502  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn Val Val Lys  
1 5 10

<210> 503  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 503  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn Leu Val Lys  
1 5 10

<210> 504  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 504  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn Ile Val Lys  
1 5 10

<210> 505  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 505  
Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn Pro Val Lys  
1 5 10

<210> 506  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 506  
Asp Asn Asp Gln Arg Pro Ser  
1 5

<210> 507  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 507  
Glu Asn Asp Gln Arg Pro Ser  
1 5

<210> 508  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 508  
Cys Asn Asp Gln Arg Pro Ser  
1 5

<210> 509  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 509  
Ser Asn Asp Gln Arg Pro Ser  
1 5

<210> 510  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 510  
Tyr Asn Asp Gln Arg Pro Ser  
1 5

<210> 511  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 511  
His Asn Asp Gln Arg Pro Ser  
1 5

<210> 512  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 512  
Lys Asn Asp Gln Arg Pro Ser  
1 5

<210> 513  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 513  
Arg Asn Asp Gln Arg Pro Ser  
1 5

<210> 514  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 514  
Asn Asn Asp Gln Arg Pro Ser  
1 5

<210> 515  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 515  
Gln Asn Asp Gln Arg Pro Ser  
1 5

<210> 516  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 516  
Thr Asn Asp Gln Arg Pro Ser  
1 5

<210> 517  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 517  
Gly Asn Asp Gln Arg Pro Ser  
1 5

<210> 518  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 518  
Ala Asn Asp Gln Arg Pro Ser  
1 5

- 104 -

<210> 519  
<211> 7  
<212> PRT  
<213> Homo sapiens  
  
<400> 519  
Val Asn Asp Gln Arg Pro Ser  
1 5

<210> 520  
<211> 7  
<212> PRT  
<213> Homo sapiens  
  
<400> 520  
Met Asn Asp Gln Arg Pro Ser  
1 5

<210> 521  
<211> 7  
<212> PRT  
<213> Homo sapiens  
  
<400> 521  
Leu Asn Asp Gln Arg Pro Ser  
1 5

<210> 522  
<211> 7  
<212> PRT  
<213> Homo sapiens  
  
<400> 522  
Ile Asn Asp Gln Arg Pro Ser  
1 5

<210> 523  
<211> 7  
<212> PRT  
<213> Homo sapiens  
  
<400> 523  
Pro Asn Asp Gln Arg Pro Ser  
1 5

<210> 524  
<211> 7  
<212> PRT  
<213> Homo sapiens  
  
<400> 524  
Trp Asn Asp Gln Arg Pro Ser  
1 5

<210> 525  
<211> 7  
<212> PRT  
<213> Homo sapiens  
  
<400> 525

Phe Asn Asp Gln Arg Pro Ser  
1 5

<210> 526  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 526  
Gly Asn Asp Ser Arg Pro Ser  
1 5

<210> 527  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 527  
Gly Asn Asp Tyr Arg Pro Ser  
1 5

<210> 528  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 528  
Gly Asn Asp Arg Arg Pro Ser  
1 5

<210> 529  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 529  
Gly Asn Asp Gln Arg Pro Ser  
1 5

<210> 530  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 530  
Gly Asn Asp Thr Arg Pro Ser  
1 5

<210> 531  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 531  
Gly Asn Asp Ala Arg Pro Ser  
1 5

<210> 532  
<211> 7

<212> PRT  
<213> Homo sapiens

<400> 532  
Gly Asn Asp Ile Arg Pro Ser  
1 5

<210> 533  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 533  
Gly Asn Asp Pro Arg Pro Ser  
1 5

<210> 534  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 534  
Gln Ser Tyr Asp Arg Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 535  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 535  
Gln Ser Tyr Cys Arg Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 536  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 536  
Gln Ser Tyr Ser Arg Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 537  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 537  
Gln Ser Tyr Tyr Arg Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 538  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 538  
Gln Ser Tyr Asn Arg Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 539  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 539  
Gln Ser Tyr Gln Arg Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 540  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 540  
Gln Ser Tyr Thr Arg Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 541  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 541  
Gln Ser Tyr Gly Arg Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 542  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 542  
Gln Ser Tyr Ala Arg Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 543  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 543  
Gln Ser Tyr Leu Arg Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 544  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 544  
Gln Ser Tyr Ile Arg Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 545  
<211> 12  
<212> PRT  
<213> Homo sapiens



- 108 -

<400> 545  
Gln Ser Tyr Trp Arg Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 546  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 546  
Gln Ser Tyr Phe Arg Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 547  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 547  
Gln Ser Tyr Asp Asp Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 548  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 548  
Gln Ser Tyr Asp Cys Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 549  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 549  
Gln Ser Tyr Asp Ser Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 550  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 550  
Gln Ser Tyr Asp Tyr Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 551  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 551  
Gln Ser Tyr Asp Arg Gly Thr His Pro Ala Leu Leu  
1 5 10

- 109 -

<210> 552  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 552  
Gln Ser Tyr Asp Asn Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 553  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 553  
Gln Ser Tyr Asp Gln Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 554  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 554  
Gln Ser Tyr Asp Thr Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 555  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 555  
Gln Ser Tyr Asp Gly Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 556  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 556  
Gln Ser Tyr Asp Ala Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 557  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 557  
Gln Ser Tyr Asp Val Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 558  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 558

- 110 -

Gln Ser Tyr Asp Met Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 559  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 559  
Gln Ser Tyr Asp Leu Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 560  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 560  
Gln Ser Tyr Asp Ile Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 561  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 561  
Gln Ser Tyr Asp Pro Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 562  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 562  
Gln Ser Tyr Asp Trp Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 563  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 563  
Gln Ser Tyr Asp Arg Asp Thr His Pro Ala Leu Leu  
1 5 10

<210> 564  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 564  
Gln Ser Tyr Asp Arg Cys Thr His Pro Ala Leu Leu  
1 5 10

<210> 565  
<211> 12

- III -

<212> PRT  
<213> Homo sapiens

<400> 565  
Gln Ser Tyr Asp Arg Ser Thr His Pro Ala Leu Leu  
1 5 10

<210> 566  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 566  
Gln Ser Tyr Asp Arg Tyr Thr His Pro Ala Leu Leu  
1 5 10

<210> 567  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 567  
Gln Ser Tyr Asp Arg His Thr His Pro Ala Leu Leu  
1 5 10

<210> 568  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 568  
Gln Ser Tyr Asp Arg Arg Thr His Pro Ala Leu Leu  
1 5 10

<210> 569  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 569  
Gln Ser Tyr Asp Arg Asn Thr His Pro Ala Leu Leu  
1 5 10

<210> 570  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 570  
Gln Ser Tyr Asp Arg Gln Thr His Pro Ala Leu Leu  
1 5 10

<210> 571  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 571  
Gln Ser Tyr Asp Arg Thr Thr His Pro Ala Leu Leu  
1 5 10

- 112 -

<210> 572  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 572  
Gln Ser Tyr Asp Arg Gly Thr His Pro Ala Leu Leu  
1 5 10

<210> 573  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 573  
Gln Ser Tyr Asp Arg Ala Thr His Pro Ala Leu Leu  
1 5 10

<210> 574  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 574  
Gln Ser Tyr Asp Arg Val Thr His Pro Ala Leu Leu  
1 5 10

<210> 575  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 575  
Gln Ser Tyr Asp Arg Leu Thr His Pro Ala Leu Leu  
1 5 10

<210> 576  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 576  
Gln Ser Tyr Asp Arg Ile Thr His Pro Ala Leu Leu  
1 5 10

<210> 577  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 577  
Gln Ser Tyr Asp Arg Pro Thr His Pro Ala Leu Leu  
1 5 10

<210> 578  
<211> 12  
<212> PRT  
<213> Homo sapiens

- 113 -

<400> 578  
 Gln Ser Tyr Asp Arg Trp Thr His Pro Ala Leu Leu  
           1                  5                  10

<210> 579  
 <211> 12  
 <212> PRT  
 <213> Homo sapiens

<400> 579  
 Gln Ser Tyr Asp Arg Phe Thr His Pro Ala Leu Leu  
           1                  5                  10

<210> 580  
 <211> 48  
 <212> DNA  
 <213> synthetic construct  
 <223> nucleotides at positions 16 to 34 can be substituted with any nucleotide such that the randomized nucleotides represent 12% of the sequence

<400> 580  
 tgcccttgg cccagtagt catagctccc actggtcgta cagtaata 46

<210> 581  
 <211> 35  
 <212> DNA  
 <213> synthetic construct

<400> 581  
 gacacctga tcagcggata acaatttcac acagg 35

<210> 582  
 <211> 15  
 <212> DNA  
 <213> synthetic construct

<400> 582  
 tggggccaag ggaca 15

<210> 583  
 <211> 45  
 <212> DNA  
 <213> synthetic construct

<400> 583  
 attcgtccta taccgttcta attgtctgc ttccagacg ttagt 45

<210> 584  
 <211> 18  
 <212> DNA  
 <213> synthetic construct

<400> 584  
 attcgtccta taccgttc 18

<210> 585  
 <211> 66  
 <212> DNA  
 <213> synthetic construct  
 <223> nucleotides from position 28 to 42 can be substituted with any nucleotide such that the

- 114 -

randomized nucleotides represent 12% of the  
sequence

<400> 585  
qgtcccagtt ccgaagaccc tcgaaccct caggtctctg tcatatgact ggcagtaata 60  
gtcagc 66

<210> 586  
<211> 15  
<212> DNA  
<213> synthetic construct

<400> 586  
tggggccaaag ggaca 15

<210> 587  
<211> 24  
<212> DNA  
<213> synthetic construct

<400> 587  
tgaagagacg gtgaccattg tccc 24

<210> 588  
<211> 16  
<212> DNA  
<213> synthetic construct

<400> 588  
gacacctcga tcagcg 16

<210> 589  
<211> 48  
<212> DNA  
<213> synthetic construct

<400> 589  
gagtcattct cgacttgctg ccgcacctag gacggtcagc ttgggtccc 48

<210> 590  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 590  
Gln Ser Tyr Asp Arg Gly Phe Thr Gly Ser Met Val  
1 5 10

<210> 591  
<211> 12  
<212> PRT  
<213> Homo sapiens

<220>  
<223> Xaa is encoded by a randomized codon of sequence  
NNS with N being any nucleotide and S being either  
deoxycytosine or deoxyguanine

<400> 591  
Xaa Xaa Xaa Xaa Xaa Xaa Phe Thr Gly Ser Met Val  
1 5 10

<210> 592  
<211> 12

- 115 -

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

<223> Xaa is encoded by a randomized codon of sequence  
 NNS with N being any nucleotide and S being either  
 deoxycytosine or deoxyguanine

&lt;400&gt; 592

Gln Ser Tyr Xaa Xaa Xaa Xaa Xaa Xaa Ser Met Val  
 1 5 10

&lt;210&gt; 593

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

<223> Xaa is encoded by a randomized codon of sequence  
 NNS with N being any nucleotide and S being either  
 deoxycytosine or deoxyguanine

&lt;400&gt; 593

Gln Ser Tyr Asp Arg Gly Xaa Xaa Xaa Xaa Xaa Xaa  
 1 5 10

&lt;210&gt; 594

&lt;211&gt; 100

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 594

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp His  
 20 25 30

Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45

Gly Arg Thr Arg Asn Lys Ala Asn Ser Tyr Thr Thr Glu Tyr Ala Ala  
 50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser  
 65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr  
 85 90 95

Tyr Cys Ala Arg  
 100

&lt;210&gt; 595

&lt;211&gt; 100

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 595

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp His



- 116 -

20 25 30

Tyr Met Ser Trp Val Arg Gln Ala Gln Gly Lys Gly Leu Glu Leu Val  
35 40 45

Gly Leu Ile Arg Asn Lys Ala Asn Ser Tyr Thr Thr Glu Tyr Ala Ala  
50 55 60

Ser Val Lys Gly Arg Leu Thr Ile Ser Arg Glu Asp Ser Lys Asn Thr  
65 70 75 80

Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr Glu Asp Leu Ala Val Tyr  
85 90 95

Tyr Cys Ala Arg  
100

<210> 596  
 <211> 100  
 <212> PRT  
 <213> Homo sapiens

<400> 596

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp His  
20 25 30

Tyr Met Ser Trp Val Arg Gln Ala Gln Gly Lys Gly Leu Glu Leu Val  
35 40 45

Gly Leu Ile Arg Asn Lys Ala Asn Ser Tyr Thr Thr Glu Tyr Ala Ala  
50 55 60

Ser Val Lys Gly Arg Leu Thr Ile Ser Arg Glu Asp Ser Lys Asn Thr  
65 70 75 80

Met Tyr Leu Gln Met Ser Asn Leu Lys Thr Glu Asp Leu Ala Val Tyr  
85 90 95

Tyr Cys Ala Arg  
100

<210> 597  
 <211> 100  
 <212> PRT  
 <213> Homo sapiens

<400> 597

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp His  
20 25 30

Tyr Met Ser Trp Val Arg Gln Ala Gln Gly Lys Gly Leu Glu Leu Val  
35 40 45

Gly Leu Ile Arg Asn Lys Ala Asn Ser Tyr Thr Thr Glu Tyr Ala Ala  
50 55 60

Ser Val Lys Gly Arg Leu Thr Ile Ser Arg Glu Asp Ser Lys Asn Thr  
65 70 75 80

```

<400> 598
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
  1             5             10             15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
             20             25             30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
             35             40             45
Ser Ser Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val
             50             55             60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
             65             70             75             80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys
             85             90             95
Ala Lys

```

```

<400> 599
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Arg Pro Gly Gly
 1          5          10
Scr Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
          20          25          30
Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
          35          40          45
Ser Gly Ile Asn Trp Asn Gly Gly Ser Thr Gly Tyr Ala Asp Ser Val
          50          55          60
Lys Gly Arg Phe Thr Ile Scr Arg Asp Asn Ala Lys Asn Ser Leu Tyr
          65          70          75          80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr His Cys
          85          90          95
Ala Arg

```

<210>	600
<211>	98

- 118 -

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 600

Glu Val Gln Leu Val Glu Ser Gly Gly Val Val Val Gln Pro Gly Gly  
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr  
 20 25 30

Thr Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45

Ser Leu Ile Ser Trp Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val  
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Ser Leu Tyr  
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Leu Tyr Tyr Cys  
 85 90 95

Ala Lys

&lt;210&gt; 601

&lt;211&gt; 98

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 601

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr  
 20 25 30

Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45

Ser Tyr Ile Ser Ser Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val  
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr  
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Arg

&lt;210&gt; 602

&lt;211&gt; 98

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 602

Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr  
 20 25 30

- 119 -

Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Tyr Ile Ser Ser Ser Ser Tyr Thr Asn Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Gln Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Arg

<210> 603  
 <211> 100  
 <212> PRT  
 <213> Homo sapiens

<400> 603  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Ser  
 20 25 30  
 Ala Met His Trp Val Arg Gln Ala Ser Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Gly Arg Ile Arg Ser Lys Ala Asn Ser Tyr Ala Thr Ala Tyr Ala Ala  
 50 55 60  
 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr  
 65 70 75 80  
 Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr  
 85 90 95  
 Tyr Cys Thr Arg  
 100

<210> 604  
 <211> 100  
 <212> PRT  
 <213> Homo sapiens

<400> 604  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala  
 20 25 30  
 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Gly Arg Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala  
 50 55 60  
 Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr  
 65 70 75 80  
 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

- 120 -

85 90 95

Tyr Cys Thr Thr  
100

<210> 605  
<211> 100  
<212> FRT  
<213> Homo sapiens

<400> 605  
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
1 5 10 15  
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala  
20 25 30  
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
35 40 45  
Gly Arg Ile Glu Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala  
50 55 60  
Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr  
65 70 75 80  
Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr  
85 90 95

Tyr Cys Thr Thr  
100

<210> 606  
<211> 100  
<212> PRT  
<213> Homo sapiens

<400> 606  
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
1 5 10 15  
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala  
20 25 30  
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
35 40 45  
Gly Arg Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala  
50 55 60  
Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr  
65 70 75 80  
Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr  
85 90 95

Tyr Cys Thr Thr  
100

<210> 607  
<211> 100  
<212> PRT  
<213> Homo sapiens

- 121 -

&lt;400&gt; 607

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala  
 20 25 30  
 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Gly Arg Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asn Tyr Ala Ala  
 50 55 60  
 Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr  
 65 70 75 80  
 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr  
 85 90 95  
 Tyr Cys Thr Thr  
 100

&lt;210&gt; 603

&lt;211&gt; 100

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 608

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala  
 20 25 30  
 Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Gly Arg Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala  
 50 55 60  
 Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr  
 65 70 75 80  
 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr  
 85 90 95  
 Tyr Cys Thr Thr  
 100

&lt;210&gt; 609

&lt;211&gt; 100

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 609

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala  
 20 25 30  
 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45

- 122 -

Gly Arg Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala  
 50 55 60  
 Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr  
 65 70 75 80  
 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr  
 85 90 95  
 Tyr Cys Thr Thr  
 100

<210> 610  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 610  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Pro Ala Ser Gly Phe Thr Phe Ser Asn His  
 20 25 30  
 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Tyr Ile Ser Gly Asp Ser Gly Tyr Thr Asn Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Asn Asn Ser Pro Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Val Lys

<210> 611  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 611  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn His  
 20 25 30  
 Tyr Thr Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Tyr Ser Ser Gly Asn Ser Gly Tyr Thr Asn Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

- 123 -

Val Lys

<210> 612  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 612  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ser  
 20 25 30  
 Asp Met Asn Trp Val His Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Gly Val Ser Trp Asn Gly Ser Arg Thr His Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Thr Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Val Arg

<210> 613  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 613  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ser  
 20 25 30  
 Asp Met Asn Trp Ala Arg Lys Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Gly Val Ser Trp Asn Gly Ser Arg Thr His Tyr Val Asp Ser Val  
 50 55 60  
 Lys Arg Arg Phe Ile Ile Ser Arg Asp Asn Ser Arg Asn Ser Leu Tyr  
 65 70 75 80  
 Leu Gln Lys Asn Arg Arg Arg Ala Glu Asp Met Ala Val Tyr Tyr Cys  
 85 90 95

Val Arg

<210> 614  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

&lt;400&gt; 614



- 124 -

Thr Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Glu Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ser  
 20 25 30  
 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Gly Val Ser Trp Asn Gly Ser Arg Thr His Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ser Arg Asn Phe Leu Tyr  
 65 70 75 80  
 Gln Gln Met Asn Ser Leu Arg Pro Glu Asp Met Ala Val Tyr Tyr Cys  
 85 90 95  
 Val Arg

<210> 615  
 <211> 97  
 <212> PRT  
 <213> Homo sapiens

<400> 615  
 Glu Val His Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ala Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr  
 20 25 30  
 Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Ala Asn Gly Thr Ala Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys  
 50 55 60  
 Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu  
 65 70 75 80  
 Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala  
 85 90 95  
 Arg

<210> 616  
 <211> 97  
 <212> PRT  
 <213> Homo sapiens

<400> 616  
 Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Ile Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn  
 20 25 30  
 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys

- 125 -

50 55 60  
 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu  
 65 70 75 80  
 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala  
 85 90 95  
 Arg

<210> 617  
 <211> 97  
 <212> PRT  
 <213> Homo sapiens

<400> 617  
 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val His Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Ala Ile Gly Thr Gly Gly Gly Thr Tyr Tyr Ala Asp Ser Val Lys  
 50 55 60  
 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu  
 65 70 75 80  
 Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val Tyr Tyr Cys Ala  
 85 90 95  
 Arg

<210> 618  
 <211> 97  
 <212> PRT  
 <213> Homo sapiens

<400> 618  
 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Ala Ile Gly Thr Gly Gly Gly Thr Tyr Tyr Ala Asp Ser Val Lys  
 50 55 60  
 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu  
 65 70 75 80  
 Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val Tyr Tyr Cys Ala  
 85 90 95  
 Arg

- 126 -

<210> 619  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 619  
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Lys

<210> 620  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 620  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Val  
 35 40 45  
 Ser Ala Ile Ser Ser Asn Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Val Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Val Lys

<210> 621  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 621  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15

- 127 -

Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
                   20                  25                  30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Val  
                   35                  40                  45

Ser Ala Ile Ser Ser Asn Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val  
                   50                  55                  60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
                   65                  70                  75                  80

Val Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
                   85                  90                  95

Val Lys

<210> 622  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 622  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
                   1                  5                  10                  15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
                   20                  25                  30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Val  
                   35                  40                  45

Ser Ala Ile Ser Ser Asn Gly Gly Ser Thr Tyr Tyr Ala Asn Ser Val  
                   50                  55                  60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
                   65                  70                  75                  80

Leu Gln Met Gly Ser Leu Arg Ala Glu Asp Met Ala Val Tyr Tyr Cys  
                   85                  90                  95

Ala Arg

<210> 623  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 623  
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
                   1                  5                  10                  15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
                   20                  25                  30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
                   35                  40                  45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Gly Asp Ser Val  
                   50                  55                  60

- 128 -

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Lys

<210> 624  
<211> 98  
<212> PRT  
<213> Homo sapiens

<400> 624  
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Thr Asp Ser Val  
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg

<210> 625  
<211> 98  
<212> PRT  
<213> Homo sapiens

<400> 625  
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg

- 129 -

<210> 626  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 626  
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Arg

<210> 627  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 627  
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Arg

<210> 628  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 628  
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

- 130 -

20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg

<210> 629  
<211> 98  
<212> PRT  
<213> Homo sapiens

<400> 629

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg

<210> 630  
<211> 98  
<212> PRT  
<213> Homo sapiens

<400> 630

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
65 70 75 80

Ala Arg

```
<210> 631
<211> 98
<212> PRT
<213> Homo sapiens
```

```

<400> 631
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
  1          5          10
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
          20          25          30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
          35          40          45
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
          50          55          60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65          70          75          80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
          85          90          95

```

Ala Arg

```
<210> 632
<211> 98
<212> PRT
<213> Homo sapiens
```

```

<400> 632
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
  1          5          10          15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
          20          25          30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
          35          40          45
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
          50          55          60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65          70          75          80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Cys
          85          90          95

```

Ala Arg

<210> 633  
<211> 98



- 132 -

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 633

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Val  
 35 40 45  
 Ser Ala Ile Ser Ser Asn Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Val Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Val Lys

&lt;210&gt; 634

&lt;211&gt; 98

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 634

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Val  
 35 40 45  
 Ser Ala Ile Ser Ser Asn Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Arg

&lt;210&gt; 635

&lt;211&gt; 98

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 635

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30

- 133 -

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60

Lys Gly Arg Phe Ala Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Arg

<210> 636  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 636  
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Arg

<210> 637  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 637  
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

- 134 -

85

90

95

Ala Lys

&lt;210&gt; 638

&lt;211&gt; 97

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 638

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30

Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val  
 35 40 45

Ser Ala Ile Gly Thr Ala Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys  
 50 55 60

Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu  
 65 70 75 80

Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala  
 85 90 95

Arg

&lt;210&gt; 639

&lt;211&gt; 98

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 639

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30

Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45

Ser Tyr Ile Ser Ser Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val  
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr  
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Arg

&lt;210&gt; 640

&lt;211&gt; 98

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

- 135 -

&lt;400&gt; 640

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Leu Arg Ala Arg Leu Cys Ile Thr Val  
 85 90 95

Arg Glu

&lt;210&gt; 641

&lt;211&gt; 98

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 641

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Arg

&lt;210&gt; 642

&lt;211&gt; 98

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 642

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45

- 136 -

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 30 35 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Arg

<210> 643  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 643  
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Arg

<210> 644  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 644  
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

- 137 -

Ala Arg

<210> 645  
 <211> 98  
 <212> FRT  
 <213> Homo sapiens

<400> 645  
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Arg

<210> 646  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 646  
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Arg

<210> 647  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

&lt;400&gt; 647

- 138 -

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Arg

<210> 648  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 648  
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Gly Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Arg

<210> 649  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 649  
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val

- 139 -

50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Lys

<210> 650  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 650  
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Lys

<210> 651  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 651  
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Arg



- 140 -

<210> 652  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 652  
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Lys

<210> 653  
 <211> 95  
 <212> PRT  
 <213> Homo sapiens

<400> 653  
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Arg Lys  
 85 90 95

<210> 654  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 654  
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30

- 141 -

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Arg

<210> 655  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 655  
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Ala  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Thr Asn Thr Leu Phe  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Arg

<210> 656  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 656  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Tyr Ile Ser Ser Ser Ser Ser Thr Ile Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr  
 65 70 75 80

- 142 -

Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Arg

<210> 657  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 657  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Ser Ile Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Arg

<210> 658  
 <211> 97  
 <212> PRT  
 <213> Homo sapiens

<400> 658  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Ser Ile Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys  
 50 55 60  
 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu  
 65 70 75 80  
 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala  
 85 90 95

Arg

<210> 659  
 <211> 98  
 <212> PRT

- 143 -

&lt;213&gt; Homo sapiens

&lt;400&gt; 659

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Arg

&lt;210&gt; 660

&lt;211&gt; 98

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 660

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Tyr Ile Ser Ser Ser Ser Ser Thr Ile Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Arg

&lt;210&gt; 661

&lt;211&gt; 97

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 661

Glu Asp Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Pro Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Ser Tyr  
 20 25 30  
 Val Leu His Trp Val Arg Arg Ala Pro Gly Lys Gly Pro Glu Trp Val

- 144 -

```

          35          40          45
Ser Ala Ile Gly Thr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Met
  50          55          60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Ser Leu Tyr Leu
  65          70          75          90
Gln Met Asn Ser Leu Ile Ala Glu Asp Met Ala Val Tyr Tyr Cys Ala
          85          90          95

```

Arg

<210> 662  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

```

<400> 662
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
  1          5          10          15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
          20          25          30
Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Val Trp Val
          35          40          45
Ser Arg Ile Asn Ser Asp Gly Ser Ser Thr Ser Tyr Ala Asp Ser Val
          50          55          60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
          65          70          75          80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
          85          90          95

```

Ala Arg

<210> 663  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

```

<400> 663
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
  1          5          10          15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
          20          25          30
Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Val Trp Val
          35          40          45
Ser Arg Ile Asn Ser Asp Gly Ser Ser Thr Ser Tyr Ala Asp Ser Val
          50          55          60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
          65          70          75          80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
          85          90          95

```

- 145 -

Ala Arg

<210> 664  
 <211> 98  
 <212> PRT  
 <213> Hcmo sapiens

<400> 664  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Arg

<210> 665  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 665  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Val Trp Val  
 35 40 45  
 Ser Arg Ile Asn Ser Asp Gly Ser Ser Thr Ser Tyr Ala Asp Ser Met  
 50 55 60  
 Lys Gly Gln Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val Tyr Tyr Cys  
 85 90 95

Thr Arg

<210> 666  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

- 146 -

&lt;400&gt; 666

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Arg

&lt;210&gt; 667

&lt;211&gt; 98

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 667

Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Lys Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Thr Thr

&lt;210&gt; 668

&lt;211&gt; 98

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 668

Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln  
 1 5 10 15  
 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn  
 20 25 30  
 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45

- 147 -

Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser  
 50 55 60  
 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln  
 65 70 75 80  
 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu  
 85 90 95  
 Ser Ala

<210> 669  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 669  
 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln  
 1 5 10 15  
 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asp Met Gly Asn Tyr  
 20 25 30  
 Ala Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45  
 Ile Tyr Glu Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser  
 50 55 60  
 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Trp  
 65 70 75 80  
 Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Leu Ala Trp Asp Thr Ser Pro  
 85 90 95  
 Arg Ala

<210> 670  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 670  
 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln  
 1 5 10 15  
 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn  
 20 25 30  
 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45  
 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60  
 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln  
 65 70 75 80  
 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu  
 85 90 95  
 Asn Gly



<210> 671  
<211> 98  
<212> PRT  
<213> Homo sapiens

<400> 671  
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln  
1 5 10 15  
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn  
20 25 30  
Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
35 40 45  
Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
50 55 60  
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg  
65 70 75 80  
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu  
85 90 95  
Ser Gly

<210> 672  
<211> 98  
<212> PRT  
<213> Homo sapiens

<400> 672  
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Glu Ala Pro Arg Gln  
1 5 10 15  
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn  
20 25 30  
Ala Val Asn Trp Tyr Gln Gln Leu Pro Gly Lys Ala Pro Lys Leu Leu  
35 40 45  
Ile Tyr Tyr Asp Asp Leu Leu Pro Ser Gly Val Ser Asp Arg Phe Ser  
50 55 60  
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln  
65 70 75 80  
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu  
85 90 95  
Asn Gly

<210> 673  
<211> 99  
<212> PRT  
<213> Homo sapiens

<400> 673  
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln

- 149 -

1 5 10 15  
 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly  
 20 25 30  
 Tyr Val Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu  
 35 40 45  
 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Gln Phe  
 50 55 60  
 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu  
 65 70 75 80  
 Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Lys Ala Trp Asp Asn Ser  
 85 90 95  
 Leu Asn Ala

<210> 674  
 <211> 99  
 <212> PRT  
 <213> Homo sapiens

<400> 674  
 Gln Ser Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln  
 1 5 10 15  
 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly  
 20 25 30  
 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu  
 35 40 45  
 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe  
 50 55 60  
 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu  
 65 70 75 80  
 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser  
 85 90 95  
 Leu Ser Gly

<210> 675  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 675  
 Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln  
 1 5 10 15  
 Arg Val Thr Ile Ser Cys Ser Gly Gly Arg Ser Asn Ile Gly Ser Asn  
 20 25 30  
 Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
 35 40 45  
 Ile Tyr Gly Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser  
 50 55 60

- 150 -

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Val Gln  
65 70 75 80

Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu  
85 90 95

Arg Gly

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 00/07946

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K16/24 C12N15/13 C12N15/63 C12N5/10 C07K16/00  
A61K39/395 G01N33/577 C12P21/08 A61P43/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

STRAND, MEDLINE, BIOSIS, WPI Data, EPO-Internal, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 659 766 A (SCHERING PLOUGH CORP) 28 June 1995 (1995-06-28) page 2, line 47-54 page 3, line 34 -page 4, line 33 claims	
A	WO 94 04679 A (GENENTECH INC) 3 March 1994 (1994-03-03) page 5, line 1 -page 7, line 3 example 3 claims	
	---	
	---	
	--- --	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

8 August 2000

Date of mailing of the international search report

23/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3018

Authorized officer

Covone, M

1

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/07946

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE BIOSIS 'Online!  BIOSCIENCES INFORMATION SERVICE,  PHILADELPHIA, PA, US; 1997  CARTER R W ET AL: "Production and  characterization of monoclonal antibodies  to human interleukin-12."  Database accession no. PREV199799787174  XP002144460  abstract  &amp; HYBRIDOMA,  vol. 16, no. 4, 1997, pages 363-369,  ISSN: 0272-457X</p> <p>---</p>	
A	<p>PINI A ET AL: "Hierarchical affinity  maturation of a phage library derived  antibody for the selective removal of  cytomegalovirus from plasma"  JOURNAL OF IMMUNOLOGICAL  METHODS,NL,ELSEVIER SCIENCE PUBLISHERS  B.V.,AMSTERDAM,  vol. 206, no. 1-2,  7 August 1997 (1997-08-07), pages 171-182,  XP004093130  ISSN: 0022-1759  the whole document</p> <p>---</p>	
A	<p>IRVING R A ET AL: "Affinity maturation of  recombinant antibodies using E.coli  mutator cells"  IMMUNOTECHNOLOGY,NL,ELSEVIER SCIENCE  PUBLISHERS BV,  vol. 2, no. 2, 1 June 1996 (1996-06-01),  pages 127-143, XP004052677  ISSN: 1380-2933  abstract  figure 1</p> <p>---</p>	
A	<p>WO 95 24918 A (GENETICS INST)  21 September 1995 (1995-09-21)  page 3, line 15 -page 4, line 14</p> <p>-----</p>	

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.1

Although claims 94,95,142 (completely) are directed to a method of treatment of the human/animal body, and claim 139 (partially) is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

## Continuation of Box I.2

In view of the large number and also the wording of the claims presently on file, which render it difficult, if not impossible, to determine the matter for which protection is sought, the present application fails to comply with the clarity and conciseness requirements of Article 6 PCT (see also Rule 6.1(a) PCT) to such an extent that a meaningful search is impossible. Moreover support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found for only a very small proportion of the compounds and methods claimed. In the present case, the claims also so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Consequently, the search has been carried out for those parts of the application which do appear to be clear, concise and supported by the experimental data, namely those parts related to human anti-IL-12 antibodies as disclosed at page 140 line 20 - page 141 line 10 (antibody Y61) and at page 143 line 12-line 32 (antibody J695) and in claims 23-26 and 41-44, including nucleic acid coding for said antibodies, host cell to express said nucleic acid and production of said protein. Thus claims 23-31, 35-45, 47-49, 53, 55-58, 60-62, 64, 66-69, 71-73 have been fully searched. The remaining claims have been partially searched, in the light of the supported subject matter.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/07946

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0659766 A	28-06-1995	AU 1209495 A	13-06-1995
		EP 0788545 A	13-08-1997
		WO 9514780 A	01-06-1995
		US 5959085 A	28-09-1999
		ZA 9409227 A	22-05-1995
WO 9404679 A	03-03-1994	US 5821337 A	13-10-1998
		AU 675916 B	27-02-1997
		AU 2250992 A	12-01-1993
		EP 0590058 A	06-04-1994
		JP 6508267 T	22-09-1994
		US 6054297 A	25-04-2000
		CA 2103059 A	15-12-1992
		EP 0940468 A	08-09-1999
		WO 9222653 A	23-12-1992
		AU 5083193 A	15-03-1994
WO 9524918 A	21-09-1995	AU 689236 B	26-03-1998
		AU 1974995 A	03-10-1995
		CA 2185565 A	21-09-1995
		EP 0750509 A	02-01-1997
		JP 9510444 T	21-10-1997
		ZA 9500960 A	10-10-1995

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**